US20070148185A1 - Novel therapeutic target for protozoal diseases - Google Patents
Novel therapeutic target for protozoal diseases Download PDFInfo
- Publication number
- US20070148185A1 US20070148185A1 US11/549,482 US54948206A US2007148185A1 US 20070148185 A1 US20070148185 A1 US 20070148185A1 US 54948206 A US54948206 A US 54948206A US 2007148185 A1 US2007148185 A1 US 2007148185A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- hydroxy
- phenyl
- ethyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 title abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 296
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 269
- 244000045947 parasite Species 0.000 claims abstract description 188
- 150000003278 haem Chemical class 0.000 claims abstract description 160
- 238000000034 method Methods 0.000 claims abstract description 144
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- 108010080417 hemozoin Proteins 0.000 claims abstract description 93
- 241000224016 Plasmodium Species 0.000 claims abstract description 78
- 238000001784 detoxification Methods 0.000 claims abstract description 12
- 101001003868 Plasmodium falciparum (isolate 3D7) Heme ligase Proteins 0.000 claims description 205
- 230000027455 binding Effects 0.000 claims description 76
- 201000004792 malaria Diseases 0.000 claims description 63
- -1 4-{[(2S)-2-ethylpiperidin-1-yl]methyl}-3-hydroxy-1-methyl-6H-benzo[c]chromen-6-one Chemical compound 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 44
- 239000002671 adjuvant Substances 0.000 claims description 40
- 239000003430 antimalarial agent Substances 0.000 claims description 38
- 230000003993 interaction Effects 0.000 claims description 38
- 241000223777 Theileria Species 0.000 claims description 34
- 230000002401 inhibitory effect Effects 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000000078 anti-malarial effect Effects 0.000 claims description 17
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- FLDYBLAUDDQRAB-UHFFFAOYSA-N (4-methylquinolin-2-yl)hydrazine Chemical compound C1=CC=C2C(C)=CC(NN)=NC2=C1 FLDYBLAUDDQRAB-UHFFFAOYSA-N 0.000 claims description 9
- XEPLXNOYANQXHI-HNRZYHPDSA-N (r)-boroabu-(+)-pinanediol Chemical compound C([C@H]1OB(O[C@]11C)[C@@H](N)CCC)[C@H]2C(C)(C)[C@@H]1C2 XEPLXNOYANQXHI-HNRZYHPDSA-N 0.000 claims description 9
- XRYUYXUOBRWERE-UHFFFAOYSA-N 2-(4-methoxyphenyl)pyridin-3-ol Chemical compound C1=CC(OC)=CC=C1C1=NC=CC=C1O XRYUYXUOBRWERE-UHFFFAOYSA-N 0.000 claims description 9
- XJKMEOFFCYJCGT-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)naphthalen-1-ol Chemical compound C1=CC2=CC=CC=C2C(O)=C1CN1CCOCC1 XJKMEOFFCYJCGT-UHFFFAOYSA-N 0.000 claims description 9
- KZMWFLOKSAEGLP-UHFFFAOYSA-N 2-[4-(2-hydroxyphenyl)buta-1,3-diynyl]phenol Chemical compound OC1=CC=CC=C1C#CC#CC1=CC=CC=C1O KZMWFLOKSAEGLP-UHFFFAOYSA-N 0.000 claims description 9
- VNHXBLBWQFQTTG-UHFFFAOYSA-N 4-phenylquinolin-2-amine Chemical compound C=12C=CC=CC2=NC(N)=CC=1C1=CC=CC=C1 VNHXBLBWQFQTTG-UHFFFAOYSA-N 0.000 claims description 9
- GIOODPXVUBAVRK-UHFFFAOYSA-N 7-chloro-n-phenylquinolin-4-amine Chemical compound C=1C=NC2=CC(Cl)=CC=C2C=1NC1=CC=CC=C1 GIOODPXVUBAVRK-UHFFFAOYSA-N 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 7
- DBYCDKBEVKWZNL-UHFFFAOYSA-N (4,6-diphenylpyrimidin-2-yl)hydrazine Chemical compound N=1C(NN)=NC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 DBYCDKBEVKWZNL-UHFFFAOYSA-N 0.000 claims description 5
- NVRHTWUJJVYNSQ-UHFFFAOYSA-N 1-ethynyl-2-phenoxybenzene Chemical compound C#CC1=CC=CC=C1OC1=CC=CC=C1 NVRHTWUJJVYNSQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 5
- FNCNNOMKQUPPIK-UHFFFAOYSA-N 7-chloro-4-piperidin-1-ylquinoline Chemical compound C=1C=NC2=CC(Cl)=CC=C2C=1N1CCCCC1 FNCNNOMKQUPPIK-UHFFFAOYSA-N 0.000 claims description 5
- 230000003281 allosteric effect Effects 0.000 claims description 5
- 125000005336 allyloxy group Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- WVRYJUACUKRKTQ-UHFFFAOYSA-N n-(2,5-dimethylphenyl)benzamide Chemical compound CC1=CC=C(C)C(NC(=O)C=2C=CC=CC=2)=C1 WVRYJUACUKRKTQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 238000006471 dimerization reaction Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 150000003248 quinolines Chemical class 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000004052 folic acid antagonist Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 230000036457 multidrug resistance Effects 0.000 claims description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001755 resorcinol Drugs 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims 16
- UUUIDRKMWAVFMJ-CYBMUJFWSA-N (1s)-1-(3,4-dichlorophenyl)-2-(2-imino-1,3-benzothiazol-3-yl)ethanol Chemical compound C1([C@@H](CN2C(SC3=CC=CC=C32)=N)O)=CC=C(Cl)C(Cl)=C1 UUUIDRKMWAVFMJ-CYBMUJFWSA-N 0.000 claims 8
- AEYVDMKRKUMSOP-NSHDSACASA-N (2s)-n-(4-chlorophenyl)-2-methyl-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C([C@@H](OC1=CC=CC=C11)C)N1C(=O)NC1=CC=C(Cl)C=C1 AEYVDMKRKUMSOP-NSHDSACASA-N 0.000 claims 8
- KRKDUNKWEPLVKA-UHFFFAOYSA-N (2z)-2-[(1-ethyl-6-methoxy-4-methylbenzo[h]quinolin-1-ium-2-yl)methylidene]-3-methyl-1,3-thiazole Chemical compound C1=C(C)C2=CC(OC)=C3C=CC=CC3=C2[N+](CC)=C1C=C1SC=CN1C KRKDUNKWEPLVKA-UHFFFAOYSA-N 0.000 claims 8
- LIGHTOPFGVEIEO-HSMVNMDESA-N (3ar,4r,9br)-8-chloro-4-(4-chlorophenyl)-9-nitro-3a,4,5,9b-tetrahydro-3h-cyclopenta[c]quinolin-6-ol Chemical compound C1([C@H]2[C@@H]3CC=C[C@H]3C=3C(=C(Cl)C=C(C=3N2)O)[N+]([O-])=O)=CC=C(Cl)C=C1 LIGHTOPFGVEIEO-HSMVNMDESA-N 0.000 claims 8
- FPBOJSZTZJVZBC-MRXNPFEDSA-N (3r)-5,7-dichloro-3-hydroxy-3-(2-methylimidazo[1,2-a]pyridin-3-yl)-1h-indol-2-one Chemical compound O=C1NC(C(=CC(Cl)=C2)Cl)=C2[C@@]1(O)C1=C(C)N=C2N1C=CC=C2 FPBOJSZTZJVZBC-MRXNPFEDSA-N 0.000 claims 8
- SOXPHOKNVXFKFW-NTUHNPAUSA-N (5e)-2-anilino-5-[(5-bromo-3-chloro-2-hydroxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound OC1=C(Cl)C=C(Br)C=C1\C=C\1C(=O)N=C(NC=2C=CC=CC=2)S/1 SOXPHOKNVXFKFW-NTUHNPAUSA-N 0.000 claims 8
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 claims 8
- ZZNGLWQDMUIOAM-GOSISDBHSA-O 1-[(2s)-3-carbazol-9-yl-2-hydroxypropyl]quinolin-1-ium-8-ol Chemical compound C1=CC(O)=C2[N+](C[C@H](CN3C4=CC=CC=C4C4=CC=CC=C43)O)=CC=CC2=C1 ZZNGLWQDMUIOAM-GOSISDBHSA-O 0.000 claims 8
- ZKHLFXGNCPJHKW-UHFFFAOYSA-N 1-n-benzo[g]quinolin-4-yl-4-n-propan-2-ylbenzene-1,4-diamine Chemical compound C1=CC(NC(C)C)=CC=C1NC1=CC=NC2=CC3=CC=CC=C3C=C12 ZKHLFXGNCPJHKW-UHFFFAOYSA-N 0.000 claims 8
- DDGHMXAZQIPINI-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1,3-benzoxazin-4-one Chemical compound C1=CC(OC)=CC=C1C1=NC(=O)C2=CC=CC=C2O1 DDGHMXAZQIPINI-UHFFFAOYSA-N 0.000 claims 8
- SGLVVBQJUSGTHI-UHFFFAOYSA-N 2-(pyridin-3-yliminomethyl)-1-benzothiophen-3-ol Chemical compound C1=CC=C2C(=C1)C(=C(S2)C=NC3=CN=CC=C3)O SGLVVBQJUSGTHI-UHFFFAOYSA-N 0.000 claims 8
- ZDFDWMPZVXIIAR-UHFFFAOYSA-N 2-[(1,6-dimethylquinolin-1-ium-2-yl)methylidene]-3-ethyl-6-methoxy-1,3-benzothiazole Chemical compound C1=C(C)C=CC2=[N+](C)C(C=C3N(C4=CC=C(OC)C=C4S3)CC)=CC=C21 ZDFDWMPZVXIIAR-UHFFFAOYSA-N 0.000 claims 8
- HIRNGMIIEYFTDX-UHFFFAOYSA-N 2-[(6-methoxy-1-methylquinolin-1-ium-2-yl)methylidene]-3-methyl-1,3-benzothiazole Chemical compound S\1C2=CC=CC=C2N(C)C/1=C/C1=[N+](C)C2=CC=C(OC)C=C2C=C1 HIRNGMIIEYFTDX-UHFFFAOYSA-N 0.000 claims 8
- OQSFPJGKCRSQOW-UHFFFAOYSA-N 2-[2-(4-hydroxyphenyl)ethyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(CCC=2C=CC(O)=CC=2)=N1 OQSFPJGKCRSQOW-UHFFFAOYSA-N 0.000 claims 8
- ZMHXYKHSAGVCPK-UHFFFAOYSA-N 2-amino-8-(azepan-1-ium-1-ylmethyl)-3-(1,3-benzothiazol-2-yl)-4-oxochromen-7-olate Chemical compound [O-]C1=CC=C2C(=O)C(C=3SC4=CC=CC=C4N=3)=C(N)OC2=C1C[NH+]1CCCCCC1 ZMHXYKHSAGVCPK-UHFFFAOYSA-N 0.000 claims 8
- XBQRPFBBTWXIFI-UHFFFAOYSA-N 2-chloro-4-[2-(3-chloro-4-hydroxyphenyl)propan-2-yl]phenol Chemical compound C=1C=C(O)C(Cl)=CC=1C(C)(C)C1=CC=C(O)C(Cl)=C1 XBQRPFBBTWXIFI-UHFFFAOYSA-N 0.000 claims 8
- KFKCHAZDYMJZOR-UHFFFAOYSA-N 2-hydroxy-n-(3-methoxybenzoyl)benzamide Chemical compound COC1=CC=CC(C(=O)NC(=O)C=2C(=CC=CC=2)O)=C1 KFKCHAZDYMJZOR-UHFFFAOYSA-N 0.000 claims 8
- SPAOHXQOULUUSP-UHFFFAOYSA-N 2-hydroxy-n-(4-propylbenzoyl)benzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC(=O)C1=CC=CC=C1O SPAOHXQOULUUSP-UHFFFAOYSA-N 0.000 claims 8
- INLBTJWNEMKYDO-UHFFFAOYSA-N 3-(2-hydroxy-5-methoxybenzoyl)-2-(4-methylphenyl)-3h-isoindol-1-one Chemical compound COC1=CC=C(O)C(C(=O)C2C3=CC=CC=C3C(=O)N2C=2C=CC(C)=CC=2)=C1 INLBTJWNEMKYDO-UHFFFAOYSA-N 0.000 claims 8
- OILMTGAXBCPFHL-UHFFFAOYSA-N 3-[(3-aminophenyl)-(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]aniline;4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid Chemical compound NC1=CC=CC(C(=C2C=CC(=N)C=C2)C=2C=C(N)C=CC=2)=C1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 OILMTGAXBCPFHL-UHFFFAOYSA-N 0.000 claims 8
- CBIWCSPBAAKJPN-UHFFFAOYSA-N 3-[3-[(2-chlorophenyl)sulfanylmethyl]phenyl]-3-oxopropanenitrile Chemical compound ClC1=CC=CC=C1SCC1=CC=CC(C(=O)CC#N)=C1 CBIWCSPBAAKJPN-UHFFFAOYSA-N 0.000 claims 8
- FXNXERVKTGHSOQ-UHFFFAOYSA-N 3-[4-(9h-fluoren-9-yl)piperazin-1-yl]-n-[3-(trifluoromethyl)phenyl]propanamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)CCN2CCN(CC2)C2C3=CC=CC=C3C3=CC=CC=C32)=C1 FXNXERVKTGHSOQ-UHFFFAOYSA-N 0.000 claims 8
- BHRXRNFQFJCZDC-UHFFFAOYSA-N 4-(6-methylimidazo[1,2-a]pyridin-2-yl)benzene-1,2-diol Chemical compound C=1N2C=C(C)C=CC2=NC=1C1=CC=C(O)C(O)=C1 BHRXRNFQFJCZDC-UHFFFAOYSA-N 0.000 claims 8
- PMQZXEBSVASLTG-UHFFFAOYSA-N 4-(7-methylimidazo[1,2-a]pyridin-2-yl)benzene-1,2-diol Chemical compound N1=C2C=C(C)C=CN2C=C1C1=CC=C(O)C(O)=C1 PMQZXEBSVASLTG-UHFFFAOYSA-N 0.000 claims 8
- KSWMZWWYMRXHDF-UHFFFAOYSA-N 4-[(2-ethylanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CCC1=CC=CC=C1NCC1=C(CO)C=NC(C)=C1O KSWMZWWYMRXHDF-UHFFFAOYSA-N 0.000 claims 8
- HPYCSMRZVJTSRQ-NRFANRHFSA-N 4-[(3S)-3-(4-fluorophenyl)-2-(4-nitrophenyl)-3,4-dihydropyrazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NN(C=2C=CC(=CC=2)[N+]([O-])=O)[C@H](C=2C=CC(F)=CC=2)C1 HPYCSMRZVJTSRQ-NRFANRHFSA-N 0.000 claims 8
- DNTFESJRYSPRGH-UHFFFAOYSA-N 4-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC(O)=CC=2)N1 DNTFESJRYSPRGH-UHFFFAOYSA-N 0.000 claims 8
- ADHLSOGCYJHJBG-UHFFFAOYSA-N 4-[5-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1,3-dihydrobenzimidazol-2-ylidene]cyclohexa-2,5-dien-1-one Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(NC4=CC=3)=C3C=CC(=O)C=C3)C2=C1 ADHLSOGCYJHJBG-UHFFFAOYSA-N 0.000 claims 8
- LNDQPZWKVCWABS-UHFFFAOYSA-N 5-(2-hydroxy-5-methylbenzoyl)-1-(4-methylphenyl)-2-oxopyridine-3-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C#N)=CC(C(=O)C=2C(=CC=C(C)C=2)O)=C1 LNDQPZWKVCWABS-UHFFFAOYSA-N 0.000 claims 8
- ZCRPFHMMWJJYAO-UHFFFAOYSA-N 5-(5-chloro-2-hydroxybenzoyl)-2-oxo-n,1-diphenylpyridine-3-carboxamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)C1=CN(C=2C=CC=CC=2)C(=O)C(C(=O)NC=2C=CC=CC=2)=C1 ZCRPFHMMWJJYAO-UHFFFAOYSA-N 0.000 claims 8
- LZXPPDSORWBMRR-UHFFFAOYSA-N 6-amino-1-ethylbenzo[cd]indol-2-one Chemical compound C1=CC(N(CC)C2=O)=C3C2=CC=CC3=C1N LZXPPDSORWBMRR-UHFFFAOYSA-N 0.000 claims 8
- PSYSOHFJJQZPOK-UHFFFAOYSA-N 6-chloro-3-[2-(4-chlorophenyl)ethyl]-2,4-dihydro-1,3-benzoxazine Chemical compound C1=CC(Cl)=CC=C1CCN1CC2=CC(Cl)=CC=C2OC1 PSYSOHFJJQZPOK-UHFFFAOYSA-N 0.000 claims 8
- MPVGHGDVDXWFTQ-UHFFFAOYSA-N 6-chloro-n-(furan-2-ylmethyl)-2-phenylchromen-4-imine Chemical compound C12=CC(Cl)=CC=C2OC(C=2C=CC=CC=2)=CC1=NCC1=CC=CO1 MPVGHGDVDXWFTQ-UHFFFAOYSA-N 0.000 claims 8
- COCYGNDCWFKTMF-UHFFFAOYSA-N 7,8-dihydroxyflavone Chemical compound OC=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 COCYGNDCWFKTMF-UHFFFAOYSA-N 0.000 claims 8
- FJAZHJWLZLBNNC-UHFFFAOYSA-N 7-hydroxy-2-methyl-6-propyl-3-(2-pyridinyl)-1-benzopyran-4-one Chemical compound C1=C(O)C(CCC)=CC(C2=O)=C1OC(C)=C2C1=CC=CC=N1 FJAZHJWLZLBNNC-UHFFFAOYSA-N 0.000 claims 8
- MFSIZHOIUMUUCK-WNAAXNPUSA-N C1=CC(OC)=CC=C1C(OC1=CC=C(C)C=C11)=C\C1=N/CCC1=CC=CC=C1 Chemical compound C1=CC(OC)=CC=C1C(OC1=CC=C(C)C=C11)=C\C1=N/CCC1=CC=CC=C1 MFSIZHOIUMUUCK-WNAAXNPUSA-N 0.000 claims 8
- YLFMCMWKHSDUCT-UHFFFAOYSA-N NS 1619 Chemical compound OC1=CC=C(C(F)(F)F)C=C1N1C(=O)NC2=CC(C(F)(F)F)=CC=C21 YLFMCMWKHSDUCT-UHFFFAOYSA-N 0.000 claims 8
- PSHCPBCQGGUKQJ-UHFFFAOYSA-N chembl587334 Chemical compound C=1C=C2OCCCOC2=CC=1C=1C(C)=NOC=1C1=CC=C(O)C=C1O PSHCPBCQGGUKQJ-UHFFFAOYSA-N 0.000 claims 8
- ALRVRMJGXNESMJ-UHFFFAOYSA-N ethyl 1-benzyl-4-[(dimethylamino)methyl]-5-hydroxy-2-phenylindole-3-carboxylate Chemical compound C=1C=CC=CC=1CN1C2=CC=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1C1=CC=CC=C1 ALRVRMJGXNESMJ-UHFFFAOYSA-N 0.000 claims 8
- NGUJCLQFUIRSTR-UHFFFAOYSA-N ethyl 2-ethoxy-5-hydroxy-1h-benzo[g]indole-3-carboxylate Chemical compound C1=C(O)C2=CC=CC=C2C2=C1C(C(=O)OCC)=C(OCC)N2 NGUJCLQFUIRSTR-UHFFFAOYSA-N 0.000 claims 8
- MOMKEBSMTUDFIX-HZHRSRAPSA-N n'-[(e)-(2-bromophenyl)methylideneamino]-n-(2-hydroxyphenyl)octanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCCC(=O)N\N=C\C1=CC=CC=C1Br MOMKEBSMTUDFIX-HZHRSRAPSA-N 0.000 claims 8
- WTZWAGSBCKGCCG-UHFFFAOYSA-N n-(2-hydroxybenzoyl)furan-3-carboxamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1=COC=C1 WTZWAGSBCKGCCG-UHFFFAOYSA-N 0.000 claims 8
- BUKGFQXPNLPRFK-UHFFFAOYSA-N n-(2-hydroxybenzoyl)thiophene-2-carboxamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1=CC=CS1 BUKGFQXPNLPRFK-UHFFFAOYSA-N 0.000 claims 8
- LPEIWHLOCJFLRY-ZXVVBBHZSA-N n-(2-hydroxyphenyl)-n'-[(e)-(4-phenylphenyl)methylideneamino]heptanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCC(=O)N\N=C\C1=CC=C(C=2C=CC=CC=2)C=C1 LPEIWHLOCJFLRY-ZXVVBBHZSA-N 0.000 claims 8
- XQNTUIOPVTWXCP-UHFFFAOYSA-N n-(3-chloro-4-hydroxynaphthalen-1-yl)-4-ethoxybenzenesulfonamide Chemical compound C1=CC(OCC)=CC=C1S(=O)(=O)NC1=CC(Cl)=C(O)C2=CC=CC=C12 XQNTUIOPVTWXCP-UHFFFAOYSA-N 0.000 claims 8
- SQCYGVGSFMDQJD-UHFFFAOYSA-N n-(4-ethylbenzoyl)-2-hydroxybenzamide Chemical compound C1=CC(CC)=CC=C1C(=O)NC(=O)C1=CC=CC=C1O SQCYGVGSFMDQJD-UHFFFAOYSA-N 0.000 claims 8
- WIPBFPCDERGUGD-LBPRGKRZSA-N n-[(1s)-1-phenylethyl]quinazolin-4-amine Chemical compound C1([C@@H](NC=2C3=CC=CC=C3N=CN=2)C)=CC=CC=C1 WIPBFPCDERGUGD-LBPRGKRZSA-N 0.000 claims 8
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 8
- SGRFKMBNHUWOIN-QGZVFWFLSA-N 2-[(3r)-1-[[4-(2-hydroxyethoxy)phenyl]methyl]piperidin-3-yl]isoindole-1,3-dione Chemical compound C1=CC(OCCO)=CC=C1CN1C[C@H](N2C(C3=CC=CC=C3C2=O)=O)CCC1 SGRFKMBNHUWOIN-QGZVFWFLSA-N 0.000 claims 7
- PEQMTEMWXRAERG-OAHLLOKOSA-N 3-[[4-[[(2r)-oxolan-2-yl]methylamino]quinazolin-2-yl]amino]phenol Chemical compound OC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC[C@@H]3OCCC3)N=2)=C1 PEQMTEMWXRAERG-OAHLLOKOSA-N 0.000 claims 7
- ZKBBGUJBGLTNEK-UHFFFAOYSA-N 4-(1h-benzimidazol-2-yl)-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC=CC=C2N1 ZKBBGUJBGLTNEK-UHFFFAOYSA-N 0.000 claims 7
- BYBYHCOEAFHGJL-VWLOTQADSA-N 4-[(2s)-3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy]-1h-indole-2-carbonitrile Chemical compound C([C@@H](COC=1C=2C=C(NC=2C=CC=1)C#N)O)N(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BYBYHCOEAFHGJL-VWLOTQADSA-N 0.000 claims 7
- AMUNNKSZVRNYLZ-UHFFFAOYSA-N 4-n-(3,5-dichlorophenyl)-6-methylpyrimidine-2,4-diamine Chemical compound NC1=NC(C)=CC(NC=2C=C(Cl)C=C(Cl)C=2)=N1 AMUNNKSZVRNYLZ-UHFFFAOYSA-N 0.000 claims 7
- ITESNYBWKVFAEV-UHFFFAOYSA-N 7-chloro-n-[2-(dimethylamino)ethyl]-4h-thieno[3,2-c]thiochromene-2-carboxamide Chemical compound C1SC2=CC(Cl)=CC=C2C2=C1C=C(C(=O)NCCN(C)C)S2 ITESNYBWKVFAEV-UHFFFAOYSA-N 0.000 claims 7
- LWKCIPORVGAZTO-UHFFFAOYSA-N chembl1540038 Chemical compound OC1=CC(OC)=CC=C1C1=C(C=2OC3=CC=CC=C3C=2)C(C(F)(F)F)=NN1 LWKCIPORVGAZTO-UHFFFAOYSA-N 0.000 claims 7
- CFHAGUUZEDUZEW-UHFFFAOYSA-N n-(2-ethoxyphenyl)-2-hydroxybenzamide Chemical compound CCOC1=CC=CC=C1NC(=O)C1=CC=CC=C1O CFHAGUUZEDUZEW-UHFFFAOYSA-N 0.000 claims 7
- IIJYHLHWHGZFRM-IBGZPJMESA-N (10s)-10-(dimethylamino)-9-methyl-10h-phenaleno[1,2-b]pyran-7-one Chemical compound C1=CC(C=2O[C@@H](C(=CC=2C2=O)C)N(C)C)=C3C2=CC=CC3=C1 IIJYHLHWHGZFRM-IBGZPJMESA-N 0.000 claims 4
- SNHJNGSEGCCYBY-QHKWOANTSA-N (1e,4e)-1-[4-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)penta-1,4-dien-3-one Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)\C=C\C=2C=CC(=CC=2)N(C)C)=C1 SNHJNGSEGCCYBY-QHKWOANTSA-N 0.000 claims 4
- PQJWDNCGZBQHRJ-CHWSQXEVSA-N (1r,3r)-1-propan-2-yl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-2-ium-3-carboxylate Chemical compound N1C2=CC=CC=C2C2=C1[C@@H](C(C)C)[NH2+][C@@H](C([O-])=O)C2 PQJWDNCGZBQHRJ-CHWSQXEVSA-N 0.000 claims 4
- KJTVDVHMTYJJJZ-UHFFFAOYSA-N (2,4-dichloronaphthalen-1-yl)-(1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl)carbamic acid Chemical compound C1=CC=C2C(N(C(O)=O)C(C)(C(F)(F)F)C(F)(F)F)=C(Cl)C=C(Cl)C2=C1 KJTVDVHMTYJJJZ-UHFFFAOYSA-N 0.000 claims 4
- MSJKOVUYADBDEH-CXUHLZMHSA-N (2e)-6-ethoxy-2-[(2-hydroxyphenyl)methylidene]-1-benzothiophen-3-one Chemical compound S1C2=CC(OCC)=CC=C2C(=O)\C1=C/C1=CC=CC=C1O MSJKOVUYADBDEH-CXUHLZMHSA-N 0.000 claims 4
- PNHFCVLKJMHHPH-GOSISDBHSA-N (2r)-1-(benzylamino)-3-(3,6-dichlorocarbazol-9-yl)propan-2-ol Chemical compound C([C@@H](O)CN1C2=CC=C(Cl)C=C2C2=CC(Cl)=CC=C21)NCC1=CC=CC=C1 PNHFCVLKJMHHPH-GOSISDBHSA-N 0.000 claims 4
- HVLZJTHVKXQUHZ-LLVKDONJSA-N (2r)-2-(2,4-dichlorophenoxy)-n-(5-oxo-1-phenyl-4h-pyrazol-3-yl)propanamide Chemical compound O([C@H](C)C(=O)NC=1CC(=O)N(N=1)C=1C=CC=CC=1)C1=CC=C(Cl)C=C1Cl HVLZJTHVKXQUHZ-LLVKDONJSA-N 0.000 claims 4
- NBMMKPSIDCKDHT-FFXRNRBCSA-N (2r)-2-[(5z)-5-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methylbutanoic acid Chemical compound COC1=C(O)C(OC)=CC(\C=C/2C(N([C@H](C(C)C)C(O)=O)C(=S)S\2)=O)=C1 NBMMKPSIDCKDHT-FFXRNRBCSA-N 0.000 claims 4
- SYHZTZFMVWUEKV-YVARQFDVSA-N (2r)-2-[(e)-2-(1,3-benzodioxol-5-yl)ethenyl]-5,6-dimethyl-2,3-dihydro-1h-thieno[2,3-d]pyrimidin-4-one Chemical compound C1=C2OCOC2=CC(/C=C/[C@H]2NC=3SC(=C(C=3C(=O)N2)C)C)=C1 SYHZTZFMVWUEKV-YVARQFDVSA-N 0.000 claims 4
- YCJMPRBLQDWITE-OAHLLOKOSA-N (2s)-2-(4-chlorophenyl)-3-oxo-4-phenylbutanenitrile Chemical compound C1=CC(Cl)=CC=C1[C@@H](C#N)C(=O)CC1=CC=CC=C1 YCJMPRBLQDWITE-OAHLLOKOSA-N 0.000 claims 4
- BEZOCJJRCCRLAY-FIJZOYEMSA-N (2s)-2-[(5e)-5-(1h-indol-3-ylmethylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanedioic acid Chemical compound O=C1N([C@@H](CC(=O)O)C(O)=O)C(=S)S\C1=C\C1=CNC2=CC=CC=C12 BEZOCJJRCCRLAY-FIJZOYEMSA-N 0.000 claims 4
- XOEGOPOWDZTUJJ-VEWQMQJVSA-N (2s,3z)-3-(1h-indol-3-ylmethylidene)-2-phenylchromen-4-one Chemical compound C1([C@H]2C(=C/C=3C4=CC=CC=C4NC=3)/C(C3=CC=CC=C3O2)=O)=CC=CC=C1 XOEGOPOWDZTUJJ-VEWQMQJVSA-N 0.000 claims 4
- DXAQWYVOBOCKDB-UHFFFAOYSA-N (3,5-dichloro-2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone Chemical compound OC1=C(Cl)C=C(Cl)C=C1C(=O)C1=CON=C1 DXAQWYVOBOCKDB-UHFFFAOYSA-N 0.000 claims 4
- LLBJGSNZMIRERE-CTNGQTDRSA-N (3as,6as)-3-benzoyl-1,5-diphenyl-3a,6a-dihydropyrrolo[3,4-c]pyrazole-4,6-dione Chemical compound O=C([C@H]1[C@@H](C2=O)N(N=C1C(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)N2C1=CC=CC=C1 LLBJGSNZMIRERE-CTNGQTDRSA-N 0.000 claims 4
- FRSIJISYFVLZLA-LJQANCHMSA-N (3r)-3-(2-hydroxy-4-methylphenyl)-n-(2-methoxyphenyl)-3-phenylpropanamide Chemical compound COC1=CC=CC=C1NC(=O)C[C@@H](C=1C(=CC(C)=CC=1)O)C1=CC=CC=C1 FRSIJISYFVLZLA-LJQANCHMSA-N 0.000 claims 4
- FLAFYDYFWBQMCJ-NRFANRHFSA-N (3s)-3-(2-hydroxy-4-methylbenzoyl)-2-(4-methylphenyl)-3h-isoindol-1-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C2=CC=CC=C2[C@H]1C(=O)C1=CC=C(C)C=C1O FLAFYDYFWBQMCJ-NRFANRHFSA-N 0.000 claims 4
- OHZDMHXAYPJNCU-GUDVDZBRSA-N (3s,3ar,6ar)-3-(5-bromo-2-hydroxyphenyl)-5-butyl-2-phenyl-3a,6a-dihydro-3h-pyrrolo[3,4-d][1,2]oxazole-4,6-dione Chemical compound C1([C@H]2N(O[C@H]3C(=O)N(C([C@@H]32)=O)CCCC)C=2C=CC=CC=2)=CC(Br)=CC=C1O OHZDMHXAYPJNCU-GUDVDZBRSA-N 0.000 claims 4
- GRJFBYPTXGMIGM-YYIAUSFCSA-N (3s,6s,7r,8ar)-3-(4-acetamidobutyl)-6-(4-hydroxyphenyl)-1,4-dioxo-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-7-carboxylic acid Chemical compound C1([C@@H]2[C@@H](C[C@@H]3C(=O)N[C@H](C(N32)=O)CCCCNC(=O)C)C(O)=O)=CC=C(O)C=C1 GRJFBYPTXGMIGM-YYIAUSFCSA-N 0.000 claims 4
- WNROXVDYBCVQOT-LCYFTJDESA-N (3z)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-1-methylindol-2-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C/1C2=CC=CC=C2N(C)C\1=O WNROXVDYBCVQOT-LCYFTJDESA-N 0.000 claims 4
- BUAKBZQBLYANHM-UHFFFAOYSA-N (4-bromo-6-chloro-2-oxo-1,3-benzoxathiol-5-yl) ethyl carbonate Chemical compound CCOC(=O)OC1=C(Cl)C=C2OC(=O)SC2=C1Br BUAKBZQBLYANHM-UHFFFAOYSA-N 0.000 claims 4
- NPCHUJMJLPDVOC-OAQYLSRUSA-N (4R)-5-(furan-2-ylmethyl)-3-(2-hydroxyphenyl)-4-phenyl-1,4-dihydropyrrolo[3,4-c]pyrazol-6-one Chemical compound OC1=CC=CC=C1C1=NNC2=C1[C@@H](C=1C=CC=CC=1)N(CC=1OC=CC=1)C2=O NPCHUJMJLPDVOC-OAQYLSRUSA-N 0.000 claims 4
- NIWSGEVIXDEOIW-GOSISDBHSA-N (4r)-3-(3,4-dichlorophenyl)-4-hydroxy-2-oxo-n-propan-2-yl-1h-quinazoline-4-carboxamide Chemical compound N1([C@](C2=CC=CC=C2NC1=O)(O)C(=O)NC(C)C)C1=CC=C(Cl)C(Cl)=C1 NIWSGEVIXDEOIW-GOSISDBHSA-N 0.000 claims 4
- AOECKCWGYHRVJH-CYBMUJFWSA-N (4r)-4-(4-bromophenyl)-1-propan-2-yl-4,8-dihydro-2h-pyrazolo[3,4-e][1,4]thiazepine-3,7-dione Chemical compound C1([C@@H]2C=3C(=O)NN(C=3NC(=O)CS2)C(C)C)=CC=C(Br)C=C1 AOECKCWGYHRVJH-CYBMUJFWSA-N 0.000 claims 4
- QAOYRLLALYQTJF-HNNXBMFYSA-N (4s)-4-(2-bromobenzoyl)-5-methyl-2-phenyl-4h-pyrazol-3-one Chemical compound O=C([C@H]1C(=O)N(N=C1C)C=1C=CC=CC=1)C1=CC=CC=C1Br QAOYRLLALYQTJF-HNNXBMFYSA-N 0.000 claims 4
- RRWANTVEMKYDHW-NSHDSACASA-N (4s)-5,7-dihydroxy-4-phenyl-3,4-dihydrochromen-2-one Chemical compound C1([C@H]2C3=C(O)C=C(C=C3OC(=O)C2)O)=CC=CC=C1 RRWANTVEMKYDHW-NSHDSACASA-N 0.000 claims 4
- VOGRXCRVILPCQN-ZFWWWQNUSA-N (4s,5s)-3,5-diphenyl-4,5-dihydro-1h-pyrazol-4-ol Chemical compound N([C@H]([C@@H]1O)C=2C=CC=CC=2)N=C1C1=CC=CC=C1 VOGRXCRVILPCQN-ZFWWWQNUSA-N 0.000 claims 4
- KBALFCXSMKSFRZ-GJZGRUSLSA-N (4s,7r)-2-amino-4-(2-methylpropyl)-5-oxo-7-phenyl-4,6,7,8-tetrahydrochromene-3-carbonitrile Chemical compound C1([C@H]2CC(=O)C3=C(C2)OC(N)=C(C#N)[C@@H]3CC(C)C)=CC=CC=C1 KBALFCXSMKSFRZ-GJZGRUSLSA-N 0.000 claims 4
- ROVLKLLVKDAQDC-UVTDQMKNSA-N (4z)-2-[2-(4-chlorophenoxy)pyridin-3-yl]-4-(dimethylaminomethylidene)-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/N(C)C)/N=C1C1=CC=CN=C1OC1=CC=C(Cl)C=C1 ROVLKLLVKDAQDC-UVTDQMKNSA-N 0.000 claims 4
- BFMNYGNNGHOTMY-FMIVXFBMSA-N (5e)-1-(4-methylpentyl)-5-(1h-pyrrol-2-ylmethylidene)-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(CCCC(C)C)C(=O)NC(=O)\C1=C/C1=CC=CN1 BFMNYGNNGHOTMY-FMIVXFBMSA-N 0.000 claims 4
- YEJGKUDVZIHDQM-MHWRWJLKSA-N (5e)-2-(3,5-dimethylanilino)-5-[(2-hydroxy-3-methoxyphenyl)methylidene]-1,3-thiazol-4-one Chemical compound COC1=CC=CC(\C=C\2C(N=C(NC=3C=C(C)C=C(C)C=3)S/2)=O)=C1O YEJGKUDVZIHDQM-MHWRWJLKSA-N 0.000 claims 4
- KDXMRGRMHDOBTR-DHZHZOJOSA-N (5e)-5-[(2-hydroxyphenyl)methylidene]-3-prop-2-enyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound OC1=CC=CC=C1\C=C\1C(=O)N(CC=C)C(=S)S/1 KDXMRGRMHDOBTR-DHZHZOJOSA-N 0.000 claims 4
- UCOSZMPNTRCHEN-SSDOTTSWSA-N (5r)-5-methyl-4-phenyl-1,3,4-thiadiazolidine-2-thione Chemical compound C[C@H]1SC(=S)NN1C1=CC=CC=C1 UCOSZMPNTRCHEN-SSDOTTSWSA-N 0.000 claims 4
- BCBOWCBDKFMKGG-GGAORHGYSA-N (5s,7r)-2,2-dimethyl-5,7-bis(2-phenylethyl)-4,5,7,8-tetrahydropyrano[4,3-d][1,3]dioxine Chemical compound C([C@@H]1CC2=C([C@@H](O1)CCC=1C=CC=CC=1)COC(O2)(C)C)CC1=CC=CC=C1 BCBOWCBDKFMKGG-GGAORHGYSA-N 0.000 claims 4
- SFNXYZZPMDZJNY-JYRVWZFOSA-N (5z)-2-(2-chloroanilino)-5-[(2-hydroxy-3-nitrophenyl)methylidene]-1,3-thiazol-4-one Chemical compound C1=CC=C([N+]([O-])=O)C(O)=C1\C=C/1C(=O)N=C(NC=2C(=CC=CC=2)Cl)S\1 SFNXYZZPMDZJNY-JYRVWZFOSA-N 0.000 claims 4
- SHXHWOPEFBMMKJ-ZSOIEALJSA-N (5z)-2-(2-chloroanilino)-5-[(4-hydroxy-3-nitrophenyl)methylidene]-1,3-thiazol-4-one Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1\C=C/1C(=O)N=C(NC=2C(=CC=CC=2)Cl)S\1 SHXHWOPEFBMMKJ-ZSOIEALJSA-N 0.000 claims 4
- AWFVCJJDTXVPDE-YFBAIUBQSA-N (5z)-5-[(4-hydroxyphenyl)methylidene]-3-[[(2r)-oxolan-2-yl]methyl]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(O)=CC=C1\C=C/1C(=O)N(C[C@@H]2OCCC2)C(=S)S\1 AWFVCJJDTXVPDE-YFBAIUBQSA-N 0.000 claims 4
- RHPQQPHKWACZIB-KHWQSYBYSA-N (6e)-5-imino-6-[(1-naphthalen-2-ylpyrrol-2-yl)methylidene]-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one Chemical compound C1=CC=CC2=CC(N3C=CC=C3/C=C3/C(=O)N=C4SC=NN4C3=N)=CC=C21 RHPQQPHKWACZIB-KHWQSYBYSA-N 0.000 claims 4
- QARNUFOLNOGNGQ-KEBDBYFISA-N (e)-1-(9-ethylcarbazol-3-yl)-n-(1,2,4-triazol-4-yl)methanimine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1\C=N\N1C=NN=C1 QARNUFOLNOGNGQ-KEBDBYFISA-N 0.000 claims 4
- ZTVIIBNOZYJWSQ-JXMROGBWSA-N (e)-3-(3,4-dimethoxyphenyl)-n-(3,4-dimethylphenyl)prop-2-enamide Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=C(C)C(C)=C1 ZTVIIBNOZYJWSQ-JXMROGBWSA-N 0.000 claims 4
- NSABOJTUOUEHNP-JXMROGBWSA-N (e)-n-(2-methyl-1,3-benzothiazol-6-yl)-3-phenylprop-2-enamide Chemical compound C1=C2SC(C)=NC2=CC=C1NC(=O)\C=C\C1=CC=CC=C1 NSABOJTUOUEHNP-JXMROGBWSA-N 0.000 claims 4
- TZTAVIMXABOWDC-PDGQHHTCSA-N (z)-2-acetamido-n-(3,5-dimethylphenyl)-3-phenylprop-2-enamide Chemical compound C=1C(C)=CC(C)=CC=1NC(=O)C(/NC(=O)C)=C/C1=CC=CC=C1 TZTAVIMXABOWDC-PDGQHHTCSA-N 0.000 claims 4
- RBSYHVABNKGETI-UHFFFAOYSA-N 1-(2,4-dihydroxy-6-methylphenyl)-2-phenoxyethanone Chemical compound CC1=CC(O)=CC(O)=C1C(=O)COC1=CC=CC=C1 RBSYHVABNKGETI-UHFFFAOYSA-N 0.000 claims 4
- QJGSIWBOOHBIIP-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-propan-2-ylphenoxy)ethanone Chemical compound C1=CC(C(C)C)=CC=C1OCC(=O)C1=CC=C(O)C=C1O QJGSIWBOOHBIIP-UHFFFAOYSA-N 0.000 claims 4
- OLLUUBHGYLRMEX-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-2-[4-(3,5-dimethoxyanilino)quinazolin-2-yl]sulfanylethanone Chemical compound COC1=CC(OC)=CC(NC=2C3=CC=CC=C3N=C(SCC(=O)C=3C=C(O)C(O)=CC=3)N=2)=C1 OLLUUBHGYLRMEX-UHFFFAOYSA-N 0.000 claims 4
- VPKUSXKFSBUBSQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-1-hydroxy-3-phenylurea Chemical compound C=1C=C(Cl)C=CC=1N(O)C(=O)NC1=CC=CC=C1 VPKUSXKFSBUBSQ-UHFFFAOYSA-N 0.000 claims 4
- KXBPBFMJLNZSRT-UHFFFAOYSA-N 1-(4-hydroxy-3,5-dimethylphenyl)-2-(4-methylphenyl)sulfanylethanone Chemical compound C1=CC(C)=CC=C1SCC(=O)C1=CC(C)=C(O)C(C)=C1 KXBPBFMJLNZSRT-UHFFFAOYSA-N 0.000 claims 4
- ABKKFERIXUERCT-UHFFFAOYSA-N 1-(5-butyl-2,4-dihydroxyphenyl)-2-pyridin-2-ylethanone Chemical compound C1=C(O)C(CCCC)=CC(C(=O)CC=2N=CC=CC=2)=C1O ABKKFERIXUERCT-UHFFFAOYSA-N 0.000 claims 4
- KAIMAPGPSLRDDN-UHFFFAOYSA-N 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(1-methylbenzimidazol-2-yl)ethanone Chemical compound C1=C(O)C(CC)=CC(C(=O)CC=2N(C3=CC=CC=C3N=2)C)=C1O KAIMAPGPSLRDDN-UHFFFAOYSA-N 0.000 claims 4
- SMCUMUSHPASMPO-UHFFFAOYSA-N 1-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCN1C1=CC=NC2=CC(Cl)=CC=C12 SMCUMUSHPASMPO-UHFFFAOYSA-N 0.000 claims 4
- CUHDRAIPXASMOU-UHFFFAOYSA-N 1-tert-butyl-1-[(3,5-dichloro-2-hydroxyphenyl)methylideneamino]-3-methylthiourea Chemical compound C(C)(C)(C)N(N=CC1=C(C(=CC(=C1)Cl)Cl)O)C(=S)NC CUHDRAIPXASMOU-UHFFFAOYSA-N 0.000 claims 4
- SOIFXIDUZIIFTO-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-1-(2,4-dihydroxy-5-propylphenyl)ethanone Chemical compound C1=C(O)C(CCC)=CC(C(=O)CC=2C=C3OCOC3=CC=2)=C1O SOIFXIDUZIIFTO-UHFFFAOYSA-N 0.000 claims 4
- STFIHXNALHEXSO-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-hydroxyimidazo[4,5-b]pyridine Chemical compound N=1C2=NC=CC=C2N(O)C=1C1=CC=C(Cl)C=C1Cl STFIHXNALHEXSO-UHFFFAOYSA-N 0.000 claims 4
- CIILIUMQOVRJCX-UHFFFAOYSA-N 2-(2-phenoxyethylsulfanyl)-1h-quinazoline-4-thione Chemical compound N1C2=CC=CC=C2C(=S)N=C1SCCOC1=CC=CC=C1 CIILIUMQOVRJCX-UHFFFAOYSA-N 0.000 claims 4
- DKIUWRPUGJJXPP-UHFFFAOYSA-N 2-(4-chlorophenyl)-1,3-benzoxazin-4-one Chemical compound C1=CC(Cl)=CC=C1C1=NC(=O)C2=CC=CC=C2O1 DKIUWRPUGJJXPP-UHFFFAOYSA-N 0.000 claims 4
- VEMBTCCVVHCOMC-UHFFFAOYSA-N 2-(4-fluoro-3-phenoxyphenyl)-3-hydroxychromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(O)=C1C(C=1)=CC=C(F)C=1OC1=CC=CC=C1 VEMBTCCVVHCOMC-UHFFFAOYSA-N 0.000 claims 4
- NBHHASVZBSJJPL-UHFFFAOYSA-N 2-(4-hydroxy-2-oxo-1h-quinolin-3-yl)-n-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1NC(=O)CC1=C(O)NC2=CC=CC=C2C1=O NBHHASVZBSJJPL-UHFFFAOYSA-N 0.000 claims 4
- RDXDIPPVTHMTNU-UHFFFAOYSA-N 2-(4-iodo-2-methylphenyl)-5-(trifluoromethyl)-1h-pyrazol-3-one Chemical compound CC1=CC(I)=CC=C1N1C(=O)C=C(C(F)(F)F)N1 RDXDIPPVTHMTNU-UHFFFAOYSA-N 0.000 claims 4
- GZBUZCUHQUUESZ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-4-(4-methoxyphenyl)imino-1-benzopyran-6-ol Chemical compound C1=CC(OC)=CC=C1N=C1C2=CC(O)=CC=C2OC(C=2C=CC(OC)=CC=2)=C1 GZBUZCUHQUUESZ-UHFFFAOYSA-N 0.000 claims 4
- IIGYEVFLZBMDAQ-UHFFFAOYSA-N 2-(4-methylphenyl)-1,3-benzoxazin-4-one Chemical compound C1=CC(C)=CC=C1C1=NC(=O)C2=CC=CC=C2O1 IIGYEVFLZBMDAQ-UHFFFAOYSA-N 0.000 claims 4
- JROKQPJBAXRTQQ-UHFFFAOYSA-N 2-(5-chloro-6-methyl-2-pyridin-2-ylpyrimidin-4-yl)sulfanyl-1-phenylethanone Chemical compound ClC=1C(C)=NC(C=2N=CC=CC=2)=NC=1SCC(=O)C1=CC=CC=C1 JROKQPJBAXRTQQ-UHFFFAOYSA-N 0.000 claims 4
- UTQRMSMAJODFEF-UHFFFAOYSA-N 2-(5-ethylsulfonyl-2-hydroxyphenyl)benzo[de]isoquinoline-1,3-dione Chemical compound CCS(=O)(=O)C1=CC=C(O)C(N2C(C=3C=CC=C4C=CC=C(C=34)C2=O)=O)=C1 UTQRMSMAJODFEF-UHFFFAOYSA-N 0.000 claims 4
- PXDCTPSRBMFVSW-UHFFFAOYSA-N 2-(benzimidazol-1-yl)-1-(5-ethyl-2,4-dihydroxyphenyl)ethanone Chemical compound C1=C(O)C(CC)=CC(C(=O)CN2C3=CC=CC=C3N=C2)=C1O PXDCTPSRBMFVSW-UHFFFAOYSA-N 0.000 claims 4
- UCNFCRXGPQHQBE-MRVPVSSYSA-N 2-[(2r)-3-oxo-2,4-dihydro-1h-quinoxalin-2-yl]acetic acid Chemical compound C1=CC=C2NC(=O)[C@@H](CC(=O)O)NC2=C1 UCNFCRXGPQHQBE-MRVPVSSYSA-N 0.000 claims 4
- VYQBBDNOTLHQED-GFCCVEGCSA-N 2-[(2r)-6,7-dimethyl-3-oxo-2,4-dihydro-1h-quinoxalin-2-yl]-n-ethylacetamide Chemical compound CC1=C(C)C=C2NC(=O)[C@@H](CC(=O)NCC)NC2=C1 VYQBBDNOTLHQED-GFCCVEGCSA-N 0.000 claims 4
- SNODLIOFGYJKHO-UHFFFAOYSA-N 2-[(3-cyano-4-methyl-6-oxo-1h-pyridin-2-yl)sulfanyl]-n-naphthalen-1-ylacetamide Chemical compound CC1=CC(=O)NC(SCC(=O)NC=2C3=CC=CC=C3C=CC=2)=C1C#N SNODLIOFGYJKHO-UHFFFAOYSA-N 0.000 claims 4
- MULMJULXBQRDJB-FQEVSTJZSA-N 2-[(3s)-2-(4-nitrophenyl)-5-phenyl-3,4-dihydropyrazol-3-yl]phenol Chemical compound OC1=CC=CC=C1[C@H]1N(C=2C=CC(=CC=2)[N+]([O-])=O)N=C(C=2C=CC=CC=2)C1 MULMJULXBQRDJB-FQEVSTJZSA-N 0.000 claims 4
- NHEGFDYEVYVPKD-XVNBXDOJSA-N 2-[(5e)-4-oxo-2-sulfanylidene-5-(thiophen-3-ylmethylidene)-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)S\C1=C\C1=CSC=C1 NHEGFDYEVYVPKD-XVNBXDOJSA-N 0.000 claims 4
- PVHVMTYHMSBZFL-KRXBUXKQSA-N 2-[(5e)-5-[(5-bromo-3-chloro-2-hydroxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid Chemical compound O=C1N(CC(=O)O)C(=S)S\C1=C\C1=CC(Br)=CC(Cl)=C1O PVHVMTYHMSBZFL-KRXBUXKQSA-N 0.000 claims 4
- BKPJDYYSPWBLRU-LICLKQGHSA-N 2-[3-[(e)-[1-(3-fluorophenyl)-2,4,6-trioxo-1,3-diazinan-5-ylidene]methyl]indol-1-yl]acetonitrile Chemical compound FC1=CC=CC(N2C(C(=C/C=3C4=CC=CC=C4N(CC#N)C=3)/C(=O)NC2=O)=O)=C1 BKPJDYYSPWBLRU-LICLKQGHSA-N 0.000 claims 4
- PTHGDYYWYNTZOD-UHFFFAOYSA-N 2-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]phenol Chemical compound COC1=CC=CC=C1C1=NN=C(C=2C(=CC=CC=2)O)O1 PTHGDYYWYNTZOD-UHFFFAOYSA-N 0.000 claims 4
- FZTAOYFNARCYNU-UHFFFAOYSA-N 2-amino-1-(2,4-dimethylphenyl)pyrrolo[3,2-b]quinoxaline-3-carbonitrile Chemical compound CC1=CC(C)=CC=C1N1C2=NC3=CC=CC=C3N=C2C(C#N)=C1N FZTAOYFNARCYNU-UHFFFAOYSA-N 0.000 claims 4
- OBZWSAQVIDTJDC-UHFFFAOYSA-N 2-amino-5-butyl-4-(4-hydroxy-3-methoxyphenyl)-6-phenylpyridine-3-carbonitrile Chemical compound CCCCC1=C(C=2C=CC=CC=2)N=C(N)C(C#N)=C1C1=CC=C(O)C(OC)=C1 OBZWSAQVIDTJDC-UHFFFAOYSA-N 0.000 claims 4
- LKRVUDKBHJWHRT-UHFFFAOYSA-N 2-chloro-5-phenyl-3-pyridin-4-yl-4h-1,4-thiazine Chemical compound C=1SC(Cl)=C(C=2C=CN=CC=2)NC=1C1=CC=CC=C1 LKRVUDKBHJWHRT-UHFFFAOYSA-N 0.000 claims 4
- FJNADZSPACHLFJ-UHFFFAOYSA-N 2-chloro-8-hydroxy-10,10-dimethyl-7-phenylpyrido[1,2-a]indol-6-one Chemical compound CC1(C)C2=CC(Cl)=CC=C2N(C2=O)C1=CC(O)=C2C1=CC=CC=C1 FJNADZSPACHLFJ-UHFFFAOYSA-N 0.000 claims 4
- QMLRNTPTRWMCOP-UHFFFAOYSA-N 2-hydroxy-n-(4-methylphenyl)benzamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=CC=CC=C1O QMLRNTPTRWMCOP-UHFFFAOYSA-N 0.000 claims 4
- UUZBKRFDIGABAB-UHFFFAOYSA-N 2-hydroxy-n-[2-(2-methoxyphenyl)acetyl]benzamide Chemical compound COC1=CC=CC=C1CC(=O)NC(=O)C1=CC=CC=C1O UUZBKRFDIGABAB-UHFFFAOYSA-N 0.000 claims 4
- UHQHSGCKGVRYHM-UHFFFAOYSA-N 2-hydroxy-n-[4-(trifluoromethyl)benzoyl]benzamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1=CC=C(C(F)(F)F)C=C1 UHQHSGCKGVRYHM-UHFFFAOYSA-N 0.000 claims 4
- CIDPBVFYISXDHA-UHFFFAOYSA-N 2-hydroxy-n-pyridin-3-ylbenzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CN=C1 CIDPBVFYISXDHA-UHFFFAOYSA-N 0.000 claims 4
- GLGRRRKQSFURGD-UHFFFAOYSA-N 2-phenyl-5-(trifluoromethyl)-4h-pyrazol-3-one Chemical compound O=C1CC(C(F)(F)F)=NN1C1=CC=CC=C1 GLGRRRKQSFURGD-UHFFFAOYSA-N 0.000 claims 4
- QAQPSZCPMGBQER-UHFFFAOYSA-N 2-phenyl-5-[[5-(trifluoromethyl)pyridin-2-yl]sulfonylmethyl]-4h-pyrazol-3-one Chemical compound N1=CC(C(F)(F)F)=CC=C1S(=O)(=O)CC1=NN(C=2C=CC=CC=2)C(=O)C1 QAQPSZCPMGBQER-UHFFFAOYSA-N 0.000 claims 4
- YKELPHWMYAKGNL-UHFFFAOYSA-N 2-phenylthiochromene-4-thione Chemical compound S1C2=CC=CC=C2C(=S)C=C1C1=CC=CC=C1 YKELPHWMYAKGNL-UHFFFAOYSA-N 0.000 claims 4
- LEIPVOCXBORBRG-UHFFFAOYSA-N 3,4-dimethoxy-n-(4-methyl-1,3-benzothiazol-2-yl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=NC2=C(C)C=CC=C2S1 LEIPVOCXBORBRG-UHFFFAOYSA-N 0.000 claims 4
- UPXQMMGMYZLGGL-UHFFFAOYSA-N 3-(1-acetylindol-3-yl)-4-hydroxychromen-2-one Chemical compound C12=CC=CC=C2N(C(=O)C)C=C1C1=C(O)C2=CC=CC=C2OC1=O UPXQMMGMYZLGGL-UHFFFAOYSA-N 0.000 claims 4
- KHSMWQLOSRGSON-UHFFFAOYSA-N 3-(1-benzimidazolyl)-6-ethyl-7-hydroxy-1-benzopyran-4-one Chemical compound C1=NC2=CC=CC=C2N1C(C1=O)=COC2=C1C=C(CC)C(O)=C2 KHSMWQLOSRGSON-UHFFFAOYSA-N 0.000 claims 4
- XXHWHHKTAAYCHI-UHFFFAOYSA-N 3-(4-bromophenyl)-7-hydroxy-2-methylchromen-4-one Chemical compound CC=1OC2=CC(O)=CC=C2C(=O)C=1C1=CC=C(Br)C=C1 XXHWHHKTAAYCHI-UHFFFAOYSA-N 0.000 claims 4
- BYBPXSWPCHYVEN-UHFFFAOYSA-N 3-[2-(4-methoxyphenyl)ethyl]-10-methyl-6-phenyl-2,4-dihydropyrano[3,2-g][1,3]benzoxazin-8-one Chemical compound C1=CC(OC)=CC=C1CCN1CC(C=C2C(OC(=O)C=C2C=2C=CC=CC=2)=C2C)=C2OC1 BYBPXSWPCHYVEN-UHFFFAOYSA-N 0.000 claims 4
- RFGXPLJCJDNKKF-UHFFFAOYSA-N 3-[2-[(1,3-dioxoinden-2-ylidene)methyl]pyrrol-1-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(N2C(=CC=C2)C=C2C(C3=CC=CC=C3C2=O)=O)=C1 RFGXPLJCJDNKKF-UHFFFAOYSA-N 0.000 claims 4
- VANQVSSUFWMCGZ-UHFFFAOYSA-N 3-[3-[(4-chlorophenyl)sulfanylmethyl]phenyl]-3-oxopropanenitrile Chemical compound C1=CC(Cl)=CC=C1SCC1=CC=CC(C(=O)CC#N)=C1 VANQVSSUFWMCGZ-UHFFFAOYSA-N 0.000 claims 4
- LFMGAYSGKKKIHC-PDGQHHTCSA-N 3-[5-[(z)-[5-(4-methylphenyl)-2-oxofuran-3-ylidene]methyl]furan-2-yl]benzoic acid Chemical compound C1=CC(C)=CC=C1C(OC1=O)=C\C1=C\C1=CC=C(C=2C=C(C=CC=2)C(O)=O)O1 LFMGAYSGKKKIHC-PDGQHHTCSA-N 0.000 claims 4
- XYZVKUSTVPKIKZ-UHFFFAOYSA-N 3-benzyl-4-hydroxy-1-phenylquinolin-2-one Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C(O)=C1CC1=CC=CC=C1 XYZVKUSTVPKIKZ-UHFFFAOYSA-N 0.000 claims 4
- NVGZWGUUHGGGEY-UHFFFAOYSA-N 3-benzyl-4-hydroxyquinolin-2(1H)-one Chemical compound OC=1NC2=CC=CC=C2C(=O)C=1CC1=CC=CC=C1 NVGZWGUUHGGGEY-UHFFFAOYSA-N 0.000 claims 4
- NLQYPKZRMQGWRA-UHFFFAOYSA-N 3-benzyl-5,6-bis(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-imine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C(C(=N)N(CC=2C=CC=CC=2)C=N2)=C2O1 NLQYPKZRMQGWRA-UHFFFAOYSA-N 0.000 claims 4
- DHYGRGNCDRODHI-UHFFFAOYSA-N 3-benzyl-5-ethyl-4-hydroxy-6-phenyl-1-(1,3-thiazol-2-yl)pyridin-2-one Chemical compound O=C1N(C=2SC=CN=2)C(C=2C=CC=CC=2)=C(CC)C(O)=C1CC1=CC=CC=C1 DHYGRGNCDRODHI-UHFFFAOYSA-N 0.000 claims 4
- WNWGQERJYTYVIK-UHFFFAOYSA-N 3-benzyl-6-ethoxy-4-hydroxy-1h-quinolin-2-one Chemical compound O=C1C2=CC(OCC)=CC=C2NC(O)=C1CC1=CC=CC=C1 WNWGQERJYTYVIK-UHFFFAOYSA-N 0.000 claims 4
- PMEDFKUWHPTEAE-UHFFFAOYSA-N 3-chloro-n-(2-hydroxybenzoyl)-1-benzothiophene-2-carboxamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1=C(Cl)C2=CC=CC=C2S1 PMEDFKUWHPTEAE-UHFFFAOYSA-N 0.000 claims 4
- RVCLBOFDMCWKSI-UHFFFAOYSA-N 3-chloro-n-(2-methylsulfanyl-1,3-benzothiazol-6-yl)benzamide Chemical compound C1=C2SC(SC)=NC2=CC=C1NC(=O)C1=CC=CC(Cl)=C1 RVCLBOFDMCWKSI-UHFFFAOYSA-N 0.000 claims 4
- FBLAHUMENIHUGG-UHFFFAOYSA-N 3-hydroxy-n-(2-methylphenyl)naphthalene-2-carboxamide Chemical compound CC1=CC=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1O FBLAHUMENIHUGG-UHFFFAOYSA-N 0.000 claims 4
- OWLAJHBXOSRKLB-UHFFFAOYSA-N 3-methoxy-2-methyl-6-[4-(1-phenylpyrazol-4-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenol Chemical compound OC1=C(C)C(OC)=CC=C1C1=NNC(C(F)(F)F)=C1C1=CN(C=2C=CC=CC=2)N=C1 OWLAJHBXOSRKLB-UHFFFAOYSA-N 0.000 claims 4
- BBNNTMCIJDDFPH-UHFFFAOYSA-N 3-methoxy-n-[3-([1,3]oxazolo[4,5-b]pyridin-2-yl)phenyl]benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2OC3=CC=CN=C3N=2)=C1 BBNNTMCIJDDFPH-UHFFFAOYSA-N 0.000 claims 4
- LOMHHLANDQPQSF-UHFFFAOYSA-N 3-oxo-3-[3-[[3-(trifluoromethyl)phenyl]sulfanylmethyl]phenyl]propanenitrile Chemical compound FC(F)(F)C1=CC=CC(SCC=2C=C(C=CC=2)C(=O)CC#N)=C1 LOMHHLANDQPQSF-UHFFFAOYSA-N 0.000 claims 4
- JIRGLJLYLOWMPD-UHFFFAOYSA-N 4-(1-propylbenzimidazol-2-yl)aniline Chemical compound N=1C2=CC=CC=C2N(CCC)C=1C1=CC=C(N)C=C1 JIRGLJLYLOWMPD-UHFFFAOYSA-N 0.000 claims 4
- RAJDNSGRBFIOLG-UHFFFAOYSA-N 4-[(4-chlorophenyl)thio]-5-methyl-2-phenyl-1H-pyrazol-3-one Chemical compound O=C1C(SC=2C=CC(Cl)=CC=2)=C(C)NN1C1=CC=CC=C1 RAJDNSGRBFIOLG-UHFFFAOYSA-N 0.000 claims 4
- LBYKVBRDNGOQMN-UHFFFAOYSA-N 4-[2,3,5,6-tetrafluoro-4-(4-hydroxyphenoxy)phenoxy]phenol Chemical compound C1=CC(O)=CC=C1OC(C(=C1F)F)=C(F)C(F)=C1OC1=CC=C(O)C=C1 LBYKVBRDNGOQMN-UHFFFAOYSA-N 0.000 claims 4
- FZAXBDIMOOZDLW-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-methylpyrazol-3-amine Chemical compound CN1N=CC(C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1N FZAXBDIMOOZDLW-UHFFFAOYSA-N 0.000 claims 4
- ZEKVQJCKCLBDEH-BQYQJAHWSA-N 4-[[(e)-3-(furan-2-yl)-3-oxoprop-1-enyl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N\C=C\C(=O)C1=CC=CO1 ZEKVQJCKCLBDEH-BQYQJAHWSA-N 0.000 claims 4
- ZNJKBUYYFGCGNR-YIXHJXPBSA-N 4-bromo-2-[(E)-1,2,4-triazol-4-yliminomethyl]phenol Chemical compound OC1=CC=C(Br)C=C1\C=N\N1C=NN=C1 ZNJKBUYYFGCGNR-YIXHJXPBSA-N 0.000 claims 4
- KQBKWPYXZQEBCF-UHFFFAOYSA-N 4-fluoro-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 KQBKWPYXZQEBCF-UHFFFAOYSA-N 0.000 claims 4
- NJJDBBUWWOAOLD-CFBAGHHKSA-N 4-hydroxy-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]chromen-2-one Chemical compound C1=CC=C2OC(=O)C(C/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(O)C2=C1 NJJDBBUWWOAOLD-CFBAGHHKSA-N 0.000 claims 4
- PVWQCBSFBXZSHH-QFXGEWDLSA-N 4-hydroxy-8-methyl-3-[(e)-[(3r)-5-oxo-1,3-diphenylpyrazolidin-4-ylidene]methyl]-1h-quinolin-2-one Chemical compound N([C@@H](\C(C1=O)=C/C2=C(O)C=3C=CC=C(C=3NC2=O)C)C=2C=CC=CC=2)N1C1=CC=CC=C1 PVWQCBSFBXZSHH-QFXGEWDLSA-N 0.000 claims 4
- HDPADVKOPBBPJW-UHFFFAOYSA-N 5,7-dihydroxy-4-propylchromen-2-one Chemical compound C1=C(O)C=C(O)C2=C1OC(=O)C=C2CCC HDPADVKOPBBPJW-UHFFFAOYSA-N 0.000 claims 4
- OWDYXLDHWHFBMJ-UHFFFAOYSA-N 5-(5-bromo-2-hydroxybenzoyl)-1-(2-fluorophenyl)-2-oxopyridine-3-carbonitrile Chemical compound OC1=CC=C(Br)C=C1C(=O)C1=CN(C=2C(=CC=CC=2)F)C(=O)C(C#N)=C1 OWDYXLDHWHFBMJ-UHFFFAOYSA-N 0.000 claims 4
- FRHNPJSKDIIXAY-UHFFFAOYSA-N 5-(diethylamino)-2-(2-phenylethyliminomethyl)phenol Chemical compound CCN(CC)C1=CC(=C(C=C1)C=NCCC2=CC=CC=C2)O FRHNPJSKDIIXAY-UHFFFAOYSA-N 0.000 claims 4
- UOJFGEAPSYQDIP-UHFFFAOYSA-N 5-[(4-methylphenyl)sulfanyl]-2,4-quinazolinediamine Chemical compound C1=CC(C)=CC=C1SC1=CC=CC2=NC(N)=NC(N)=C12 UOJFGEAPSYQDIP-UHFFFAOYSA-N 0.000 claims 4
- PPXRWUYGZGTKCQ-UHFFFAOYSA-N 5-[2-(3,4-dichlorophenyl)sulfanylethyl]-2-methylpyridine Chemical compound C1=NC(C)=CC=C1CCSC1=CC=C(Cl)C(Cl)=C1 PPXRWUYGZGTKCQ-UHFFFAOYSA-N 0.000 claims 4
- DMSPKRGZUJVHRT-UHFFFAOYSA-N 5-benzamido-1-n,3-n-bis(2-hydroxyphenyl)benzene-1,3-dicarboxamide Chemical compound OC1=CC=CC=C1NC(=O)C1=CC(NC(=O)C=2C=CC=CC=2)=CC(C(=O)NC=2C(=CC=CC=2)O)=C1 DMSPKRGZUJVHRT-UHFFFAOYSA-N 0.000 claims 4
- QKSQZNZUYZVFCS-UHFFFAOYSA-N 5-benzyl-3-phenylpyrazolo[4,3-c]quinoline Chemical class C1=C2C(C=3C=CC=CC=3)=NN=C2C2=CC=CC=C2N1CC1=CC=CC=C1 QKSQZNZUYZVFCS-UHFFFAOYSA-N 0.000 claims 4
- KGYNGVVNFRUOOZ-UHFFFAOYSA-N 5-chloro-2-hydroxy-n-phenylbenzamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=CC=C1 KGYNGVVNFRUOOZ-UHFFFAOYSA-N 0.000 claims 4
- UDMRRUFQIPTYHI-UHFFFAOYSA-N 5-hydroxy-4-methyl-7-propylchromen-2-one Chemical compound CC1=CC(=O)OC2=CC(CCC)=CC(O)=C21 UDMRRUFQIPTYHI-UHFFFAOYSA-N 0.000 claims 4
- ZOZBHANUXDXBIN-UHFFFAOYSA-N 5-methyl-2-[3-(trifluoromethyl)phenyl]-1h-pyrazol-3-one Chemical compound N1C(C)=CC(=O)N1C1=CC=CC(C(F)(F)F)=C1 ZOZBHANUXDXBIN-UHFFFAOYSA-N 0.000 claims 4
- UIQFTNWTHDRGNT-UHFFFAOYSA-N 6-(4-chlorophenyl)-7-hydroxy-1,3-dimethyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2C(O)=C1C1=CC=C(Cl)C=C1 UIQFTNWTHDRGNT-UHFFFAOYSA-N 0.000 claims 4
- REPZBQITAZZVLI-FQEVSTJZSA-N 6-(4-methylpiperidin-1-yl)sulfonyl-4-oxo-n-[(2s)-1-phenylbutan-2-yl]-1h-quinoline-3-carboxamide Chemical compound C([C@H](CC)NC(=O)C=1C(C2=CC(=CC=C2NC=1)S(=O)(=O)N1CCC(C)CC1)=O)C1=CC=CC=C1 REPZBQITAZZVLI-FQEVSTJZSA-N 0.000 claims 4
- GFFHTABJSQSYGU-INIZCTEOSA-N 6-[(2-ethylphenyl)sulfamoyl]-4-oxo-n-[[(2s)-oxolan-2-yl]methyl]-1h-quinoline-3-carboxamide Chemical compound CCC1=CC=CC=C1NS(=O)(=O)C1=CC=C(NC=C(C(=O)NC[C@H]2OCCC2)C2=O)C2=C1 GFFHTABJSQSYGU-INIZCTEOSA-N 0.000 claims 4
- IKEIAIGEDXVXHL-SFHVURJKSA-N 6-[(4-ethoxyphenyl)-methylsulfamoyl]-4-oxo-n-[[(2s)-oxolan-2-yl]methyl]-1h-quinoline-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1N(C)S(=O)(=O)C1=CC=C(NC=C(C(=O)NC[C@H]2OCCC2)C2=O)C2=C1 IKEIAIGEDXVXHL-SFHVURJKSA-N 0.000 claims 4
- IWOZRLGQTHWMKK-NRFANRHFSA-N 6-[(s)-[4-(dimethylamino)phenyl]-piperidin-1-ylmethyl]-1,3-benzodioxol-5-ol Chemical compound C1=CC(N(C)C)=CC=C1[C@@H](C=1C(=CC=2OCOC=2C=1)O)N1CCCCC1 IWOZRLGQTHWMKK-NRFANRHFSA-N 0.000 claims 4
- UDYYPRWBKNVMLH-UHFFFAOYSA-N 6-[[(4-chlorophenyl)thio]methyl]-2-phenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione Chemical compound C1=CC(Cl)=CC=C1SCC(N1)=CC(=O)C(C2=O)=C1NN2C1=CC=CC=C1 UDYYPRWBKNVMLH-UHFFFAOYSA-N 0.000 claims 4
- HIBGBUAHZUWVNW-UHFFFAOYSA-N 6-bromo-2-(trifluoromethyl)-1h-quinolin-4-one Chemical compound BrC1=CC=C2NC(C(F)(F)F)=CC(=O)C2=C1 HIBGBUAHZUWVNW-UHFFFAOYSA-N 0.000 claims 4
- VLSGAOYACVQQIC-UHFFFAOYSA-N 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[[(4-methylphenyl)thio]methyl]-3-indolecarboxylic acid ethyl ester Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=C(C)C=C1 VLSGAOYACVQQIC-UHFFFAOYSA-N 0.000 claims 4
- PVIYSCVBHCYIMY-UHFFFAOYSA-N 6-butyl-2-(furan-2-yl)-5-methyl-1h-pyrazolo[1,5-a]pyrimidin-7-one Chemical compound N1N2C(=O)C(CCCC)=C(C)N=C2C=C1C1=CC=CO1 PVIYSCVBHCYIMY-UHFFFAOYSA-N 0.000 claims 4
- KHMMSGPBDXPKAX-UHFFFAOYSA-N 6-chloro-2-(4-chlorophenyl)-1-hydroxybenzimidazole Chemical compound N=1C2=CC=C(Cl)C=C2N(O)C=1C1=CC=C(Cl)C=C1 KHMMSGPBDXPKAX-UHFFFAOYSA-N 0.000 claims 4
- BISMLDRQEHMPSO-UHFFFAOYSA-N 6-chloro-3-(4-methylphenyl)-2,4-dihydro-1,3-benzoxazine Chemical compound C1=CC(C)=CC=C1N1CC2=CC(Cl)=CC=C2OC1 BISMLDRQEHMPSO-UHFFFAOYSA-N 0.000 claims 4
- DSAJLEKUBMUVMP-UHFFFAOYSA-N 6-ethyl-7-hydroxy-3-(1-methylbenzimidazol-2-yl)-2-(trifluoromethyl)chromen-4-one Chemical compound C1=CC=C2N(C)C(C3=C(OC4=C(C3=O)C=C(C(=C4)O)CC)C(F)(F)F)=NC2=C1 DSAJLEKUBMUVMP-UHFFFAOYSA-N 0.000 claims 4
- PAKRTZACNPEEEU-UHFFFAOYSA-N 6-fluoro-4-hydroxy-3-phenyl-1h-quinolin-2-one Chemical compound OC=1NC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 PAKRTZACNPEEEU-UHFFFAOYSA-N 0.000 claims 4
- CCKFFRXAFQLLDF-UHFFFAOYSA-N 6-quinolin-6-ylquinoline Chemical compound N1=CC=CC2=CC(C=3C=CC4=NC=CC=C4C=3)=CC=C21 CCKFFRXAFQLLDF-UHFFFAOYSA-N 0.000 claims 4
- JRVIIPJSVKTPBK-UHFFFAOYSA-N 7,8-dihydroxy-4-phenyl-2h-chromen-2-one Chemical compound C=1C(=O)OC2=C(O)C(O)=CC=C2C=1C1=CC=CC=C1 JRVIIPJSVKTPBK-UHFFFAOYSA-N 0.000 claims 4
- CQRIOEIVAKXNPL-UHFFFAOYSA-N 7-(4-bromophenyl)-5-hydroxy-1,3-benzoxathiol-2-one Chemical compound C=12OC(=O)SC2=CC(O)=CC=1C1=CC=C(Br)C=C1 CQRIOEIVAKXNPL-UHFFFAOYSA-N 0.000 claims 4
- AAVFBARFNBCGIP-UHFFFAOYSA-N 7-[2-chloro-5-(trifluoromethyl)phenyl]-5-hydroxy-1,3-benzoxathiol-2-one Chemical compound C=12OC(=O)SC2=CC(O)=CC=1C1=CC(C(F)(F)F)=CC=C1Cl AAVFBARFNBCGIP-UHFFFAOYSA-N 0.000 claims 4
- XZMYPYMXQWLBLS-UHFFFAOYSA-N 7-benzyl-8-hydroxy-10,10-dimethylpyrido[1,2-a]indol-6-one Chemical compound CC1(C)C2=CC=CC=C2N(C2=O)C1=CC(O)=C2CC1=CC=CC=C1 XZMYPYMXQWLBLS-UHFFFAOYSA-N 0.000 claims 4
- VSMYSOUPRUUSEK-UHFFFAOYSA-N 7-chloro-n-(3-fluoro-4-methylphenyl)quinolin-4-amine Chemical compound C1=C(F)C(C)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 VSMYSOUPRUUSEK-UHFFFAOYSA-N 0.000 claims 4
- ZDDBOIKRVOGUCB-UHFFFAOYSA-N 7-hydroxy-4,8-dimethyl-6-prop-2-enylchromen-2-one Chemical compound CC1=C(O)C(CC=C)=CC2=C1OC(=O)C=C2C ZDDBOIKRVOGUCB-UHFFFAOYSA-N 0.000 claims 4
- MLIVIWFJXJNITH-UHFFFAOYSA-N 7-hydroxy-6-methyl-3-(4-methyl-1,3-thiazol-2-yl)-2-(trifluoromethyl)chromen-4-one Chemical compound CC1=CSC(C=2C(C3=CC(C)=C(O)C=C3OC=2C(F)(F)F)=O)=N1 MLIVIWFJXJNITH-UHFFFAOYSA-N 0.000 claims 4
- NPILHDIBEBFVPW-UHFFFAOYSA-N 8-(trifluoromethoxy)-2-(trifluoromethyl)-1h-quinolin-4-one Chemical compound N1C(C(F)(F)F)=CC(=O)C2=C1C(OC(F)(F)F)=CC=C2 NPILHDIBEBFVPW-UHFFFAOYSA-N 0.000 claims 4
- MALMEVUZLXCESV-UHFFFAOYSA-N 8-methoxy-n,n-dimethyl-5h-pyrimido[5,4-b]indol-4-amine Chemical compound N1=CN=C2C3=CC(OC)=CC=C3NC2=C1N(C)C MALMEVUZLXCESV-UHFFFAOYSA-N 0.000 claims 4
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims 4
- BFOVJIGBVCJLAW-GOSISDBHSA-N C1([C@H]2C3=C(O)N(N=C3NC3=C2C(=O)CC(C3)(C)C)C=2C=CC=CC=2)=CC=CO1 Chemical compound C1([C@H]2C3=C(O)N(N=C3NC3=C2C(=O)CC(C3)(C)C)C=2C=CC=CC=2)=CC=CO1 BFOVJIGBVCJLAW-GOSISDBHSA-N 0.000 claims 4
- DTQRNIAVHDQBTH-FQEVSTJZSA-N C1=CC(CC)=CC=C1[C@H]1C(C(=O)CCC2)=C2NC2=NN(C=3C=CC=CC=3)C(O)=C12 Chemical compound C1=CC(CC)=CC=C1[C@H]1C(C(=O)CCC2)=C2NC2=NN(C=3C=CC=CC=3)C(O)=C12 DTQRNIAVHDQBTH-FQEVSTJZSA-N 0.000 claims 4
- YNSUBNJKGLTLLL-UHFFFAOYSA-N CC(C)(C)C(=O)NC1=CC=C(O)C(C=2SC3=CC=CC=C3N=2)=C1 Chemical compound CC(C)(C)C(=O)NC1=CC=C(O)C(C=2SC3=CC=CC=C3N=2)=C1 YNSUBNJKGLTLLL-UHFFFAOYSA-N 0.000 claims 4
- FORCNTSOYUUEBC-UHFFFAOYSA-N CC1=NN(C=2C=CC=CC=2)C(O)=C1CC1=C(Cl)C=CC=C1Cl Chemical compound CC1=NN(C=2C=CC=CC=2)C(O)=C1CC1=C(Cl)C=CC=C1Cl FORCNTSOYUUEBC-UHFFFAOYSA-N 0.000 claims 4
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 claims 4
- UJHGHNWTOKTBFN-UHFFFAOYSA-N N-[(2-hydroxyphenyl)-oxomethyl]-2,3-dihydrobenzofuran-5-carboxamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1=CC=C(OCC2)C2=C1 UJHGHNWTOKTBFN-UHFFFAOYSA-N 0.000 claims 4
- QILKXMYRDNWICE-UHFFFAOYSA-N OC1=CC(O)=CC=C1C1=NNC(C(F)(F)F)=C1C1=CN(C=2C=CC=CC=2)N=C1 Chemical compound OC1=CC(O)=CC=C1C1=NNC(C(F)(F)F)=C1C1=CN(C=2C=CC=CC=2)N=C1 QILKXMYRDNWICE-UHFFFAOYSA-N 0.000 claims 4
- ZHNFHCUXPQBBDH-UHFFFAOYSA-N OC1=CC2=NN=NN2N=C1C1=CC=CC=C1 Chemical compound OC1=CC2=NN=NN2N=C1C1=CC=CC=C1 ZHNFHCUXPQBBDH-UHFFFAOYSA-N 0.000 claims 4
- DJGZEJHCLVHBOA-UHFFFAOYSA-N [3-(quinazolin-4-ylamino)phenyl] thiophene-2-carboxylate Chemical compound C=1C=CC(NC=2C3=CC=CC=C3N=CN=2)=CC=1OC(=O)C1=CC=CS1 DJGZEJHCLVHBOA-UHFFFAOYSA-N 0.000 claims 4
- VTULUSNMAXYDHN-UHFFFAOYSA-N [4-(4-methylphenyl)sulfonylphenyl]hydrazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC=C(NN)C=C1 VTULUSNMAXYDHN-UHFFFAOYSA-N 0.000 claims 4
- KKVJHDVXPYWVAQ-UHFFFAOYSA-N [5-methyl-4-(4-methylphenyl)sulfanyl-2-phenylpyrazol-3-yl] 2-methoxyacetate Chemical compound CC1=NN(C=2C=CC=CC=2)C(OC(=O)COC)=C1SC1=CC=C(C)C=C1 KKVJHDVXPYWVAQ-UHFFFAOYSA-N 0.000 claims 4
- AWYXUZHAOIWLOY-UHFFFAOYSA-N ac1md751 Chemical compound O=C1N(C=23)C4=CC=CC=C4C3=CC=CC=2C(O)=C1C1=CC=CC=C1 AWYXUZHAOIWLOY-UHFFFAOYSA-N 0.000 claims 4
- ZTGOAIMRLCHKBE-UHFFFAOYSA-N ac1md7cd Chemical compound O=C1N(C=23)C4=CC=CC=C4C3=CC=CC=2C(O)=C1CC1=CC=CC=C1 ZTGOAIMRLCHKBE-UHFFFAOYSA-N 0.000 claims 4
- MZCBOGPEKPFLEL-UHFFFAOYSA-N ac1md7no Chemical compound O=C1N(C=23)CCCC3=CC=CC=2C(O)=C1CC1=CC=CC=C1 MZCBOGPEKPFLEL-UHFFFAOYSA-N 0.000 claims 4
- ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 claims 4
- ZICFMECLGKYUTO-UHFFFAOYSA-N chembl1300358 Chemical compound OC1=CC=C(Br)C=C1C1=NNC(C=2OC=CC=2)=C1 ZICFMECLGKYUTO-UHFFFAOYSA-N 0.000 claims 4
- LFWRNBBHBHBODY-UHFFFAOYSA-N chembl1384202 Chemical compound OC1=CC(OC)=CC=C1C1=C(C=2N=CSC=2)C(C)=NO1 LFWRNBBHBHBODY-UHFFFAOYSA-N 0.000 claims 4
- GJSKWHZFSLFJED-UHFFFAOYSA-N chembl1421125 Chemical compound OC1=CC(C)=CC=C1C1=NNC(C=2SC=CC=2)=C1 GJSKWHZFSLFJED-UHFFFAOYSA-N 0.000 claims 4
- SBVOOAOEAYENPN-UHFFFAOYSA-N chembl1534784 Chemical compound C1=C(O)C(OC)=CC(CN2C3=CC=CC=C3N=C2C=2C=C(OC)C(O)=CC=2)=C1 SBVOOAOEAYENPN-UHFFFAOYSA-N 0.000 claims 4
- OHDNJHMRIZHSHL-UHFFFAOYSA-N chembl1598131 Chemical compound C1=2NC(=O)C=C(C(F)(F)F)C=2C(C)=NN1C1=CC=CC=C1 OHDNJHMRIZHSHL-UHFFFAOYSA-N 0.000 claims 4
- ZINUBXHFNNZJJX-UHFFFAOYSA-N chembl1625226 Chemical compound N=1C2=CC=CC=C2SC=1C1=C(C)NN=C1C1=CC=C(O)C=C1O ZINUBXHFNNZJJX-UHFFFAOYSA-N 0.000 claims 4
- SPSHMSUVPRAWBV-FYJGNVAPSA-N chembl3198088 Chemical compound C1=CC=C2N(CCC)C(\N=C\C=3C4=CC=CC=C4NC=3)=NC2=C1 SPSHMSUVPRAWBV-FYJGNVAPSA-N 0.000 claims 4
- WUIHXPQLHWILPY-ZZXKWVIFSA-N ethyl (e)-3-(2-hydroxy-5-nitrophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC([N+]([O-])=O)=CC=C1O WUIHXPQLHWILPY-ZZXKWVIFSA-N 0.000 claims 4
- OKHVYJJRZQBZPW-UHFFFAOYSA-N ethyl 4-(2-phenylethylamino)quinoline-3-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CC=CC2=C1NCCC1=CC=CC=C1 OKHVYJJRZQBZPW-UHFFFAOYSA-N 0.000 claims 4
- ZPGNLZJITSLBES-UHFFFAOYSA-N ethyl 4-(benzylamino)-6-ethoxyquinoline-3-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CC(OCC)=CC2=C1NCC1=CC=CC=C1 ZPGNLZJITSLBES-UHFFFAOYSA-N 0.000 claims 4
- FKMQQJYJQXKPAE-GFCCVEGCSA-N ethyl 4-[[(2r)-butan-2-yl]amino]-6-ethoxyquinoline-3-carboxylate Chemical compound C1=CC(OCC)=CC2=C(N[C@H](C)CC)C(C(=O)OCC)=CN=C21 FKMQQJYJQXKPAE-GFCCVEGCSA-N 0.000 claims 4
- PCSKWRHNPYKODH-MDZDMXLPSA-N ethyl 4-[[(e)-3-thiophen-2-ylprop-2-enoyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)\C=C\C1=CC=CS1 PCSKWRHNPYKODH-MDZDMXLPSA-N 0.000 claims 4
- SRTNLWOMFUGTBQ-UHFFFAOYSA-N ethyl 4-[[2-[[(5r)-5-ethyl-4,6-dioxo-1h-pyrimidin-2-yl]sulfanyl]acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)CSC1=NC(=O)C(CC)C(=O)N1 SRTNLWOMFUGTBQ-UHFFFAOYSA-N 0.000 claims 4
- OTKPJORJFHKENB-UHFFFAOYSA-N ethyl 6-methyl-4-(4-morpholin-4-ylanilino)quinoline-3-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CC(C)=CC2=C1NC(C=C1)=CC=C1N1CCOCC1 OTKPJORJFHKENB-UHFFFAOYSA-N 0.000 claims 4
- ANUSOIHIIPAHJV-UHFFFAOYSA-N fenticlor Chemical compound OC1=CC=C(Cl)C=C1SC1=CC(Cl)=CC=C1O ANUSOIHIIPAHJV-UHFFFAOYSA-N 0.000 claims 4
- PTQFQYKDIQOOMX-NVNXTCNLSA-N methyl (2z)-2-[(4-hydroxyphenyl)methylidene]-3-oxo-1-benzofuran-5-carboxylate Chemical compound O=C1C2=CC(C(=O)OC)=CC=C2O\C1=C/C1=CC=C(O)C=C1 PTQFQYKDIQOOMX-NVNXTCNLSA-N 0.000 claims 4
- WQZLXXQTPIPUET-UHFFFAOYSA-N methyl 3-methyl-1-oxo-5h-pyrido[1,2-a]benzimidazole-4-carboxylate Chemical compound C1=CC=C2NC3=C(C(=O)OC)C(C)=CC(=O)N3C2=C1 WQZLXXQTPIPUET-UHFFFAOYSA-N 0.000 claims 4
- QYOGFQFLYFXWEW-UHFFFAOYSA-N methyl 3-oxo-2-[4-(trifluoromethyl)phenyl]-1h-pyrazole-5-carboxylate Chemical compound N1C(C(=O)OC)=CC(=O)N1C1=CC=C(C(F)(F)F)C=C1 QYOGFQFLYFXWEW-UHFFFAOYSA-N 0.000 claims 4
- LYGILDLOPGSGHR-MTDXEUNCSA-N n'-[(e)-(3-fluoro-4-phenylphenyl)methylideneamino]-n-(2-hydroxyphenyl)heptanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCC(=O)N\N=C\C1=CC=C(C=2C=CC=CC=2)C(F)=C1 LYGILDLOPGSGHR-MTDXEUNCSA-N 0.000 claims 4
- YAXNOENTFQEXAS-MTDXEUNCSA-N n'-[(e)-(4-fluoro-3-phenoxyphenyl)methylideneamino]-n-(2-hydroxyphenyl)heptanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCC(=O)N\N=C\C1=CC=C(F)C(OC=2C=CC=CC=2)=C1 YAXNOENTFQEXAS-MTDXEUNCSA-N 0.000 claims 4
- IOUHSSNRKKUJRS-BUVRLJJBSA-N n'-[(e)-(5-bromo-2-methoxyphenyl)methylideneamino]-n-(2-hydroxyphenyl)octanediamide Chemical compound COC1=CC=C(Br)C=C1\C=N\NC(=O)CCCCCCC(=O)NC1=CC=CC=C1O IOUHSSNRKKUJRS-BUVRLJJBSA-N 0.000 claims 4
- QHYAPZMBKRBZQU-ZMOGYAJESA-N n'-[(e)-(6-bromo-1,3-benzodioxol-5-yl)methylideneamino]-n-(2-hydroxyphenyl)octanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCCC(=O)N\N=C\C(C(=C1)Br)=CC2=C1OCO2 QHYAPZMBKRBZQU-ZMOGYAJESA-N 0.000 claims 4
- CMVDRFFMSYMSRT-UHFFFAOYSA-N n,2-diphenylquinazolin-4-amine Chemical compound N=1C(C=2C=CC=CC=2)=NC2=CC=CC=C2C=1NC1=CC=CC=C1 CMVDRFFMSYMSRT-UHFFFAOYSA-N 0.000 claims 4
- UKBRIGBOECICTE-UHFFFAOYSA-N n,n,8-trimethyl-5h-pyrimido[5,4-b]indol-4-amine Chemical compound C12=CC(C)=CC=C2NC2=C1N=CN=C2N(C)C UKBRIGBOECICTE-UHFFFAOYSA-N 0.000 claims 4
- GTYHUTFJIOHWKO-UHFFFAOYSA-N n,n-diethyl-8-methyl-5h-pyrimido[5,4-b]indol-4-amine Chemical compound C12=CC(C)=CC=C2NC2=C1N=CN=C2N(CC)CC GTYHUTFJIOHWKO-UHFFFAOYSA-N 0.000 claims 4
- HTJMOFNXWGEQDA-UHFFFAOYSA-N n,n-dimethyl-4-(6-methylimidazo[1,2-a]pyridin-2-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CN(C=C(C)C=C2)C2=N1 HTJMOFNXWGEQDA-UHFFFAOYSA-N 0.000 claims 4
- UWSPBYIZLDIQHB-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-7-chloroquinolin-4-amine Chemical compound C1=C2OCOC2=CC(NC=2C3=CC=C(C=C3N=CC=2)Cl)=C1 UWSPBYIZLDIQHB-UHFFFAOYSA-N 0.000 claims 4
- JSZHTHZRYQYAPD-UHFFFAOYSA-N n-(2-hydroxy-4-methylphenyl)-4-(methylsulfanylmethyl)benzamide Chemical compound C1=CC(CSC)=CC=C1C(=O)NC1=CC=C(C)C=C1O JSZHTHZRYQYAPD-UHFFFAOYSA-N 0.000 claims 4
- CXPQGIPRANGQFN-UHFFFAOYSA-N n-(2-hydroxybenzoyl)-2-(4-methylphenoxy)pyridine-3-carboxamide Chemical compound C1=CC(C)=CC=C1OC1=NC=CC=C1C(=O)NC(=O)C1=CC=CC=C1O CXPQGIPRANGQFN-UHFFFAOYSA-N 0.000 claims 4
- PJJXLNVMEVEGKI-UHFFFAOYSA-N n-(2-hydroxybenzoyl)-4-methyl-2-phenyl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=CC=CC=2)SC=1C(=O)NC(=O)C1=CC=CC=C1O PJJXLNVMEVEGKI-UHFFFAOYSA-N 0.000 claims 4
- IXZXHBFNASABNS-NLRVBDNBSA-N n-(2-hydroxyphenyl)-n'-[(e)-naphthalen-1-ylmethylideneamino]octanediamide Chemical compound OC1=CC=CC=C1NC(=O)CCCCCCC(=O)N\N=C\C1=CC=CC2=CC=CC=C12 IXZXHBFNASABNS-NLRVBDNBSA-N 0.000 claims 4
- WZAQJAOJSYRYDC-UHFFFAOYSA-N n-(2-hydroxyphenyl)-n-[(4-methoxyphenyl)methyl]-3-(1,1,3-trioxo-1,2-benzothiazol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1CN(C=1C(=CC=CC=1)O)C(=O)CCN1S(=O)(=O)C2=CC=CC=C2C1=O WZAQJAOJSYRYDC-UHFFFAOYSA-N 0.000 claims 4
- JZDPAQVHVBRUGI-UHFFFAOYSA-N n-(3-bromo-4-hydroxynaphthalen-1-yl)-4-chlorobenzenesulfonamide Chemical compound C12=CC=CC=C2C(O)=C(Br)C=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 JZDPAQVHVBRUGI-UHFFFAOYSA-N 0.000 claims 4
- HVPYAJGZCFPPDK-UHFFFAOYSA-N n-(3-chlorophenyl)-4-(3-oxo-2-phenyl-1h-pyrazol-5-yl)piperidine-1-carbothioamide Chemical compound ClC1=CC=CC(NC(=S)N2CCC(CC2)C=2NN(C(=O)C=2)C=2C=CC=CC=2)=C1 HVPYAJGZCFPPDK-UHFFFAOYSA-N 0.000 claims 4
- HDVVWQQDMUWDIT-UHFFFAOYSA-N n-(3-hydroxypyridin-2-yl)-4-phenoxybenzamide Chemical compound OC1=CC=CN=C1NC(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 HDVVWQQDMUWDIT-UHFFFAOYSA-N 0.000 claims 4
- CNUHVAISLIVBJN-UHFFFAOYSA-N n-(3-imidazo[1,2-a]pyrimidin-2-ylphenyl)cyclopentanecarboxamide Chemical compound C=1C=CC(C=2N=C3N=CC=CN3C=2)=CC=1NC(=O)C1CCCC1 CNUHVAISLIVBJN-UHFFFAOYSA-N 0.000 claims 4
- GJQRWYHEWWJLLL-UHFFFAOYSA-N n-(4-bromophenyl)-2-[(3-cyano-4-methyl-6-oxo-1h-pyridin-2-yl)sulfanyl]acetamide Chemical compound CC1=CC(=O)NC(SCC(=O)NC=2C=CC(Br)=CC=2)=C1C#N GJQRWYHEWWJLLL-UHFFFAOYSA-N 0.000 claims 4
- JHZOEAMDVAOQOJ-UHFFFAOYSA-N n-(4-carbamoylphenyl)-1-phenyl-3-thiophen-2-ylpyrazole-4-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1NC(=O)C1=CN(C=2C=CC=CC=2)N=C1C1=CC=CS1 JHZOEAMDVAOQOJ-UHFFFAOYSA-N 0.000 claims 4
- JMQMBTOFFLLXHD-UHFFFAOYSA-N n-(4-ethylsulfonyl-2-hydroxyphenyl)benzamide Chemical compound OC1=CC(S(=O)(=O)CC)=CC=C1NC(=O)C1=CC=CC=C1 JMQMBTOFFLLXHD-UHFFFAOYSA-N 0.000 claims 4
- RAUPQAQXMISRFW-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(4-hydroxy-2-oxo-1h-quinolin-3-yl)acetamide Chemical compound OC=1NC2=CC=CC=C2C(=O)C=1CC(=O)NC1=CC=C(F)C=C1 RAUPQAQXMISRFW-UHFFFAOYSA-N 0.000 claims 4
- FGCWLLOXWVFLOV-UHFFFAOYSA-N n-(5-ethylsulfonyl-2-hydroxyphenyl)-2-(4-methoxyphenoxy)acetamide Chemical compound CCS(=O)(=O)C1=CC=C(O)C(NC(=O)COC=2C=CC(OC)=CC=2)=C1 FGCWLLOXWVFLOV-UHFFFAOYSA-N 0.000 claims 4
- CJQANEIQSNYREL-UHFFFAOYSA-N n-(5-hydroxynaphthalen-1-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC2=C(O)C=CC=C12 CJQANEIQSNYREL-UHFFFAOYSA-N 0.000 claims 4
- WWHQWVQIQOJOSU-UHFFFAOYSA-N n-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)C1=CC=CS1 WWHQWVQIQOJOSU-UHFFFAOYSA-N 0.000 claims 4
- UKLZHMGBGBIUNC-UHFFFAOYSA-N n-(cyclohexanecarbonyl)-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NC(=O)C1CCCCC1 UKLZHMGBGBIUNC-UHFFFAOYSA-N 0.000 claims 4
- LTHZCLMINLAMQZ-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-(4-hydroxy-2-oxo-1h-quinolin-3-yl)acetamide Chemical compound OC=1NC2=CC=CC=C2C(=O)C=1CC(=O)NCC1=CC=CC=C1Cl LTHZCLMINLAMQZ-UHFFFAOYSA-N 0.000 claims 4
- WZJOJFDQGBQDMF-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-phenyl-3h-benzimidazole-5-sulfonamide Chemical compound ClC1=CC=CC=C1CNS(=O)(=O)C1=CC=C(N=C(N2)C=3C=CC=CC=3)C2=C1 WZJOJFDQGBQDMF-UHFFFAOYSA-N 0.000 claims 4
- WTVPYWLISICORX-JTQLQIEISA-N n-[(2s)-butan-2-yl]-6-methoxyfuro[2,3-b]quinoline-2-carboxamide Chemical compound COC1=CC=C2N=C(OC(C(=O)N[C@@H](C)CC)=C3)C3=CC2=C1 WTVPYWLISICORX-JTQLQIEISA-N 0.000 claims 4
- OLGMRMJENRKJRP-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 OLGMRMJENRKJRP-UHFFFAOYSA-N 0.000 claims 4
- KOOAAKUOFZWUSD-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-(4,4-dimethyl-2,6-dioxocyclohexyl)acetamide Chemical compound O=C1CC(C)(C)CC(=O)C1CC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl KOOAAKUOFZWUSD-UHFFFAOYSA-N 0.000 claims 4
- UULUSOGICWLJPW-UHFFFAOYSA-N n-[2-hydroxy-3-(4-oxochromen-2-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1O UULUSOGICWLJPW-UHFFFAOYSA-N 0.000 claims 4
- QNCXLJHWIBYWBM-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-ylsulfanyl)-4-hydroxyphenyl]benzenesulfonamide Chemical compound C1=C(SC=2SC3=CC=CC=C3N=2)C(O)=CC=C1NS(=O)(=O)C1=CC=CC=C1 QNCXLJHWIBYWBM-UHFFFAOYSA-N 0.000 claims 4
- CZMUKMGKQXFQOQ-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-ylsulfanyl)-4-hydroxyphenyl]thiophene-2-sulfonamide Chemical compound C1=C(SC=2SC3=CC=CC=C3N=2)C(O)=CC=C1NS(=O)(=O)C1=CC=CS1 CZMUKMGKQXFQOQ-UHFFFAOYSA-N 0.000 claims 4
- PEKJYYPPMDIETF-UHFFFAOYSA-N n-[4-(1h-benzimidazol-2-yl)phenyl]-2-(2-methoxyphenyl)acetamide Chemical compound COC1=CC=CC=C1CC(=O)NC1=CC=C(C=2NC3=CC=CC=C3N=2)C=C1 PEKJYYPPMDIETF-UHFFFAOYSA-N 0.000 claims 4
- DEAVYRXCNSSHPG-QMMMGPOBSA-N n-[5-[(2s)-butan-2-yl]sulfanyl-1,3,4-thiadiazol-2-yl]-2-(trifluoromethyl)benzamide Chemical compound S1C(S[C@@H](C)CC)=NN=C1NC(=O)C1=CC=CC=C1C(F)(F)F DEAVYRXCNSSHPG-QMMMGPOBSA-N 0.000 claims 4
- RHVSVZXFVMCNAT-UHFFFAOYSA-N n-[bis[4-(dimethylamino)phenyl]methylidene]hydroxylamine Chemical compound C1=CC(N(C)C)=CC=C1C(=NO)C1=CC=C(N(C)C)C=C1 RHVSVZXFVMCNAT-UHFFFAOYSA-N 0.000 claims 4
- FVJQVTFCHRSIMH-UHFFFAOYSA-N n-benzyl-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NCC1=CC=CC=C1 FVJQVTFCHRSIMH-UHFFFAOYSA-N 0.000 claims 4
- RPDFYILWPXBVRN-UHFFFAOYSA-N n-benzyl-6-[(3-methoxyphenyl)sulfamoyl]-n-methyl-4-oxo-1h-quinoline-3-carboxamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=C3C(=O)C(C(=O)N(C)CC=4C=CC=CC=4)=CNC3=CC=2)=C1 RPDFYILWPXBVRN-UHFFFAOYSA-N 0.000 claims 4
- QNNJXJQMWWOELA-UHFFFAOYSA-N n-phenyl-3-phenyliminoisoindol-1-amine Chemical compound C=1C=CC=CC=1NC(C1=CC=CC=C11)=NC1=NC1=CC=CC=C1 QNNJXJQMWWOELA-UHFFFAOYSA-N 0.000 claims 4
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims 4
- PGOKBMWPBDRDGN-SKFMWMRISA-N propan-2-yl (2s)-2-[[(2s)-2-[(2s,3r)-2-[[(2s)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoate Chemical compound SC[C@@H](N)CN[C@@H]([C@H](C)CC)CO[C@H](C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)CC1=CC=CC=C1 PGOKBMWPBDRDGN-SKFMWMRISA-N 0.000 claims 4
- JGUZGNYPMHHYRK-UHFFFAOYSA-N rhamnetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 JGUZGNYPMHHYRK-UHFFFAOYSA-N 0.000 claims 4
- ZETBOUSTTZXVAL-UHFFFAOYSA-N (2-anilino-2-oxoethyl) 2-(4-chlorobenzoyl)benzoate Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=CC=C1C(=O)OCC(=O)NC1=CC=CC=C1 ZETBOUSTTZXVAL-UHFFFAOYSA-N 0.000 claims 3
- MFTBCXHEICTXTM-XAPLUZPNSA-N (2r,3z)-6-chloro-3-(dimethylaminomethylidene)-2-methylthiochromen-4-one Chemical compound C1=C(Cl)C=C2C(=O)\C(=C\N(C)C)[C@@H](C)SC2=C1 MFTBCXHEICTXTM-XAPLUZPNSA-N 0.000 claims 3
- JXCDWDUKJBIHEU-XSFVSMFZSA-N (5e)-5-[[4-(diethylamino)phenyl]methylidene]-3-[(2-methoxyanilino)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(N(CC)CC)=CC=C1\C=C\1C(=O)N(CNC=2C(=CC=CC=2)OC)C(=O)S/1 JXCDWDUKJBIHEU-XSFVSMFZSA-N 0.000 claims 3
- KSFJMRVFQMIAPZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-[(4-pyridin-3-ylpyrimidin-2-yl)sulfanylmethyl]-4h-pyrazol-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CSC=2N=C(C=CN=2)C=2C=NC=CC=2)=N1 KSFJMRVFQMIAPZ-UHFFFAOYSA-N 0.000 claims 3
- CKETYLIKMVJPGC-UHFFFAOYSA-N 4-hydroxy-3-propyl-1h-quinolin-2-one Chemical compound C1=CC=C2C(=O)C(CCC)=C(O)NC2=C1 CKETYLIKMVJPGC-UHFFFAOYSA-N 0.000 claims 3
- AICWQXZGHCIEFC-UHFFFAOYSA-N 7-hydroxy-5-methyl-3-(1-phenylpyrazol-4-yl)-2-(trifluoromethyl)chromen-4-one Chemical compound O=C1C=2C(C)=CC(O)=CC=2OC(C(F)(F)F)=C1C(=C1)C=NN1C1=CC=CC=C1 AICWQXZGHCIEFC-UHFFFAOYSA-N 0.000 claims 3
- KGKHMIDZXHFCKO-UHFFFAOYSA-N chembl1502749 Chemical compound C1=C(O)C(CC)=CC(C=2C(=CNN=2)C=2N(C3=CC=CC=C3N=2)C)=C1O KGKHMIDZXHFCKO-UHFFFAOYSA-N 0.000 claims 3
- MHVHZKJQOOJSQV-UHFFFAOYSA-N ethyl 4-[(2-anilino-2-oxoethyl)sulfanylmethyl]-5-hydroxy-2-phenyl-1-benzofuran-3-carboxylate Chemical compound C=12C(C(=O)OCC)=C(C=3C=CC=CC=3)OC2=CC=C(O)C=1CSCC(=O)NC1=CC=CC=C1 MHVHZKJQOOJSQV-UHFFFAOYSA-N 0.000 claims 3
- ARSRJFRKVXALTF-UHFFFAOYSA-N tricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 ARSRJFRKVXALTF-UHFFFAOYSA-N 0.000 claims 3
- OJLYEMIKKNONNE-UHFFFAOYSA-N 3-(2-anilino-2-oxoethyl)-2-(4-chlorobenzoyl)benzoic acid Chemical compound C1=CC=C(C=C1)NC(=O)CC2=C(C(=CC=C2)C(=O)O)C(=O)C3=CC=C(C=C3)Cl OJLYEMIKKNONNE-UHFFFAOYSA-N 0.000 claims 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 45
- 102000036639 antigens Human genes 0.000 abstract description 45
- 239000000427 antigen Substances 0.000 abstract description 43
- 239000000203 mixture Substances 0.000 abstract description 39
- 238000011161 development Methods 0.000 abstract description 28
- 230000009545 invasion Effects 0.000 abstract description 28
- 239000000853 adhesive Substances 0.000 abstract description 16
- 230000001070 adhesive effect Effects 0.000 abstract description 16
- 229940021995 DNA vaccine Drugs 0.000 abstract description 12
- 238000006116 polymerization reaction Methods 0.000 abstract description 12
- 230000000890 antigenic effect Effects 0.000 abstract description 10
- 238000006386 neutralization reaction Methods 0.000 abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 229940023143 protein vaccine Drugs 0.000 abstract description 2
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011005 laboratory method Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 262
- 235000018102 proteins Nutrition 0.000 description 262
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 242
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 188
- 108090000765 processed proteins & peptides Proteins 0.000 description 102
- 102000004196 processed proteins & peptides Human genes 0.000 description 81
- 229960005486 vaccine Drugs 0.000 description 74
- 150000007523 nucleic acids Chemical group 0.000 description 70
- 125000003275 alpha amino acid group Chemical group 0.000 description 67
- 241000223960 Plasmodium falciparum Species 0.000 description 65
- 210000003046 sporozoite Anatomy 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 63
- 230000000694 effects Effects 0.000 description 56
- 210000005229 liver cell Anatomy 0.000 description 49
- 230000015572 biosynthetic process Effects 0.000 description 48
- 229920001184 polypeptide Polymers 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 47
- 150000001413 amino acids Chemical class 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 40
- 102000039446 nucleic acids Human genes 0.000 description 34
- 108020004707 nucleic acids Proteins 0.000 description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 description 33
- 239000013598 vector Substances 0.000 description 33
- 101710172176 Fasciclin-1 Proteins 0.000 description 31
- 230000028993 immune response Effects 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 30
- 238000003556 assay Methods 0.000 description 30
- 230000018109 developmental process Effects 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 26
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 25
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 25
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 23
- 238000005516 engineering process Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 208000030852 Parasitic disease Diseases 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 230000001404 mediated effect Effects 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- 238000002649 immunization Methods 0.000 description 19
- 235000013305 food Nutrition 0.000 description 18
- 210000003934 vacuole Anatomy 0.000 description 18
- 102000001554 Hemoglobins Human genes 0.000 description 17
- 108010054147 Hemoglobins Proteins 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 241000223830 Plasmodium yoelii Species 0.000 description 15
- 230000002238 attenuated effect Effects 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 239000008188 pellet Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
- 108010041986 DNA Vaccines Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 241000223810 Plasmodium vivax Species 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 101710117490 Circumsporozoite protein Proteins 0.000 description 10
- 101710104031 Thrombospondin-related anonymous protein Proteins 0.000 description 10
- 230000021164 cell adhesion Effects 0.000 description 10
- 230000004709 cell invasion Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000008506 pathogenesis Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 208000009182 Parasitemia Diseases 0.000 description 8
- 229960003677 chloroquine Drugs 0.000 description 8
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 8
- 210000000172 cytosol Anatomy 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 238000000386 microscopy Methods 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002823 phage display Methods 0.000 description 8
- 229920002704 polyhistidine Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 241000224017 Plasmodium berghei Species 0.000 description 7
- 241000223801 Plasmodium knowlesi Species 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 7
- 210000003000 inclusion body Anatomy 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 229940125575 vaccine candidate Drugs 0.000 description 7
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 6
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000255925 Diptera Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010022901 Heparin Lyase Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000223992 Plasmodium gallinaceum Species 0.000 description 6
- 241000223808 Plasmodium reichenowi Species 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000013537 high throughput screening Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008001 CAPS buffer Substances 0.000 description 5
- 101100532584 Clostridium perfringens (strain 13 / Type A) sspC1 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101100095550 Homo sapiens SENP7 gene Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 101150098865 SSP2 gene Proteins 0.000 description 5
- 102100031406 Sentrin-specific protease 7 Human genes 0.000 description 5
- 229940033495 antimalarials Drugs 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 238000002716 delivery method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 210000003956 transport vesicle Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102100034612 Annexin A4 Human genes 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 description 4
- 101150103621 HDP gene Proteins 0.000 description 4
- 101710169678 Histidine-rich protein Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 4
- 241000223779 Theileria parva Species 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 239000003596 drug target Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000001641 gel filtration chromatography Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102100035406 Cysteine desulfurase, mitochondrial Human genes 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 101001023837 Homo sapiens Cysteine desulfurase, mitochondrial Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 208000000474 Poliomyelitis Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 241000223778 Theileria annulata Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000002095 exotoxin Substances 0.000 description 3
- 231100000776 exotoxin Toxicity 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000009650 gentamicin protection assay Methods 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000000111 isothermal titration calorimetry Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000010807 negative regulation of binding Effects 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 210000004929 secretory organelle Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 229940031572 toxoid vaccine Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- FIXDIFPJOFIIEC-RITPCOANSA-N (3r)-3-hydroxy-n-[(3s)-2-oxooxolan-3-yl]butanamide Chemical compound C[C@@H](O)CC(=O)N[C@H]1CCOC1=O FIXDIFPJOFIIEC-RITPCOANSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HTWMTDKMOSSPMU-UHFFFAOYSA-N 1,2-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)C=NOC2=C1 HTWMTDKMOSSPMU-UHFFFAOYSA-N 0.000 description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 2
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- SDECALZHPDNOHC-UHFFFAOYSA-N 5h-pyrimido[5,4-b]indol-4-amine Chemical compound C12=CC=CC=C2NC2=C1N=CN=C2N SDECALZHPDNOHC-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102100031607 Kunitz-type protease inhibitor 1 Human genes 0.000 description 2
- 101710165137 Kunitz-type protease inhibitor 1 Proteins 0.000 description 2
- 101710165138 Kunitz-type protease inhibitor 2 Proteins 0.000 description 2
- 102100039020 Kunitz-type protease inhibitor 2 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710203389 Outer membrane porin F Proteins 0.000 description 2
- 101710160104 Outer membrane protein F Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241001442539 Plasmodium sp. Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 208000001117 Theileriasis Diseases 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 244000042288 Trichotosia annulata Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000012452 Xenomouse strains Methods 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 101150078331 ama-1 gene Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 108010051269 heme polymerase Proteins 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007110 pathogen host interaction Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000037369 susceptibility to malaria Diseases 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 1
- NJQRAAHKQQPUIT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CNC1 NJQRAAHKQQPUIT-UHFFFAOYSA-N 0.000 description 1
- TWCKZRPQNIFPKA-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxamide Chemical compound C1=CC=C2CC(C(=O)N)=CNC2=C1 TWCKZRPQNIFPKA-UHFFFAOYSA-N 0.000 description 1
- YLTWLZKMMXUOMC-UHFFFAOYSA-N 1-(1,3-thiazol-2-yl)pyridin-2-one Chemical compound O=C1C=CC=CN1C1=NC=CS1 YLTWLZKMMXUOMC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IRSPCJLMPFDMGD-UHFFFAOYSA-N 1-hydroxybenzimidazole Chemical compound C1=CC=C2N(O)C=NC2=C1 IRSPCJLMPFDMGD-UHFFFAOYSA-N 0.000 description 1
- NFNIRGPPIRJASP-UHFFFAOYSA-N 1-hydroxyquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(O)C2=C1 NFNIRGPPIRJASP-UHFFFAOYSA-N 0.000 description 1
- UJDGVHVIOMSXMR-UHFFFAOYSA-N 1-phenylpyrazolo[3,4-b]pyridine Chemical compound C12=NC=CC=C2C=NN1C1=CC=CC=C1 UJDGVHVIOMSXMR-UHFFFAOYSA-N 0.000 description 1
- PWKSXJWFZTYXJC-UHFFFAOYSA-N 1h-benzo[g]indole-3-carboxylic acid Chemical compound C1=CC2=CC=CC=C2C2=C1C(C(=O)O)=CN2 PWKSXJWFZTYXJC-UHFFFAOYSA-N 0.000 description 1
- KAUABWYBFARJAF-UHFFFAOYSA-N 1h-pyrazol-4-ol Chemical compound OC=1C=NNC=1 KAUABWYBFARJAF-UHFFFAOYSA-N 0.000 description 1
- KGVPNVYKWGRCHO-UHFFFAOYSA-N 1h-pyrrolo[2,1-c][1,4]oxazine Chemical compound C1OC=CN2C=CC=C12 KGVPNVYKWGRCHO-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- ROEBZXSZCODZCO-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound C1=CC=C2C3CC(C(=O)O)NCC3=NC2=C1 ROEBZXSZCODZCO-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- CUOCFYGQAWZNBQ-UHFFFAOYSA-N 2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=CC=C2N(C(=O)N)CCOC2=C1 CUOCFYGQAWZNBQ-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- WLFCMWZKAJJZMR-UHFFFAOYSA-N 2-(4-methylphenyl)-3h-isoindol-1-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C2=CC=CC=C2C1 WLFCMWZKAJJZMR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- QVCRGJALYOLXDC-UHFFFAOYSA-N 2-chloroquinolin-4-amine Chemical compound C1=CC=C2C(N)=CC(Cl)=NC2=C1 QVCRGJALYOLXDC-UHFFFAOYSA-N 0.000 description 1
- ZKPVBDCWESAKGC-UHFFFAOYSA-N 2-ethoxybenzenesulfonamide Chemical compound CCOC1=CC=CC=C1S(N)(=O)=O ZKPVBDCWESAKGC-UHFFFAOYSA-N 0.000 description 1
- QCHYXCVMLLIGTA-UHFFFAOYSA-N 2-ethoxyquinoline-3-carboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(OCC)=NC2=C1 QCHYXCVMLLIGTA-UHFFFAOYSA-N 0.000 description 1
- MNWSGMTUGXNYHJ-UHFFFAOYSA-N 2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(N)=O MNWSGMTUGXNYHJ-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- AQSRRZGQRFFFGS-UHFFFAOYSA-N 2-methylpyridin-3-ol Chemical compound CC1=NC=CC=C1O AQSRRZGQRFFFGS-UHFFFAOYSA-N 0.000 description 1
- CJCOBMTYEDBBSY-UHFFFAOYSA-N 2-phenoxybenzamide Chemical compound NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 CJCOBMTYEDBBSY-UHFFFAOYSA-N 0.000 description 1
- HTNDATZONOWSFF-UHFFFAOYSA-M 2-phenyl-1h-indole-3-carboxylate Chemical compound N1C2=CC=CC=C2C(C(=O)[O-])=C1C1=CC=CC=C1 HTNDATZONOWSFF-UHFFFAOYSA-M 0.000 description 1
- IZPUPXNVRNBDSW-UHFFFAOYSA-N 2-phenylbutanenitrile Chemical compound CCC(C#N)C1=CC=CC=C1 IZPUPXNVRNBDSW-UHFFFAOYSA-N 0.000 description 1
- WNYJRJRHKRZXEO-UHFFFAOYSA-N 2-propan-2-ylbenzene-1,4-diamine Chemical compound CC(C)C1=CC(N)=CC=C1N WNYJRJRHKRZXEO-UHFFFAOYSA-N 0.000 description 1
- OLYNYFQPPNPFSP-UHFFFAOYSA-N 2-pyridin-2-ylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=N1 OLYNYFQPPNPFSP-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- WTAVYBAEMMFITK-UHFFFAOYSA-N 3,4-dihydro-2h-1,3-benzoxazine Chemical compound C1=CC=C2OCNCC2=C1 WTAVYBAEMMFITK-UHFFFAOYSA-N 0.000 description 1
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 description 1
- LUZCIQGVIMIORG-UHFFFAOYSA-N 3-phenyl-3,4-dihydrochromen-2-one Chemical compound O=C1OC2=CC=CC=C2CC1C1=CC=CC=C1 LUZCIQGVIMIORG-UHFFFAOYSA-N 0.000 description 1
- ZQKGKAKJYABQAK-UHFFFAOYSA-N 4-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=CC(CO)=C1O ZQKGKAKJYABQAK-UHFFFAOYSA-N 0.000 description 1
- DANLZOIRUUHIIX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DANLZOIRUUHIIX-UHFFFAOYSA-N 0.000 description 1
- QGMGHALXLXKCBD-UHFFFAOYSA-N 4-amino-n-(2-aminophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=CC=C1N QGMGHALXLXKCBD-UHFFFAOYSA-N 0.000 description 1
- HHHDJHHNEURCNV-UHFFFAOYSA-N 4-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C=C1 HHHDJHHNEURCNV-UHFFFAOYSA-N 0.000 description 1
- OWBBAPRUYLEWRR-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=C2OC(O)=CC(=O)C2=C1 OWBBAPRUYLEWRR-UHFFFAOYSA-N 0.000 description 1
- RXYIYUOOCZCTQP-UHFFFAOYSA-N 5-methylpyrimidine-2,4-diamine Chemical compound CC1=CN=C(N)N=C1N RXYIYUOOCZCTQP-UHFFFAOYSA-N 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- 102220510810 APC membrane recruitment protein 1_F90A_mutation Human genes 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PSXIAMJLDYXXFC-UHFFFAOYSA-N C1=CC=C2N=C(OC(C(=O)N)=C3)C3=CC2=C1 Chemical compound C1=CC=C2N=C(OC(C(=O)N)=C3)C3=CC2=C1 PSXIAMJLDYXXFC-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 102100024170 Cyclin-C Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102220472023 Delta-aminolevulinic acid dehydratase_H44A_mutation Human genes 0.000 description 1
- 102220472020 Delta-aminolevulinic acid dehydratase_H79A_mutation Human genes 0.000 description 1
- 101000802895 Dendroaspis angusticeps Fasciculin-1 Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108700004922 F42A Proteins 0.000 description 1
- 229940124895 FluMist Drugs 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 101710169603 Hemoglobin-1 Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000980770 Homo sapiens Cyclin-C Proteins 0.000 description 1
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102220467370 Hypoxia-inducible lipid droplet-associated protein_Y39A_mutation Human genes 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- WQZGKKKJIJFFOK-ZNVMLXAYSA-N L-idopyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-ZNVMLXAYSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 102220567325 Lipoprotein lipase_F64A_mutation Human genes 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- JWTQCDGFHZWWRT-UHFFFAOYSA-N Oc1ccnn1C(F)(F)F Chemical compound Oc1ccnn1C(F)(F)F JWTQCDGFHZWWRT-UHFFFAOYSA-N 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N Oxindol Natural products C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000053208 Porcellio laevis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101710192036 Sporozoite surface protein 2 Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- WZJYKHNJTSNBHV-UHFFFAOYSA-O benzo[h]quinolin-1-ium Chemical compound C1=C[NH+]=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-O 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004197 benzothien-3-yl group Chemical group [H]C1=C(*)C2=C([H])C([H])=C([H])C([H])=C2S1 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- ISYJGPYKJNWIQE-BNOMVYTKSA-N butyl (2r)-2-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O ISYJGPYKJNWIQE-BNOMVYTKSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- SCNUFWNKVSUNIP-UHFFFAOYSA-N chembl32526 Chemical compound C1=CC=C2C(=O)C(O)=C(O)OC2=C1 SCNUFWNKVSUNIP-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- WGHKKEJHRMUKDK-UHFFFAOYSA-N cyclohexa-2,5-dien-1-one Chemical compound O=C1C=CCC=C1 WGHKKEJHRMUKDK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960005097 diphtheria vaccines Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126576 edible vaccine Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000004050 enoyl group Chemical group 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 210000000020 growth cone Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 108091022907 heme binding Proteins 0.000 description 1
- 102000028546 heme binding Human genes 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 108091012216 heparin binding proteins Proteins 0.000 description 1
- 102000022382 heparin binding proteins Human genes 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000001832 mitochondrialike Effects 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 108700017543 murabutide Proteins 0.000 description 1
- 229950009571 murabutide Drugs 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- IMVBLMFOMDOSHL-UHFFFAOYSA-N n-(2-methoxyphenyl)-3-phenylpropanamide Chemical compound COC1=CC=CC=C1NC(=O)CCC1=CC=CC=C1 IMVBLMFOMDOSHL-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940127241 oral polio vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- UERQMZVFUXRQOD-UHFFFAOYSA-N piperidine-1-carbothioamide Chemical compound NC(=S)N1CCCCC1 UERQMZVFUXRQOD-UHFFFAOYSA-N 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-M quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-M 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- XSQUNQSLEIFIHF-UHFFFAOYSA-N s-(4-methylphenyl) ethanethioate Chemical compound CC(=O)SC1=CC=C(C)C=C1 XSQUNQSLEIFIHF-UHFFFAOYSA-N 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/445—Plasmodium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention generally relates to therapies for the treatment and prevention of certain parasitic diseases.
- the invention provides method of inhibiting the ability of Heme Detoxification Protein (HDP) to form hemozoin from heme, thereby treating or preventing diseases caused by Plasmodium and/or Theileria species.
- HDP Heme Detoxification Protein
- Malaria infection starts with the introduction of Plasmodium sporozoites into the blood stream of its human host, when it is bitten by an infected mosquito.
- P. falciparum is the most virulent—resulting in severe anemia and cerebral malaria, which can be fatal.
- Fewer than 200 sporozoites are introduced and even fewer succeed in invading liver cells, the target organ for the onset of malaria infection in a host.
- a successful adhesion and liver cell invasion by the sporozoite is critical for this onset and is therefore, the Achilles heel of the parasite.
- the parasite Once inside the liver cell, the parasite rapidly multiplies and within a few days releases thousands of parasites, which leads to the clinical pathology of this disease.
- an ideal approach to control malaria is to develop a vaccine or therapeutic, which either prevents the sporozoite from infecting liver cells or destroys the parasite during liver stages of its life cycle.
- a vaccine is feasible as animals and human volunteers immunized with Plasmodium sporozoites that have been attenuated by exposure to X-Ray or gamma radiation, are protected when subsequently challenged with infectious sporozoites (Hoffman, et al. (2002) J Infect Dis, 1155-1164; Nussenzweig et al. (1967) Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature, 216, 160-162.).
- antigen(s) selected as a vaccine candidate in a given pathosystem are (i) present on the surface of the pathogen, (ii) are generally involved in host-pathogen interactions and are therefore, one of the first molecules that are recognized by the host immune system (Moxon, R. and Rappuoli, R. (2002) Br Med Bull, 62, 45-58).
- CSP Circumsporozoite protein
- TRIP Thrombospondin-related anonymous protein
- the Plasmodium parasite Upon entering red blood cells, the Plasmodium parasite undergoes rapid multiplication giving rise to 28-32 parasites in less than 48 hours. Hemoglobin represents ⁇ 95% of the total RBC content, and the parasite digests up to 75% of the hemoglobin, which serves as its source of amino acids. While this process of hemoglobin digestion provides the parasite with a ready source of amino acids, it also releases free heme, which in the absence of a globin moiety, is extremely toxic for the parasite (Gluzman, et al. (1994) J Clin Invest, 93, 1602-1608.).
- hemozoin a non-toxic and polymerized product known as hemozoin, which is chemically identical to ⁇ -hematin (Francis,et al. (1997) Annu Rev Microbiol, 51, 97-123.
- Most of the currently available antimalarials have been shown to be binding to free heme, which inhibits its polymerization, and the toxicity resulting from the free heme causes the death of the parasite (Slater and Cerami (1992) Nature, 355, 167-169). Therefore, pathway(s) that lead to hemozoin formation are extremely attractive drug targets. Unfortunately, the mechanism(s) in use by the parasite for the polymerization process is poorly understood.
- FRAP Fesciclin Related Adhesive Protein
- HDP Heme Detoxification Protein
- FRAP catalyzes the neutralization of toxic heme into non-toxic hemozoin.
- FRAP HDP
- Such therapies may include, for example, the use of compounds that bind to the HDP protein to either prevent the binding of heme, or to prevent the conversion of bound heme to hemozoin.
- Such therapies may involve the use of compounds that bind to heme to prevent it from binding to HDP, or to prevent its conversion to hemozoin after binding. The details of these and other mechanisms of action are described in detail below.
- the present invention provides a composition for eliciting an immune response to Plasmodium .
- the composition comprises a substantially purified synthesized or recombinant protein comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a substantially purified synthesized or recombinant protein comprising an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25.
- the composition may further include at least one of: one or more additional antigens, and one or more adjuvants.
- the composition may further include one or more additional peptides, polypeptides or proteins each of which is different from said substantially purified synthesized or recombinant protein.
- the invention also provides a composition for eliciting an immune response to Plasmodium , which comprises a substantially purified synthesized or recombinant peptide, polypeptide or protein comprising an amino acid sequence represented by SEQ ID NO: 37.
- the substantially purified synthesized or recombinant peptide, polypeptide or protein may comprise an amino acid sequence represented by SEQ ID NO: 24, or an amino acid sequence that displays at least about 85% identity to SEQ ID NO: 24.
- the composition may further include at least one of: one or more additional antigens, and one or more adjuvants.
- the composition may further include one or more additional peptides, polypeptides or proteins each of which is different from the substantially purified synthesized or recombinant peptide, polypeptide or protein.
- the invention provides a vaccine comprising a substantially purified synthesized or recombinant protein comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a substantially purified synthesized or recombinant protein comprising an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25.
- the vaccine may further include at least one of one or more additional antigens, and one or more adjuvants.
- the invention provides a vaccine comprising a substantially purified synthesized or recombinant peptide, polypeptide or protein comprising an amino acid sequence represented by SEQ ID NO: 37.
- the substantially purified synthesized or recombinant peptide, polypeptide or protein may comprise an amino acid sequence represented by SEQ ID NO: 24, or an amino acid sequence that is at least 85% identical to SEQ ID NO: 24.
- the vaccine may include at least one of: one or more additional antigens, and one or more adjuvants.
- the vaccine may further include one or more additional peptides, polypeptides or proteins each of which is different from the substantially purified synthesized or recombinant peptide, polypeptide or protein.
- the invention provides a substantially purified synthesized or recombinantly produced antibody specific for: a protein with an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a protein with an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25.
- the antibody is chimeric, humanized, or fully human.
- the invention provides a substantially purified synthesized or recombinantly produced antibody specific for: a peptide with an amino acid sequence represented by SEQ ID NO: 37, or a peptide with an amino acid sequence represented by SEQ ID NO: 24.
- the antibody is chimeric, humanized, or fully human.
- the invention further provides a transfected cell comprising expressable recombinant DNA that encodes: one or more of a peptide, polypeptide or protein which is or includes an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 37; or one or more of a peptide, polypeptide or protein which is or includes an amino acid sequences that displays at least 90% identity with one or more of SEQ ID NO: 1, SEQ ID NO: 25, or SEQ ID NO: 37, or at least about 85% identity with SEQ ID NO: 24.
- such transfected cells are used to elicit an immune response and/or to serve as a vaccine.
- the invention provides a method of treating or preventing a disease caused by a Plasmodium parasite in a patient in need thereof.
- the method comprises the step of administering to the patient one or more antibodies specific for one or more amino acid sequences represented by SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 37.
- the antibody may be synthesized or recombinantly produced.
- the invention provides a method of eliciting an immune response to a Plasmodium parasite in a patient in need thereof.
- the method comprises the step of administering to the patient one or more peptides, polypeptides or proteins which comprise one or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 37, and amino acid sequences which display at least 90% identity with SEQ ID NO: 1, SEQ ID NO: 25, SEQ ID NO: 37, or at least about 85% identity with SEQ ID NO: 24.
- the peptides, polypeptides or proteins may be synthesized or recombinantly produced.
- the invention provides a method of treating or preventing a disease caused by a Plasmodium or Theileria parasite in a patient in need thereof.
- the method comprises the step of administering to the patient a compound that inhibits FRAP protein.
- the patient is an animal.
- the compound is an antibody.
- the compound interacts with a peptide, polypeptide protein that comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37.
- the compound may bind to or interact with one or more of amino acid residues F42, H44 and H122 of FRAP protein encoded by SEQ ID NOS: 1, 7 and 11, or with one or more equivalent amino acid residues in other FRAP proteins, i.e.
- amino acid residues that fulfill the same or a similar function in another FRAP protein such as the proteins encoded by SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19.
- the invention provides a whole organism vaccine against a parasite.
- the vaccine comprises an attenuated parasite which is unable to produce a fully functional FRAP protein.
- the attenuated parasite may include one or more mutations or deletions in a coding region that encodes the fully functional FRAP protein.
- One or more mutations may be in a coding region that encodes the fully functional FRAP protein at a site which encodes for an amino acid residue selected from the group consisting of phenylalanine 42, histidine 44, phenylalanine 64, histidine 79, phenylalanine 90, histidine 122, cysteine 191, histidine 192 and histidine 197 of FRAP proteins encoded by SEQ ID NOS: 1, 7 and 11, or the equivalent amino acid residues in other FRAP proteins, i.e.
- the parasite is unable to produce a fully functional FRAP protein due to RNA silencing. In another embodiment, the parasite is unable to produce normal levels of a fully functional FRAP protein due to attenuation of a promoter that is operably linked to DNA encoding FRAP.
- the invention also provides a method for high throughput screening for antimalarial agents that inhibit the conversion of heme to hemozoin.
- the method comprises the steps of: providing a potential antimalarial agent; determining a first level of conversion of heme substrate to hemozoin by FRAP in the presence of said potential antimalarial agent, and a second level of conversion of heme substrate to hemozoin by FRAP in the absence of said potential antimalarial agent; and comparing said first level of conversion to said second level of conversion, wherein if said second level of said conversion is higher than said first level of conversion, said potential antimalarial agent inhibits the conversion of heme to hemozoin.
- FRAP has one or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.
- the invention also provides a method for expression and purification of a recombinant protein.
- the method comprises the step of providing a vector that operably encodes the recombinant protein, wherein said recombinant protein comprises one or more of SEQ ID NO: 1 or SEQ ID NO: 25.
- the recombinant protein may be a fusion protein, and may comprise one or more copies of SEQ ID NO: 24 or SEQ ID NO: 37.
- the vector may also encode an antigen such as CSP or TRAP.
- the invention also provides a method for diagnosing prior exposure to Plasmodium or Theileria .
- the method comprises the steps of: obtaining a biological sample from a patient and determining whether at least one of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37, or an antibody to at least one of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37 is present in said biological sample.
- the invention also provides a diagnostic assay for determining exposure to Plasmodium or Theileria , comprising: one or more substances capable of selectively binding i) at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37; or ii) an antibody to at least one of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37; and one or more labels which are activated upon binding by said one or more substances.
- the invention also provides a method for identifying compounds that inhibit heme neutralization by FRAP.
- the method comprises the steps of a) contacting FRAP, or an extract containing FRAP, with a known amount of heme, in the presence or absence of a known dilution of a test compound; and b) quantitating a percent inhibition of said heme neutralization by said test compound by comparing differences in said heme neutralization in the presence and absence of said test compound.
- FRAP may have one or more amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.
- the invention also provides a method for diagnosing exposure (prior or ongoing) to Plasmodium or Theileria .
- the method comprises the steps of: obtaining a biological sample from a patient and determining whether at least one of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 38, is present in said biological sample.
- the step of determining may be performed using polymerase chain reaction.
- the invention also provides a diagnostic kit or assay for determining exposure (prior or ongoing) to Plasmodium or Theileria .
- the kit or assay comprises: one or more nucleic acids which hybridize to one or more nucleic acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 39; and a mechanism for detecting hybridization.
- the kit may further comprise means for quantifying an amount of hybridization, and the one or more nucleic acids may be bound to a substrate, such as a biochip.
- the invention further provides a composition for eliciting an immune response to Plasmodium .
- the composition comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 1. SEQ ID NO: 7 or SEQ ID NO: 25.
- the nucleic acid sequence may be SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26 or a sequence that displays at least 90% homology to SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26.
- the composition may contain one or more adjuvants.
- the composition may contain a nucleic acid encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26.
- the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- the invention also provides a composition for eliciting an immune response to Plasmodium which comprises a nucleic acid sequence encoding the amino acid sequence represented by SEQ ID NO: 37.
- the nucleic acid sequence comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 24.
- the nucleic acid sequence may be SEQ ID NO: 38 or SEQ ID NO: 39, or a sequence that displays at least 90% homology to SEQ ID NO: 38, or a sequence that displays at least 85% homology to SEQ ID NO: 39.
- composition may contain one or more adjuvants, and may further comprise nucleic acids encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 38 or SEQ ID NO: 39.
- nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- the invention also provides a vaccine for eliciting an immune response to Plasmodium , the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 7 or SEQ ID NO: 25.
- the nucleic acid sequence is SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26, or a sequence that displays at least 90% homology to SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26.
- the composition may contain one or more adjuvants, and may comprise a nucleic acid encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26.
- the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- the invention further provides a vaccine for eliciting an immune response to Plasmodium , the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 37.
- the nucleic acid sequence comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 24.
- the nucleic acid sequence may be SEQ ID NO: 38 or SEQ ID NO: 39, or a sequence that displays at least 90% homology to SEQ ID NO: 38, or a sequence that displays at least 85% homology to SEQ ID NO: 39.
- the composition may contain one or more adjuvants, and may comprise nucleic acids encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 38 or SEQ ID NO: 39.
- the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- the invention further provides a vaccine for eliciting an immune response to Theileria , the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 17 or SEQ ID NO: 19.
- the nucleic acid sequence is SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence that displays at least 90% homology to SEQ ID NO: 18 or SEQ ID NO: 20.
- the invention further provides a method of treating or preventing a disease caused by a Plasmodium or Theileria parasite in an individual in need thereof.
- the method comprises the step of inhibiting interaction of heme and Heme Detoxification Protein (HDP) in the individual.
- HDP Heme Detoxification Protein
- Such individuals are typically mammals, and can be of any species that are susceptible to infection by Plasmodium or Theileria parasites, e.g. humans, cows, etc.
- the step of inhibiting is carried out by administering to the individual one or more compounds that inhibit interaction of heme and HDP.
- the one or more compounds bind to heme and may, for example, 1) prevent heme from binding to HDP, or 2) allow the binding of heme to HDP but prevent detoxification of heme by HDP.
- the one or more compounds bind to HDP and may, for example, 1) prevent binding of heme to HDP, 2) prevent the production of hemozoin from bound heme, 3) bind at the active site of HDP, or 4) bind at an allosteric site of HDP.
- the step of inhibiting is carried out by modification of a cell membrane of the Plasmodium or Theileria parasite. In yet another embodiment, the step of inhibiting is carried out by inhibiting secretion of HDP from the Plasmodium or Theileria parasite.
- the disease that is treated or prevented is malaria.
- the compound may be administered to an individual in combination with one or more of: an additional antimalarial agent, an agent for reversing antimalarial resistance, and an adjuvant. Administration of the compound may be prior to, concurrent with, or subsequent to administration of the additional antimalarial agent or said agent for reversing antimalarial resistance.
- Suitable additional antimalarial agents include a) quinolines, b) folic acid antagonists, c) sulfonamides, and d) antibiotics.
- Suitable agents for reversing antimalarial resistance are, for example, inhibitors of multidrug resistance. Administration may be accomplished, for example, orally, parenterally, sublingually, rectally, topically or with an inhalation spray.
- the invention further provides a method of treating an individual infected with Plasmodium or Theileria or who has been or will be exposed to Plasmodium or Theileria ,
- the method comprises the step of providing the individual with one or more compounds that inhibit the ability of HDP to produce hemozoin from heme.
- the one or more compounds bind to heme and may, for example, 1) prevent heme from binding to HDP, or 2) allow the binding of heme to HDP but prevent detoxification of heme by HDP.
- the one or more compounds bind to HDP and may, for example, 1) prevent binding of heme to HDP, 2) prevent the production of hemozoin from bound heme, 3) bind at the active site of HDP, or 4) bind at an allosteric site of HDP.
- the invention further provides a method for identifying compounds that inhibit HDP expression.
- the method comprises the steps of a) contacting Plasmodium with a test compound and b) determining whether the Plasmodium expresses HDP.
- the step of determining may be carried out, for example, by measuring mRNA or by measuring HDP.
- the invention further provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an antimalarially effective amount of at least one compound selected Table 11 below.
- FIG. 1A -J This figure shows the amino acid sequences of the FRAP protein in a variety of organisms as follows: A, Plasmodium falciparum ; B, Plasmodium vivax ; C, Plasmodium gallinaceum ; D, Plasmodium knowlesi ; E, Plasmodium vraowi ; F, Plasmodium yoelii ; G, Plasmodium berghei ; H, Plasmodium chaubaudi ; I, Theileria parva , and J, Theileria annulata.
- FIG. 2A -J This figure shows the nucleic acid sequences that encode the FRAP protein in a variety of organisms as follows: A, Plasmodium falciparum ; B, Plasmodium vivax ; C, Plasmodium gallinaceum ; D, Plasmodium knowlesi ; E, Plasmodium vraowi ; F, Plasmodium yoelii ; G, Plasmodium berghei ; H, Plasmodium chaubaudi ; I, Theileria parva , and J, Theileria annulata .
- the sequences represent the coding sequence of FRAP from different parasites.
- the gene itself is present on three separate exons and the sequence provided below is intron-free and represents only the coding sequence of the protein.
- FIG. 3 Multiple sequence alignment of FRAP from Plasmodium and Theileria parasites. Sequences were aligned using the Clustal W algorithm. Amino acids in bold (60 total) represent residues that are conserved across the two genera of phylum apicomplexa. Residues marked with an asterisk represent amino acid positions that are identical only in the Plasmodial genus. Overall, the Plasmodial sequences have 60% sequence identity. FAS1 domain of FRAP has been aligned with the consensus sequence of FAS1 domain (SEQ ID NO: 21) and has an e-value of 2e-10. The two conserved motifs have been underlined.
- FIG. 4 Schematic representation of P. falciparum FRAP gene organization and the expressed recombinant proteins.
- FRAP represents the full length protein encoding 205 amino acids.
- FRAP 2 represents a truncated version of the full length protein containing only amino acids 1-87, while FRAP 3 represents amino acids 88-205, encoding the Fasciclin 1 domain.
- B RT-PCR analysis of PfFRAP. DNA encoding the coding region of FRAP was amplified by RT-PCR using total RNA from sporozoite stage of the parasite's lifecycle.
- FRAP proteins Full-length FRAP (lane 1) and its truncated variants, FRAP2 (lane 2) and FRAP3 (lane 3) were purified to homogeneity by a two step chromatography.
- D Western Blot analysis. Purified proteins were resolved on a 12% Nu-PAGE gel; transferred onto a nitrocellulose membrane and the membrane was probed using anti-FRAP2 antibody followed by an anti-mouse HRP conjugate.
- FIG. 5 Binding analysis of FRAP proteins on HepG2 cells. Five different concentrations of recombinant proteins were investigated for their potential to bind to liver cells. Bound protein was detected using anti-polyhistidine monoclonal followed by the addition of anti-mouse alkaline phosphatase conjugate and a fluorescent substrate. Fluorescence was measured using a plate reader with excitation at 350 nm and emission at 460 nm. Black bars: CS protein; Hashed bars: FRAP; Grey bars: FRAP2; White bars: FRAP3.
- FIG. 6 Nature of FRAP receptor on liver cells. Binding activity of the FRAP proteins was evaluated on liver cells in the absence or presence of different concentrations of heparin and Chondroitin sulfate A.
- Panel A FRAP
- Panel B FRAP2. Blank and hashed bars represent inhibition of binding activity in the presence of different concentrations of heparin and chondroitin sulfate A, respectively.
- FIG. 7 Overlap between FRAP-based peptides. Ten overlapping peptides spanning the FRAP2 sequence were synthesized and utilized for the identification of regions(s) recognized by antibodies specific for FRAP.
- FIG. 8 FRAP-mediated neutralization of toxic heme into non-toxic Hemozoin. 500 pmoles of each of the protein was incubated with different concentrations of free heme at 37° C. for 16 hours, under acidic conditions (500 mM Sodium acetate pH 5.2). After 16 hours, free heme was removed by washing and the insoluble pellet representing hemozoin was solubalized in sodium hydroxide and estimated using a spectrophotometer. FRAP showed 10-20 fold more activity in comparison to HRPII, indicating that it could be the major protein responsible for polymerization of heme in the parasite.
- FIG. 9 FRAP-mediated hemozoin formation requires intact protein. Hemozoin formation was investigated with FRAP pretreated with proteinase K, a nonspecific protease or with buffer alone. Incubation of FRAP with Proteinase K led to a complete loss of activity suggesting that the conversion of heme into hemozoin requires intact FRAP protein.
- FIG. 10 Chemical structure of hemozoin. Dimerization of heme through a Fe1-O41 linkage leads to the formation of ⁇ -hematin. Oxygen mediated non-covalent interaction between ⁇ -hematin units leads to the stacking and the polymerized product is known as hemozoin. Adapted from (Pagola et al., 2000)
- FIG. 11 Spectroscopic verification of FRAP-mediated polymerized heme as hemozoin. Heme polymerized into hemozoin was subjected to Fourier transform-Infra Red (FT-IR) spectroscopy to verify its chemical nature. The insoluble product showed a dramatic decrease in transmittance at 1664 and 1211 cm ⁇ 1 , a well established spectroscopic signature of ⁇ -hematin.
- FT-IR Fourier transform-Infra Red
- FIG. 12 Time Kinetics of hemozoin formation. FRAP-mediated hemozoin formation was investigated with respect to time. 500 pmoles of protein was incubated with 300 nmoles of heme for different times and the amount of heme polymerized was measured as previously described. Hemozoin formation was found to be essentially complete by 5 hours.
- FIG. 13 Stoichiometry of FRAP-Heme Interaction. Stoichiometry of the FRAP-Heme interaction was determined spectrophotometrically by continuous variation method (Job Plot). Change in absorbance was measured by using different molar ratios of FRAP-heme complex. FRAP-Heme have a 1:1 stoichiometry.
- FIG. 14 Inhibition of FRAP-mediated hemozoin formation by Chloroquine. Hemozoin formation was investigated in the absence or presence of different concentrations of chloroquine, an antimalarial drug with high affinity for heme. Chloroquine inhibited heme polymerization in a dose dependent manner. This indicates that blocking FRAP-Heme interaction could serve as an effective antimalarial strategy.
- FIG. 15A and B A, amino acid and B, nucleic acid encoding the FRAP2 derivative of FRAP.
- FIG. 16A -F HDP detoxifies and sequesters heme as Hz.
- HDP black bar
- mediated Hz production is dose dependent and could be up to 20 fold higher than HRP II (light grey bar), oleic acid (dark grey bar) or mono-oleoyl glycerol (white bar). Values are mean ⁇ s.d
- HRP II light grey bar
- oleic acid dark grey bar
- mono-oleoyl glycerol white bar.
- Values are mean ⁇ s.d
- Hz production increases, with increasing amount of HDP (0-0.5 nmol) in a reaction containing 300 nmol of free heme.
- Fourier transform infrared spectrum of HDP-derived product showed absorption peaks at 1660 and 1210 cm-1, which validated it as Hz.
- HDP-mediated Hz production is restricted to a pH range found inside the food vacuole.
- e Native P. falciparum HDP purified from intraerythrocytic parasites. Silver stained gel (left panel), Immunoblot (right panel).
- f Native HDP (black bar) can produce Hz. Hashed bar represents recombinant protein.
- FIG. 17A -B HDP gene is important for the survival of the parasite.
- a Schematic representation of strategy used for targeting HDP locus through single cross over recombination. The anticipated cross-over event at the HDP locus and restriction enzyme sites Bam HI (B) and Eco RV (E) are shown.
- b Lanes a and b depict Bam HI-linearized pHDPKO (6.3 kb) and Bam HI and Eco RV digested DNA from wild type P. falciparum parasites containing the HDP locus (5.3 kb), respectively. Parasites surviving after three selection cycles (lanes c, d) had an intact HDP locus and an episomal copy of the pHDPKO plasmid expressing hDHFR. Bar represents 500 bp.
- FIG. 18A -C Structural and biochemical analysis of HDP-mediated Hz formation.
- a Heme (100 ⁇ M) solution was titrated into protein (5 ⁇ M) and the heat evolved was measured by Isothermal titration calorimetry. Binding isotherm integrating the data from the top panel.
- b Full length HDP is necessary for Hz formation as HDP2 (circle) and HDP3 (triangle) alone could not produce Hz.
- c Hz formation activity of P. yoelii HDP (grey bars) is indistinguishable from its P. falciparum ortholog (black bars). Values are mean ⁇ s.d. with data from at least two independent experiments.
- FIG. 19A -D Cloning, expression and purification of HDP proteins.
- a RT-PCR amplification of HDP coding sequence.
- b Schematic representation of HDP gene structure, HDP protein and its two truncated variants.
- c Recombinantly expressed and purified HDP proteins on a 12% Coomassie stained gel under reducing conditions.
- d Immunoblot of purified proteins with anti-HDP antibodies.
- FIG. 20A -D Circuitous transport and delivery of HDP to the food vacuole.
- HDP is secreted into the cytosol of infected erythrocytes (arrowhead) in early ring stages before any Hz could be detected inside the parasite.
- b After secreting it into the host cell cytosol, parasite intakes HDP through the cytostome c, HDP could be found in transport vesicles destined to the food vacuole.
- Transport vesicles deliver HDP to the food vacuole where it was present in close proximity of Hz crystals.
- cytostome cytostome
- fvm food vacuole membrane
- fv food vacuole
- hz hemozoin
- hdp heme detoxification protein
- hb hemoglobin
- nu nucleus
- par parasite
- ppm parasite plasma membrane
- pvm parasitophorous vacuole membrane
- irbc infected red blood cell
- rbcm RBC membrane
- tv transport vesicle. Bar, 0.5 ⁇ m.
- FIG. 21A -C HDP is transported to food vacuole along with hemoglobin.
- a HDP(18 nm particles) was found in the cytosol of infected cells.
- Inset b HDP is being internalized along with hemoglobin (12 nm particles).
- Inset c Transport vesicle ready to deliver both, HDP and hemoglobin to the food vacuole. Bar, 0.5 ⁇ m.
- FIG. 22 Comparison of Hemozoin production by HDP protein from P. vivax and P. falciparum.
- FIG. 23 Results of immunization of mice with either DNA encoding HDP from P. yoelii or with P. yoelii HDP protein.
- the present invention is based on the discovery of several surprising properties of a previously uncharacterized family of parasite proteins.
- the protein family has been designated “FRAP” for “Fasciclin Related Adhesive Protein”.
- the protein is denominated “HDP” for “Heme Detoxification Protein”.
- FRAP and HDP designate the same entity.
- This protein is expressed by Plasmodium and Theileria parasites and is intimately involved in the onset of parasitic infections.
- the FRAP (HDP) family of proteins, and the nucleic acids that encode them are ideal targets for the treatment and/or prevention of certain parasitic diseases.
- the initial FRAP protein was selected for study based on a systematic analysis of the genome of Plasmodium falciparum using a combination of in-silico algorithms, microarray and proteomic techniques. This process is described in detail in Example 1 of the Examples section. The study predicted that FRAP should be expressed on the surface of the P. falciparum sporozoite, and thus would be involved in early interactions between the sporozoite and host cells, making it an attractive target for therapeutic intervention. These predictions have been confirmed. FRAP protein is present in micronemes, a specialized secretory organelle that transports proteins to the surface of the Plasmodium sporozoite.
- FRAP and an 87 amino acid polypeptide derivative, FRAP2 (amino acid sequence, SEQ ID NO: 25; nucleic acid sequence, SEQ ID NO: 26; FIG. 15 ) bind to liver cells, thereby preventing sporozoite invasion. Further, antibodies specific for FRAP2 also prevent sporozoite invasion of liver cells. A thirty-two amino acid sequence that is recognized by these antibodies, encodes the inhibitory epitope and is common to the FRAP family of proteins (TRSGGLRKPQKVTNDPESINRKVYWCFEHKPV, SEQ ID NO: 24), has also been discovered. This sequence shows 100% sequence homology and 87.5% sequence identity within the Plasmodium genus. In addition, the enzymatic activity of FRAP has been elucidated. FRAP catalyzes the neutralization of toxic heme into non-toxic hemozoin, making this protein a highly significant target for inhibitory drug therapy.
- FRAP proteins and various derivatives of FRAP proteins are useful as vaccine components.
- the inhibition of FRAP proteins or nucleic acids that encode them e.g. by compounds that bind to the active site of the protein, or by RNA silencing
- the invention provides diagnostic tools related to the detection of parasites harboring either the FRAP protein or nucleic acids encoding FRAP.
- the invention provides methods and compositions for inhibiting the ability of HDP to detoxify heme, i.e. to convert heme to hemozoin.
- the methods and compositions are useful for the treatment or prevention of diseases caused by Plasmodium and Theileria parasites.
- the protein is encoded by the nucleic acid sequence represented by SEQ ID NO: 2 ( FIG. 2 ).
- the FRAP family of proteins is not limited to those originating from P. falciparum .
- FRAP orthologs from Plasmodium species other than P. falciparum have been identified, for example, FRAP orthologs from human ( P. vivax ) simian ( P. knowlesi, P. vraowi ), avian ( P. gallinaceum ) and rodent ( P. berghei, P. yoelii and P.
- FRAP has extremely high sequence homology across the Plasmodium genus and the region encoding the inhibitory epitope identified in P. falciparum protein is very highly conserved in all known FRAP orthologs. Furthermore, polymerization of human heme into hemozoin by FRAP from rodent malaria parasite P. yoelii has been demonstrated. Therefore, FRAP sequences between different species of the parasites are functionally interchangeable and transgenic malaria parasites expressing the FRAP sequence from any member of the Plasmodium genus can be utilized for human malaria drug and for vaccine development.
- FRAP orthologs present in many related species such as Theileria may also be utilized for use in drug and vaccine development for the diseases they cause, e.g. bovine tropical theileriosis (Preston et al., Innate and adaptive immune responses co-operate to protect cattle against Theileria annulata . Parasitol Today. 1999 July; 15(7):268-74). All such orthologs, examples of which are given in FIG. 1 , are encompassed by the present invention.
- the nucleic acids that encode some exemplary FRAP proteins are presented in FIG. 2 .
- FRAP protein need not have an exact sequence as depicted in FIG. 1 in order to be suitable for use in the practice of the present invention. Rather, the invention also encompasses variants (derivatives) of such proteins.
- protein refers to sequences of about 100 or more amino acids;
- polypeptide refers to sequences of about 100 amino acids or less, although these terms may be used interchangeably. (Shorter sequences, e.g. about 35 or fewer amino acids, will generally be referred to as peptides.) Variants or derivatives of FRAP proteins may be isolated from nature or be purposefully constructed. The primary sequence of such a variant or derivative may differ from the original sequence (e.g. as represented in FIG.
- conservative amino acid substitutions in any of several ways, including the following: conservative amino acid substitutions; non-conservative amino acid substitutions; truncation by, for example, deletion of amino acids at the amino or carboxy terminus, or internally within the molecule; or by addition of amino acids at the amino or carboxy terminus, or internally within the molecule (e.g. the addition of a histidine tag for purposes of facilitating protein isolation, the substitution of residues to alter solubility properties, the replacement of residues which comprise protease cleavage sites to eliminate cleavage and increase stability, the replacement of residues to form a convenient protease cleavage site, the addition or elimination of glycosylation sites, and the like, for any reason).
- Such variants may be naturally occurring (e.g.
- amino acid sequences may be in a variety of forms, including a neutral (uncharged) forms, or forms which are salts, and may contain modifications such as glycosylation, side chain oxidation or deamidation, phosphorylation and the like. Also included are amino acid sequences modified by additional substituents such as glycosyl units, lipids, or inorganic ions such as phosphates, as well as modifications relating to chemical conversions or the chains, such as oxidation of sulfhydryl groups.
- amino acid identity will be in the range of about 50 to 100%, and preferably about 60 to 100%, or more preferably about 70 to 100%, or even more preferably about 80 to 100%, or most preferably about 90 to 100%, or even about 95 to 100%, of the disclosed sequences.
- the identity is with reference to the portion of the amino acid sequence that corresponds to the original amino acid sequence as translated directly from the nucleic acid sequences disclosed herein, i.e.
- such protein/polypeptide variants retain at least about 50 to 100% or more of the activity of the original polypeptide, and preferably about 60 to 100% or more, or more preferably about 70 to 100% or more, or even more preferably about 80 to 100% or more, and most preferably about 90 to 100% or more of the activity of the original sequence.
- activity we mean the activity or role of the amino acid sequence in the parasite from which is was isolated, which may include but is not limited to: characteristic enzyme activity, activity as a structural component, role as a membrane component, binding activity, etc.
- the peptides, polypeptides and proteins of the present invention are generally provided as recombinant molecules, although the amino acid sequences may also be produced synthetically via known peptide synthesis techniques.
- the peptides, polypeptides and proteins of the present invention are provided in a substantially purified form, i.e. they are generally free of extraneous materials (such as other proteins, nucleic acids, lipids, cellular debris, etc.) and will generally be at least about 75% pure, preferably about 85% pure, and most preferably at least about 90-95% or more pure, as would be understood by one of ordinary skill in the art.
- the proteins and polypeptides of the invention are produced in recombinant expression systems.
- the recombinant system is an E. coli recombinant system.
- they may also be produced in a variety of other recombinant expression systems.
- yeast, insect cells using for example, a baculovirus expression vector
- plant cells e.g. tobacco, potato, corn, etc.
- transgenic animals or mammalian cell culture systems
- mammalian cell culture systems can be used for expression of recombinant proteins.
- Any appropriate expression system that suitably produces the proteins and polypeptides of the invention may be used in the practice of the invention.
- Such systems and their use for the production of recombinant proteins are well known to those of ordinary skill in the art.
- the invention also provides antigenic peptides, in particular an antigenic epitope common to the FRAP family of proteins.
- the epitope has the amino acid sequence TRSGGLRKPQKVTNDPESINRKVYWCFEHKPV (SEQ ID NO: 24). Some modification of this sequence may be tolerated without compromising the antigenicity of the sequence.
- peptides may be obtained by several means, including but not limited to chemical synthesis methods, production using genetic engineering techniques, enzymatic digestion of larger polypeptides, etc.
- the particular source of a peptide is not a crucial feature of the invention. In a preferred embodiment, the peptide will be chemically synthesized.
- the FRAP epitope will be used as an antigen in combination with at least one other known parasite antigenic epitope.
- genetic engineering techniques may be employed to construct chimeric polypeptides or proteins containing two or more of such epitopes on the same molecule.
- separate preparations of the peptidic epitopes may be prepared and mixed into a single solution, for example, to be administered as a vaccine.
- the present invention also encompasses use of the nucleic acids that encode such amino acid sequences.
- Exemplary DNA sequences that encode FRAP proteins are given in FIG. 2A -J.
- the nucleic acids may be used as a tool, e.g. to produce a protein.
- the nucleic acid sequences themselves may be used in certain aspects of the invention, e.g. as components of DNA vaccines, or for gene silencing applications (see below).
- Those of skill in the art will recognize that many variants (derivatives) of such sequences may exist in nature or be constructed which would still be suitable for use in the practice of the present invention.
- nucleic acid sequences may be constructed for purposes related to other aspects of the invention, for example: for cloning strategies (e.g.
- restriction enzyme cleavage sites for ease of manipulation of a sequence for insertion into a vector, for rendering the sequence compatible with the cloning system vector or host, for enabling fluorescent or affinity labeling technologies, etc.
- modifying transcription e.g. the introduction of specific promoter or enhancer sequences, insertion or deletion of splice signals, for enhancing or negatively regulating transcription levels, for regulating polyadenylation, for controlling termination, and the like
- modification of active or inactive domains for elimination or modification of certain activities or domains, for optimizing expression due to codon usage or other compositional biases, for addition of immunologically relevant (enhancing or inhibiting) sequences or for any other suitable purpose.
- nucleic acid sequences encoding the proteins, polypeptides and peptides disclosed herein are intended to be encompassed by the present invention, provided the sequences display homology in the range of about 50 to 100%, and preferably about 60 to 100%, or more preferably about 70 to 100%, or even more preferably about 80 to 100%, or most preferably about 90 to 100% or about 95 to 100% to the disclosed sequences.
- the homology is with reference to the portion of the nucleic acid sequence that corresponds to the original sequence, and is not intended to apply to additional elements such as promoters, vector-derived sequences, restriction enzyme cleavage sites, etc. derived from other sources.
- nucleic acids are not limited to DNA, but are intended to encompass other nucleic acids as well, such as mRNA, RNA-DNA hybrids, and various modified forms of DNA and RNA known to those of skill in the art.
- nucleic acids may be modified to resist degradation via structural modification (e.g. by the introduction of secondary structures, such as stem loops, or via phosphate backbone modifications, etc.).
- the nucleic acids may include phosphothioate or phosphodithioate rather than phosphodiesterase linkages within the backbone of the molecule, or methylphosphorothiate terminal linkages.
- nucleic acid molecules include but are not limited to: nontraditional bases such as inosine and queosine; acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine; stabilized nucleic acid molecules such as nonionic DNA analogs, alkyl- and aryl phosphonates; nucleic acid molecules which contain a diol, such as tetrahyleneglycol or hexaethyleneglycol, at either or both termini; etc. Further, the nucleic acid molecules may be either single or double stranded, or may comprise segments of both single and double strand nucleic acid.
- nontraditional bases such as inosine and queosine
- stabilized nucleic acid molecules such as nonionic DNA analogs, alkyl
- FRAP-related nucleic acid molecules may be cloned into one of many suitable vectors.
- vectors containing nucleic acid sequences e.g. DNA
- Such vectors may contain DNA encoding more than one amino acid sequence, either as separate, discrete sequences, or combined into a single chimeric sequence.
- two or more nucleic acids according to the invention may be present in the vector, and the nucleic acids may be expressed separately, resulting in the translation of one amino acid sequence for each nucleic acid.
- a single polypeptide chain containing more than one amino acid sequence of the invention, or portions of more than one amino acid sequence of the invention may be combined in tandem.
- one or more highly antigenic proteins or regions of proteins of the invention may be expressed as a chimera from a single DNA sequence.
- the amino acid sequences of the invention may be expressed as part of a chimeric protein comprising amino acid sequences from another source, e.g. antigenic sequences known to be useful as adjuvants (e.g.
- PADRE Pan-DR T helper cell epitope
- hepatitis B core antigen DNA sequences CPG, other chemokines, CTB or cholera toxin B subunit, Ricin B and other plant toxin subunits, LPS or lipopolysaccharide, KLH [key hole limpet hemocyanin], Freund's complete and Freund's incomplete adjuvant, and many other reagents, etc.), sequences that permit targeting of the protein to a specific location within the cell (e.g.
- nucleus nucleolus or nuclear membrane
- mitochondrion/mitosome/mitochondria-like organelle membrane
- endoplasmic reticulum golgi, rhoptry, dense granules, calcisomes or acidocalcisomes, and other subcellular organelles compartments, etc.
- One application of the present invention is the provision of vaccines that provide immunity to disease caused by parasites such as Plasmodium .
- immuno we mean that administration to an individual of one or more proteins, polypeptides or peptides of the invention, or nucleic acids encoding them, either alone or in combination with other antigenic entities prevents the development of disease symptoms in that individual after exposure to or infection by a parasite.
- the disease symptoms that develop in the individual may be milder than those that would otherwise develop in, for example, a matched control individual.
- controls when comparing results of individuals or populations that have been exposed to different variables (e.g. vaccinated or not).
- the inhibitory epitope peptide of the invention may be used in combination with one or more other antigenic epitopes for the production of a multicomponent vaccine.
- a vaccine addresses previous lackluster vaccine performance by presenting several highly immunogenic epitopes to the immune system of a vaccinated individual in a single preparation. This type of vaccine closely mimics the natural in vivo presentation of antigens on the surface of a parasite, and thus elicits a robust immune response.
- the vaccine may either be prophylactic (i.e. to prevent or attenuate symptoms of infection) or therapeutic (i.e. to treat disease after infection).
- Such vaccines comprise one or more of: immunizing antigen(s), immunogen(s), polypeptide(s), protein(s) and nucleic acid(s) from the FRAP family (as described herein), usually in combination with “pharmaceutically acceptable carriers,” which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.
- Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents (“adjuvants”). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori , etc. pathogens.
- Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (I) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach , eds.
- aluminum salts alum
- oil-in-water emulsion formulations with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components
- MF59TM WO 90/14837
- Span 85 containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 100Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RibiTM adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (MPL), trehalose dimycolate (TDM), and cell wall skeleton (MPL), trehalose dimycol
- interferons eg. gamma interferon
- M-CSF macrophage colony stimulating factor
- tumor necrosis factor etc
- other substances that act as immunostimulating agents to enhance the effectiveness of the composition eg. gamma interferon
- M-CSF macrophage colony stimulating factor
- tumor necrosis factor e.g. IL-12
- Alum and MF59TM are preferred.
- the immunogenic compositions typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
- the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.
- Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed.
- immunologically effective amount it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for eliciting the production of antibodies, for eliciting a cellular immune response, (or both), and/or for treatment or prevention of disease. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g.
- the immunogenic compositions are conventionally administered parenterally, eg. by injection, either subcutaneously, intramuscularly, intranasally, or transdermally/transcutaneously. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- the vaccine may be administered in conjunction with other immunoregulatory agents.
- DNA vaccination may be employed [eg. Robinson & Torres (1997) Seminars in Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol 15:617-648].
- Vaccines can be composed of live, attenuated or killed organisms, or chemically inactivated toxins (toxoids), against which the body can raise an effective immune response, leading to effective protection against the live agent or active toxins produced during the infection.
- Combination vaccines make it possible to immunize individuals against multiple pathogens at a time. Examples of combination vaccines are DTaP (Diphtheria, Tetanus, combined with acellular Pertussis) or MMR (Measles, Mumps, and Rubella).
- Conjugated vaccines such as PCV (Pneumococcal Conjugated Vaccine) provide better immunization of infants.
- polysaccharide antigens are chemically linked to protein antigens which provide a better stimulus for the immature immune system.
- polysaccharide antigens are chemically linked to protein antigens which provide a better stimulus for the immature immune system.
- recombinant DNA technology it is possible to isolate and express individual genes or combinations of genes, encoding antigens from pathogens and produce vaccines by fermentation.
- genomics and proteomics of (re-)emerging pathogens will enable entirely new generations of vaccine based on identification of surface proteins.
- Table 1 lists common types of vaccines in current use or in development, and some important attributes.
- vaccines in Table 1 are administered by subcutaneous or intramuscular injection.
- the oral route of administration is occasionally used in case of Oral Polio Vaccine.
- New vaccine technology is being developed to produce vaccines that (i) generate stronger and broader immunity, (ii) meet more stringent safety and quality requirements, and (iii) that have greater ease of delivery at lower cost. Therefore, a significant amount of research is ongoing to develop new delivery methods and adjuvants.
- adjuvants are emulsions or formulations, often containing lipids or aluminum salts, which provide for slow release of the antigen into the plasma, and also stimulate the immune response in ways that are not fully understood.
- New physical administration methods being developed include delivery by inhalation, oral delivery, or transdermal delivery.
- Inhalation delivery includes intranasal delivery for delivery to the upper respiratory tract, which is being used in FluMist (influenza vaccine) or other powder or particle based methods to deliver immunization to the lower respiratory tract.
- Oral delivery includes new formulations to allow antigens to pass through the stomach and intestinal tract without acid or protease inactivation.
- New methods of oral delivery include edible vaccines, where plants such as potatoes, tomatoes, or bananas are genetically engineered to express the antigen in parts of the plant that are consumed by humans.
- New transdermal delivery methods that avoid injection are being explored as well.
- the large size (high molecular weight) of the antigen(s) usually is a limitation for this delivery method.
- a relatively new delivery method is expression of antigens in a strain of virus or a bacterium that is not naturally pathogenic, or is made avirulent either through mutation or genetic engineering. Attenuated viruses such as polio, or bacteria such as Vibrio cholerae and Salmonella typhi , are being explored as delivery vehicles.
- Production methods for vaccines vary with the type of vaccine.
- Live, attenuated or killed virus vaccines are produced in mammalian cell culture. In the latter case virus particles are killed by chemical inactivation, heat or radiation.
- a major concern of mammalian cell culture based production methods is contamination with other pathogens, specifically retroviruses such as HIV, or other as of yet uncharacterized mammalian viruses.
- Influenza vaccine is produced either through cell culture or growth of virus in fertilized chicken eggs, followed by purification from the yolk.
- Live, attenuated or killed bacterial vaccines are produced by microbial fermentation. Concerns with this method are contamination with other micro-organisms (bio-burden), or presence of bacterial endo- or exo-toxins that can cause anaphylactic shock.
- Toxoid vaccines such as diphtheria or tetanus vaccines, are produced by microbial fermentation and harvesting of the exo-toxins from the culture medium.
- Toxoid vaccines can also be produced with recombinant DNA technology, followed by purification of the recombinant protein.
- Conjugated vaccine components are produced through multiple methods. The polysaccharide component is harvested from bacteria grown in culture, and the protein component of the antigen can be produced through fermentation or recombinant DNA technology. The conjugation step is done through a chemical reaction.
- Subunit vaccines existing of specific protein antigens (or combinations) are made through fermentation or recombinant DNA technology.
- DNA vaccines are produced using recombinant DNA technology.
- Vector vaccines are produced through genetic engineering of the vector, i.e. to produce the antigens of interest, and either microbial fermentation or mammalian cell culture.
- U.S. Pat. No. 6,214,804 (Felgner, et al., 2001, the complete contents of which is hereby incorporated by reference) describes the induction of a protective immune response in a mammal by injecting a DNA sequence.
- Methods for delivering an isolated polynucleotide to the interior of a cell in a vertebrate are provided. The methods can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.
- U.S. Pat. No. 6,923,958 (Xiang et al., 2005, the complete contents of which is hereby incorporated by reference) describes DNA vaccines encoding carcinoembryonic antigen (CEA) and a CD40 ligand and methods of their use.
- the DNA vaccine is effective for eliciting an immune response against cells that present a carcinoembryonic antigen, and could be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier.
- the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells.
- the mammal may be further treated with recombinant antibody fusion proteins to enhance the immune response effectiveness of the vaccine.
- antibody refers to a polypeptide or group of polypeptides composed of at least one antibody combining site.
- An “antibody combining site” is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows binding of the antibody with the antigen.
- Antibody includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, fully human antibodies, altered antibodies, univalent antibodies, Fab proteins and fragments, and single domain antibodies.
- Antibodies to the polypeptides and peptides of the invention may be prepared by conventional methods that are well-known to those of skill in the art. If desired, the antibodies (whether polyclonal or monoclonal) may also be labeled using conventional techniques.
- Antibodies for therapeutic applications for the prevention or treatment of malarial disease, or diagnostic applications in the detection of parasite infection can be made by standard methods. In most cases the antibodies will be of monoclonal origin, and either produced in rats or mice.
- Protein for immunization is made by recombinant methods. Any of the proteins from the group of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, or portions thereof, can be produced by cloning the corresponding DNA sequences of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, or portions thereof, in recombinant protein expression vectors. Protein can be produced in this manner in E. coli , yeast, fungi, plants, mammalian, or insect cells. It is obvious that the preferred protein used for immunization is from the Plasmodium species that infect humans, i.e. SEQ ID NOS: 1 and 7. However, in principle SEQ ID NOS: 3, 5, 9, 11, 13 and 15, could also be used to generate antibodies that are effective as therapeutics or diagnostic tools. Immunization material for short peptides and small proteins can also be made through chemical synthesis.
- the 8-mer peptide represented by SEQ ID NO: 37 may be encoded by: ACCAACGACCC AGAAAGTATAAAT (SEQ ID 38), or other sequences; and the 32-mer peptide represented by SEQ ID NO: 24 may be encoded by: ACACGAAGTGGCGGTTTAAGAAAACCTCAAAAGG TAACCAACGACCCAGAAA GT ATAAATAGAAAAGTATATTGGTGTTTTGAACATAA GCCTGTA (SEQ ID 39), or other sequences.
- the these peptides may be chemically synthesized.
- Expressed protein can be purified with standard HPLC and other chromatographic methods, in quantities and sufficient purity to be injected in the mice or standard rats. Rats or mice are injected in the presence of adjuvants, and in a standard schedule of injections and boosters, in order to generate a vigorous immune response.
- spleen cells are harvested from the animals and fused with immortalized cell lines. Numerous immortalized cell lines are screened for their ability to secrete antibodies that bind the original antigen used in immunizations. Positive cell lines are purified and cloned, and their antibodies are characterized and screened to identify antibodies that have strong binding characteristics. Upon identification of such cell lines, the antibody genes are cloned, sequenced and can be used to engineer mammalian cell culture strains for high level production.
- the sequence of the monoclonal antibody is modified to most closely resemble the sequence of native human antibodies. This is done by recombinant DNA methods, through selective replacement of the significant portions of the munine antibody light and heavy chain sequences with human sequences (chimeras), or through replacement of almost all of the non-variable sections of the murine antibody light and heavy chains, with those from human antibody chain conserved sequences, while maintaining the original rat or mouse sequence of the hyper-variable domain which is responsible for antigen recognition and binding (‘CDR grafting’ or ‘humanization’).
- CDR grafting hyper-variable domain which is responsible for antigen recognition and binding
- Fully human monoclonal antibodies can be made in mice directly, when these mice are engineered to produce only human antibody chains.
- the technology practiced by companies such as Abgenix Inc. [XenoMouse technology, U.S. Pat. No. 6,657,103], Medarex Inc. and GenMab A/S [HuMab Mouse or UltiMAB technology; WO2005023177] can be used. Purified proteins as described above are used to immunize such engineered mice. Monoclonals produced in this manner are produced, screened and characterized in the standard manner. Fully human antibodies can also be produced using phage display methods by screening against human antibody phage display libraries. For example technologies practiced by companies such as Cambridge Antibody Technology [U.S. Pat. No.
- Such antibodies may be used, for example, for affinity chromatography, immunoassays, and for distinguishing or identifying parasite proteins or portions thereof.
- such antibodies may be used therapeutically, e.g. for administration to patients suffering from a parasitic disease such as malaria, or prophylactically in order to prevent a parasitic disease in patients at risk for developing the disease.
- the cell may be a host cell that harbors one or more vectors containing nucleic acid sequences used in the invention (e.g. DNA or RNA) and/or amino acid sequences of the invention translated from such vectors.
- nucleic acid sequences used in the invention e.g. DNA or RNA
- amino acid sequences of the invention translated from such vectors Such cells may contain multiple vectors, and the vectors may be the same or different.
- the cells may be either in vitro or in vivo.
- the invention also comprehends pharmaceutical compositions and their use.
- the pharmaceutical compositions can comprise one or more proteins, polypeptides, peptides, antibodies, or nucleic acids according to the invention, or combinations of these.
- compositions may include compounds that inhibit the interaction of HDP and heme, thereby preventing or vitiating the ability of HDP to detoxify heme, e.g. to form hemozoin from heme.
- the pharmaceutical compositions comprise a therapeutically effective amount of such molecules.
- therapeutically effective amount refers to an amount of a therapeutic agent that is sufficient to treat, ameliorate, or prevent a disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction of physical symptoms of the parasitic disease.
- an effective dose will be from about 0.01 mg/kg to 50 mg/kg or about 0.05 mg/kg to about 10 mg/kg of active, therapeutic agent.
- a pharmaceutical composition may also contain a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, inhibitory compounds, and other therapeutic agents. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
- Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
- mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like
- organic acids such as acetates, propionates, malonates, benzoates, and the like.
- pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol.
- auxiliary substances such as wetting or emulsifying agents, pH buffering substances, adjuvants, and the like, may be present in such vehicles.
- the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.
- compositions of the invention are administered to the subject.
- the subjects to be treated may be animals; in particular, human subjects can be treated.
- Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue.
- Other modes of administration include oral and pulmonary administration, suppositories, and intranasal, transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays.
- Dosage treatment may be a single dose schedule or a multiple dose schedule.
- Yet another embodiment of the invention provides tools and methods for the diagnosis of parasitic infections.
- Such tools include primers containing nucleotide sequences that specifically hybridize to nucleic acid sequences that are unique to FRAP. Hybridization of the primers to such a unique sequence permits amplification of the unique sequence (for example, by polymerase chain reaction (PCR)), thus providing a means to specifically identify the presence of FRAP in biological samples (blood, feces, sputum, urine, bronchoaveloar lavage, etc.). Amplification may be directly from the genome of the organism located in the sample, or from RNA, e.g. mRNA.
- primer we mean a nucleotide sequence that hybridizes to another nucleotide sequence of interest, the primer typically being a relatively short nucleotide sequence (e.g. from about 10 to about 100 base pairs) and the nucleotide sequence of interest typically being transcribed from the genome of an organism. PCR amplification techniques are well-known to those of skill in the art. In general, two primers are selected that target sites that flank the sequence of interest (e.g. a gene encoding FRAP) for diagnostics or identification. These primers are designed to recognize only the target sequence; i.e., they will hybridize only to the target sequence and to no other sequences.
- sequence of interest e.g. a gene encoding FRAP
- the primers generally range from 18-nucleotides in length (but can be longer or shorter), have Tm's (melting temperatures) that are selected to be compatible with both amplification conditions and with specificity, have little or no internal structure (stem-loop structures caused by internal complementarity), little or no ability to dimerize with themselves, little or no ability to dimerize with the other primer, have few homopolymeric stretches, etc.
- Tm's melting temperatures
- Many computer programs e.g., Primer3, Oligo, etc.
- an internal fluorescent probe is also included for specific use in even more sensitive and automated tests. The internal probe is fluorescently labeled such that it is specifically degraded and therefore fluoresces only if it specifically hybridizes to the target sequence.
- a positive amplification result is indicative of the presence of FRAP in the biological sample, and thus of infection by a parasite whose genome encodes FRAP. Similar tests can be carried out with antibodies specific for FRAP. In this case, a positive result indicates that the biological sample being tested contains FRAP, and thus, by inference, the individual from whom the sample was obtained is infected with a parasite that produced FRAP.
- the invention further provides methods for treating or preventing a disease caused by a Plasmodium or Theileria parasite in an individual in need thereof. In one embodiment, this is accomplished by inhibiting one or more interactions of heme and Heme Detoxification Protein (HDP). Typically, inhibition is brought about by the administration of one or more compounds that inhibit one or more interactions of heme and HDP. In other words, the ability of HDP to produce hemozoin from heme (i.e. to detoxify heme) is eliminated or impaired by administration of the compound. Examples of diseases that can be treated in this manner include but are not limited to malaria, East Coast Fever caused by Theileria parasites, etc. Exemplary compounds that may be used in such methods are listed in Table 11 in the Examples section below. One or more compounds from one or more of these classes may be administered, in a quantity sufficient to prevent or ameliorate disease symptoms.
- HDP Heme Detoxification Protein
- the mechanism of action of the compounds that are administered can be any of many known or not yet elucidated types, and that the precise mechanism(s) will depend on the compound(s) administered.
- the compound may bind to the HDP enzyme and prevent the enzyme from binding to heme.
- the compound may bind to HDP and allow heme to also bind to HDP, but prevent further catalysis and the production of hemozoin.
- the compound may bind at the active site or near the active site and sterically prevent the binding of heme; or the compound may bind at an allosteric site that influences (e.g.
- the compound may cause heme to bind to HDP irreversibly or with so great an affinity that the ability of HDP to detoxify heme is eliminated or attenuated.
- the compound may bind to heme.
- binding of the compound to heme may prevent the heme from then binding to HDP, or may allow the heme-compound complex to bind but not be further processed to hemozoin.
- the binding of compounds to HDP or to heme may be reversible or irreversible, realizing that all binding events involve an equilibrium distribution of bound and free agents.
- the criteria for the use of a compound in the present invention is that the compound, regardless of its mechanism of action, decrease the production of hemozoin from heme by at least about 10 to 25%, preferably from about 25 to 50%, and more preferably from about 50 to 75%, or even from about 75 to 10%.
- Other possible mechanisms of action of the compounds that are administered include but are not limited to: modification of a cell membrane of the Plasmodium or Theileria parasite; inhibiting secretion of HDP from the Plasmodium or Theileria parasite, inhibiting transport of HDP to the food vacuole, the site of hemozoin formatin; by binding to free heme (the substrate of HDP) and preventing its detoxification into Hemozoin; etc.
- the administration of the compound(s) may be carried out by any suitable means, examples of which include but are not limited to orally, parenterally, sublingually, rectally, topically or with an inhalation spray.
- the disease that is prevented or treated is malaria.
- the compound that is administered may be administered in combination with one or more additional agents such as other antimalarial agents, agents for reversing antimalarial resistance, and various adjuvants.
- Administration of one or more additional antimalarial agents or agents for reversing antimalarial resistance may occur prior to, concurrent with, or subsequent to administration of the compound.
- additional antimalarial agents include but are not limited to quinolines, folic acid antagonists, sulfonamides, and antibiotics.
- An exemplary agent for reversing antimalarial resistance is an inhibitor of multidrug resistance.
- Exemplary adjuvants include but are not limited to those which are suggested above for use in vaccine preparations, e.g. alum, etc.
- compositions comprising a pharmaceutically acceptable carrier and an antimalarially effective amount of at least one compound.
- antimalarially effective amount we mean that the compound is present in the composition in amount that, upon administration to an individual in need, prevents or lessens the occurrence of symptoms associated with malaria in the recipient.
- Such compositions may include other active agents as well, e.g. adjuvants, other antimalarial agents (quinolines, etc.), agents that reverse resistance to malaria, etc.
- the invention also provides method of inhibiting heme detoxification in a Plasmodium or Theileria parasite by preventing or attenuating the production of hemozoin by HDP in the parasite.
- routes of inhibition may be effective. For example: inhibiting interaction of heme and HDP; preventing an interaction of HDP or heme with cofactors; preventing dimerization of HDP; preventing interaction of HDP or heme with lipids; and others.
- Exemplary cofactors, the interaction of which with HDP or heme may be disrupted include but are not limited to metal ions, natural ligands and protein factors.
- the invention also provides methods for identifying compounds that inhibit HDP expression.
- the methods include the steps of a) contacting Plasmodium with a test compound and b) determining whether HDP is expressed by the Plasmodium .
- Those of skill in the art will recognize that there are several suitable methods to evaluate the outcome of such tests, including but not limited to measuring mRNA that encodes HDP, measuring HDP protein production directly (i.e. detecting and measuring the protein itself), etc.
- the following Examples describe: the discovery and characterization of the novel FRAP protein family; the expression, localization and purification of recombinantly expressed FRAP; the generation of antibodies to FRAP2; experiments demonstrating the binding of FRAP to liver cells; prevention of sporozoite invasion of liver cells by FRAP and antibodies to FRAP2; discovery of the inhibitory epitope of FRAP; FRAP as a drug target; the use of FRAP in high throughput assays for hemozoin formation for screening novel antimalarials; siRNA mediated inhibition of FRAP; the creation of FRAP variant attenuated parasites for use as whole organism vaccines; and the use of FRAP as a tool for high levels of expression and purification of recombinant proteins; the screening of compounds that inhibit HDP; the results of in vivo testing of DNA that encodes HDP as a vaccine.
- Plasmodium falciparum protein involved in sporozoite-liver cell interactions. Orthologs of this protein were identified in seven other Plasmodium species, representing the four distinct phylogenetic clades, and the protein showed 60% sequence identity within the genus. Additionally, amino acids 88-205 have a 20% sequence identity to fasciclin 1, an ancient adhesive domain found in prokaryotes, plants and animal proteins. The DNA encoding the protein was cloned, expressed in E. coli and the protein was purified to homogeneity.
- a bite by a parasite-infected mosquito delivers Plasmodium sporozoites in the blood stream, which is followed by its entry into the liver cells.
- a successful adhesion and invasion of liver cells by the parasite sets the stage for rapid multiplication, development and subsequent release of parasites in circulation, leading to the erythrocytic infection and the clinical pathology associated with malaria. It is widely believed that the host cell adhesion and invasion is a multistep process involving several parasitic proteins, many of which are currently not known.
- Circumsporozoite (CS) and Sporozoite Surface Protein-2/Thrombospondin-Related Anonymous Protein (SSP2/TRAP) have been extensively investigated (1, 2).
- FAS1 is an adhesive domain named due to its initial discovery in proteins involved in fasciculating axons and growth cones (14). It is an ancient extracellular adhesive module found in proteins of prokaryotic, plant and animal origin (15-18). Most of the FAS1 domain-containing proteins possess multiple copies of the domain, though proteins encoding only a single copy, have also been identified (17). A large number of FAS1 domain containing proteins have been reported in Drosophila and Grasshopper, where they are involved in neuronal development (19, 20).
- FAS1 domains have been found in a large multi-domain scavenger receptor protein on endothelial cells, involved in the removal of hyaluronan from blood stream (21), as well as in extracellular matrix protein, where they mediate corneal epithelial cell adhesion (22).
- FAS1 domains show huge sequence diversity; typically have 20% sequence identity in a pairwise alignment (23) and are recognized by only two short semi-conserved sequence motifs (underlined in FIG. 3 ).
- Sequence analysis and identification of FRAP orthologs Sequences for P. falciparum (Accession #AAN37059), P. berghei (Accession #CAH94515) and P. chaubaudi (Accession #CAH77280) FRAP were obtained from GenBank, where they have been deposited as part of the parasite genome sequencing projects (8, 24) Using P. falciparum FRAP sequence, orthologs were identified from unannotated genome sequences of P. gallinaceum, P. venezowi, P. vivax, P. yoelii and P. knowlesi parasites, available at PlasmoDB, Sanger Center and TIGR web sites (25).
- FRAP orthologs from Theileria parva (Accession #EAN32245) and T. annulata (Accession #CA176887) were from the published genome sequence (26, 27).
- the nucleic acid sequences of the genes are provided in FIG. 2A -J.
- the amino acid sequences were aligned using Clustal W algorithm (28) for multiple sequence alignment, using the DNASTAR package.
- the amino acid sequences are depicted in FIG. 1 , and the alignment is given in FIG. 3 .
- the forward primers encoded a tetra nucleotide CACC, which facilitated the directional cloning of amplified fragments in the expression vector.
- the authenticity of the clone was verified by DNA sequencing.
- Two other FRAP constructs, encoding amino acids 1-87 and 88-205 were generated by PCR-based subcloning using pFRAP as template, giving rise to plasmid pFRAP2 and pFRAP3 respectively. Authenticity of these constructs was verified by DNA sequencing. Sequencing was performed at the core laboratory sequencing facility of the Virginia Bioinformatics Institute.
- pCS271IVC a plasmid with a polyhistidine tag at the carboxyl terminus (1) was expressed in BL21 E. coli cells and the protein was purified from the periplasm as previously described (31).
- the sections were immunolabeled with mouse anti-FRAP antibodies (1:1000 in PBS/1% fish skin gelatin), then with anti-mouse IgG antibodies, followed directly by 10 nm protein A-gold particles (Department of Cell Biology, Medical School, Utrecht University, the Netherlands) before examination with a Philips CM120 Electron Microscope (Eindhoven, the Netherlands) under 80 kV.
- Liver Cell binding assay The binding of proteins was assayed on HepG2 cells as described previously (1, 31). Briefly, cells were plated at a density of 25,000 cells/well, in a 96 well plate, 36 hours before the start of the experiment. The cells were fixed with paraformaldehyde, blocked with 1% BSA, followed by the addition of equimolar concentrations of recombinant proteins. Bound protein was detected using anti-polyhistidine tag monoclonal antibody (1:10,000) and anti-mouse antibody conjugated to alkaline phosphatase (1:2000).
- Amount of bound protein was detected by using 4-methylumbelliferyl phosphate, a fluorescent substrate, and measurement of fluorescence using a fluorescent plate reader (Molecular Devices, CA) with excitation and emission set at 350 nm and 460 nm respectively. Results are shown as mean ⁇ standard deviation of mean of a representative experiment performed in triplicate. Binding inhibition assays were performed by combining the recombinant proteins with increasing amounts of glycosaminoglycans and incubating at 37° C. for 15 min. For enzyme treatment, cells were incubated with different concentrations of Heparinase I or Chondroitinase ABC for 90 minutes at 37° C. as previously described (31), before the addition of proteins. The bound protein was assayed as described above.
- Invasion assay was performed with HepG2 (Human hepatoma) cells as previously described (31). Briefly, HepG2 cells were plated (50,000 cells/0.3 ml) and incubated overnight at 37° C. in a CO 2 incubator. Next day, medium was removed and 50 ⁇ l of diluted FRAP proteins (final concentrations: 20 and 10 ⁇ g/ml) or anti-FRAP2 antibodies (40 ⁇ g/ml final concentration) were added per well. Anti CS monoclonal antibody NFS1 was used at a final concentration of 100 ⁇ g/ml. All protein concentrations and serum dilutions were evaluated in triplicate.
- P. falciparum (strain NF54) sporozoites were obtained from the salivary glands of An. stephensi mosquitoes as described by Ozaki (33). The sporozoites were allowed to invade liver cells for three hours followed by the washing of cells with PBS at pH 7.4. Subsequently, the cells were fixed with cold methanol. Sporozoites were visualized by immunostaining using NFS1 as primary antibody and anti-mouse IgG-peroxidase conjugate. The slides were mounted with Paramount and only intracellular sporozoites were counted as described (31). Percentage inhibition of invasion was calculated with the following formula: [(Control-test)/control] ⁇ 100
- FIG. 1 depicts the FRAP protein sequence and its alignment with the consensus sequence of FAS1 domain in the database.
- FAS1 domains are known for their huge sequence diversity and typically have 20% sequence identity in a pairwise alignment (23). They are recognized by only two short semi-conserved sequence motifs (underlined in FIG. 3 ). A similar pattern is seen in FRAP as its FAS1 domain has 21% sequence identity with the consensus sequence.
- P. falciparum FRAP orthologs were identified in all Plasmodial species that have been sequenced till date or are currently undergoing sequencing ( FIG. 1 ).
- Orthologs of P. falciparum FRAP were found in avian ( P. gallinaceum ), rodent ( P. berghei, P. yoelii and P. chaubaudi ) simian ( P. knowlesi and P. vraowi ) and human ( P.
- FRAP protein is most likely present in all the members of Plasmodium genus and, hence, could be playing an important role in the biology of the parasite.
- the protein maintains a 60% sequence identity ( FIG. 3 ) with 124 out of 205 residues being identical.
- FRAP homologs were only found in the two recently sequenced Theileria genomes (26, 27) with an overall sequence identity of 29% ( FIG. 3 ).
- FRAP homologs could not be found in the recently sequenced Leishmania (35) and Trypanosome genomes (36). This selective presence in Plasmodium and Theileria genomes could point towards a common function of the protein between otherwise two very different parasites.
- This PCR product was not due to the presence of contaminating genomic DNA in the RNA preparation, as a parallel reaction performed in the absence of reverse transcriptase enzyme, showed no amplification. Also, the size of the amplified fragment, viz. 615 bp, matched the size of the predicted mature mRNA ( FIG. 4 b ).
- the amplified fragment from the sporozoite stage was cloned in a T7 promoter-based E. coli expression vector, giving rise to plasmid pFRAP. Sequencing of the cloned DNA fragment authenticated the predicted exon structure and coding sequence for the FRAP protein (data not shown).
- pFRAP2 encoded the DNA sequence for amino acids 1-87 of the full length protein while pFRAP3 encoded the FAS1 domain represented by amino acids 88-205 ( FIG. 4 a ).
- the authenticity of these clones was also verified by sequencing.
- Recombinant Expression and Purification of FRAP proteins To obtain recombinant FRAP proteins, the desired construct was transformed in E. coli BL21 cells and the expression was induced with IPTG.
- the culture was harvested and the site of accumulation of the recombinant protein was evaluated by sub-cellular fractionation.
- the expression was localized in the spheroplast in the form of insoluble inclusion bodies (data not shown).
- Spheroplast pellet was further processed to isolate inclusion bodies, as previously described (30).
- Inclusion bodies were solubilized and the proteins were purified by a combination of affinity and gel filtration chromatography.
- the presence of a polyhistidine tag at the carboxyl terminus of the recombinantly expressed proteins facilitated the purification and all three proteins were initially purified on a His-Trap affinity column (data not shown). The proteins at this stage were 95% pure.
- FRAP is localized in the micronemes of the sporozoites: To detect the expression of FRAP on sporozoites, protein-specific antibodies were raised by immunizing mice with FRAP2 protein. Anti-FRAP2 antibodies readily recognized the expression of FRAP protein on the sporozoite (not shown). The binding was specific as pre-immune serum did not recognize any expression on the sporozoites. This indicated that transcription of FRAP mRNA can be correlated to its expression during the sporozoite stage of the lifecycle. Immunoelectron microscopy using anti-FRAP2 antibodies revealed that FRAP was localized in the lumen of micronemes, a specialized secretory organelle in the cytoplasm (not shown).
- FRAP is involved in adhesion of sporozoites to liver cells: FRAP was investigated for its possible role in host cell adhesion using a human hepatocyte cell line, HepG2, an established model for investigating sporozoite-liver cell interactions in malaria (1, 31). FRAP showed a dose dependent binding on liver cells ( FIG.
- FRAP binds liver cells through heparan sulfate proteoglycans: As FRAP showed potent liver cell binding, the nature of its receptor on liver cells was investigated by utilizing glycosaminoglycans as competitive inhibitors. Inhibition of adherence by the addition of soluble glycosaminoglycans in an assay may suggest that the involved host receptor is a proteoglycan (31, 39). In the presence of free heparin, binding activity of FRAP and FRAP2 was reduced by 55 and 60% respectively ( FIG. 6 ).
- chondroitin sulfate A showed no inhibition at the highest concentration evaluated in the assay ( FIG. 6 ).
- FRAP utilizes heparan sulfate-based proteoglycans (HSPG) as a receptor for adhesion.
- HSPG heparan sulfate-based proteoglycans
- HSPG The involvement of HSPG as a receptor was further verified by evaluating the binding of the protein on liver cells that were pretreated with specific glycosaminoglycan-cleaving enzymes.
- Cells were pre-treated with heparinase I or chondroitinase ABC followed by the evaluation of binding activity of FRAP and FRAP2.
- Heparinase I selectively removes heparan sulfate while chondroitinase ABC cleaves chondroitin sulfate A, B and C type sugars from the liver cell surface.
- FRAP and FRAP2 lost 50% of their binding activity on heparinase I treated cells (Table 4) confirming the involvement of a heparin-based receptor on the liver cell surface.
- CS protein which binds hepatocytes through HSPG (39) also showed a similar decrease in binding activity.
- treatment of liver cells with chondroitinase ABC resulted in no loss of activity.
- TABLE 4 Binding of FRAP proteins to hepatocytes is inhibited by pretreatment of cells with glycosaminoglycan cleaving enzyme. Cells were pretreated with different concentrations of either Heparinase I or Chondroitinase ABC for 90 minutes followed by the addition of 100 nM of protein. Inhibition of binding was calculated by comparing the binding of respective proteins on non-treated HepG2 cells in the same plate.
- FRAP is involved in liver cell invasion: As FRAP proteins efficiently bound to HepG2 cells, we investigated the ability of the two proteins and the anti-FRAP2 antibodies in preventing invasion of human liver cells by P. falciparum sporozoites in culture. Both FRAP and FRAP2 could prevent sporozoites from invading liver cells by 89.5% and 92.4% respectively, at the highest concentration of the protein used in the assay. This activity was comparable to the invasion inhibition activity of CSP protein, which at a similar concentration could also inhibit the invasion by 92.6%.
- Anti-FRAP2 antibodies showed extreme potency as at a concentration of 40 ⁇ g/ml, it inhibited sporozoite invasion by 94.6%, a level comparable to the inhibitory activity of anti-CS monoclonal antibody NFS1 (Table 5). This indicated that (i) FRAP not only plays a role in binding, it is also involved in the invasion process (ii) the protein utilizes its amino terminus (amino acids 1-87) for its invasion activity and (iii) a potent antibody response against FRAP2 by the host may play a role in malaria control. TABLE 5 FRAP is involved in invasion of liver cells by P. falciparum sporozoites. Invasion of HepG2 cells by P.
- % inhibition represents the decrease in the number of sporozoites that invaded liver cells in comparision to the invasion level in cells incubated with culture medium.
- Concentration Treatment ⁇ g/ml % Inhibition Culture Medium — FRAP 20 89.5 + 1.0 10 80.9 + 1.0 FRAP2 20 92.4 + 3.5 10 88.1 + 4.6 CS Protein 20 92.6 + 2.0 Anti-FRAP2 antibody 40 94.6 + 1.2 Anti-CS monoclonal 100 97.4 + 0.7 Discussion
- P. falciparum FRAP a new parasite protein and showed that it is expressed during the sporozoite stage of the lifecycle.
- Orthologs of P. falciparum FRAP were identified in rodent, avian, simian and human malaria species and multiple sequence alignment revealed that the protein has 60% sequence identity within the Plasmodium genus ( FIG. 3 ). Its universal presence and conserved nature suggested that the protein plays an important role in the biology of the parasite.
- Micronemes are specialized secretory organelles in Plasmodium and during the sporozoite stage secrete a wide variety of proteins involved in parasite motility, traversal and host cell infection.
- TRAP/SSP2 and SPECT two sporozoite proteins with adhesive Thrombospondin type I repeat (TSR) domains have been found in the micronemes and have subsequently been shown to be involved in the infectivity process (13, 37).
- TSR Thrombospondin type I repeat
- the protein was recombinantly expressed in E. coli and purified to homogeneity by column chromatography ( FIG. 4 c ).
- the purified protein showed robust and dose dependent binding to liver cells indicating that it is involved in the attachment of sporozoites to liver cells ( FIG. 5 ).
- This activity was comparable to the binding activity of CS protein, considered to be the primary binding ligand, suggesting that FRAP could be one of the primary parasite proteins involved in attachment of sporozoites to liver cells.
- ⁇ ig-h3 a FAS1 domain-containing human protein involved in corneal cell adhesion, the adhesion activities of the protein completely resides in the FAS1 domain (22).
- FAS1 domain In FRAP, we expressed FAS1 domain alone (amino acids 88-205, protein FRAP3) and evaluated its cell binding activity on HepG2 cells. The protein did not show any cell binding activity ( FIG. 5 ), indicating that the deleted segment (amino acids 1-87) of the protein plays an important role in the binding activity of the protein.
- FRAP2 protein FRAP2
- FRAP2 was capable of binding to liver cells, albeit at only half the strength of its full length protein, FRAP.
- amino terminus region of the protein plays an important role in the host cell binding, however, an intact FRAP molecule is required for its optimal activity.
- the loss of activity seen here could be due to loss of the required tertiary conformation of the binding domain (due to the absence of the FAS1 domain) and/or part of the binding motif is present in the FAS1 domain of the protein.
- CS protein where the unique amino terminus region plays an important role in liver cell binding and invasion activities of the protein (31).
- FRAP exploited heparan sulfate proteoglycans, expressed on liver cell surface, as receptor for its biological activities (Table 4). This was revealed by competition studies with defined carbohydrates, as well as loss of binding upon enzymatic removal of host glycans. Heparan sulfate-protein interactions involve positively charged residues of the protein, which interact with the negatively charged carboxylate and sulfate ions of the glycosaminoglycan chain. The amino terminus of FRAP possesses a disproportionate number of positively charged residues (13 out of the first 50) some of which are extremely conserved within the Plasmodium genus ( FIG. 3 ). Their conserved nature suggests that they could possibly be involved in these interactions. Parallels exist for such mechanism in other heparin-binding proteins where a large number of positively charged residues involved in heparin/HS interaction are present in a close proximity in the protein (40).
- FRAP is also transcribed and expressed during the erythrocytic stages of the lifecycle, especially during the schizonts, which is immediately followed by the release of merozoites and invasion of red blood cells (9, 42, 43).
- AMA1 and MAEBL two micronemal proteins that are expressed at sporozoites and erythrocytic stages of the lifecycle, are involved in pathogenesis, both, at pre-erythrocytic and blood stages, where they play a role in host cell adhesion and invasion (41, 44-46). With its multistage expression, it is possible that FRAP could also be involved in host-parasite interactions during erythrocytic stages of the lifecycle.
- the 32 amino acid region has 100% sequence homology or 87.5% sequence identity within the Plasmodium genus implying that this region plays a critical role in all the Plasmodium species and an immune response(s) generated against this region of the protein in one species could be a factual representation of immnune responses against other species, generated by its host.
- HAI-7 and HAI-2 Two other peptides (HAI-7 and HAI-10) were also recognized by the anti-protein antibodies suggesting that their recognition is also important in preventing parasites from initiating an infection. TABLE 6 Sequence of peptides chemically synthesized for identification of inhibitory epitope.
- Optimal recognition of an epitope by the host immune system requires that the epitope maintains its structural conformation. While short amino acid sequences can be easily recognized in vitro, their recognition under in-vivo conditions almost always requires them to be present as part of a much larger polypeptide. This is especially important for configurational epitopes present in the surface antigens of malaria parasite whose recognition requires that a continuous stretch of amino acids, larger than its identified epitope, be present for its optimal recognition. Therefore, a 32 amino acid long region is most likely required for optimal recognition of FRAP protein by the host immune system and it could be utilized either alone or in combination with other known and unknown malarial antigens in a vaccine.
- FRAP is a Malaria Drug Target
- heme prosthetic group serves as a challenge to its survivability. Free heme released from hemoglobin is lethal for the parasite and to escape its deleterious effects the parasite enzymatically polymerizes heme into a non-toxic byproduct known as hemozoin. Therefore, any mechanism by which polymerization of heme into nontoxic hemozoin can be inhibited will lead to a very effective therapeutic for malaria.
- FRAP is responsible for this activity.
- FRAP effectively converted toxic heme into inactive hemozoin in a dose dependent manner ( FIG. 8 ).
- the hemozoin formation activity was 10-20-fold higher in comparison to histidine rich protein II, the only known parasite protein capable of making hemozoin. This activity was specific as it was lost when the protein was pre-treated with proteinase K (a non specific protease) suggesting that an intact protein is required for this activity ( FIG. 9 ).
- the activity requires the complete protein as two truncated variants of FRAP (FRAP2 and FRAP3) did not show any hemozoin formation ( FIG. 8 ).
- the authenticity of the polymerized heme as hemozoin was verified by FT-IR spectroscopy.
- the IR spectra of hemozoin contains an intense absorbance at 1664 and 1211 cm ⁇ 1 , that are absent in the spectra of free heme (Slater et al., 1991). These are characteristics of a carboxylate group coordinated to the iron center of ferriporphyrin (Fe01-O41) arising from stretching of the localized carbon-oxygen double and single bonds, respectively (Slater et al., 1991).
- the chemical structure of ⁇ -hematin is depicted in FIG. 10 (adapted from (Pagola et al., 2000)).
- the infra red spectra of the FRAP-generated product showed the characteristic decrease in transmittance at 1664 and 1211 cm ⁇ 1 , chemically validating that the product formed was indeed hemozoin ( FIG. 11 ).
- FRAP residues involved in heme polymerization were identified by generating 11 variants of FRAP by site-directed mutagenesis. Evaluation of these mutants for heme polymerization-activity revealed that three residues viz., F42, H44 & H122 are critically involved in hemozoin formation, as their conversion to alanine lead to a complete loss of activity (Table 9).
- FRAP protein shows remarkably high amount of sequence homology between different Plasmodium species.
- a highly conserved protein sequence has biological relevance as the residues shown to be involved in hemozoin formation viz., F42, H44, H122 (Table 9) are not only conserved within the Plasmodium genus, they are also conserved in Theileria parasites. This indicates that FRAP protein from a non-human malaria parasite can be used as target for screening and development of novel inhibitors for FRAP protein of human malaria parasite.
- a time kinetic analysis for hemozoin formation revealed that the conversion of heme into hemozoin was complete within 5 hours and was pH dependent where a pH of 5.2 was required for optimal activity ( FIG. 12 ).
- Stoichiometric analysis for FRAP-Heme interaction using continuous variation method revealed that the protein has a 1:1 stoichiometry with heme ( FIG. 13 ).
- Hemozoin formation could be effectively inhibited by chloroquine, an antimalarial that is known to exerts its activity by binding to free heme and preventing its polymerization into hemozoin ( FIG. 14 ).
- FRAP is responsible for neutralization of heme through a polymerase activity and (ii) the polymerization can be inhibited by chloroquine.
- the active site residues that are critical for this activity were identified. Therefore, FRAP is an efficient drug target for malaria drug development, for example, for the design of small molecules that bind to the active site and inhibit the catalytic capability of FRAP.
- the first assay describes in detail how the hemozoin formation is investigated. This is the complete detail of the assay documenting every step of the process. This assay will be used for studying the role of an inhibitor, as inhibition of FRAP activity will cause a decrease in hemozoin formation which will b easily quantifiable by this assay. This assay was used to inhibit hemozoin formation using chloroquine and has been described as assay 2.
- the standard assay contained in a total volume of 1.0 ml: 500 mM sodium acetate pH 5.2, 300 nmol/ml hemin-Cl (as substrate) and 500 pmol/ml FRAP, as the source of heme polymerase activity.
- the amount of FRAP added was chosen such that 50% of the substrate was converted into product (insoluble hemozoin) during the assay.
- the reaction was initiated by protein addition and allowed to proceed for 16 hours at 37 degree.
- the reaction was terminated by adding 0.01 ml of 10% SDS solution.
- the reaction tube was centrifuged at 13,000 rpm for 15 minutes at 23 degrees and the supernatant was carefully removed.
- the pellet which contained the polymerized and insoluble hemozoin, was resuspended in 1 ml of 0.1M sodium bicarbonate pH 9.1 containing 2.5% SDS. At this step, any free heme present in the pellet will go into the solution at it is soluble in sodium bicarbonate while the hemozoin is insoluble. This process essentially removes any free heme that could be present in the pellet.
- the suspension was spun at 13,000 rpm and the supernatant, containing unpolymerized substrate was removed. This process was repeated thrice, followed by washing of the pellet in pure water.
- the pellet obtained after final washing was dissolved in 0.3 ml of 0.1N NaOH and the absorbance of the solution was measured at 405 nm using a spectrophotometer. Amount of heme polymerized was calculated utilizing a standard curve, prepared by dissolving known amounts of commercially available beta-hematin in 0.1N NaOH. Chemically synthesized beta-hematin and biologically polymerized hemozoin are chemically identical (Pagola et al, 2000 Nature ).
- heme polymerized was due specifically to the action of FRAP
- a parallel control incubations were performed which either did not contain any protein or contained bovine serum albumin, which was used a non-specific protein control.
- bovine serum albumin which was used a non-specific protein control.
- the hemozoin formation was also evaluated with truncated variants and point mutants of FRAP to not only describe its structural requirements, but also pin point the residues that are involved in the polymerization process.
- the inhibitor under examination was added to the standard assay cocktail (as described above) at the desired concentration and the FRAP-mediated hemozoin formation activity was compared to that found in control (minus inhibitor) incubations which lacked inhibitor.
- This assay system will be utilized for screening FRAP inhibitors. A difference in the amount of hemozoin seen in the presence of an inhibitor with respect to the reaction where the inhibitor was absent is directly attributable to the activity of the inhibitor in the reaction.
- siRNA Mediated Inhibition of FRAP Activities and Genetic Mechanisms that can Downregulate FRAP Expression Leading to Malaria Control
- DNA encoding a short segment of FRAP was cloned into a vector encoding the gene for Dihydrofolate reductase (DHFR) as a selection marker.
- DHFR Dihydrofolate reductase
- the resulting plasmid vector was transfected into parasites in culture, and the parasites were then subjected to drug pressure (e.g. Drug WR99210) to select for parasites that do not encode a functional FRAP gene.
- drug pressure e.g. Drug WR99210
- siRNA small inhibitory RNA
- sequences are delivered to the cytosol of the parasite through a plasmid DNA construct. Once in the cytosol, transcription of the siRNA occurs and prevents the expression of FRAP. The result is loss of the activity of this critical protein, without which the parasite is not able to survive.
- human Plasmodium parasites can be transformed with vectors expressing one or more siRNA molecules based on SEQ ID NOS: 2 or 8.
- Methods for design of siRNA molecules have been published by a number of sources.
- Dharmacon Inc. Reynolds, A. et al., Rational design for RNA interference (2004), Nature Biotechnology 22: 326-330
- eight design criteria optimal for effective siRNA design The siDESIGNTM Center Program provided by Dharmacon Inc.
- siRNA molecules can be used to design optimal siRNA molecules based on the SEQIDs 2 or 8, that have one or more of the following features: have low G/C nucleotide content (30-52% G/C); three or more A/U nucleotides at the 3′-terminus of the sense strand (the mRNA coding strand); a lack of internal repeats that can form secondary structures; and sequence-specific preferences at the following positions on the sense strand—an A at position 19, an A at position 3, a U at position 10, and an absence of a G or C at position 19 and a G at position 13.
- siRNA oligonucleotides can be cloned as a small hairpin RNAs (shRNA) between a Plasmodium RNA Polymerase III (Pol III) promoter, which initiates synthesis at a defined distance from the promoter, and a termination sequence consisting of a string of 4-5 uridines, or other suitable constitutive promoters can be used as well.
- shRNA small hairpin RNAs
- Poly III Plasmodium RNA Polymerase III
- siRNA expression will reduce the levels of the endogenous mRNAs corresponding to SEQ ID 2 or 8.
- WO0044895 (Kreutzer and Limmer) specifically covers the use of small dsRNAs as therapeutics, and specifically to methods and medicaments involving the use of small dsRNAs formed from two separate strands and having a region complementary to the target gene.
- FRAP performs the critical neutralization of toxic heme into non-toxic hemozoin.
- amino acids in FRAP whose conversion result in protein variants in which the heme polymerase activity has been totally lost or has been compromised (Table 7).
- Attenuated parasites may also be produced using siRNA vectors as described in the section above.
- FRAP-based fusions proteins are purified by affinity chromatography by exploiting its heme-binding properties in a column chromatography system, where the fusion protein binds to the column through available heme moiety and is cluted by excess of free heme.
- Various fusion proteins of FRAP having epitopes of CSP and TRAP may be produced by this method for use, e.g. in a vaccine.
- Fully human monoclonal antibodies against Plasmodium or Theileria antigens are made in mice directly, when these mice are engineered to produce only human antibody chains.
- the technology practiced by companies such as Abgenix Inc. [XenoMouse technology, U.S. Pat. No. 6,657,103], Medarex Inc. and GenMab A/S [HuMab Mouse or UltiMAB technology; WO2005023177] can be used. Purified proteins as described above are used to immunize such engineered mice. Monoclonals produced in this manner are produced, screened and characterized in the standard manner. Fully human antibodies are produced using phage display methods by screening against human antibody phage display libraries. For example technologies practiced by companies such as Cambridge Antibody Technology [U.S.
- Pat. No. 5,969,108 and U.S. Pat. No. 6,172,197] and others, can be used to identify fully human antibodies in this manner.
- Phage display screening has as an added advantage that the process does not rely on animal immunization.
- the genes for fully human antibodies produced using engineered mice, or identified through phage display, are isolated, sequenced and cloned for expression in mammalian cell lines for high level expression using standard methods.
- the identification, genetic characterization and functional activity of a novel Plasmodium falciparum protein that efficiently converts free heme into Hz is described.
- the protein readily converts up to 50% of free heme into Hz, at a rate that is at least an order of magnitude higher than any of the known parasite factors 6.9 capable of Hz synthesis. Therefore, the polypeptide has been designated heme detoxification protein or HDP.
- the protein may also be designated “Fasciclin Related Adhesive Protein” or “FRAP”, as is the case in the previous examples.
- HDP orthologs have also been identified in rodent, simian and avian Plasmodium species.
- HDP is highly conserved within the Plasmodium genus and appears to be essential as it's gene disruption could not be achieved in P. falciparum parasites.
- immunoelectron microscopy studies it has ben demonstrated that after merozoite invasion, ring form parasites express and secrete this protein into the erythrocyte cytosol before any detectable amount of Hz is visible inside the parasite.
- HDP accompanied by host hemoglobin, is delivered to the parasite food vacuole, the site of Hz formation. Together, these results establish HDP as a key parasite protein responsible for heme detoxification and therefore, its targeting could lead to the discovery of novel antimalarial drugs.
- Hz ⁇ -hematin 2.3
- HDP a single copy, three-exon encoded 10 , 205 amino acid long P. falciparum polypeptide (GenBank Acc#NP — 702335; FIG. 3 ) that potently detoxifies heme into Hz ( FIG. 4 c and 4 d ) was identified.
- the HDP gene was found to be actively transcribed and expressed during the intraerythrocytic stages, a phase of the lifecycle where Hz is produced by the parasite ( FIG. 4 b ).
- the coding sequence of HDP corresponding to amino acid 1-205 (SEQ ID NO: 1) was cloned in a T7 promoter-based E. coli expression plasmid and recombinant HDP was produced and purified to homogeneity ( FIG. 4 a ).
- Hz production increased with an increase in the concentration of either free heme ( FIG. 16 a ) or HDP ( FIG. 16 b ), converting up to 50% of free heme into Hz, until the reaction reached equilibrium ( FIG. 16 a ).
- HDP produced Hz at a rate of 21 nmol/hr, which was at least 20 fold higher than that of Histidine Rich Protein II (HRP II) and unsaturated (oleic acid and mono-oleoyl glycerol) lipids ( FIG. 16 a ), the only known parasite components capable of Hz synthesis. This process was HDP-dependent, as in its absence, Hz production occurred at baseline (0.1-0.2 nmol/hr) levels.
- HRP II Histidine Rich Protein II
- unsaturated (oleic acid and mono-oleoyl glycerol) lipids FIG. 16 a
- native HDP from erythrocytic stage P. falciparum parasites was purified.
- native HDP showed an approximate molecular weight of ⁇ 60 KDa, possibly due to dimerization, and was recognized by anti-HDP antibodies on a western blot ( FIG. 16 e ).
- native HDP was able to produce Hz at levels comparable to the recombinant protein ( FIG. 16 f ), which indicated that in vivo, HDP could indeed be involved in Hz formation.
- Hz formation is an indispensable step in parasite's lifecycle.
- a genetic knockout experiment in erythrocytic stage P. falciparum parasites.
- Disruption of the HDP locus was attempted by a plasmid-based single cross over recombination ( FIG. 17 a ).
- transfected parasites were subjected to three drug selection cycles over a 12 week period.
- parasites with a disrupted HDP locus could not be obtained and the resulting transfectants episomally carried the pHDPKO plasmid ( FIG. 17 b ) and expressed HDP at levels comparable to the wild type parasites (not shown), Therefore, it is highly likely that HDP plays a critical role in Hz formation and its inactivation may not be possible.
- HDP sequence were analysed for the presence of any known heme binding motif using SMART20, a domain identification tool. While HDP has no homology to any of the known heme-binding proteins, the analysis revealed that the carboxyl terminus region (amino acids 88-205) of the protein has homology (e value 3e- 10 ) to fasciclin-l, an ancient adhesive and highly diverse domain, present in proteins of prokaryotic 21 and eukaryotic 22 origin ( FIG. 3 ).
- HDP II and HRP III are only found in P. falciparum parasites but Hz formation occurs in all known species of Plasmodium .
- the genomes of seven other species of Plasmodium 23.24 were examined in silico ( FIG. 3 ).
- HDP orthologs were found in all the species with protein showing 60% sequence identity.
- the protein is functionally conserved as a recombinantly produced P. yoelii HDP generated Hz at levels indistinguishable from its P. falciparum ortholog ( FIG. 18 c ).
- HDP seems to have an ancient lineage as its homolog was found in Theileria 25 genome ( FIG. 3 ), a hemoprotozoan that sequesters heme into non-toxic aggregates during the intraerythrocytic stages of its lifecycle.
- HDP As Hz formation occurs inside the food vacuole, to be functionally relevant, one would anticipate HDP to be present inside this organelle.
- the protein lacks a classical N-terminal signal sequence or any known translocation signal that could predict its possible sorting and transport to its destined site, the presence of HDP was detected inside the food vacuole ( FIG. 20 a - d ). Therefore, to comprehend its intracellular trafficking, intraerythrocytic parasites were analyzed at different stages of development, for HDP expression. It was discovered that from the early (ring) stages of infection, HDP is secreted to the host cell cytosol, before any detectable amount of Hz was visible inside the parasite ( FIG. 20 a ). The protein accumulated inside the cytosol of the host cell ( FIG.
- This novel and circuitous trafficking of HDP is indicative of a functional convergence in the parasite where host hemoglobin, HDP and parasite protease26 involved in hemoglobin proteolysis (and located in the vesicular membrane), are transported together to the food vacliole.
- Hz formation assay The assay was performed as previously described 6 . Briefly, equimolar amounts (0.5 nmol) of HDP, HRP II or unsaturated lipids were added to freshly prepared heme solution in 500 mM sodium acetate buffer pH 5.2, followed by incubation at 37° C. for 16 hrs. The reaction was stopped by adding SDS (0.1% final conc.). Unsequestered heme was removed by repeated washing of the pellet with 2.5% SDS and 0.1 M sodium bicarbonate (pH 9.1) followed by distilled water till no soluble heme was visible in the supernatant. Hz pellet was resuspended in 0.1 N NaOH and absorbance was measured at 400 nm.
- a standard curve using different concentrations of ⁇ -hematin was prepared to quantitate the amount of heme incorporated into Hz.
- a reaction containing buffered heme alone was used as negative control.
- pH dependence of HDP was evaluated in 500 MM sodium acetate buffer of different pH (pH 3.2-6.0). All the Hz formation assays were performed at least three times in triplicates.
- Anti-HDP antibodies were raised in rabbits and affinity purified using standard protocols.
- Trophozoite stage P. falciparum (3D7 strain) parasites were isolated from a 20 ml culture using a MACS column (Miltenyi Biotec), and resuspended in 0.2 ml of solubilization buffer (20 mM Tris-Cl pH 7.4, 0.5% NP-40, 1 ⁇ Protease Inhibitor Cocktail). The suspension was subjected to a single freeze-thaw cycle and the protein extract was clarified by centrifugation at 15,000 g for 15 min at 4° C.
- Affinity purified anti-HDP antibodies were coupled to AminoLink® Plus Coupling Gel using the Seize® Primary Immunoprecipitation kit (Pierce Biotechnology), and utilized for immunoprecipitation of native HDP from the total protein extract, as per manufacturer's instructions. Purity of the protein was established by silver staining and the purified protein was authenticated by an ECL-based immunoblotting system (GE Health Care).
- Binding affinity of HDP for heme was evaluated by Isothermal titration calorimetry where freshly prepared heme solution was incrementally added to 5 ⁇ M HDP (in 50 mM MES, pH 5.6) present inside the ITC cell. Data was collected at 30° C. at a 420 rpm stir rate using 10 ⁇ l injections of the 100 ⁇ M heme into the protein solution. The resulting measurements delta H vs. molar ratio were fit to a single binding site model using the MicroCal Origin analysis software.
- HDP P. falciparum 3D7 parasites was cultured in human O+erythrocytes as described previously. Ring stage parasites at 10% parasitemia were transfected by electroporation with 100 ⁇ g of super coiled pHDPKO, a pHD22Y based transfection vector containing a 509 bp fragment from the 5′ end of the HDP gene (SEQ ID NO: 2) along with human DHFR selection cassette, using low voltage/high capacitance conditions 28 .
- Transfectants were selected in the presence of 10 nM WR99210 (a gift from Jacobus Pharmaceuticals, Princeton N.J.) and subjected to three drug selection cycles, each consisting of 21 days of growth in absence of WR99210 followed by reselection of parasites in the presence of 10 nM WR99210.
- Genotypes were analyzed by probing blots of Eco RV-Bam HI digested total parasite DNA, with a PCR amplified 509 bp fragment of HDP that has been cloned in the transfection vector. The signal was generated with an Alk Phos direct labelling and detection kit (GE Healthcare).
- Immunofluorescence Methanol fixed smears of infected RBC at 5% parasitemia were blocked with 2.5% normal goat serum (NGS) for 30 min and incubated with rabbit anti HDP antibodies at 1:200 for 1 h. Bound antibodies were detected using fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG diluted to 1:200. Parasite nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI).
- FITC fluorescein isothiocyanate
- HDP Coding sequence of HDP (SEQ ID NO: 2) was amplified by RT-PCR using total RNA from the P. falciparum (3D7 strain) erythrocytic stage parasites. The amplified fragment was cloned in pET101, a V5 epitope and polyhistidine-tag encoding, T7 promoter-based E. coli expression vector, giving rise to plasmid pHDP. Protein, expressed in BL21 cells, was localized in inclusion bodies, which were isolated as described previously 29 .
- Purified inclusion bodies were solubilized in 50 mM CAPS buffer (pH 11.0) containing 1.5% N-lauryl sarkosine and 0.3 M NaCl, for 30 min and the solubilized protein was separated by centrifugation (10,000 g; 30 min). Protein was purified by affinity chromatography on His-Trap, a high performance nickel affinity column (GE Health Care) using an imidazole gradient in 50 mM CAPS pH 11.0 containing 0.3% N-lauryl sarkosine and 0.3 M NaCl.
- Protein-containing fractions were pooled and purified to homogeneity by gel filtration chromatography on Superdex 200 10/300 GL column (GE Health Care), equilibrated in 25 mM CAPS (pH 11.0) containing 135 mM NaCl.
- PyHDP SEQ ID NO:10
- RT-PCR total erythrocytic stage P. yoelii RNA and cloned in pET101 plasmid.
- Plasmids encoding protein HDP2 and HDP3 were generated by sub-cloning using pHDP as template. Their expression and purification was performed as described above.
- DNA encoding P. falciparum Histidine rich protein II was cloned in pET101 and its expression and purification was performed as described previously.
- HDP as an Antimalarial Drug Target for the Two Major Species ( P. falciparum & P. vivax ) of Human Malaria
- P. falciparum HDP produces hemozoin in the parasite.
- the HDP ortholog from P. vivax parasites (SEQ ID NO:7) can also produce Hemozoin ( FIG. 22 ).
- the experiment was performed as described according to methods described above for the previous examples.
- P. vivax is the second most important human malaria parasite, responsible for almost 50% of the total malaria cases. Though rarely lethal, it causes severe morbidity and is a major problem in the southeastern Asia and Latin America. Therefore, with the demonstration that HDP from P. vivax (SEQ ID NO:7) also produces Hemozoin, inhibitors of HDP developed against P. falciparum parasite could also be used to prevent or treat P. vivax malaria infections.
- RNA from Plasmodium yoelii was used for amplification of the PyHDP gene.
- Primers were designed to amplify a region encoding amino acids 1 to 205 of the PyHDP gene (SEQ ID NO:9).
- a BamHI site [bold sequence] was incorporated into the 5′ primer (GGAATTCAGGAGCCCTTCGGATCCAAAAAAAAATTGTAT, SEQ ID NO: 40) and the 3′ primer (CTTCGAATTGAGCTCGGATC CTC AAATTATTGGCTTATCTATGAT SEQ ID NO: 41).
- the 3′ primer also incorporated a stop codon [underlined sequence].
- the PCR fragment (618 bp) was purified using the PCR purification kit from Qiagen and digested with BamHI.
- the base vector pVR1020 1 containing a kanamycin resistance gene was also digested with BamHI for 3 hrs at 37° C. During the last 30 min of digestion 1 unit/ ⁇ l of shrimp alkaline phosphatase was added to dephosphorylate the ends of the vector.
- the digested PCR product and pVR1020 were purified after electrophoresis on a 1% agarose gel. Ligation was carried out with various vector to insert ratios. The ligation was performed for 16 hrs at 14° C.
- mice All animal experiments were conducted in accordance with the guidelines indicated in the National Institutes of Health Guide to Laboratory Animal Care and were approved by the Virginia Tech Animal Care and Use Committee. Six week-old female BALB/c and A/j mice were used for the immunization and challenge experiment. Three groups of eight mice each were immunized as indicated in Table 10. This immunization schedule was repeated twice at intervals of 21 days for all the groups. Groups 1 and 2 were controls for protein and plasmid immunizations, and were immunized with PBS and base vector pVR1020, respectively. Purified recombinant PyHDP was used for subcutaneous immunizations at 110 ⁇ g/100 ⁇ l/mouse (group 3).
- the first dose was prepared in complete freunds adjuvant with subsequent doses given in incomplete freunds adjuvant.
- DNA was injected intramuscularly (i.m.) into the gastrocnemius muscle with a 29-gauge needle using 100 ⁇ g of DNA in 100 ⁇ l of phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- the last dose of the DNA vaccine immunization regime was with recombinant PyHDP at 100 ⁇ g/100 ⁇ l/mouse prepared with incomplete freunds adjuvant and was administered subcutaneously.
- Sporozoite preparation Anopheles stephensi mosquitoes were reared in cages at 27° C. and >80% relative humidity and were fed with 10% sucrose solution every alternate day [2]. For the development of the sporozoite stage, mosquitoes starved of sucrose for 24 hrs, were allowed to blood feed on anesthetized P yoelii infected mice for 10 minutes. Samples of salivary glands and stomach were prepared beginning 10 days post feeding to monitor the development of the mosquito stages of the parasite.
- Sporozoites were isolated using the Ozaki method 3 . Briefly, on the day of challenge (day 0) the mosquitoes were anesthetized with chloroform and thorax dissected in complete M199 medium. Crushed thorax was loaded on a silanized glass wool column prepared in Eppendorf tubes, and was centrifuged at 2500 rpm to collect the flow through. The pellet from 2-3 such tubes were resuspended and pooled. Sporozoites were counted using a hemocytometer and resuspended in complete M199 medium at a concentration of 100 sporozoites per 100 ⁇ l. Immunized mice were challenged with 100 sporozoites injected via the tail vein.
- a panel of candidate compounds were tested for their ability to inhibit HDP from P. falciparum .
- the protein was prepared as described above. The testing was carried out as follows:
- HTS screening for identification of HDP inhibitors. HTS screening was performed at the Chemical Genomics Center of the Broad Institute of Harvard and MIT (Cambridge, Mass.). A 2 ⁇ protein stock (10 ⁇ M) was prepared in 200 mM Sodium acetate buffer at pH 5.6. and 35 ⁇ l of this solution was dispensed in each well of a 384 well plate, using an automated dispenser. Through a robotized transfer mechanism involving steel pins, each of the protein-containing well (in a 384 well plate) received 300 nl of a compound. After the addition of the compound, the plate was incubated at room temperature for 60 minutes, followed by an addition of 35 ⁇ l of freshly prepared heme solution at a concentration of 20 ⁇ M.
- HTS was performed in 384 well plates where in typical reaction 5 ⁇ M HDP was allowed to interact with 10 ⁇ M heme in the absence (control) or presence of excess of a chemical compound. The concentration of the chemical compound was in 40-50 ⁇ M range. HDP-heme interaction was measured at 414 nm in the presence of the compounds and compared with control reactions that only received the carrier (DMSO). The final concentration of DMSO in the reaction was 0.4%.
- Antimalarial activity of HDP-inhibitors on P. falciparum parasites A total of 327 inhibitors were screened for their antimalarial activity in a P. falciparum parasite-based cellular assay. Rescreening of these compounds was performed at 20-40 micromolar final concentration. Parasites were incubated with the compounds for 60 hours followed by the measurement of parasite DNA content utilizing a fluorometric assay. The results presented in Table 11 show the percent inhibition for compounds at the highest concentration tested in the cell-based antimalaria assay. At the highest concentration tested, this screen identified 73 compounds that showed statistically significant >50% inhibition of the growth of human malaria parasite in culture (Table 11).
- versions of these compounds may also be developed that are optimized for in vivo use, i.e. for bioactivity.
- optimization may involve, for example, modifications to increase or decrease the charge of the molecule (e.g. to increase or decrease solubility, hydrophilicity, hydrophobicity, affinity for biological membranes, etc.); to increase toxicity to the parasite; or to decrease toxicity to the individual being treated.
- modification may also involve the substitution of charged groups (e.g. carboxyl groups replaced by sulfates or vice versa); the substitution or replacement of carbon chains (e.g.
- the present invention additionally provides methods for obtaining such derivatives by applying one or more well-known chemical reactions to a given compound, to provide a derivative wherein one or more phenolic hydroxyl group(s) may instead be replaced by an ester, sulfonate ester, or ether group; one or more methyl ether group(s) may instead be replaced by a phenolic hydroxyl group; one or more phenolic hydroxyl group(s) may instead be replaced be an aromatic hydrogen substituent; one or more secondary amine site(s) may instead be replaced by an amide, sulfonamide, tertiary amine, or alkyl quaternary ammonium salt; one or more tertiary amine site(s) may instead by replaced by a secondary amine; and
- one or more aromatic hydrogen substituent(s) may instead be replaced by a halogen, nitro, amino, hydroxyl, thiol, or cyano substituent.
Abstract
Description
- This application is a continuation-in-part of and claims benefit of U.S. patent application Ser. No. 11/249,355, the complete contents of which are hereby incorporated by reference.
- 1. Field of the Invention
- The invention generally relates to therapies for the treatment and prevention of certain parasitic diseases. In particular, the invention provides method of inhibiting the ability of Heme Detoxification Protein (HDP) to form hemozoin from heme, thereby treating or preventing diseases caused by Plasmodium and/or Theileria species.
- 2. Background of the Invention
- Malaria, a blood-borne infection caused by Plasmodium parasites, is a major health issue in the tropics, with 300-500 million clinical episodes of this disease occurring each year. A licensed vaccine against malaria is not available and the parasite is developing resistance against most of the currently available antimalarials. There is an urgent need to develop new therapeutics (drugs and vaccines) against malaria, which will reduce the morbidity and mortality associated with this disease. The genome of Plasmodium falciparum has been sequenced and can be exploited to understand the molecular basis of the onset and sustenance of infection by these pathogens. Deciphering these mechanisms will unravel the complex interplay between the troika of host, pathogen and its environment, which is vital for identifying new targets for intervention.
- Malaria infection starts with the introduction of Plasmodium sporozoites into the blood stream of its human host, when it is bitten by an infected mosquito. Of the four Plasmodium species that infect humans, P. falciparum is the most virulent—resulting in severe anemia and cerebral malaria, which can be fatal. Fewer than 200 sporozoites are introduced and even fewer succeed in invading liver cells, the target organ for the onset of malaria infection in a host. A successful adhesion and liver cell invasion by the sporozoite is critical for this onset and is therefore, the Achilles heel of the parasite. Once inside the liver cell, the parasite rapidly multiplies and within a few days releases thousands of parasites, which leads to the clinical pathology of this disease. Therefore, an ideal approach to control malaria is to develop a vaccine or therapeutic, which either prevents the sporozoite from infecting liver cells or destroys the parasite during liver stages of its life cycle. Such a vaccine is feasible as animals and human volunteers immunized with Plasmodium sporozoites that have been attenuated by exposure to X-Ray or gamma radiation, are protected when subsequently challenged with infectious sporozoites (Hoffman, et al. (2002) J Infect Dis, 1155-1164; Nussenzweig et al. (1967) Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature, 216, 160-162.). While this groundbreaking discovery clearly indicated that it is feasible to make a vaccine against malaria, the biggest stumbling block for malaria researchers worldwide has been to decipher the parasite antigens recognized by the host and to understand the immune mechanisms underlying this protection. Extensive immunological studies with known sporozoite antigens have concluded that this protection is not conferred due to a dominant immune response against a single antigen but is mediated by the summation of many modest humoral and cell-mediated immune responses against a large variety of antigens, many of which are currently not known (Hoffman, S. (1996) Malaria Vaccine Development: A multi immune response approach. ASM press, Washington, D.C.). Identification of these antigens is not only the major challenge, it is vital for the development of a successful vaccine against malaria.
- Historically, antigen(s) selected as a vaccine candidate in a given pathosystem are (i) present on the surface of the pathogen, (ii) are generally involved in host-pathogen interactions and are therefore, one of the first molecules that are recognized by the host immune system (Moxon, R. and Rappuoli, R. (2002) Br Med Bull, 62, 45-58). These criteria are also valid for malaria parasite as the two major vaccine candidates viz., Circumsporozoite protein (CSP) (Cerami, C. et al. (1992) Cell, 70, 1021-1033) and Thrombospondin-related anonymous protein (TRAP) (Robson, et al. (1995) Embo J, 14, 3883-3894) are involved in the invasion of liver cells by the parasite.
- Upon entering red blood cells, the Plasmodium parasite undergoes rapid multiplication giving rise to 28-32 parasites in less than 48 hours. Hemoglobin represents ˜95% of the total RBC content, and the parasite digests up to 75% of the hemoglobin, which serves as its source of amino acids. While this process of hemoglobin digestion provides the parasite with a ready source of amino acids, it also releases free heme, which in the absence of a globin moiety, is extremely toxic for the parasite (Gluzman, et al. (1994) J Clin Invest, 93, 1602-1608.). The parasite survives by effectively neutralizing toxic heme into a non-toxic and polymerized product known as hemozoin, which is chemically identical to β-hematin (Francis,et al. (1997) Annu Rev Microbiol, 51, 97-123. Most of the currently available antimalarials have been shown to be binding to free heme, which inhibits its polymerization, and the toxicity resulting from the free heme causes the death of the parasite (Slater and Cerami (1992) Nature, 355, 167-169). Therefore, pathway(s) that lead to hemozoin formation are extremely attractive drug targets. Unfortunately, the mechanism(s) in use by the parasite for the polymerization process is poorly understood. Two parasite proteins viz., Histidine rich protein II and III have been proposed to be responsible for this activity (Sullivan, et al. (1996) Science, 271, 219-222.), though parasites lacking either or both of the proteins make copious amounts of hemozoin without any loss of activity (Wellems, et al. (1991) Proc Natl Acad Sci USA, 88, 3382-3386). Therefore, an unknown protein(s) has been long thought to be responsible for this activity.
- The prior art has thus far failed to provide satisfactory vaccines or drug therapies to combat diseases caused by parasites such as Plasmodium. There is thus an ongoing need to identify and characterize potential targets for such therapeutic intervention.
- The parasite protein “Fasciclin Related Adhesive Protein” (“FRAP”), which is also referred to as “Heme Detoxification Protein (“HDP”) herein, has been discovered, and its use as a target for therapeutic intervention in parasitic diseases is described herein. The designations “FRAP” and “HDP” are used interchangeably herein. FRAP (HDP) is expressed during the infective forms of parasites such as Plasmodium and Theileria, is intimately involved in the onset of parasitic infections, and key sequences of the protein are highly conserved across Plasmodium species and related genera. Thus, this protein is an ideal target for the treatment and/or prevention of parasitic diseases by a variety of methods, including vaccine development. In addition, FRAP (HDP) catalyzes the neutralization of toxic heme into non-toxic hemozoin. Thus, FRAP (HDP) is an attractive target for inhibitory drug therapies. Such therapies may include, for example, the use of compounds that bind to the HDP protein to either prevent the binding of heme, or to prevent the conversion of bound heme to hemozoin. Alternatively, such therapies may involve the use of compounds that bind to heme to prevent it from binding to HDP, or to prevent its conversion to hemozoin after binding. The details of these and other mechanisms of action are described in detail below.
- The present invention provides a composition for eliciting an immune response to Plasmodium. The composition comprises a substantially purified synthesized or recombinant protein comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a substantially purified synthesized or recombinant protein comprising an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25. The composition may further include at least one of: one or more additional antigens, and one or more adjuvants. The composition may further include one or more additional peptides, polypeptides or proteins each of which is different from said substantially purified synthesized or recombinant protein.
- The invention also provides a composition for eliciting an immune response to Plasmodium, which comprises a substantially purified synthesized or recombinant peptide, polypeptide or protein comprising an amino acid sequence represented by SEQ ID NO: 37. The substantially purified synthesized or recombinant peptide, polypeptide or protein may comprise an amino acid sequence represented by SEQ ID NO: 24, or an amino acid sequence that displays at least about 85% identity to SEQ ID NO: 24. The composition may further include at least one of: one or more additional antigens, and one or more adjuvants. The composition may further include one or more additional peptides, polypeptides or proteins each of which is different from the substantially purified synthesized or recombinant peptide, polypeptide or protein.
- In addition, the invention provides a vaccine comprising a substantially purified synthesized or recombinant protein comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a substantially purified synthesized or recombinant protein comprising an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25. The vaccine may further include at least one of one or more additional antigens, and one or more adjuvants.
- In another embodiment, the invention provides a vaccine comprising a substantially purified synthesized or recombinant peptide, polypeptide or protein comprising an amino acid sequence represented by SEQ ID NO: 37. The substantially purified synthesized or recombinant peptide, polypeptide or protein may comprise an amino acid sequence represented by SEQ ID NO: 24, or an amino acid sequence that is at least 85% identical to SEQ ID NO: 24. The vaccine may include at least one of: one or more additional antigens, and one or more adjuvants. The vaccine may further include one or more additional peptides, polypeptides or proteins each of which is different from the substantially purified synthesized or recombinant peptide, polypeptide or protein.
- In another embodiment, the invention provides a substantially purified synthesized or recombinantly produced antibody specific for: a protein with an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 25; or a protein with an amino acid sequence that displays at least 90% identity to SEQ ID NO: 1 or SEQ ID NO: 25. In some embodiments, the antibody is chimeric, humanized, or fully human.
- In another embodiment, the invention provides a substantially purified synthesized or recombinantly produced antibody specific for: a peptide with an amino acid sequence represented by SEQ ID NO: 37, or a peptide with an amino acid sequence represented by SEQ ID NO: 24. In some embodiments, the antibody is chimeric, humanized, or fully human.
- The invention further provides a transfected cell comprising expressable recombinant DNA that encodes: one or more of a peptide, polypeptide or protein which is or includes an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 37; or one or more of a peptide, polypeptide or protein which is or includes an amino acid sequences that displays at least 90% identity with one or more of SEQ ID NO: 1, SEQ ID NO: 25, or SEQ ID NO: 37, or at least about 85% identity with SEQ ID NO: 24. In another embodiment, such transfected cells are used to elicit an immune response and/or to serve as a vaccine.
- In yet another embodiment, the invention provides a method of treating or preventing a disease caused by a Plasmodium parasite in a patient in need thereof. The method comprises the step of administering to the patient one or more antibodies specific for one or more amino acid sequences represented by SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 37.
- The antibody may be synthesized or recombinantly produced.
- In yet another embodiment, the invention provides a method of eliciting an immune response to a Plasmodium parasite in a patient in need thereof. The method comprises the step of administering to the patient one or more peptides, polypeptides or proteins which comprise one or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 37, and amino acid sequences which display at least 90% identity with SEQ ID NO: 1, SEQ ID NO: 25, SEQ ID NO: 37, or at least about 85% identity with SEQ ID NO: 24. The peptides, polypeptides or proteins may be synthesized or recombinantly produced.
- In yet another embodiment, the invention provides a method of treating or preventing a disease caused by a Plasmodium or Theileria parasite in a patient in need thereof. The method comprises the step of administering to the patient a compound that inhibits FRAP protein. In one embodiment, the patient is an animal. In one embodiment, the compound is an antibody.
- In some instances, the compound interacts with a peptide, polypeptide protein that comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37. In addition, the compound may bind to or interact with one or more of amino acid residues F42, H44 and H122 of FRAP protein encoded by SEQ ID NOS: 1, 7 and 11, or with one or more equivalent amino acid residues in other FRAP proteins, i.e. amino acid residues that fulfill the same or a similar function in another FRAP protein, such as the proteins encoded by SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19.
- In yet another embodiment, the invention provides a whole organism vaccine against a parasite. The vaccine comprises an attenuated parasite which is unable to produce a fully functional FRAP protein. The attenuated parasite may include one or more mutations or deletions in a coding region that encodes the fully functional FRAP protein. One or more mutations may be in a coding region that encodes the fully functional FRAP protein at a site which encodes for an amino acid residue selected from the group consisting of phenylalanine 42, histidine 44, phenylalanine 64, histidine 79,
phenylalanine 90, histidine 122, cysteine 191, histidine 192 and histidine 197 of FRAP proteins encoded by SEQ ID NOS: 1, 7 and 11, or the equivalent amino acid residues in other FRAP proteins, i.e. amino acid residues that fulfill the same or a similar function in another FRAP protein, such as the proteins encoded by SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19. In one embodiment, the parasite is unable to produce a fully functional FRAP protein due to RNA silencing. In another embodiment, the parasite is unable to produce normal levels of a fully functional FRAP protein due to attenuation of a promoter that is operably linked to DNA encoding FRAP. - The invention also provides a method for high throughput screening for antimalarial agents that inhibit the conversion of heme to hemozoin. The method comprises the steps of: providing a potential antimalarial agent; determining a first level of conversion of heme substrate to hemozoin by FRAP in the presence of said potential antimalarial agent, and a second level of conversion of heme substrate to hemozoin by FRAP in the absence of said potential antimalarial agent; and comparing said first level of conversion to said second level of conversion, wherein if said second level of said conversion is higher than said first level of conversion, said potential antimalarial agent inhibits the conversion of heme to hemozoin. In some embodiments, FRAP has one or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.
- The invention also provides a method for expression and purification of a recombinant protein. The method comprises the step of providing a vector that operably encodes the recombinant protein, wherein said recombinant protein comprises one or more of SEQ ID NO: 1 or SEQ ID NO: 25. The recombinant protein may be a fusion protein, and may comprise one or more copies of SEQ ID NO: 24 or SEQ ID NO: 37. The vector may also encode an antigen such as CSP or TRAP.
- The invention also provides a method for diagnosing prior exposure to Plasmodium or Theileria. The method comprises the steps of: obtaining a biological sample from a patient and determining whether at least one of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37, or an antibody to at least one of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37 is present in said biological sample.
- The invention also provides a diagnostic assay for determining exposure to Plasmodium or Theileria, comprising: one or more substances capable of selectively binding i) at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37; or ii) an antibody to at least one of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 37; and one or more labels which are activated upon binding by said one or more substances.
- The invention also provides a method for identifying compounds that inhibit heme neutralization by FRAP. The method comprises the steps of a) contacting FRAP, or an extract containing FRAP, with a known amount of heme, in the presence or absence of a known dilution of a test compound; and b) quantitating a percent inhibition of said heme neutralization by said test compound by comparing differences in said heme neutralization in the presence and absence of said test compound. FRAP may have one or more amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.
- The invention also provides a method for diagnosing exposure (prior or ongoing) to Plasmodium or Theileria. The method comprises the steps of: obtaining a biological sample from a patient and determining whether at least one of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 38, is present in said biological sample. The step of determining may be performed using polymerase chain reaction.
- The invention also provides a diagnostic kit or assay for determining exposure (prior or ongoing) to Plasmodium or Theileria. The kit or assay comprises: one or more nucleic acids which hybridize to one or more nucleic acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 39; and a mechanism for detecting hybridization. The kit may further comprise means for quantifying an amount of hybridization, and the one or more nucleic acids may be bound to a substrate, such as a biochip.
- The invention further provides a composition for eliciting an immune response to Plasmodium. The composition comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 1. SEQ ID NO: 7 or SEQ ID NO: 25. The nucleic acid sequence may be SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26 or a sequence that displays at least 90% homology to SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26. The composition may contain one or more adjuvants. The composition may contain a nucleic acid encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26. In one embodiment, the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- The invention also provides a composition for eliciting an immune response to Plasmodium which comprises a nucleic acid sequence encoding the amino acid sequence represented by SEQ ID NO: 37. In one embodiment, the nucleic acid sequence comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 24. The nucleic acid sequence may be SEQ ID NO: 38 or SEQ ID NO: 39, or a sequence that displays at least 90% homology to SEQ ID NO: 38, or a sequence that displays at least 85% homology to SEQ ID NO: 39. The composition may contain one or more adjuvants, and may further comprise nucleic acids encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 38 or SEQ ID NO: 39. In one embodiment, the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- The invention also provides a vaccine for eliciting an immune response to Plasmodium, the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 7 or SEQ ID NO: 25. In some embodiments, the nucleic acid sequence is SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26, or a sequence that displays at least 90% homology to SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26. The composition may contain one or more adjuvants, and may comprise a nucleic acid encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 26. In one embodiment, the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- The invention further provides a vaccine for eliciting an immune response to Plasmodium, the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 37. In one embodiment, the nucleic acid sequence comprises a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 24. The nucleic acid sequence may be SEQ ID NO: 38 or SEQ ID NO: 39, or a sequence that displays at least 90% homology to SEQ ID NO: 38, or a sequence that displays at least 85% homology to SEQ ID NO: 39. The composition may contain one or more adjuvants, and may comprise nucleic acids encoding one or more peptides, polypeptides or proteins which are not encoded by SEQ ID NO: 38 or SEQ ID NO: 39. In one embodiment, the nucleic acid sequence is contained in a vector, for example, an adenoviral vector.
- The invention further provides a vaccine for eliciting an immune response to Theileria, the vaccine comprising a nucleic acid sequence encoding an amino acid sequence represented by SEQ ID NO: 17 or SEQ ID NO: 19. In some embodiments, the nucleic acid sequence is SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence that displays at least 90% homology to SEQ ID NO: 18 or SEQ ID NO: 20.
- The invention further provides a method of treating or preventing a disease caused by a Plasmodium or Theileria parasite in an individual in need thereof. The method comprises the step of inhibiting interaction of heme and Heme Detoxification Protein (HDP) in the individual. Such individuals are typically mammals, and can be of any species that are susceptible to infection by Plasmodium or Theileria parasites, e.g. humans, cows, etc.
- In one embodiment of the invention, the step of inhibiting is carried out by administering to the individual one or more compounds that inhibit interaction of heme and HDP. In some cases, the one or more compounds bind to heme and may, for example, 1) prevent heme from binding to HDP, or 2) allow the binding of heme to HDP but prevent detoxification of heme by HDP. In other embodiments, the one or more compounds bind to HDP and may, for example, 1) prevent binding of heme to HDP, 2) prevent the production of hemozoin from bound heme, 3) bind at the active site of HDP, or 4) bind at an allosteric site of HDP. In other embodiments, the step of inhibiting is carried out by modification of a cell membrane of the Plasmodium or Theileria parasite. In yet another embodiment, the step of inhibiting is carried out by inhibiting secretion of HDP from the Plasmodium or Theileria parasite.
- In a preferred embodiment of the inveniton, the disease that is treated or prevented is malaria. In this case, the compound may be administered to an individual in combination with one or more of: an additional antimalarial agent, an agent for reversing antimalarial resistance, and an adjuvant. Administration of the compound may be prior to, concurrent with, or subsequent to administration of the additional antimalarial agent or said agent for reversing antimalarial resistance. Suitable additional antimalarial agents include a) quinolines, b) folic acid antagonists, c) sulfonamides, and d) antibiotics. Suitable agents for reversing antimalarial resistance are, for example, inhibitors of multidrug resistance. Administration may be accomplished, for example, orally, parenterally, sublingually, rectally, topically or with an inhalation spray.
- The invention further provides a method of treating an individual infected with Plasmodium or Theileria or who has been or will be exposed to Plasmodium or Theileria, The method comprises the step of providing the individual with one or more compounds that inhibit the ability of HDP to produce hemozoin from heme. In some cases, the one or more compounds bind to heme and may, for example, 1) prevent heme from binding to HDP, or 2) allow the binding of heme to HDP but prevent detoxification of heme by HDP. In other embodiments, the one or more compounds bind to HDP and may, for example, 1) prevent binding of heme to HDP, 2) prevent the production of hemozoin from bound heme, 3) bind at the active site of HDP, or 4) bind at an allosteric site of HDP.
- The invention further provides a method for identifying compounds that inhibit HDP expression. The method comprises the steps of a) contacting Plasmodium with a test compound and b) determining whether the Plasmodium expresses HDP. The step of determining may be carried out, for example, by measuring mRNA or by measuring HDP.
- The invention further provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an antimalarially effective amount of at least one compound selected Table 11 below.
-
FIG. 1A -J. This figure shows the amino acid sequences of the FRAP protein in a variety of organisms as follows: A, Plasmodium falciparum; B, Plasmodium vivax; C, Plasmodium gallinaceum; D, Plasmodium knowlesi; E, Plasmodium reichenowi; F, Plasmodium yoelii; G, Plasmodium berghei; H, Plasmodium chaubaudi; I, Theileria parva, and J, Theileria annulata. -
FIG. 2A -J. This figure shows the nucleic acid sequences that encode the FRAP protein in a variety of organisms as follows: A, Plasmodium falciparum; B, Plasmodium vivax; C, Plasmodium gallinaceum; D, Plasmodium knowlesi; E, Plasmodium reichenowi; F, Plasmodium yoelii; G, Plasmodium berghei; H, Plasmodium chaubaudi; I, Theileria parva, and J, Theileria annulata. The sequences represent the coding sequence of FRAP from different parasites. The gene itself is present on three separate exons and the sequence provided below is intron-free and represents only the coding sequence of the protein. -
FIG. 3 : Multiple sequence alignment of FRAP from Plasmodium and Theileria parasites. Sequences were aligned using the Clustal W algorithm. Amino acids in bold (60 total) represent residues that are conserved across the two genera of phylum apicomplexa. Residues marked with an asterisk represent amino acid positions that are identical only in the Plasmodial genus. Overall, the Plasmodial sequences have 60% sequence identity. FAS1 domain of FRAP has been aligned with the consensus sequence of FAS1 domain (SEQ ID NO: 21) and has an e-value of 2e-10. The two conserved motifs have been underlined. -
FIG. 4 . Schematic representation of P. falciparum FRAP gene organization and the expressed recombinant proteins. (A) FRAP represents the fulllength protein encoding 205 amino acids.FRAP 2 represents a truncated version of the full length protein containing only amino acids 1-87, whileFRAP 3 represents amino acids 88-205, encoding theFasciclin 1 domain. (B) RT-PCR analysis of PfFRAP. DNA encoding the coding region of FRAP was amplified by RT-PCR using total RNA from sporozoite stage of the parasite's lifecycle. The amplification was performed in the presence (+RT) and absence of reverse transcriptase (−RT) to rule out the direct amplification from any contaminating genomic DNA. (C) Recombinant Expression and Purification of PfFRAP proteins. Full-length FRAP (lane 1) and its truncated variants, FRAP2 (lane 2) and FRAP3 (lane 3) were purified to homogeneity by a two step chromatography. (D) Western Blot analysis. Purified proteins were resolved on a 12% Nu-PAGE gel; transferred onto a nitrocellulose membrane and the membrane was probed using anti-FRAP2 antibody followed by an anti-mouse HRP conjugate. -
FIG. 5 . Binding analysis of FRAP proteins on HepG2 cells. Five different concentrations of recombinant proteins were investigated for their potential to bind to liver cells. Bound protein was detected using anti-polyhistidine monoclonal followed by the addition of anti-mouse alkaline phosphatase conjugate and a fluorescent substrate. Fluorescence was measured using a plate reader with excitation at 350 nm and emission at 460 nm. Black bars: CS protein; Hashed bars: FRAP; Grey bars: FRAP2; White bars: FRAP3. -
FIG. 6 . Nature of FRAP receptor on liver cells. Binding activity of the FRAP proteins was evaluated on liver cells in the absence or presence of different concentrations of heparin and Chondroitin sulfate A. Panel A: FRAP; Panel B: FRAP2. Blank and hashed bars represent inhibition of binding activity in the presence of different concentrations of heparin and chondroitin sulfate A, respectively.FIG. 7 . Overlap between FRAP-based peptides. Ten overlapping peptides spanning the FRAP2 sequence were synthesized and utilized for the identification of regions(s) recognized by antibodies specific for FRAP. -
FIG. 8 . FRAP-mediated neutralization of toxic heme into non-toxic Hemozoin. 500 pmoles of each of the protein was incubated with different concentrations of free heme at 37° C. for 16 hours, under acidic conditions (500 mM Sodium acetate pH 5.2). After 16 hours, free heme was removed by washing and the insoluble pellet representing hemozoin was solubalized in sodium hydroxide and estimated using a spectrophotometer. FRAP showed 10-20 fold more activity in comparison to HRPII, indicating that it could be the major protein responsible for polymerization of heme in the parasite. -
FIG. 9 . FRAP-mediated hemozoin formation requires intact protein. Hemozoin formation was investigated with FRAP pretreated with proteinase K, a nonspecific protease or with buffer alone. Incubation of FRAP with Proteinase K led to a complete loss of activity suggesting that the conversion of heme into hemozoin requires intact FRAP protein. -
FIG. 10 . Chemical structure of hemozoin. Dimerization of heme through a Fe1-O41 linkage leads to the formation of β-hematin. Oxygen mediated non-covalent interaction between β-hematin units leads to the stacking and the polymerized product is known as hemozoin. Adapted from (Pagola et al., 2000) -
FIG. 11 . Spectroscopic verification of FRAP-mediated polymerized heme as hemozoin. Heme polymerized into hemozoin was subjected to Fourier transform-Infra Red (FT-IR) spectroscopy to verify its chemical nature. The insoluble product showed a dramatic decrease in transmittance at 1664 and 1211 cm−1, a well established spectroscopic signature of β-hematin. -
FIG. 12 . Time Kinetics of hemozoin formation. FRAP-mediated hemozoin formation was investigated with respect to time. 500 pmoles of protein was incubated with 300 nmoles of heme for different times and the amount of heme polymerized was measured as previously described. Hemozoin formation was found to be essentially complete by 5 hours. -
FIG. 13 . Stoichiometry of FRAP-Heme Interaction. Stoichiometry of the FRAP-Heme interaction was determined spectrophotometrically by continuous variation method (Job Plot). Change in absorbance was measured by using different molar ratios of FRAP-heme complex. FRAP-Heme have a 1:1 stoichiometry. -
FIG. 14 . Inhibition of FRAP-mediated hemozoin formation by Chloroquine. Hemozoin formation was investigated in the absence or presence of different concentrations of chloroquine, an antimalarial drug with high affinity for heme. Chloroquine inhibited heme polymerization in a dose dependent manner. This indicates that blocking FRAP-Heme interaction could serve as an effective antimalarial strategy. -
FIG. 15A and B. A, amino acid and B, nucleic acid encoding the FRAP2 derivative of FRAP. -
FIG. 16A -F. HDP detoxifies and sequesters heme as Hz. a, HDP (black bar) mediated Hz production is dose dependent and could be up to 20 fold higher than HRP II (light grey bar), oleic acid (dark grey bar) or mono-oleoyl glycerol (white bar). Values are mean ±s.d b, Hz production increases, with increasing amount of HDP (0-0.5 nmol) in a reaction containing 300 nmol of free heme. c, Fourier transform infrared spectrum of HDP-derived product showed absorption peaks at 1660 and 1210 cm-1, which validated it as Hz. d, HDP-mediated Hz production is restricted to a pH range found inside the food vacuole. e, Native P. falciparum HDP purified from intraerythrocytic parasites. Silver stained gel (left panel), Immunoblot (right panel). f, Native HDP (black bar) can produce Hz. Hashed bar represents recombinant protein. -
FIG. 17A -B. HDP gene is important for the survival of the parasite. a, Schematic representation of strategy used for targeting HDP locus through single cross over recombination. The anticipated cross-over event at the HDP locus and restriction enzyme sites Bam HI (B) and Eco RV (E) are shown. b, Lanes a and b depict Bam HI-linearized pHDPKO (6.3 kb) and Bam HI and Eco RV digested DNA from wild type P. falciparum parasites containing the HDP locus (5.3 kb), respectively. Parasites surviving after three selection cycles (lanes c, d) had an intact HDP locus and an episomal copy of the pHDPKO plasmid expressing hDHFR. Bar represents 500 bp. -
FIG. 18A -C. Structural and biochemical analysis of HDP-mediated Hz formation.a, Heme (100 μM) solution was titrated into protein (5 μM) and the heat evolved was measured by Isothermal titration calorimetry. Binding isotherm integrating the data from the top panel. b, Full length HDP is necessary for Hz formation as HDP2 (circle) and HDP3 (triangle) alone could not produce Hz. c, Hz formation activity of P. yoelii HDP (grey bars) is indistinguishable from its P. falciparum ortholog (black bars). Values are mean ±s.d. with data from at least two independent experiments. -
FIG. 19A -D. Cloning, expression and purification of HDP proteins. a, RT-PCR amplification of HDP coding sequence. b, Schematic representation of HDP gene structure, HDP protein and its two truncated variants. c, Recombinantly expressed and purified HDP proteins on a 12% Coomassie stained gel under reducing conditions. d, Immunoblot of purified proteins with anti-HDP antibodies. -
FIG. 20A -D. Circuitous transport and delivery of HDP to the food vacuole. a, HDP is secreted into the cytosol of infected erythrocytes (arrowhead) in early ring stages before any Hz could be detected inside the parasite. b, After secreting it into the host cell cytosol, parasite intakes HDP through the cytostome c, HDP could be found in transport vesicles destined to the food vacuole. d, Transport vesicles deliver HDP to the food vacuole where it was present in close proximity of Hz crystals. cyt, cytostome; fvm, food vacuole membrane; fv, food vacuole; hz, hemozoin; hdp, heme detoxification protein; hb, hemoglobin; nu, nucleus; par, parasite; ppm, parasite plasma membrane; pvm, parasitophorous vacuole membrane; irbc, infected red blood cell; rbcm, RBC membrane; tv, transport vesicle. Bar, 0.5 μm. -
FIG. 21A -C. HDP is transported to food vacuole along with hemoglobin. a, HDP(18 nm particles) was found in the cytosol of infected cells. Inset b, HDP is being internalized along with hemoglobin (12 nm particles). Inset c, Transport vesicle ready to deliver both, HDP and hemoglobin to the food vacuole. Bar, 0.5 μm. -
FIG. 22 . Comparison of Hemozoin production by HDP protein from P. vivax and P. falciparum. -
FIG. 23 . Results of immunization of mice with either DNA encoding HDP from P. yoelii or with P. yoelii HDP protein. - The present invention is based on the discovery of several surprising properties of a previously uncharacterized family of parasite proteins. The protein family has been designated “FRAP” for “Fasciclin Related Adhesive Protein”. Alternatively, the protein is denominated “HDP” for “Heme Detoxification Protein”. Herein “FRAP” and “HDP” designate the same entity. This protein is expressed by Plasmodium and Theileria parasites and is intimately involved in the onset of parasitic infections. Hence, the FRAP (HDP) family of proteins, and the nucleic acids that encode them, are ideal targets for the treatment and/or prevention of certain parasitic diseases.
- The initial FRAP protein was selected for study based on a systematic analysis of the genome of Plasmodium falciparum using a combination of in-silico algorithms, microarray and proteomic techniques. This process is described in detail in Example 1 of the Examples section. The study predicted that FRAP should be expressed on the surface of the P. falciparum sporozoite, and thus would be involved in early interactions between the sporozoite and host cells, making it an attractive target for therapeutic intervention. These predictions have been confirmed. FRAP protein is present in micronemes, a specialized secretory organelle that transports proteins to the surface of the Plasmodium sporozoite. FRAP and an 87 amino acid polypeptide derivative, FRAP2 (amino acid sequence, SEQ ID NO: 25; nucleic acid sequence, SEQ ID NO: 26;
FIG. 15 ) bind to liver cells, thereby preventing sporozoite invasion. Further, antibodies specific for FRAP2 also prevent sporozoite invasion of liver cells. A thirty-two amino acid sequence that is recognized by these antibodies, encodes the inhibitory epitope and is common to the FRAP family of proteins (TRSGGLRKPQKVTNDPESINRKVYWCFEHKPV, SEQ ID NO: 24), has also been discovered. This sequence shows 100% sequence homology and 87.5% sequence identity within the Plasmodium genus. In addition, the enzymatic activity of FRAP has been elucidated. FRAP catalyzes the neutralization of toxic heme into non-toxic hemozoin, making this protein a highly significant target for inhibitory drug therapy. - Herein we describe the application of these discoveries to the prevention and treatment of parasitic diseases. For example, FRAP proteins and various derivatives of FRAP proteins, including the antigenic epitope, and the nucleic acids that encode them, are useful as vaccine components. In addition, the inhibition of FRAP proteins or nucleic acids that encode them (e.g. by compounds that bind to the active site of the protein, or by RNA silencing) also provides a strategy for therapeutic intervention in parasitic disease. Further, the invention provides diagnostic tools related to the detection of parasites harboring either the FRAP protein or nucleic acids encoding FRAP. Further, the invention provides methods and compositions for inhibiting the ability of HDP to detoxify heme, i.e. to convert heme to hemozoin. Thus, the methods and compositions are useful for the treatment or prevention of diseases caused by Plasmodium and Theileria parasites. These and other aspects of the invention are discussed in detail below.
- The FRAP protein that was first identified in (originated from) P. falciparum and is represented by SEQ ID NO: 1 (see
FIG. 1 ). The protein is encoded by the nucleic acid sequence represented by SEQ ID NO: 2 (FIG. 2 ). However, the FRAP family of proteins is not limited to those originating from P. falciparum. FRAP orthologs from Plasmodium species other than P. falciparum have been identified, for example, FRAP orthologs from human (P. vivax) simian (P. knowlesi, P. reichenowi), avian (P. gallinaceum) and rodent (P. berghei, P. yoelii and P. chaubaudi) malaria parasites. Overall, FRAP has extremely high sequence homology across the Plasmodium genus and the region encoding the inhibitory epitope identified in P. falciparum protein is very highly conserved in all known FRAP orthologs. Furthermore, polymerization of human heme into hemozoin by FRAP from rodent malaria parasite P. yoelii has been demonstrated. Therefore, FRAP sequences between different species of the parasites are functionally interchangeable and transgenic malaria parasites expressing the FRAP sequence from any member of the Plasmodium genus can be utilized for human malaria drug and for vaccine development. In addition, FRAP orthologs present in many related species such as Theileria may also be utilized for use in drug and vaccine development for the diseases they cause, e.g. bovine tropical theileriosis (Preston et al., Innate and adaptive immune responses co-operate to protect cattle against Theileria annulata. Parasitol Today. 1999 July; 15(7):268-74). All such orthologs, examples of which are given inFIG. 1 , are encompassed by the present invention. The nucleic acids that encode some exemplary FRAP proteins are presented inFIG. 2 . - Those of skill in the art will recognize that a FRAP protein need not have an exact sequence as depicted in
FIG. 1 in order to be suitable for use in the practice of the present invention. Rather, the invention also encompasses variants (derivatives) of such proteins. The term “protein” as used herein refers to sequences of about 100 or more amino acids; and - the term “polypeptide” refers to sequences of about 100 amino acids or less, although these terms may be used interchangeably. (Shorter sequences, e.g. about 35 or fewer amino acids, will generally be referred to as peptides.) Variants or derivatives of FRAP proteins may be isolated from nature or be purposefully constructed. The primary sequence of such a variant or derivative may differ from the original sequence (e.g. as represented in
FIG. 1 ) in any of several ways, including the following: conservative amino acid substitutions; non-conservative amino acid substitutions; truncation by, for example, deletion of amino acids at the amino or carboxy terminus, or internally within the molecule; or by addition of amino acids at the amino or carboxy terminus, or internally within the molecule (e.g. the addition of a histidine tag for purposes of facilitating protein isolation, the substitution of residues to alter solubility properties, the replacement of residues which comprise protease cleavage sites to eliminate cleavage and increase stability, the replacement of residues to form a convenient protease cleavage site, the addition or elimination of glycosylation sites, and the like, for any reason). Such variants may be naturally occurring (e.g. as the result of natural variations between species or between individuals, or as a result of different expression systems used to produce the amino acid sequence, etc.); or they may be purposefully introduced (e.g. in a laboratory setting using genetic engineering techniques). The amino acid sequences may be in a variety of forms, including a neutral (uncharged) forms, or forms which are salts, and may contain modifications such as glycosylation, side chain oxidation or deamidation, phosphorylation and the like. Also included are amino acid sequences modified by additional substituents such as glycosyl units, lipids, or inorganic ions such as phosphates, as well as modifications relating to chemical conversions or the chains, such as oxidation of sulfhydryl groups. - All such variants of the amino acid sequences disclosed herein are intended to be encompassed by the teachings of the present invention, provided the variant protein/polypeptide displays sufficient identity to the original sequence as disclosed herein, or an amino acid sequence that can be translated from a nucleic acid sequence disclosed herein. Preferably, amino acid identity will be in the range of about 50 to 100%, and preferably about 60 to 100%, or more preferably about 70 to 100%, or even more preferably about 80 to 100%, or most preferably about 90 to 100%, or even about 95 to 100%, of the disclosed sequences. The identity is with reference to the portion of the amino acid sequence that corresponds to the original amino acid sequence as translated directly from the nucleic acid sequences disclosed herein, i.e. not including additional elements that might be added, such as sequences added to form chimeric proteins, histidine tags, etc. Those of skill in the art are well acquainted with the methods available for determining the identity between amino acid sequences, for example, FASTA, FASTP, the BLAST suite of comparison software, ClustalW, Lineup, Pileup, or many other alignment software packages.
- In addition, such protein/polypeptide variants retain at least about 50 to 100% or more of the activity of the original polypeptide, and preferably about 60 to 100% or more, or more preferably about 70 to 100% or more, or even more preferably about 80 to 100% or more, and most preferably about 90 to 100% or more of the activity of the original sequence. By “activity” we mean the activity or role of the amino acid sequence in the parasite from which is was isolated, which may include but is not limited to: characteristic enzyme activity, activity as a structural component, role as a membrane component, binding activity, etc.
- The peptides, polypeptides and proteins of the present invention are generally provided as recombinant molecules, although the amino acid sequences may also be produced synthetically via known peptide synthesis techniques. The peptides, polypeptides and proteins of the present invention are provided in a substantially purified form, i.e. they are generally free of extraneous materials (such as other proteins, nucleic acids, lipids, cellular debris, etc.) and will generally be at least about 75% pure, preferably about 85% pure, and most preferably at least about 90-95% or more pure, as would be understood by one of ordinary skill in the art.
- In general, the proteins and polypeptides of the invention are produced in recombinant expression systems. In a preferred embodiment of the present invention, the recombinant system is an E. coli recombinant system. However, they may also be produced in a variety of other recombinant expression systems. For example, yeast, insect cells (using for example, a baculovirus expression vector), plant cells (e.g. tobacco, potato, corn, etc.), transgenic animals, or mammalian cell culture systems can be used for expression of recombinant proteins. Any appropriate expression system that suitably produces the proteins and polypeptides of the invention may be used in the practice of the invention. Such systems and their use for the production of recombinant proteins are well known to those of ordinary skill in the art.
- The invention also provides antigenic peptides, in particular an antigenic epitope common to the FRAP family of proteins. The epitope has the amino acid sequence TRSGGLRKPQKVTNDPESINRKVYWCFEHKPV (SEQ ID NO: 24). Some modification of this sequence may be tolerated without compromising the antigenicity of the sequence. Those of skill in the art will recognize that peptides may be obtained by several means, including but not limited to chemical synthesis methods, production using genetic engineering techniques, enzymatic digestion of larger polypeptides, etc. The particular source of a peptide is not a crucial feature of the invention. In a preferred embodiment, the peptide will be chemically synthesized. In some embodiments of the invention, the FRAP epitope will be used as an antigen in combination with at least one other known parasite antigenic epitope. For example, genetic engineering techniques may be employed to construct chimeric polypeptides or proteins containing two or more of such epitopes on the same molecule. Alternatively, separate preparations of the peptidic epitopes may be prepared and mixed into a single solution, for example, to be administered as a vaccine.
- In addition to utilizing FRAP proteins, polypeptides and peptides, the present invention also encompasses use of the nucleic acids that encode such amino acid sequences. Exemplary DNA sequences that encode FRAP proteins are given in
FIG. 2A -J. The nucleic acids may be used as a tool, e.g. to produce a protein. Alternatively, the nucleic acid sequences themselves may be used in certain aspects of the invention, e.g. as components of DNA vaccines, or for gene silencing applications (see below). Those of skill in the art will recognize that many variants (derivatives) of such sequences may exist in nature or be constructed which would still be suitable for use in the practice of the present invention. For example, with respect to the translation of amino acid sequences from the nucleic acid sequences, due to the redundancy of the genetic code, more than one codon may be used to code for an amino acid. Further, as described above, changes in the amino acid primary sequence may be desired, and this would necessitate changes in the encoding nucleic acid sequences. In addition, those of skill in the art will recognize that many variations of the nucleic acid sequences may be constructed for purposes related to other aspects of the invention, for example: for cloning strategies (e.g. the introduction of restriction enzyme cleavage sites for ease of manipulation of a sequence for insertion into a vector, for rendering the sequence compatible with the cloning system vector or host, for enabling fluorescent or affinity labeling technologies, etc.), for purposes of modifying transcription (e.g. the introduction of specific promoter or enhancer sequences, insertion or deletion of splice signals, for enhancing or negatively regulating transcription levels, for regulating polyadenylation, for controlling termination, and the like), or for modification of active or inactive domains, for elimination or modification of certain activities or domains, for optimizing expression due to codon usage or other compositional biases, for addition of immunologically relevant (enhancing or inhibiting) sequences or for any other suitable purpose. All such variants of the nucleic acid sequences encoding the proteins, polypeptides and peptides disclosed herein are intended to be encompassed by the present invention, provided the sequences display homology in the range of about 50 to 100%, and preferably about 60 to 100%, or more preferably about 70 to 100%, or even more preferably about 80 to 100%, or most preferably about 90 to 100% or about 95 to 100% to the disclosed sequences. The homology is with reference to the portion of the nucleic acid sequence that corresponds to the original sequence, and is not intended to apply to additional elements such as promoters, vector-derived sequences, restriction enzyme cleavage sites, etc. derived from other sources. Those of skill in the art are well-acquainted with methods to determine nucleic acid similarity or identity using simple software alignment tools such as FASTA, the BLAST suite of programs, CLUSTAL W, Lineup, Pileup (GCG), or many others. - In addition, the nucleic acids are not limited to DNA, but are intended to encompass other nucleic acids as well, such as mRNA, RNA-DNA hybrids, and various modified forms of DNA and RNA known to those of skill in the art. For example, for use in vivo, nucleic acids may be modified to resist degradation via structural modification (e.g. by the introduction of secondary structures, such as stem loops, or via phosphate backbone modifications, etc.). Alternatively, the nucleic acids may include phosphothioate or phosphodithioate rather than phosphodiesterase linkages within the backbone of the molecule, or methylphosphorothiate terminal linkages. Other variations include but are not limited to: nontraditional bases such as inosine and queosine; acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine; stabilized nucleic acid molecules such as nonionic DNA analogs, alkyl- and aryl phosphonates; nucleic acid molecules which contain a diol, such as tetrahyleneglycol or hexaethyleneglycol, at either or both termini; etc. Further, the nucleic acid molecules may be either single or double stranded, or may comprise segments of both single and double strand nucleic acid.
- In the course of practicing the invention, FRAP-related nucleic acid molecules may be cloned into one of many suitable vectors. In some embodiments, vectors containing nucleic acid sequences (e.g. DNA) that encode the amino acid sequences of the invention will encode a single protein, polypeptide, or peptide. However, this need not always be the case. Such vectors may contain DNA encoding more than one amino acid sequence, either as separate, discrete sequences, or combined into a single chimeric sequence. For example, in the case of an expression vector, two or more nucleic acids according to the invention may be present in the vector, and the nucleic acids may be expressed separately, resulting in the translation of one amino acid sequence for each nucleic acid. Alternatively, a single polypeptide chain containing more than one amino acid sequence of the invention, or portions of more than one amino acid sequence of the invention, may be combined in tandem. For example, one or more highly antigenic proteins or regions of proteins of the invention may be expressed as a chimera from a single DNA sequence. Alternatively, the amino acid sequences of the invention may be expressed as part of a chimeric protein comprising amino acid sequences from another source, e.g. antigenic sequences known to be useful as adjuvants (e.g. PADRE [and other Pan-DR T helper cell epitope], hepatitis B core antigen, DNA sequences CPG, other chemokines, CTB or cholera toxin B subunit, Ricin B and other plant toxin subunits, LPS or lipopolysaccharide, KLH [key hole limpet hemocyanin], Freund's complete and Freund's incomplete adjuvant, and many other reagents, etc.), sequences that permit targeting of the protein to a specific location within the cell (e.g. nucleus, nucleolus or nuclear membrane, mitochondrion/mitosome/mitochondria-like organelle, membrane, endoplasmic reticulum, golgi, rhoptry, dense granules, calcisomes or acidocalcisomes, and other subcellular organelles compartments, etc.).
- One application of the present invention is the provision of vaccines that provide immunity to disease caused by parasites such as Plasmodium. By “immunity” we mean that administration to an individual of one or more proteins, polypeptides or peptides of the invention, or nucleic acids encoding them, either alone or in combination with other antigenic entities prevents the development of disease symptoms in that individual after exposure to or infection by a parasite. Alternatively, the disease symptoms that develop in the individual may be milder than those that would otherwise develop in, for example, a matched control individual. Those of skill in the art are well acquainted with the use and meaning of “controls” when comparing results of individuals or populations that have been exposed to different variables (e.g. vaccinated or not). In particular, the inhibitory epitope peptide of the invention may be used in combination with one or more other antigenic epitopes for the production of a multicomponent vaccine. Such a vaccine addresses previous lackluster vaccine performance by presenting several highly immunogenic epitopes to the immune system of a vaccinated individual in a single preparation. This type of vaccine closely mimics the natural in vivo presentation of antigens on the surface of a parasite, and thus elicits a robust immune response.
- According to an embodiment of the invention, the vaccine may either be prophylactic (i.e. to prevent or attenuate symptoms of infection) or therapeutic (i.e. to treat disease after infection). Such vaccines comprise one or more of: immunizing antigen(s), immunogen(s), polypeptide(s), protein(s) and nucleic acid(s) from the FRAP family (as described herein), usually in combination with “pharmaceutically acceptable carriers,” which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents (“adjuvants”). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogens. Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (I) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59™ (WO 90/14837; Chapter 10 in Vaccine design: the subunit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 100Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox™); (3) saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (eg. gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor, etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59™ are preferred.
- The immunogenic compositions (eg. the immunizing antigen/immunogen/polypeptide/protein/nucleic acid, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.
- Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic or immunogenic polypeptides, as well as any other of the above-mentioned components, as needed. By “immunologically effective amount”, it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for eliciting the production of antibodies, for eliciting a cellular immune response, (or both), and/or for treatment or prevention of disease. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g. nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. The immunogenic compositions are conventionally administered parenterally, eg. by injection, either subcutaneously, intramuscularly, intranasally, or transdermally/transcutaneously. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents. As an alternative to protein-based vaccines, DNA vaccination may be employed [eg. Robinson & Torres (1997) Seminars in Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol 15:617-648].
- Vaccines can be composed of live, attenuated or killed organisms, or chemically inactivated toxins (toxoids), against which the body can raise an effective immune response, leading to effective protection against the live agent or active toxins produced during the infection. Combination vaccines make it possible to immunize individuals against multiple pathogens at a time. Examples of combination vaccines are DTaP (Diphtheria, Tetanus, combined with acellular Pertussis) or MMR (Measles, Mumps, and Rubella). Conjugated vaccines, such as PCV (Pneumococcal Conjugated Vaccine) provide better immunization of infants. In conjugated vaccines polysaccharide antigens are chemically linked to protein antigens which provide a better stimulus for the immature immune system. Through the use of recombinant DNA technology it is possible to isolate and express individual genes or combinations of genes, encoding antigens from pathogens and produce vaccines by fermentation. Recent advances in genomics and proteomics of (re-)emerging pathogens will enable entirely new generations of vaccine based on identification of surface proteins. Table 1 lists common types of vaccines in current use or in development, and some important attributes.
TABLE 1 Vaccine types in current use and development Type Vaccine Advantages Disadvantages Live, attenuated Measles, mumps, Produce a strong Remote possibility vaccines rubella, polio (Sabin immune response; that the live microbe vaccine), yellow often give lifelong could mutate back to fever immunity with one a virulent form; or two doses must be refrigerated to stay potent Inactivated or Cholera, flu, Safer and more Produce a weaker “killed” vaccines hepatitis A, Japanese stable than live immune response encephalitis, plague, vaccines; don't than live vaccines; polio (Salk vaccine), require refrigeration; usually require rabies more easily stored, additional doses transported Toxoid vaccine Diphtheria, tetanus Teaches immune Protect only against system to fight off deleterious effect of bacterial toxins; toxin, but do not often easy to provide protection produce from pathogen Subunit vaccines Hepatitis B, Targeted to very When developing a pertussis, specific parts of the new vaccine, pneumonia caused microbe; fewer identifying the best by Streptococcus antigens, so lower antigens can be pneumoniae chance of adverse difficult and time reactions consuming Conjugate vaccines Haemophilus Allow infant influenzae type B, immune systems to pneumonia caused recognize certain by Streptococcus antigens pneumoniae DNA vaccines In development Produce a strong Still in experimental antibody and stages cellular immune response; relatively easy and inexpensive to produce Recombinant vector In development Closely mimic a Still in experimental vaccines natural infection, stages stimulating a strong immune response
Source: Understanding Vaccines: What they are, how they work. U.S. DHHS/NIH/NIAID, NIH Publication No. 03-4219, 2003. - Most vaccines in Table 1 are administered by subcutaneous or intramuscular injection. The oral route of administration is occasionally used in case of Oral Polio Vaccine. New vaccine technology is being developed to produce vaccines that (i) generate stronger and broader immunity, (ii) meet more stringent safety and quality requirements, and (iii) that have greater ease of delivery at lower cost. Therefore, a significant amount of research is ongoing to develop new delivery methods and adjuvants. For effective immunization most vaccines are delivered using adjuvants. Adjuvants are emulsions or formulations, often containing lipids or aluminum salts, which provide for slow release of the antigen into the plasma, and also stimulate the immune response in ways that are not fully understood. Slow release of the antigen is also important to prevent metabolism and removal from the plasma prior to the initiation of the immune response. Delivery of antigen to the cells that participate in antigen presentation, macrophages and dendritic cells, is also improved by the use of adjuvants. Table 2 lists a number of commonly used adjuvants and new adjuvant delivery methods in development.
TABLE 2 Commonly used adjuvants and new products in development. Adjuvant Category New product or method Comments/Examples Gel type Aluminium hydroxide/phosphate Improve delivery to APCs and Calcium phosphate secondary lymphoid organs Microbial Muramyl dipeptide (MDP) Bacterial exotoxins Cholera toxin (CT) Endotoxin based adjuvants Escherichia coli heat labile toxin (LT) Monophosphoryl lipid A (MLA) Particulate Biodegradable polymer microspheres Immuno-stimulatory complexes (ISCOMs) Liposomes Oil emulsion/ Freunds incomplete adjuvant Animal experimental uses only surfactant Microfluidized emulsions MF59 (Squalene), SAF Saponins Qs-21 Synthetic Muramyl peptide derivatives Murabutide, Threonyl-MDP Non-ionic block co-polymers L121 Polyphosphazene (PCPP) Cytokines Interleukin-2, -12 Molecules secreted by GM-CSF macrophages or dendritic cells Interferon gamma that stimulate the inflammatory and immune response Genetic Genes encoding cytokines or co- IL-12, IL-2, IFNg, CD40L stimulatory molecules delivered by plasmids
Sources: Progress in Immunologic Adjuvant Development 1982-2002, The Jordan Report 2002, US DHHS/NIH/NIAID, and the website located at www.niaid.nih.gov/daids/vaccine/pdf/compendium.pdf. - New physical administration methods being developed include delivery by inhalation, oral delivery, or transdermal delivery. Inhalation delivery includes intranasal delivery for delivery to the upper respiratory tract, which is being used in FluMist (influenza vaccine) or other powder or particle based methods to deliver immunization to the lower respiratory tract. Oral delivery includes new formulations to allow antigens to pass through the stomach and intestinal tract without acid or protease inactivation. New methods of oral delivery include edible vaccines, where plants such as potatoes, tomatoes, or bananas are genetically engineered to express the antigen in parts of the plant that are consumed by humans. New transdermal delivery methods that avoid injection are being explored as well. However the large size (high molecular weight) of the antigen(s) usually is a limitation for this delivery method. A relatively new delivery method is expression of antigens in a strain of virus or a bacterium that is not naturally pathogenic, or is made avirulent either through mutation or genetic engineering. Attenuated viruses such as polio, or bacteria such as Vibrio cholerae and Salmonella typhi, are being explored as delivery vehicles.
- Production methods for vaccines vary with the type of vaccine. Live, attenuated or killed virus vaccines are produced in mammalian cell culture. In the latter case virus particles are killed by chemical inactivation, heat or radiation. A major concern of mammalian cell culture based production methods is contamination with other pathogens, specifically retroviruses such as HIV, or other as of yet uncharacterized mammalian viruses. Influenza vaccine is produced either through cell culture or growth of virus in fertilized chicken eggs, followed by purification from the yolk. Live, attenuated or killed bacterial vaccines are produced by microbial fermentation. Concerns with this method are contamination with other micro-organisms (bio-burden), or presence of bacterial endo- or exo-toxins that can cause anaphylactic shock. Toxoid vaccines, such as diphtheria or tetanus vaccines, are produced by microbial fermentation and harvesting of the exo-toxins from the culture medium. Toxoid vaccines can also be produced with recombinant DNA technology, followed by purification of the recombinant protein. Conjugated vaccine components are produced through multiple methods. The polysaccharide component is harvested from bacteria grown in culture, and the protein component of the antigen can be produced through fermentation or recombinant DNA technology. The conjugation step is done through a chemical reaction. Subunit vaccines, existing of specific protein antigens (or combinations) are made through fermentation or recombinant DNA technology. Other transgenic production methods, such as expression in the milk of transgenic animals, or production in genetically engineered plants, are being explored for subunit vaccines as well. DNA vaccines are produced using recombinant DNA technology. Vector vaccines are produced through genetic engineering of the vector, i.e. to produce the antigens of interest, and either microbial fermentation or mammalian cell culture.
- In particular, with respect to DNA vaccines, U.S. Pat. No. 6,214,804 (Felgner, et al., 2001, the complete contents of which is hereby incorporated by reference) describes the induction of a protective immune response in a mammal by injecting a DNA sequence. Methods for delivering an isolated polynucleotide to the interior of a cell in a vertebrate are provided. The methods can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.
- In addition, U.S. Pat. No. 6,923,958 (Xiang et al., 2005, the complete contents of which is hereby incorporated by reference) describes DNA vaccines encoding carcinoembryonic antigen (CEA) and a CD40 ligand and methods of their use. The DNA vaccine is effective for eliciting an immune response against cells that present a carcinoembryonic antigen, and could be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. Alternatively, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. The mammal may be further treated with recombinant antibody fusion proteins to enhance the immune response effectiveness of the vaccine.
- Another embodiment of the invention provides antibodies specific for FRAP proteins, polypeptides and peptides. As used herein, the term “antibody” refers to a polypeptide or group of polypeptides composed of at least one antibody combining site. An “antibody combining site” is the three-dimensional binding space with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows binding of the antibody with the antigen. “Antibody” includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, humanised antibodies, fully human antibodies, altered antibodies, univalent antibodies, Fab proteins and fragments, and single domain antibodies. Antibodies to the polypeptides and peptides of the invention, both polyclonal and monoclonal, may be prepared by conventional methods that are well-known to those of skill in the art. If desired, the antibodies (whether polyclonal or monoclonal) may also be labeled using conventional techniques.
- Antibodies for therapeutic applications for the prevention or treatment of malarial disease, or diagnostic applications in the detection of parasite infection, can be made by standard methods. In most cases the antibodies will be of monoclonal origin, and either produced in rats or mice.
- Protein for immunization is made by recombinant methods. Any of the proteins from the group of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, or portions thereof, can be produced by cloning the corresponding DNA sequences of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20, or portions thereof, in recombinant protein expression vectors. Protein can be produced in this manner in E. coli, yeast, fungi, plants, mammalian, or insect cells. It is obvious that the preferred protein used for immunization is from the Plasmodium species that infect humans, i.e. SEQ ID NOS: 1 and 7. However, in principle SEQ ID NOS: 3, 5, 9, 11, 13 and 15, could also be used to generate antibodies that are effective as therapeutics or diagnostic tools. Immunization material for short peptides and small proteins can also be made through chemical synthesis.
- For example the 8-mer peptide represented by SEQ ID NO: 37 may be encoded by: ACCAACGACCC AGAAAGTATAAAT (SEQ ID 38), or other sequences; and the 32-mer peptide represented by SEQ ID NO: 24 may be encoded by: ACACGAAGTGGCGGTTTAAGAAAACCTCAAAAGG TAACCAACGACCCAGAAA GT ATAAATAGAAAAGTATATTGGTGTTTTGAACATAA GCCTGTA (SEQ ID 39), or other sequences. Alternatively, the these peptides may be chemically synthesized.
- Expressed protein can be purified with standard HPLC and other chromatographic methods, in quantities and sufficient purity to be injected in the mice or standard rats. Rats or mice are injected in the presence of adjuvants, and in a standard schedule of injections and boosters, in order to generate a vigorous immune response. In order to make monoclonal antibodies, spleen cells are harvested from the animals and fused with immortalized cell lines. Numerous immortalized cell lines are screened for their ability to secrete antibodies that bind the original antigen used in immunizations. Positive cell lines are purified and cloned, and their antibodies are characterized and screened to identify antibodies that have strong binding characteristics. Upon identification of such cell lines, the antibody genes are cloned, sequenced and can be used to engineer mammalian cell culture strains for high level production.
- In order to avoid a human immune response against the therapeutic antibody, the sequence of the monoclonal antibody is modified to most closely resemble the sequence of native human antibodies. This is done by recombinant DNA methods, through selective replacement of the significant portions of the munine antibody light and heavy chain sequences with human sequences (chimeras), or through replacement of almost all of the non-variable sections of the murine antibody light and heavy chains, with those from human antibody chain conserved sequences, while maintaining the original rat or mouse sequence of the hyper-variable domain which is responsible for antigen recognition and binding (‘CDR grafting’ or ‘humanization’). For example U.S. Pat. No. 6,500,931 describes the method of humanizing antibodies.
- Alternatively, fully human monoclonal antibodies can be made in mice directly, when these mice are engineered to produce only human antibody chains. For example the technology practiced by companies such as Abgenix Inc. [XenoMouse technology, U.S. Pat. No. 6,657,103], Medarex Inc. and GenMab A/S [HuMab Mouse or UltiMAB technology; WO2005023177] can be used. Purified proteins as described above are used to immunize such engineered mice. Monoclonals produced in this manner are produced, screened and characterized in the standard manner. Fully human antibodies can also be produced using phage display methods by screening against human antibody phage display libraries. For example technologies practiced by companies such as Cambridge Antibody Technology [U.S. Pat. No. 5,969,108 and U.S. Pat. No. 6,172,197] and others, can be used to identify fully human antibodies in this manner. Phage display screening has an added advantage in that the process does not rely on animal immunization. The genes for fully human antibodies produced using engineered mice, or identified through phage display, can be isolated, sequenced and cloned for expression in mammalian cell lines for high level expression using standard methods.
- Patents describing this technology in detail are incorporated herein by reference.
- Such antibodies may be used, for example, for affinity chromatography, immunoassays, and for distinguishing or identifying parasite proteins or portions thereof. In a preferred embodiment of the invention, such antibodies may be used therapeutically, e.g. for administration to patients suffering from a parasitic disease such as malaria, or prophylactically in order to prevent a parasitic disease in patients at risk for developing the disease.
- In yet another embodiments of the invention cells or cell lines containing the nucleic acids and/or the amino acid sequences of the invention as described herein. For example, the cell may be a host cell that harbors one or more vectors containing nucleic acid sequences used in the invention (e.g. DNA or RNA) and/or amino acid sequences of the invention translated from such vectors. Such cells may contain multiple vectors, and the vectors may be the same or different. Further, the cells may be either in vitro or in vivo. The invention also comprehends pharmaceutical compositions and their use. The pharmaceutical compositions can comprise one or more proteins, polypeptides, peptides, antibodies, or nucleic acids according to the invention, or combinations of these. In addition, the compositions may include compounds that inhibit the interaction of HDP and heme, thereby preventing or vitiating the ability of HDP to detoxify heme, e.g. to form hemozoin from heme. The pharmaceutical compositions comprise a therapeutically effective amount of such molecules. The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent that is sufficient to treat, ameliorate, or prevent a disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction of physical symptoms of the parasitic disease. The precise effective amount for a subject will depend upon several parameters, including the subject's size, general health, gender, age, etc., and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation can be determined by routine experimentation and is within the judgement of those of skill in the art, e.g. a physician. For purposes of the present invention, an effective dose will be from about 0.01 mg/kg to 50 mg/kg or about 0.05 mg/kg to about 10 mg/kg of active, therapeutic agent.
- A pharmaceutical composition may also contain a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, inhibitory compounds, and other therapeutic agents. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
- In addition, pharmaceutically acceptable carriers in therapeutic compositions may contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, adjuvants, and the like, may be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.
- Once formulated, the compositions of the invention are administered to the subject. The subjects to be treated may be animals; in particular, human subjects can be treated. Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly or delivered to the interstitial space of a tissue. Other modes of administration include oral and pulmonary administration, suppositories, and intranasal, transdermal or transcutaneous applications (eg. see WO98/20734), needles, and gene guns or hyposprays. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- Yet another embodiment of the invention provides tools and methods for the diagnosis of parasitic infections. Such tools include primers containing nucleotide sequences that specifically hybridize to nucleic acid sequences that are unique to FRAP. Hybridization of the primers to such a unique sequence permits amplification of the unique sequence (for example, by polymerase chain reaction (PCR)), thus providing a means to specifically identify the presence of FRAP in biological samples (blood, feces, sputum, urine, bronchoaveloar lavage, etc.). Amplification may be directly from the genome of the organism located in the sample, or from RNA, e.g. mRNA.
- By “primer” we mean a nucleotide sequence that hybridizes to another nucleotide sequence of interest, the primer typically being a relatively short nucleotide sequence (e.g. from about 10 to about 100 base pairs) and the nucleotide sequence of interest typically being transcribed from the genome of an organism. PCR amplification techniques are well-known to those of skill in the art. In general, two primers are selected that target sites that flank the sequence of interest (e.g. a gene encoding FRAP) for diagnostics or identification. These primers are designed to recognize only the target sequence; i.e., they will hybridize only to the target sequence and to no other sequences. The primers generally range from 18-nucleotides in length (but can be longer or shorter), have Tm's (melting temperatures) that are selected to be compatible with both amplification conditions and with specificity, have little or no internal structure (stem-loop structures caused by internal complementarity), little or no ability to dimerize with themselves, little or no ability to dimerize with the other primer, have few homopolymeric stretches, etc. Many computer programs (e.g., Primer3, Oligo, etc.) are available for primer design. At times, an internal fluorescent probe is also included for specific use in even more sensitive and automated tests. The internal probe is fluorescently labeled such that it is specifically degraded and therefore fluoresces only if it specifically hybridizes to the target sequence. Alternately, other fluorescent probes can be designed that only fluoresce upon binding specifically to an amplified specific sequence. Thus, several alternative approaches are available for the generation and detection of specific sequences amplified by PCR, and any of these can be applied for diagnostic or identification purposes. (See, for example: Mullis, K., F. Faloona, S. Scharf, R. Saki, G. Horn, and H. Erlich. (1986) Specific enzymatic amplication of DNA in vitro: The Polymerase Chain Reaction. Cold Spring Harbor Symposia on Quantitative Biology 51: 263; Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. (1988) Primer-directed enzymatic amplification of DNA with a thernostable DNA polymerase. Science 239:487; Schutzbank T E, Stern H J. (1993) Principles and applications of the polymerase chain reaction. J Int Fed Clin Chem. 1993 July;5(3):96-105; Erlich H A. (1999) Principles and applications of the polymerase chain reaction. Rev Immunogenet. 1(2):127-34; Wang, A. M., Doyle, M. V., and D. F. Mark. (1989) Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA. 1989 December; 86(24): 9717-9721; Kawasaki, E. S., and A. M. Wang. (1989) Detection of gene expression. In: Erlich, H. A., ed., PCR Technology: Principles and Applications of DNA Amplification. Stockton Press, Inc., New York, N.Y., pp. 89-97; Dieter Klein (2002) Quantification using real-time PCR technology: applications and limitations. Trends in Molecular Medicine, 8(6):257-260; Buck GE. (1996) The polymerase chain reaction: a revolutionary new procedure for the laboratory diagnosis of infectious disease. J Ky Med Assoc. Apr; 94(4):148-52.)
- Because the primers are unique to FRAP, a positive amplification result is indicative of the presence of FRAP in the biological sample, and thus of infection by a parasite whose genome encodes FRAP. Similar tests can be carried out with antibodies specific for FRAP. In this case, a positive result indicates that the biological sample being tested contains FRAP, and thus, by inference, the individual from whom the sample was obtained is infected with a parasite that produced FRAP.
- The invention further provides methods for treating or preventing a disease caused by a Plasmodium or Theileria parasite in an individual in need thereof. In one embodiment, this is accomplished by inhibiting one or more interactions of heme and Heme Detoxification Protein (HDP). Typically, inhibition is brought about by the administration of one or more compounds that inhibit one or more interactions of heme and HDP. In other words, the ability of HDP to produce hemozoin from heme (i.e. to detoxify heme) is eliminated or impaired by administration of the compound. Examples of diseases that can be treated in this manner include but are not limited to malaria, East Coast Fever caused by Theileria parasites, etc. Exemplary compounds that may be used in such methods are listed in Table 11 in the Examples section below. One or more compounds from one or more of these classes may be administered, in a quantity sufficient to prevent or ameliorate disease symptoms.
- Those of skill in the art will recognize that the mechanism of action of the compounds that are administered can be any of many known or not yet elucidated types, and that the precise mechanism(s) will depend on the compound(s) administered. For example, the compound may bind to the HDP enzyme and prevent the enzyme from binding to heme. Alternatively, the compound may bind to HDP and allow heme to also bind to HDP, but prevent further catalysis and the production of hemozoin. For example, the compound may bind at the active site or near the active site and sterically prevent the binding of heme; or the compound may bind at an allosteric site that influences (e.g. decreases) the activity of the enzyme; or the compound may cause heme to bind to HDP irreversibly or with so great an affinity that the ability of HDP to detoxify heme is eliminated or attenuated. Alternatively, the compound may bind to heme. In this case, binding of the compound to heme may prevent the heme from then binding to HDP, or may allow the heme-compound complex to bind but not be further processed to hemozoin. Those of skill in the art will recognize that in all cases, the binding of compounds to HDP or to heme may be reversible or irreversible, realizing that all binding events involve an equilibrium distribution of bound and free agents. The criteria for the use of a compound in the present invention is that the compound, regardless of its mechanism of action, decrease the production of hemozoin from heme by at least about 10 to 25%, preferably from about 25 to 50%, and more preferably from about 50 to 75%, or even from about 75 to 10%.
- Other possible mechanisms of action of the compounds that are administered include but are not limited to: modification of a cell membrane of the Plasmodium or Theileria parasite; inhibiting secretion of HDP from the Plasmodium or Theileria parasite, inhibiting transport of HDP to the food vacuole, the site of hemozoin formatin; by binding to free heme (the substrate of HDP) and preventing its detoxification into Hemozoin; etc.
- The administration of the compound(s) may be carried out by any suitable means, examples of which include but are not limited to orally, parenterally, sublingually, rectally, topically or with an inhalation spray.
- In a preferred embodiment of the invention, the disease that is prevented or treated is malaria. In this case, the compound that is administered may be administered in combination with one or more additional agents such as other antimalarial agents, agents for reversing antimalarial resistance, and various adjuvants. Administration of one or more additional antimalarial agents or agents for reversing antimalarial resistance may occur prior to, concurrent with, or subsequent to administration of the compound. Exemplary additional antimalarial agents include but are not limited to quinolines, folic acid antagonists, sulfonamides, and antibiotics. An exemplary agent for reversing antimalarial resistance is an inhibitor of multidrug resistance. Exemplary adjuvants include but are not limited to those which are suggested above for use in vaccine preparations, e.g. alum, etc.
- The invention further comprehends pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an antimalarially effective amount of at least one compound. By “antimalarially effective amount” we mean that the compound is present in the composition in amount that, upon administration to an individual in need, prevents or lessens the occurrence of symptoms associated with malaria in the recipient. Such compositions may include other active agents as well, e.g. adjuvants, other antimalarial agents (quinolines, etc.), agents that reverse resistance to malaria, etc.
- The invention also provides method of inhibiting heme detoxification in a Plasmodium or Theileria parasite by preventing or attenuating the production of hemozoin by HDP in the parasite. Those of skill in the art will recognize that various routes of inhibition may be effective. For example: inhibiting interaction of heme and HDP; preventing an interaction of HDP or heme with cofactors; preventing dimerization of HDP; preventing interaction of HDP or heme with lipids; and others. Exemplary cofactors, the interaction of which with HDP or heme may be disrupted, include but are not limited to metal ions, natural ligands and protein factors.
- The invention also provides methods for identifying compounds that inhibit HDP expression. The methods include the steps of a) contacting Plasmodium with a test compound and b) determining whether HDP is expressed by the Plasmodium. Those of skill in the art will recognize that there are several suitable methods to evaluate the outcome of such tests, including but not limited to measuring mRNA that encodes HDP, measuring HDP protein production directly (i.e. detecting and measuring the protein itself), etc.
- The following Examples describe: the discovery and characterization of the novel FRAP protein family; the expression, localization and purification of recombinantly expressed FRAP; the generation of antibodies to FRAP2; experiments demonstrating the binding of FRAP to liver cells; prevention of sporozoite invasion of liver cells by FRAP and antibodies to FRAP2; discovery of the inhibitory epitope of FRAP; FRAP as a drug target; the use of FRAP in high throughput assays for hemozoin formation for screening novel antimalarials; siRNA mediated inhibition of FRAP; the creation of FRAP variant attenuated parasites for use as whole organism vaccines; and the use of FRAP as a tool for high levels of expression and purification of recombinant proteins; the screening of compounds that inhibit HDP; the results of in vivo testing of DNA that encodes HDP as a vaccine.
- While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above and in the Examples section below, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.
- Plasmodium sporozoites adhere to and invade host liver cells, leading to the onset of malaria. Here we describe a novel, 205 amino acids long, Plasmodium falciparum protein involved in sporozoite-liver cell interactions. Orthologs of this protein were identified in seven other Plasmodium species, representing the four distinct phylogenetic clades, and the protein showed 60% sequence identity within the genus. Additionally, amino acids 88-205 have a 20% sequence identity to
fasciclin 1, an ancient adhesive domain found in prokaryotes, plants and animal proteins. The DNA encoding the protein was cloned, expressed in E. coli and the protein was purified to homogeneity. Immunoelectron microscopy showed that the protein was localized in the micronemes of the sporozoites. The protein contributes to sporozoite's adhesion and invasion activities and antibodies raised against this protein can prevent >94% of P. falciparum sporozoites from invading liver cells, thus suggesting a role for this protein in malaria pathogenesis. Furthermore, we provide evidence that the protein exploits heparan sulfate proteoglycans expressed on the liver cell surface as its receptor. Due to its role in host cell adhesion and the presence offasciclin 1 domain, we have named this protein as Fasciclin Related Adhesive Protein or FRAP. Our results show that FRAP is an excellent target for malaria vaccine development. - A bite by a parasite-infected mosquito delivers Plasmodium sporozoites in the blood stream, which is followed by its entry into the liver cells. A successful adhesion and invasion of liver cells by the parasite sets the stage for rapid multiplication, development and subsequent release of parasites in circulation, leading to the erythrocytic infection and the clinical pathology associated with malaria. It is widely believed that the host cell adhesion and invasion is a multistep process involving several parasitic proteins, many of which are currently not known. Of these, Circumsporozoite (CS) and Sporozoite Surface Protein-2/Thrombospondin-Related Anonymous Protein (SSP2/TRAP), have been extensively investigated (1, 2). Across pathosystems, proteins involved in host-pathogen interactions are the molecules of choice for vaccine development. Likewise, CS and SSP2/TRAP have become major targets for intervention and are being actively pursued as vaccine candidates (3-6). While the results from these trials have been encouraging, they have revealed that the immunological protection against malaria is not conferred due to a dominant immune response against a single antigen but is mediated by the summation of many modest humoral and cell-mediated immune responses against a large variety of known and unknown antigens (7). Therefore, identification of malarial proteins that are involved in disease pathogenesis will not only lead to a better understanding of the disease process, but is also vital for the development of a successful vaccine against malaria. With the availability of the genome sequence and proteome analysis of P. falciparum parasites (8, 9), efforts are now being made to mine this information for identification and characterization of proteins that contribute towards pathogenesis (10).
- In recent years, the concept of protein domains and domain families has risen to greater prominence due to an increasing realization that by organizing proteins sequences from distinct organisms into domain families, one can often reliably predict their molecular functions (11, 12). In case of pathogens, identification of adhesive domain-containing proteins has played a pivotal role in deciphering the mechanics of disease pathogenesis. For example, the Plasmodium genome encodes several proteins that contain an adhesive thrombospondin type I repeat (TSR) domain, most of which have now been shown to be involved in host-parasite interactions (1, 2, 10, 13). Therefore, identification and characterization of parasite proteins containing adhesive domains will improve our understanding of the disease process and here we describe a novel malarial protein that encodes a single fasciclin 1 (FAS1) domain.
- FAS1 is an adhesive domain named due to its initial discovery in proteins involved in fasciculating axons and growth cones (14). It is an ancient extracellular adhesive module found in proteins of prokaryotic, plant and animal origin (15-18). Most of the FAS1 domain-containing proteins possess multiple copies of the domain, though proteins encoding only a single copy, have also been identified (17). A large number of FAS1 domain containing proteins have been reported in Drosophila and Grasshopper, where they are involved in neuronal development (19, 20). In contrast, in humans, FAS1 domains have been found in a large multi-domain scavenger receptor protein on endothelial cells, involved in the removal of hyaluronan from blood stream (21), as well as in extracellular matrix protein, where they mediate corneal epithelial cell adhesion (22). However, unlike many domains which show a high degree of sequence conservation, FAS1 domains show huge sequence diversity; typically have 20% sequence identity in a pairwise alignment (23) and are recognized by only two short semi-conserved sequence motifs (underlined in
FIG. 3 ). - Here we describe a novel P. falciparum FAS1 domain-containing protein and its role in malaria infectivity during sporozoite stage of the lifecycle. We demonstrate that the protein contributes towards liver cell adhesion and invasion by the parasite and have named it as Fasciclin Related Adhesive Protein or FRAP.
- Materials and Methods
- Sequence analysis and identification of FRAP orthologs: Sequences for P. falciparum (Accession #AAN37059), P. berghei (Accession #CAH94515) and P. chaubaudi (Accession #CAH77280) FRAP were obtained from GenBank, where they have been deposited as part of the parasite genome sequencing projects (8, 24) Using P. falciparum FRAP sequence, orthologs were identified from unannotated genome sequences of P. gallinaceum, P. reichenowi, P. vivax, P. yoelii and P. knowlesi parasites, available at PlasmoDB, Sanger Center and TIGR web sites (25). FRAP orthologs from Theileria parva (Accession #EAN32245) and T. annulata (Accession #CA176887) were from the published genome sequence (26, 27). The nucleic acid sequences of the genes are provided in
FIG. 2A -J. The amino acid sequences were aligned using Clustal W algorithm (28) for multiple sequence alignment, using the DNASTAR package. The amino acid sequences are depicted inFIG. 1 , and the alignment is given inFIG. 3 . - Reverse Transcription, Amplification and Cloning of FRAP proteins: Total RNA was obtained from highly purified preparations of P. falciparum (3D7 strain) sporozoites (29). 2μg of total RNA was reverse transcribed and amplified with the forward 5′
CACCATGAAAAATAGATTTTATTATAATTTG 3′ (SEQ ID NO: 22) and reverse 5′AAAAATGATGGGCTTATCTACTATATG 3′ (SEQ ID NO: 23) primers, using Promega Access RT-PCR kit. The amplified fragment was cloned inpET101-TOPO (Invitrogen) an E. coli expression vector containing a C-terminal [His]6 tag, giving rise to plasmid pFRAP. The forward primers encoded a tetra nucleotide CACC, which facilitated the directional cloning of amplified fragments in the expression vector. The authenticity of the clone was verified by DNA sequencing. Two other FRAP constructs, encoding amino acids 1-87 and 88-205 were generated by PCR-based subcloning using pFRAP as template, giving rise to plasmid pFRAP2 and pFRAP3 respectively. Authenticity of these constructs was verified by DNA sequencing. Sequencing was performed at the core laboratory sequencing facility of the Virginia Bioinformatics Institute. - Expression, localization and purification of recombinantly expressed FRAP protein: For protein expression, E. coli BL21 cells were transformed with a desired plasmid, grown in super broth, and at the
OD 600=1.0, expression was induced with IPTG, at a final concentration of 1 mM. Three hours post-induction, the culture was harvested by centrifugation at 3000 g for 10 minutes. To identify the intracellular site of accumulation of the protein, pellet was resuspended in 20% sucrose solution in 20 mM Tris pH 7.5 and incubated on ice for 10 min. Cells were spun at 5000 g for 20 min and the pellet was resuspended in chilled water for 10 minutes. This was followed by centrifugation at 8000 g for 20 minutes to isolate periplasmic fluid. Spheroplast pellet was further processed to isolate inclusion bodies, as previously described (30). Inclusion bodies were solubilized in 1550 mM CAPS buffer containing 0.3% N-lauryl sarkosine and 0.3 M NaCl, pH 11.0 for 30 min and centrifuged at 10000 g for 30 min at room temperature. The supernatant was loaded onto a His-Trap High Performance affinity column (GE Health Care) and bound protein was eluted using an imidazole gradient in 50 mM CAPS pH 11.0 containing 0.3% N-lauryl sarkosine and 0.3 M NaCl. Relevant fractions were pooled and purified to homogeneity by gel filtration chromatography onSuperdex 200 10/300 GL column (GE Health Care). Authenticity of the purified protein was verified by amino terminal sequencing and western blotting using anti-polyhistidine tag monoclonal antibody. For obtaining recombinant CS protein, pCS271IVC a plasmid with a polyhistidine tag at the carboxyl terminus (1) was expressed in BL21 E. coli cells and the protein was purified from the periplasm as previously described (31). - Generation of anti-FRAP2 antibodies: The protocol for antibody generation was approved by the animal care committee at Virginia Tech. 6-8 weeks old female CD1 mice were subcutaneously immunized with 10 μg of purified FRAP2 emulsified in complete Freunds adjuvant. Two subsequent booster doses in incomplete Freunds adjuvant were administered on
days 21 and 35, after the first immunization. Sera were collected two weeks after the last booster. Antibodies were purified on a Protein G affinity column using AKTA FPLC chromatography system. - Confocal analysis: Purified P. falciparum sporozoites were air dried on a glass slide. The slide was blocked with 5% normal goat serum in phosphate buffer saline (PBS). Subsequently, the slide was incubated with doubling dilutions (1:20 to 1:20480) of anti-FRAP2 or pre immune mouse serum and incubated at room temperature, in a humidified chamber, for one hour. Unbound antibodies were removed by washing the slide with TBS containing 0.05
% Tween 20 followed by the addition of an anti-mouse FITC conjugate (1:500 dilution). Confocal imaging was performed using BioRad Radiance confocal microscope. - Immunoelectron microscopy: Preparations of Plasmodium falciparum-infected salivary glands were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, PA) in 0.25 M HEPES (pH 7.4) for 1 hr at room temperature, then in 8% paraformaldehyde in the same buffer overnight at 4° C. They were infiltrated, frozen and sectioned as previously described (32). The sections were immunolabeled with mouse anti-FRAP antibodies (1:1000 in PBS/1% fish skin gelatin), then with anti-mouse IgG antibodies, followed directly by 10 nm protein A-gold particles (Department of Cell Biology, Medical School, Utrecht University, the Netherlands) before examination with a Philips CM120 Electron Microscope (Eindhoven, the Netherlands) under 80 kV.
- Liver Cell binding assay: The binding of proteins was assayed on HepG2 cells as described previously (1, 31). Briefly, cells were plated at a density of 25,000 cells/well, in a 96 well plate, 36 hours before the start of the experiment. The cells were fixed with paraformaldehyde, blocked with 1% BSA, followed by the addition of equimolar concentrations of recombinant proteins. Bound protein was detected using anti-polyhistidine tag monoclonal antibody (1:10,000) and anti-mouse antibody conjugated to alkaline phosphatase (1:2000). Amount of bound protein was detected by using 4-methylumbelliferyl phosphate, a fluorescent substrate, and measurement of fluorescence using a fluorescent plate reader (Molecular Devices, CA) with excitation and emission set at 350 nm and 460 nm respectively. Results are shown as mean±standard deviation of mean of a representative experiment performed in triplicate. Binding inhibition assays were performed by combining the recombinant proteins with increasing amounts of glycosaminoglycans and incubating at 37° C. for 15 min. For enzyme treatment, cells were incubated with different concentrations of Heparinase I or Chondroitinase ABC for 90 minutes at 37° C. as previously described (31), before the addition of proteins. The bound protein was assayed as described above.
- All the proteins used in the binding assay possessed a polyhistidine tag at their carboxyl terminus. Therefore, binding activity was probed using a polyhistidine tag monoclonal antibody. This excluded the possibility of misinterpretation of the data due to differences in antibody affinities.
- Sporozoite Invasion Assay: Invasion assay was performed with HepG2 (Human hepatoma) cells as previously described (31). Briefly, HepG2 cells were plated (50,000 cells/0.3 ml) and incubated overnight at 37° C. in a CO2 incubator. Next day, medium was removed and 50 μl of diluted FRAP proteins (final concentrations: 20 and 10 μg/ml) or anti-FRAP2 antibodies (40 μg/ml final concentration) were added per well. Anti CS monoclonal antibody NFS1 was used at a final concentration of 100 μg/ml. All protein concentrations and serum dilutions were evaluated in triplicate. This was immediately followed by the addition of 20,000 sporozoites in 50 μl of medium to each well. P. falciparum (strain NF54) sporozoites were obtained from the salivary glands of An. stephensi mosquitoes as described by Ozaki (33). The sporozoites were allowed to invade liver cells for three hours followed by the washing of cells with PBS at pH 7.4. Subsequently, the cells were fixed with cold methanol. Sporozoites were visualized by immunostaining using NFS1 as primary antibody and anti-mouse IgG-peroxidase conjugate. The slides were mounted with Paramount and only intracellular sporozoites were counted as described (31). Percentage inhibition of invasion was calculated with the following formula: [(Control-test)/control]×100
- Results
- Identification and sequence analysis of FRAP: Analysis of the published DNA sequence of
chromosome 14 of P. falciparum (8) identified a 824 nucleotide sequence (Accession #NP702335) containing a hypothetical, single copy, three-exon gene, encoding a 205 amino acids long protein (FIG. 1 , SEQ ID NO: 1). Bioinformatical analysis of the predicted protein using the NCBI conserved domain database (CDD) search tool (34), revealed that the protein encodes a Fasciclin (FAS1) domain (SMART accession no. SM00554) from amino acids 88-204 with an e-value of 2e-10.FIG. 1 depicts the FRAP protein sequence and its alignment with the consensus sequence of FAS1 domain in the database. FAS1 domains are known for their huge sequence diversity and typically have 20% sequence identity in a pairwise alignment (23). They are recognized by only two short semi-conserved sequence motifs (underlined inFIG. 3 ). A similar pattern is seen in FRAP as its FAS1 domain has 21% sequence identity with the consensus sequence. - Using published, unpublished and unannotated sequences in the databases for pathogens at Sanger, PlasmoDB and TIGR web sites, P. falciparum FRAP orthologs were identified in all Plasmodial species that have been sequenced till date or are currently undergoing sequencing (
FIG. 1 ). Orthologs of P. falciparum FRAP were found in avian (P. gallinaceum), rodent (P. berghei, P. yoelii and P. chaubaudi) simian (P. knowlesi and P. reichenowi) and human (P. vivax) malaria parasites suggesting that the FRAP protein is most likely present in all the members of Plasmodium genus and, hence, could be playing an important role in the biology of the parasite. Within the Plasmodium genus, the protein maintains a 60% sequence identity (FIG. 3 ) with 124 out of 205 residues being identical. Beyond Plasmodium, FRAP homologs were only found in the two recently sequenced Theileria genomes (26, 27) with an overall sequence identity of 29% (FIG. 3 ). In contrast, FRAP homologs could not be found in the recently sequenced Leishmania (35) and Trypanosome genomes (36). This selective presence in Plasmodium and Theileria genomes could point towards a common function of the protein between otherwise two very different parasites. - The amino acid sequences for the FRAP proteins discussed above are depicted in
FIG. 1 , the nucleic acid sequences that encode the proteins are depicted inFIG. 2 , and the corresponding SEQ ID NOS: are given in Table 3.TABLE 3 SEQ ID NOS: for amino acid and nucleic acid SEQ ID NO: Organism Amino acid sequence Nucleic acid sequence P. falciparum SEQ ID NO: 1 SEQ ID NO: 2 P. gallinaceum SEQ ID NO: 3 SEQ ID NO: 4 P. reichenowi SEQ ID NO: 5 SEQ ID NO: 6 P. vivax SEQ ID NO: 7 SEQ ID NO: 8 P. yoelii SEQ ID NO: 9 SEQ ID NO: 10 P. knowlesi SEQ ID NO: 11 SEQ ID NO: 12 P. chaubaudi SEQ ID NO: 13 SEQ ID NO: 14 P. berghei SEQ ID NO: 15 SEQ ID NO: 16 T. parva SEQ ID NO: 17 SEQ ID NO: 18 T. annulata SEQ ID NO: 19 SEQ ID NO: 20
Cloning of P. falciparum FRAP: Coding sequence of P. falciparum FRAP was amplified by RT-PCR using total RNA from the sporozoite stage of the parasite, giving rise to a 615 bp fragment. This PCR product was not due to the presence of contaminating genomic DNA in the RNA preparation, as a parallel reaction performed in the absence of reverse transcriptase enzyme, showed no amplification. Also, the size of the amplified fragment, viz. 615 bp, matched the size of the predicted mature mRNA (FIG. 4 b). The amplified fragment from the sporozoite stage was cloned in a T7 promoter-based E. coli expression vector, giving rise to plasmid pFRAP. Sequencing of the cloned DNA fragment authenticated the predicted exon structure and coding sequence for the FRAP protein (data not shown). To investigate the role of FAS1 domain in the biology of the protein, two more plasmid constructs viz., pFRAP2 and pFRAP3, were generated by sub-cloning, using pFRAP as template. pFRAP2 encoded the DNA sequence for amino acids 1-87 of the full length protein while pFRAP3 encoded the FAS1 domain represented by amino acids 88-205 (FIG. 4 a). The authenticity of these clones was also verified by sequencing.
Recombinant Expression and Purification of FRAP proteins: To obtain recombinant FRAP proteins, the desired construct was transformed in E. coli BL21 cells and the expression was induced with IPTG. Three hours post induction, the culture was harvested and the site of accumulation of the recombinant protein was evaluated by sub-cellular fractionation. For all three FRAP proteins, the expression was localized in the spheroplast in the form of insoluble inclusion bodies (data not shown). Spheroplast pellet was further processed to isolate inclusion bodies, as previously described (30). Inclusion bodies were solubilized and the proteins were purified by a combination of affinity and gel filtration chromatography. The presence of a polyhistidine tag at the carboxyl terminus of the recombinantly expressed proteins facilitated the purification and all three proteins were initially purified on a His-Trap affinity column (data not shown). The proteins at this stage were 95% pure. Further purification to apparent homogeneity was done by gel filtration chromatography (FIG. 4 c). Purified FRAP, FRAP2 and FRAP3 had the expected molecular weights of 27.8, 12.3 and 17.7 kDa respectively and were recognized by a monoclonal antibody directed against the polyhistidine tag present at the carboxyl terminus of all the proteins (FIG. 4 d). The first 15 residues of each of the proteins were also verified by amino terminal sequencing (data not shown). Together, these results authenticated the recombinant proteins and suggested that they were structurally intact.
FRAP is localized in the micronemes of the sporozoites: To detect the expression of FRAP on sporozoites, protein-specific antibodies were raised by immunizing mice with FRAP2 protein. Anti-FRAP2 antibodies readily recognized the expression of FRAP protein on the sporozoite (not shown). The binding was specific as pre-immune serum did not recognize any expression on the sporozoites. This indicated that transcription of FRAP mRNA can be correlated to its expression during the sporozoite stage of the lifecycle. Immunoelectron microscopy using anti-FRAP2 antibodies revealed that FRAP was localized in the lumen of micronemes, a specialized secretory organelle in the cytoplasm (not shown). The protein was present in the apical micronemes, suggesting that it could be secreted during the infectivity process. In Plasmodium, micronemes contain several adhesive domain-containing proteins that are associated with host cell adhesion and invasion at both, sporozoite and erythrocytic stages of its lifecycle (13, 37, 38). This suggested that FRAP could be playing a role in the infectivity process.
FRAP is involved in adhesion of sporozoites to liver cells: FRAP was investigated for its possible role in host cell adhesion using a human hepatocyte cell line, HepG2, an established model for investigating sporozoite-liver cell interactions in malaria (1, 31). FRAP showed a dose dependent binding on liver cells (FIG. 5 ) which was comparable to the binding activity of CS protein, a known parasite protein involved in the adhesion and invasion of liver cells by the sporozoites (1). This suggested that FRAP could be serving as one of the parasite ligands in host-parasite interactions. This host-cell binding activity of FRAP was not due to the presence of the FAS1 domain alone, as FRAP3, a protein encoding only the FAS1 domain (amino acids 88-205) did not bind to liver cells, even at the highest concentration used in the assay (54). AlthoughFAS 1 domain alone did not show any binding, its deletion from the full length protein (protein FRAP2) lead to a 50% loss of activity, in comparison to the full length protein (FIG. 5 ). This suggested that both, FAS1 domain and the amino terminus region, contribute to the binding activity of the protein and an intact FRAP is required for its optimal activity.
FRAP binds liver cells through heparan sulfate proteoglycans: As FRAP showed potent liver cell binding, the nature of its receptor on liver cells was investigated by utilizing glycosaminoglycans as competitive inhibitors. Inhibition of adherence by the addition of soluble glycosaminoglycans in an assay may suggest that the involved host receptor is a proteoglycan (31, 39). In the presence of free heparin, binding activity of FRAP and FRAP2 was reduced by 55 and 60% respectively (FIG. 6 ). In contrast, chondroitin sulfate A showed no inhibition at the highest concentration evaluated in the assay (FIG. 6 ). This suggested that FRAP utilizes heparan sulfate-based proteoglycans (HSPG) as a receptor for adhesion. - The involvement of HSPG as a receptor was further verified by evaluating the binding of the protein on liver cells that were pretreated with specific glycosaminoglycan-cleaving enzymes. Cells were pre-treated with heparinase I or chondroitinase ABC followed by the evaluation of binding activity of FRAP and FRAP2. Heparinase I selectively removes heparan sulfate while chondroitinase ABC cleaves chondroitin sulfate A, B and C type sugars from the liver cell surface. Both, FRAP and FRAP2 lost 50% of their binding activity on heparinase I treated cells (Table 4) confirming the involvement of a heparin-based receptor on the liver cell surface. CS protein, which binds hepatocytes through HSPG (39) also showed a similar decrease in binding activity. In contrast, treatment of liver cells with chondroitinase ABC resulted in no loss of activity.
TABLE 4 Binding of FRAP proteins to hepatocytes is inhibited by pretreatment of cells with glycosaminoglycan cleaving enzyme. Cells were pretreated with different concentrations of either Heparinase I or Chondroitinase ABC for 90 minutes followed by the addition of 100 nM of protein. Inhibition of binding was calculated by comparing the binding of respective proteins on non-treated HepG2 cells in the same plate. Inhibition of Binding (%) Enzyme, U/ml FRAP FRAP2 CSP Heparinase I 1.25 39.4 ± 4.2 42.3 ± 10.4 48.1 ± 12.0 2.50 42.1 ± 7.6 41.4 ± 1.5 57.7 ± 7.9 5.00 47.8 ± 1.4 49.4 ± 9.2 59.1 ± 6.5 Chondroitinase ABC 0.01 — — — 0.12 — — — 1.25 — — — - FRAP is involved in liver cell invasion: As FRAP proteins efficiently bound to HepG2 cells, we investigated the ability of the two proteins and the anti-FRAP2 antibodies in preventing invasion of human liver cells by P. falciparum sporozoites in culture. Both FRAP and FRAP2 could prevent sporozoites from invading liver cells by 89.5% and 92.4% respectively, at the highest concentration of the protein used in the assay. This activity was comparable to the invasion inhibition activity of CSP protein, which at a similar concentration could also inhibit the invasion by 92.6%. Anti-FRAP2 antibodies showed extreme potency as at a concentration of 40 μg/ml, it inhibited sporozoite invasion by 94.6%, a level comparable to the inhibitory activity of anti-CS monoclonal antibody NFS1 (Table 5). This indicated that (i) FRAP not only plays a role in binding, it is also involved in the invasion process (ii) the protein utilizes its amino terminus (amino acids 1-87) for its invasion activity and (iii) a potent antibody response against FRAP2 by the host may play a role in malaria control.
TABLE 5 FRAP is involved in invasion of liver cells by P. falciparum sporozoites. Invasion of HepG2 cells by P. falciparum sporozoites was evaluated in the presence of different concentrations of free proteins or anti-FRAP2 antibodies and compared with the invasion activity in the presence of culture medium. % inhibition represents the decrease in the number of sporozoites that invaded liver cells in comparision to the invasion level in cells incubated with culture medium. Concentration Treatment μg/ml % Inhibition Culture Medium — FRAP 20 89.5 + 1.0 10 80.9 + 1.0 FRAP2 20 92.4 + 3.5 10 88.1 + 4.6 CS Protein 20 92.6 + 2.0 Anti-FRAP2 antibody 40 94.6 + 1.2 Anti-CS monoclonal 100 97.4 + 0.7
Discussion - Deciphering the mechanism of infectivity of the malaria parasite is a major prerequisite for developing intervention strategies. Key to this process is the unique set of proteins, many of them currently unknown, expressed by the parasite to bind and invade host cells. Therefore, a combination of biochemical and functional studies of malarial genes is required to identify parasitic proteins involved in pathogenesis.
- We identified P. falciparum FRAP, a new parasite protein and showed that it is expressed during the sporozoite stage of the lifecycle. Orthologs of P. falciparum FRAP were identified in rodent, avian, simian and human malaria species and multiple sequence alignment revealed that the protein has 60% sequence identity within the Plasmodium genus (
FIG. 3 ). Its universal presence and conserved nature suggested that the protein plays an important role in the biology of the parasite. - The protein was localized in the sporozoite micronemes by immunoelectron microscopy. Micronemes are specialized secretory organelles in Plasmodium and during the sporozoite stage secrete a wide variety of proteins involved in parasite motility, traversal and host cell infection. Previously, TRAP/SSP2 and SPECT, two sporozoite proteins with adhesive Thrombospondin type I repeat (TSR) domains have been found in the micronemes and have subsequently been shown to be involved in the infectivity process (13, 37). As FRAP encoded FAS1, an ancient adhesive domain present in both prokaryotes and eukaryotes, we therefore investigated the role of FRAP in host cell adhesion and invasion by the sporozoites.
- The protein was recombinantly expressed in E. coli and purified to homogeneity by column chromatography (
FIG. 4 c). The purified protein showed robust and dose dependent binding to liver cells indicating that it is involved in the attachment of sporozoites to liver cells (FIG. 5 ). This activity was comparable to the binding activity of CS protein, considered to be the primary binding ligand, suggesting that FRAP could be one of the primary parasite proteins involved in attachment of sporozoites to liver cells. In βig-h3, a FAS1 domain-containing human protein involved in corneal cell adhesion, the adhesion activities of the protein completely resides in the FAS1 domain (22). To investigate the role of FAS1 domain in FRAP, we expressed FAS1 domain alone (amino acids 88-205, protein FRAP3) and evaluated its cell binding activity on HepG2 cells. The protein did not show any cell binding activity (FIG. 5 ), indicating that the deleted segment (amino acids 1-87) of the protein plays an important role in the binding activity of the protein. - This was investigated by expressing amino acids 1-87 (protein FRAP2) in E. coli and evaluation of its cell binding activities on the liver cell line. FRAP2 was capable of binding to liver cells, albeit at only half the strength of its full length protein, FRAP. This suggested that amino terminus region of the protein plays an important role in the host cell binding, however, an intact FRAP molecule is required for its optimal activity. The loss of activity seen here could be due to loss of the required tertiary conformation of the binding domain (due to the absence of the FAS1 domain) and/or part of the binding motif is present in the FAS1 domain of the protein. A similar situation exists in the case of CS protein, where the unique amino terminus region plays an important role in liver cell binding and invasion activities of the protein (31).
- FRAP exploited heparan sulfate proteoglycans, expressed on liver cell surface, as receptor for its biological activities (Table 4). This was revealed by competition studies with defined carbohydrates, as well as loss of binding upon enzymatic removal of host glycans. Heparan sulfate-protein interactions involve positively charged residues of the protein, which interact with the negatively charged carboxylate and sulfate ions of the glycosaminoglycan chain. The amino terminus of FRAP possesses a disproportionate number of positively charged residues (13 out of the first 50) some of which are extremely conserved within the Plasmodium genus (
FIG. 3 ). Their conserved nature suggests that they could possibly be involved in these interactions. Parallels exist for such mechanism in other heparin-binding proteins where a large number of positively charged residues involved in heparin/HS interaction are present in a close proximity in the protein (40). - Entry of sporozoites into the hepatocyte is a multistep process, where the initial attachment to the hepatocytes is followed by the invasion of liver cells, by the parasite. To investigate the role of FRAP in the invasion process, recombinant FRAP proteins and anti-FRAP2 antibodies were used as competitors in an in vitro invasion assay. Proteins FRAP, FRAP2 and anti-FRAP2 antibodies inhibited the invasion of liver cells by P. falciparum sporozoites with extreme competence, showing as high as 94.6% inhibition (Table 5) in the assay. These levels were comparable to the inhibitory activity of CSP protein and anti-CSP monoclonal antibody. These results indicated that FRAP is utilized by sporozoites for both adhesion and subsequent invasion of liver cells and the amino terminal region plays an important role in these processes. It is noteworthy that similar level (>90%) of inhibition has only been possible by targeting CSP, SSP2/TRAP and the recently discovered SPATR protein (10). Recently, AMA1 has been shown to be involved in liver cell invasion but antibodies against the protein could inhibit the invasion only by about 50% (41). CSP and SSP2/TRAP are being vigorously pursued as vaccine candidates and are currently being evaluated in the clinic (4, 5). Involvement of FRAP in liver cell invasion and its strong inhibition by antibodies suggest that a potent immunological response against this protein in vivo could serve as a strategy for intervention and the immunological competence of FRAP as a vaccine candidate needs to be investigated.
- Although we have investigated the role of FRAP in the liver cell adhesion and invasion by the sporozoites, it is noteworthy that microarray and proteomic studies have revealed that FRAP is also transcribed and expressed during the erythrocytic stages of the lifecycle, especially during the schizonts, which is immediately followed by the release of merozoites and invasion of red blood cells (9, 42, 43). AMA1 and MAEBL, two micronemal proteins that are expressed at sporozoites and erythrocytic stages of the lifecycle, are involved in pathogenesis, both, at pre-erythrocytic and blood stages, where they play a role in host cell adhesion and invasion (41, 44-46). With its multistage expression, it is possible that FRAP could also be involved in host-parasite interactions during erythrocytic stages of the lifecycle.
- In conclusion, we have identified and characterized a new parasite protein involved in malaria pathogenesis at the sporozoite stage of the lifecycle. It's involvement in pathogenesis indicates that developing intervention strategies targeting FRAP creates new treatment options for controlling malaria.
-
- 1. Cerami, C., Frevert, U., Sinnis, P., Takacs, B., Clavijo, P., Santos, M. J. & Nussenzweig, V. (1992)
Cell 70, 1021-33. - 2. Robson, K. J., Frevert, U., Reckmann, I., Cowan, G., Beier, J., Scragg, I. G., Takehara, K., Bishop, D. H., Pradel, G., Sinden, R. & et al. (1995)
Embo J 14, 3883-94. - 3. Wang, R., Doolan, D. L., Le, T. P., Hedstrom, R. C., Coonan, K. M., Charoenvit, Y., Jones, T. R., Hobart, P., Margalith, M., Ng, J., Weiss, W. R., Sedegah, M., de Taisne, C., Norman, J. A. & Hoffman, S. L. (1998) Science 282, 476-80.
- 4. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., Bassat, Q., Aide, P., Ofori-Anyinam, O., Navia, M. M., Corachan, S., Ceuppens, M., Dubois, M. C., Demoitie, M. A., Dubovsky, F., Menendez, C., Tornieporth, N., Ballou, W. R., Thompson, R. & Cohen, J. (2004) Lancet 364, 1411-20.
- 5. Moorthy, V. S., Imoukhuede, E. B., Keating, S., Pinder, M., Webster, D., Skinner, M. A., Gilbert, S. C., Walraven, G. & Hill, A. V. (2004) J Infect Dis 189, 2213-9.
- 6. Nardin, E. H., Calvo-Calle, J. M., Oliveira, G. A., Nussenzweig, R. S., Schneider, M., Tiercy, J. M., Loutan, L., Hochstrasser, D. & Rose, K. (2001) J Immunol 166, 481-9.
- 7. Hoffman, S. (1996) Malaria Vaccine Developmtent: A multi immune response approach (ASM press, Washington, D.C.).
- 8. Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M. S., Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M., Fairlamb, A. H., Fraunholz, M. J., Roos, D. S., Ralph, S. A., McFadden, G. I., Cummings, L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoffman, S. L., Newbold, C., Davis, R. W., Fraser, C. M. & Barrell, B. (2002) Nature 419, 498-511.
- 9. Florens, L., Washburn, M. P., Raine, J. D., Anthony, R. M., Grainger, M., Haynes, J. D., Moch, J. K., Muster, N., Sacci, J. B., Tabb, D. L., Witney, A. A., Wolters, D., Wu, Y., Gardner, M. J., Holder, A. A., Sinden, R. E., Yates, J. R. & Carucci, D. J. (2002) Nature 5419, 520-6.
- 10. Chattopadhyay, R., Rathore, D., Fujioka, H., Kumar, S., De La Vega, P., Haynes, D., Moch, K., Fryauff, D., Wang, R., Carucci, D. J. & Hoffman, S. L. (2003) J Biol Chem 278, 25977-25981.
- 11. Bateman, A., Coin, L., Durbin, R., Finn, R. D., Hollich, V., Griffiths-Jones, S., Khanna, A., Marshall, M., Moxon, S., Sonnhammer, E. L., Studholme, D. J., Yeats, C. & Eddy, S. R. (2004) Nucleic Acids Res 32, D138-41.
- 12. Letunic, I., Copley, R. R., Schmidt, S., Ciccarelli, F. D., Doerks, T., Schultz, J., Ponting, C. P. & Bork, P. (2004) Nucleic Acids Res 32, D142-4.
- 13. Ishino, T., Yano, K., Chinzei, Y. & Yuda, M. (2004)
PLoS Biol 2, E4. - 14. Bastiani, M. J., Harrelson, A. L., Snow, P. M. & Goodman, C. S. (1987) Cell 48, 745-55.
- 15. Terasaka, K., Yamaguchi, R., Matsuo, K., Yamazaki, A., Nagai, S. & Yamada, T. (1989) FEMS Microbiol Lett 49, 273-6.
- 16. Snow, P. M., Zinn, K., Harrelson, A. L., McAllister, L., Schilling, J., Bastiani, M. J., Makk, G. & Goodman, C. S. (1988) Proc Natl
Acad Sci USA 85, 5291-5. - 17. Johnson, K. L., Jones, B. J., Bacic, A. & Schultz, C. J. (2003) Plant Physiol 133, 1911-25.
- 18. Wang, W. C., Zinn, K. & Bjorkman, P. J. (1993) J Biol Chem 268,1448-55.
- 19. Hu, S., Sonnenfeld, M., Stahl, S. & Crews, S. T. (1998)
J Neurobiol 35, 77-93. - 20. Zinn, K., McAllister, L. & Goodman, C. S. (1988) Cell 53, 577-87.
- 21. Politz, O., Gratchev, A., McCourt, P. A., Schledzewski, K., Guillot, P., Johansson, S., Svineng, G., Franke, P., Kannicht, C., Kzhyshkowska, J., Longati, P., Velten, F. W. & Goerdt, S. (2002) Biochem J 362, 155-64.
- 22. Kim, J. E., Kim, S. J., Lee, B. H., Park, R. W., Kim, K. S. & Kim, I. S. (2000) J Biol Chem 275, 30907-15.
- 23. Clout, N. J., Tisi, D. & Hohenester, E. (2003) Structure (Camb) 11, 197-203.
- 24. Hall, N., Karras, M., Raine, J. D., Carlton, J. M., Kooij, T. W., Berriman, M., Florens, L., Janssen, C. S., Pain, A., Christophides, G. K., James, K., Rutherford, K., Harris, B., Harris, D., Churcher, C., Quail, M. A., Ormond, D., Doggett, J., Trueman, H. E., Mendoza, J., Bidwell, S. L., Rajandream, M. A., Carucci, D. J., Yates, J. R., 3rd, Kafatos, F. C., Janse, C. J., Barrell, B., Turner, C. M., Waters, A. P. & Sinden, R. E. (2005) Science 307, 82-6.
- 25. Bahl, A., Brunk, B., Coppel, R. L., Crabtree, J., Diskin, S. J., Fraunholz, M. J., Grant, G. R., Gupta, D., Huestis, R. L., Kissinger, J. C., Labo, P., Li, L., McWeeney, S. K., Milgram, A. J., Roos, D. S., Schug, J. & Stoeckert, C. J., Jr. (2002)
Nucleic Acids Res 30, 87-90. - 26. Gardner, M. J., Bishop, R., Shah, T., de Villiers, E. P., Carlton, J. M., Hall, N., Ren, Q., Paulsen, I. T., Pain, A., Berriman, M., Wilson, R. J., Sato, S., Ralph, S. A., Mann, D. J., Xiong, Z., Shallom, S. J., Weidman, J., Jiang, L., Lynn, J., Weaver, B., Shoaibi, A., Domingo, A. R., Wasawo, D., Crabtree, J., Wortman, J. R., Haas, B., Angiuoli, S. V., Creasy, T. H., Lu, C., Suh, B., Silva, J. C., Utterback, T. R., Feldblyum, T. V., Pertea, M., Allen, J., Nierman, W. C., Taracha, E. L., Salzberg, S. L., White, O. R., Fitzhugh, H. A., Morzaria, S., Venter, J. C., Fraser, C. M. & Nene, V. (2005) Science 309, 134-7.
- 27. Pain, A., Renauld, H., Berriman, M., Murphy, L., Yeats, C. A., Weir, W., Kerhomou, A., Aslett, M., Bishop, R., Bouchier, C., Cochet, M., Coulson, R. M., Cronin, A., de Villiers, E. P., Fraser, A., Fosker, N., Gardner, M., Goble, A., Griffiths-Jones, S., Harris, D. E., Katzer, F., Larke, N., Lord, A., Maser, P., McKellar, S., Mooney, P., Morton, F., Nene, V., O'Neil, S., Price, C., Quail, M. A., Rabbinowitsch, E., Rawlings, N. D., Rutter, S., Saunders, D., Seeger, K., Shah, T., Squares, R., Squares, S., Tivey, A., Walker, A. R., Woodward, J., Dobbelaere, D. A., Langsley, G., Rajandream, M. A., McKeever, D., Shiels, B., Tait, A., Barrell, B. & Hall, N. (2005) Science 309, 131-3.
- 28. Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994) Nucleic Acids Res 22, 4673-80.
- 29. Haynes, J. D. & Moch, J. K. (2002) Methods Mol Med 72, 489-97.
- 30. Rathore, D., Hrstka, S. C., Sacci, J. B., Jr., De la Vega, P., Linhardt, R. J., Kumar, S. & McCutchan, T. F. (2003) J Biol Chem 278, 40905-10.
- 31. Rathore, D., Sacci, J. B., de la Vega, P. & McCutchan, T. F. (2002) J Biol Chem 277, 7092-8.
- 32. Folsch, H., Pypaert, M., Schu, P. & Mellman, I. (2001) J Cell Biol 152, 595-606.
- 33. Ozaki, L. S., Gwadz, R. W. & Godson, G. N. (1984)
J Parasitol 70, 831-3. - 34. Marchler-Bauer, A. & Bryant, S. H. (2004) Nucleic Acids Res 32, W327-31.
- 35. Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M. A., Adlem, E., Aert, R., Anupama, A., Apostolou, Z., Attipoe, P., Bason, N., Bauser, C., Beck, A., Beverley, S. M., Bianchettin, G., Borzym, K., Bothe, G., Bruschi, C. V., Collins, M., Cadag, E., Ciarloni, L., Clayton, C., Coulson, R. M., Cronin, A., Cruz, A. K., Davies, R. M., De Gaudenzi, J., Dobson, D. E., Duesterhoeft, A., Fazelina, G., Fosker, N., Frasch, A. C., Fraser, A., Fuchs, M., Gabel, C., Goble, A., Goffeau, A., Harris, D., Hertz-Fowler, C., Hilbert, H., Horn, D., Huang, Y., Klages, S., Knights, A., Kube, M., Larke, N., Litvin, L., Lord, A., Louie, T., Marra, M., Masuy, D., Matthews, K., Michaeli, S., Mottram, J. C., Muller-Auer, S., Munden, H., Nelson, S., Norbertczak, H., Oliver, K., O'Neil, S., Pentony, M., Pohl, T. M., Price, C., Purnelle, B., Quail, M. A., Rabbinowitsch, E., Reinhardt, R., Rieger, M., Rinta, J., Robben, J., Robertson, L., Ruiz, J. C., Rutter, S., Saunders, D., Schafer, M., Schein, J., Schwartz, D. C., Seeger, K., Seyler, A., Sharp, S., Shin, H., Sivam, D., Squares, R., Squares, S., Tosato, V., Vogt, C., Volckaert, G., Wambutt, R., Warren, T., Wedler, H., Woodward, J., Zhou, S., Zimmermann, W., Smith, D. F., Blackwell, J. M., Stuart, K. D., Barrell, B., et al. (2005) Science 309, 436-42.
- 36. Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., Bartholomeu, D. C., Lennard, N. J., Caler, E., Hamlin, N. E., Haas, B., Bohme, U., Hannick, L., Aslett, M. A., Shallom, J., Marcello, L., Hou, L., Wickstead, B., Alsmark, U. C., Arrowsmith, C., Atkin, R. J., Barron, A. J., Bringaud, F., Brooks, K., Carrington, M., Cherevach, I., Chillingworth, T. J., Churcher, C., Clark, L. N., Corton, C. H., Cronin, A., Davies, R. M., Doggett, J., Djikeng, A., Feldblyum, T., Field, M. C., Fraser, A., Goodhead, I., Hance, Z., Harper, D., Harris, B. R., Hauser, H., Hostetler, J., Ivens, A., Jagels, K., Johnson, D., Johnson, J., Jones, K., Kerhomou, A. X., Koo, H., Larke, N., Landfear, S., Larkin, C., Leech, V., Line, A., Lord, A., Macleod, A., Mooney, P. J., Moule, S., Martin, D. M., Morgan, G. W., Mungall, K., Norbertczak, H., Ormond, D., Pai, G., Peacock, C. S., Peterson, J., Quail, M. A., Rabbinowitsch, E., Rajandream, M. A., Reitter, C., Salzberg, S. L., Sanders, M., Schobel, S., Sharp, S., Simmonds, M., Simpson, A. J., Tallon, L., Turner, C. M., Tait, A., Tivey, A. R., Van Aken, S., Walker, D., Wanless, D., Wang, S., White, B., White, O., Whitehead, S., Woodward, J., Wortman, J., Adams, M. D., Embley, T. M., Gull, K., Ullu, E., Barry, J. D., Fairlamb, A. H., Opperdoes, F., Barrell, B. G., Donelson, J. E., Hall, N., Fraser, C. M., et al. (2005) Science 309, 416-22.
- 37. Muller, H. M., Reckmann, I., Hollingdale, M. R., Bujard, H., Robson, K. J. & Crisanti, A. (1993)
Embo J 12, 2881-9. - 38. Sim, B. K., Chitnis, C. E., Wasniowska, K., Hadley, T. J. & Miller, L. H. (1994) Science 264, 1941-4.
- 39. Frevert, U., Sinnis, P., Cerami, C., Shreffler, W., Takacs, B. & Nussenzweig, V. (1993) J Exp Med 177, 1287-98.
- 40. Hileman, R. E., Fromm, J. R., Weiler, J. M. & Linhardt, R. J. (1998) Bioessays 20, 156-67.
- 41. Silvie, O., Franetich, J. F., Charrin, S., Mueller, M. S., Siau, A., Bodescot, M., Rubinstein, E., Hannoun, L., Charoenvit, Y., Kocken, C. H., Thomas, A. W., Van Gemert, G. J., Sauerwein, R. W., Blackman, M. J., Anders, R. F., Pluschke, G. & Mazier, D. (2004) J Biol Chem 279, 9490-6.
- 42. Bozdech, Z., Zhu, J., Joachimiak, M. P., Cohen, F. E., Pulliam, B. & DeRisi, J. L. (2003)
Genome Biol 4, R9. - 43. Bozdech, Z., Llinas, M., Pulliam, B. L., Wong, E. D., Zhu, J. & DeRisi, J. L. (2003)
PLoS Biol 1, E5. - 44. Preiser, P., Renia, L., Singh, N., Balu, B., Jarra, W., Voza, T., Kaneko, O., Blair, P., Torii, M., Landau, I. & Adams, J. H. (2004) Infect Immun 72, 3604-8.
- 45. Kappe, S. H., Noe, A. R., Fraser, T. S., Blair, P. L. & Adams, J. H. (1998) Proc Natl Acad Sci USA 95, 1230-5.
- 46. Mitchell, G. H., Thomas, A. W., Margos, G., Dluzewski, A. R. & Bannister, L. H. (2004) Infect Immun 72, 154-8.
- Identification of Inhibitory epitope by peptide mapping As we have demonstrated that antibodies against FRAP2, an 87 amino acid polypeptide can prevent invasion, the region of the protein responsible for this recognition was mapped by developing a set of overlapping peptides that were utilized for ELISA. A set of 10 overlapping peptides (Table 6) were chemically synthesized and used as coating antigen to identify the epitope recognized by these antibodies. Overlapping Peptides HAI-3,4, & 5 were predominantly recognized by these antibodies, suggesting that a 32 amino acid sequence (TRSGGLRKPQKVTNDPESINRKVYWCFEHKPV, SEQ ID NO: 24), comprised by these peptides is being recognized by the inhibitory antibodies (Table 7). A sequence comparison of these peptides reveals that an 8 amino acid sequence (TNDPESIN, SEQ ID NO: 37) is present in all of them (
FIG. 7 ) suggesting that this sequence could be an important component of the region recognized by the anti-protein antibodies. Therefore, the 32 amino acid sequence or portion thereof can be exploited as part of a multi-epitope subunit vaccine. The 32 amino acid region has 100% sequence homology or 87.5% sequence identity within the Plasmodium genus implying that this region plays a critical role in all the Plasmodium species and an immune response(s) generated against this region of the protein in one species could be a factual representation of immnune responses against other species, generated by its host. Two other peptides (HAI-7 and HAI-10) were also recognized by the anti-protein antibodies suggesting that their recognition is also important in preventing parasites from initiating an infection.TABLE 6 Sequence of peptides chemically synthesized for identification of inhibitory epitope. Peptide Sequence SEQ ID NO HAI-1 MKNRFYYNLIIKRLYTRSGG SEQ ID NO: 27 HAI-2 NLIIKRLYTRSGGLRKPQKV SEQ ID NO: 28 HAI-3 TRSGGLRKPQKVTNDPESIN SEQ ID NO: 29 HAI-4 GLRKPQKVTNDPESINRKVY SEQ ID NO: 30 HAI-5 TNDPESINRKVYWCFEHKPV SEQ ID NO: 31 HAI-6 VYWCFEHKPVKRTIINLIYS SEQ ID NO: 32 HAI-7 KPVKRTIINLIYSHNELKIF SEQ ID NO: 33 HAI-8 NLIYSHNELKIFSNLLNHPT SEQ ID NO: 34 HAI-9 NELKIFSNLLNHPTVGSSLI SEQ ID NO: 35 HAI-10 NLLNHPTVGSSLIHELSLDG SEQ ID NO: 36 -
TABLE 7 Recognition of FRAP-derived peptides by ELISA. Peptides were coated onto the ELISA plate followed by the addition of log dilutions of antibodies followed by anti-mouse antibodies conjugated to alkaline phosphatase. Recognition was measured at 405 nm using an ELISA plate reader. Peptide/ 1:100 1:1000 1:10K Antigen FRAP FRAP2 FRAP FRAP2 FRAP FRAP2 HAI-1 0.010 0.015 — — — — HAI-2 0.010 0.020 — — — — HAI-3 0.710 0.530 0.223 0.190 0.026 0.020 HAI-4 0.789 0.710 0.4445 0.630 0.063 0.230 HAI-5 0.660 0.636 0.290 0.465 0.030 0.110 HAI-6 0.005 — — — — — HAI-7 0.730 0.065 0.550 0.026 0.165 — HAI-8 0.020 0.290 — 0.039 — — HAI-9 0.030 — — — — — HAI-10 0.250 0.300 0.030 0.045 — — FRAP* 0.670 0.600 0.650 0.465 0.340 0.130 FRAP** 0.210 0.260 0.070 0.400 — 0.190
*4 pmol of protein
**2 nmol of each peptide in 50 ul coating buffer
- Optimal recognition of an epitope by the host immune system requires that the epitope maintains its structural conformation. While short amino acid sequences can be easily recognized in vitro, their recognition under in-vivo conditions almost always requires them to be present as part of a much larger polypeptide. This is especially important for configurational epitopes present in the surface antigens of malaria parasite whose recognition requires that a continuous stretch of amino acids, larger than its identified epitope, be present for its optimal recognition. Therefore, a 32 amino acid long region is most likely required for optimal recognition of FRAP protein by the host immune system and it could be utilized either alone or in combination with other known and unknown malarial antigens in a vaccine.
- FRAP is recognized by the host immune system of malaria-infected subjects. Sera from 17 malaria infected subjects was screened for the presence of anti-FRAP antibodies, by ELISA.
- 0.5 microgram of purified FRAP protein was coated as antigen and its recognition was probed with sera at 1:200 dilution. 4 sera samples from north American volunteers, who have never been exposed to malaria were used as control. A cutoff value of OD405=0.378, which represented mean of OD+2 SD was used to determine samples that were positive. The ELISA results indicated that 10 out of 17 (58.8%) infected subjects had anti-FRAP antibodies (Table 8) with OD values above the set cutoff
TABLE 8 Recognition of full length FRAP by sera from infected subjects living in Bandiagara, a malaria-endemic district in Mali. Sample ID Absorbance, 405 nm Positive 1A-001 0.79 ± 0.07 Y 1A-002 1.03 ± 0.05 Y 1A-004 0.47 ± 0.02 Y 1A-005 0.23 ± 0.01 N 1A-007 0.23 ± 0.01 N 1A-008 0.49 ± 0.07 Y 1A-010 0.26 ± 0.01 N 1A-011 0.21 ± 0.01 N 1A-013 0.91 ± 0.00 Y 1A-014 0.30 ± 0.01 N 1A-016 0.60 ± 0.01 Y 1A-017 0.15 ± 0.01 N 1A-019 0.43 ± 0.00 Y 1A-020 0.56 ± 0.01 Y 1A-021 0.40 ± 0.00 Y 1A-023 0.41 ± 0.02 Y 1A-024 0.20 ± 0.00 N - Once a malaria parasite infects red blood cells, host hemoglobin serves as its primary source of amino acids required for its geometric increase in infection. It achieves its goal by cannibalizing hemoglobin to its constituent amino acids, which it recycles for its own protein synthesis. While the parasite is extremely effective in digesting the protein (globin) component of hemoglobin the heme prosthetic group serves as a challenge to its survivability. Free heme released from hemoglobin is lethal for the parasite and to escape its deleterious effects the parasite enzymatically polymerizes heme into a non-toxic byproduct known as hemozoin. Therefore, any mechanism by which polymerization of heme into nontoxic hemozoin can be inhibited will lead to a very effective therapeutic for malaria.
- We show here that FRAP is responsible for this activity. FRAP effectively converted toxic heme into inactive hemozoin in a dose dependent manner (
FIG. 8 ). The hemozoin formation activity was 10-20-fold higher in comparison to histidine rich protein II, the only known parasite protein capable of making hemozoin. This activity was specific as it was lost when the protein was pre-treated with proteinase K (a non specific protease) suggesting that an intact protein is required for this activity (FIG. 9 ). The activity requires the complete protein as two truncated variants of FRAP (FRAP2 and FRAP3) did not show any hemozoin formation (FIG. 8 ). - The authenticity of the polymerized heme as hemozoin was verified by FT-IR spectroscopy. The IR spectra of hemozoin contains an intense absorbance at 1664 and 1211 cm−1, that are absent in the spectra of free heme (Slater et al., 1991). These are characteristics of a carboxylate group coordinated to the iron center of ferriporphyrin (Fe01-O41) arising from stretching of the localized carbon-oxygen double and single bonds, respectively (Slater et al., 1991). The chemical structure of β-hematin is depicted in
FIG. 10 (adapted from (Pagola et al., 2000)). The infra red spectra of the FRAP-generated product showed the characteristic decrease in transmittance at 1664 and 1211 cm−1, chemically validating that the product formed was indeed hemozoin (FIG. 11 ). - FRAP residues involved in heme polymerization were identified by generating 11 variants of FRAP by site-directed mutagenesis. Evaluation of these mutants for heme polymerization-activity revealed that three residues viz., F42, H44 & H122 are critically involved in hemozoin formation, as their conversion to alanine lead to a complete loss of activity (Table 9).
- FRAP protein shows remarkably high amount of sequence homology between different Plasmodium species. In FRAP, a highly conserved protein sequence has biological relevance as the residues shown to be involved in hemozoin formation viz., F42, H44, H122 (Table 9) are not only conserved within the Plasmodium genus, they are also conserved in Theileria parasites. This indicates that FRAP protein from a non-human malaria parasite can be used as target for screening and development of novel inhibitors for FRAP protein of human malaria parasite.
- This can be achieved by screening a library of small molecules/inhibitors in vitro in the FRAP-mediated hemozoin formation assay, which will lead to the identification of a candidate molecule(s). These molecules can be subsequently evaluated in an in vitro P. falciparum culture in the laboratory. Once their efficacy has been proved in vitro, these molecules can be evaluated in a rodent malaria parasite model. This will be feasible due to the extremely conserved nature of the protein and the amino acids residues of FRAP involved in the process of hemozoin formation (F42, H44, H122), as seen by site-directed mutagenesis, being identical between all known FRAP proteins (Table 9,
FIG. 3 ). - Once a small molecule shows efficacy in the mouse malaria model, it can be directly evaluated in a monkey model without requiring extensive experimentation as FRAP in P. knowlesi, the monkey malaria parasite, has the same residues in its active site. Therefore, it is possible to develop FRAP inhibitors for human malaria parasite by targeting FRAP sequence from other species of Plasmodium.
TABLE 9 Identification of FRAP residues involved in Hemozoin formation. 11 FRAP residues were individually mutated to alanine by site-directed mutagenesis; proteins were expressed in E. coli and purified to homogeneity. Polymerization of heme was investigated with 500 pmoles of each of the proteins and their activity was compared with the unmutated FRAP. Conversion of F42, H44 and H122 lead to a complete loss of activity, suggesting a critical role for these residues in the polymerase activity of the protein. Heme Polymerized Protein (nmoles) % Decrease FRAP 139.2 — Y39A 155.2 — F42A 0.6 99.5 H44A 6.7 95.1 F64A 102.2 26.6 H79A 133.5 4.1 F90A 111.1 20.1 H122A 0.9 99.3 C191A 104.9 24.6 H192A 115.6 16.9 H197A 106.4 23.5 - A time kinetic analysis for hemozoin formation revealed that the conversion of heme into hemozoin was complete within 5 hours and was pH dependent where a pH of 5.2 was required for optimal activity (
FIG. 12 ). Stoichiometric analysis for FRAP-Heme interaction using continuous variation method (Job's Plot) revealed that the protein has a 1:1 stoichiometry with heme (FIG. 13 ). Hemozoin formation could be effectively inhibited by chloroquine, an antimalarial that is known to exerts its activity by binding to free heme and preventing its polymerization into hemozoin (FIG. 14 ). - These results clearly demonstrate that (i) FRAP is responsible for neutralization of heme through a polymerase activity and (ii) the polymerization can be inhibited by chloroquine. In addition, the active site residues that are critical for this activity were identified. Therefore, FRAP is an efficient drug target for malaria drug development, for example, for the design of small molecules that bind to the active site and inhibit the catalytic capability of FRAP.
-
- 1. Francis, S. E., Sullivan, D. J., Jr. and Goldberg, D. E. (1997) Annu Rev Microbiol, 51, 97-123.
- 2. Gluzman, I. Y., Francis, S. E., Oksman, A., Smith, C. E., Duffin, K. L. and Goldberg, D. E. (1994) J Clin Invest, 93, 1602-1608.
- 3. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D. and Madsen, S. K. (2000) Nature, 404, 307-310.
- 4. Slater, A. F. and Cerami, A. (1992) Nature, 355, 167-169.
- 5. Slater, A. F., Swiggard, W. J., Orton, B. R., Flitter, W. D., Goldberg, D. E., Cerami, A. and Henderson, G. B. (1991) Proc Natl AcadSci USA, 88,325-329.
- 6. Sullivan, D. J., Jr., Gluzman, I. Y. and Goldberg, D. E. (1996) Plasmodium hemozoin formation mediated by histidine-rich proteins. Science, 271, 219-222.
- 7. Wellems, T. E., Walker-Jonah, A. and Panton, L. J. (1991) Proc Natl Acad Sci USA, 88, 3382-3386.
- As described above, the pathway for conversion of heme to hemozoin is a major drug target. Until now, in vitro screening of small molecules capable of this blockage has been performed by evaluating their activity in an assay of hemozoin formation, where polymerization is being performed using parasite lysate or is chemically driven requiring extremely high salt concentrations. These conditions, though yielding hemozoin, are far from perfect as a typical experiment requires a 16 hour reaction and less than 10% of the substrate is converted into a product (Tripathi et al., 2004). Our FRAP-based methodology of hemozoin formation is extremely superior to the currently available technology, as it mimics the in vivo process, converts >50% of the initial substrate into product and can be completed in as little as 5 hours. Therefore, a FRAP-based assay system for the identification of antimalarials is an assay system of choice for these processes.
- Screening Procedure for Inhibitors of FRAP-mediated Hemozoin Formation.
- The first assay describes in detail how the hemozoin formation is investigated. This is the complete detail of the assay documenting every step of the process. This assay will be used for studying the role of an inhibitor, as inhibition of FRAP activity will cause a decrease in hemozoin formation which will b easily quantifiable by this assay. This assay was used to inhibit hemozoin formation using chloroquine and has been described as
assay 2. - Assay 1: FRAP-mediated Hemozoin formation Assay (all temperatures in degree C.):
- The standard assay contained in a total volume of 1.0 ml: 500 mM sodium acetate pH 5.2, 300 nmol/ml hemin-Cl (as substrate) and 500 pmol/ml FRAP, as the source of heme polymerase activity. The amount of FRAP added was chosen such that 50% of the substrate was converted into product (insoluble hemozoin) during the assay. The reaction was initiated by protein addition and allowed to proceed for 16 hours at 37 degree. The reaction was terminated by adding 0.01 ml of 10% SDS solution. The reaction tube was centrifuged at 13,000 rpm for 15 minutes at 23 degrees and the supernatant was carefully removed. The pellet, which contained the polymerized and insoluble hemozoin, was resuspended in 1 ml of 0.1M sodium bicarbonate pH 9.1 containing 2.5% SDS. At this step, any free heme present in the pellet will go into the solution at it is soluble in sodium bicarbonate while the hemozoin is insoluble. This process essentially removes any free heme that could be present in the pellet. The suspension was spun at 13,000 rpm and the supernatant, containing unpolymerized substrate was removed. This process was repeated thrice, followed by washing of the pellet in pure water. The pellet obtained after final washing was dissolved in 0.3 ml of 0.1N NaOH and the absorbance of the solution was measured at 405 nm using a spectrophotometer. Amount of heme polymerized was calculated utilizing a standard curve, prepared by dissolving known amounts of commercially available beta-hematin in 0.1N NaOH. Chemically synthesized beta-hematin and biologically polymerized hemozoin are chemically identical (Pagola et al, 2000 Nature).
- To assure that the heme polymerized was due specifically to the action of FRAP, a parallel control incubations were performed which either did not contain any protein or contained bovine serum albumin, which was used a non-specific protein control. Furthermore, the hemozoin formation was also evaluated with truncated variants and point mutants of FRAP to not only describe its structural requirements, but also pin point the residues that are involved in the polymerization process.
- Assay 2: Inhibition of FRAP-mediated hemozoin formation
- For inhibition studies, the inhibitor under examination was added to the standard assay cocktail (as described above) at the desired concentration and the FRAP-mediated hemozoin formation activity was compared to that found in control (minus inhibitor) incubations which lacked inhibitor.
- This assay system will be utilized for screening FRAP inhibitors. A difference in the amount of hemozoin seen in the presence of an inhibitor with respect to the reaction where the inhibitor was absent is directly attributable to the activity of the inhibitor in the reaction.
- Gene knockout experiments were performed for FRAP to study its criticality in the life of the parasite. DNA encoding a short segment of FRAP was cloned into a vector encoding the gene for Dihydrofolate reductase (DHFR) as a selection marker. The resulting plasmid vector was transfected into parasites in culture, and the parasites were then subjected to drug pressure (e.g. Drug WR99210) to select for parasites that do not encode a functional FRAP gene. Deletion of FRAP from the genome led to the death of the parasites indicating that (i) this gene is critical for the survival of the parasite and (ii) any strategy that can either prevent the expression of the FRAP gene product or decrease its level of expression can be exploited for controlling malaria. This result also gains credence from the biological role of this protein described by inventors where they have shown that the protein is involved in the infectivity process and in neutralization of heme, which is critical for the survival of the parasite. Therefore, methods that can neutralize the FRAP gene product will automatically lead to malaria control.
- In the last few years, inhibition of a gene function by utilizing small inhibitory RNA (siRNA) has been shown to be feasible for a variety of pathogens. This technology has proved to be extremely effective in Trypanosome parasites, where it has been extensively utilized for understanding the role of a particular gene in the infectivity process and pathogenicity (Best et al., 2005; Ullu et al., 2002). As deletion of FRAP from the genome is lethal, and the protein plays an important role in the disease process, therefore, siRNA mediated gene silencing can be an effective method for controlling malaria. This is achieved by designing short segments of sense and anti-sense RNA fragments that are complementary to the coding sequence of FRAP. These sequences are delivered to the cytosol of the parasite through a plasmid DNA construct. Once in the cytosol, transcription of the siRNA occurs and prevents the expression of FRAP. The result is loss of the activity of this critical protein, without which the parasite is not able to survive.
- For example, human Plasmodium parasites can be transformed with vectors expressing one or more siRNA molecules based on SEQ ID NOS: 2 or 8. Methods for design of siRNA molecules have been published by a number of sources. A recent publication by Dharmacon Inc. (Reynolds, A. et al., Rational design for RNA interference (2004), Nature Biotechnology 22: 326-330) suggests eight design criteria optimal for effective siRNA design. The siDESIGN™ Center Program provided by Dharmacon Inc. can be used to design optimal siRNA molecules based on the
SEQIDs position 19, an A atposition 3, a U atposition 10, and an absence of a G or C atposition 19 and a G atposition 13. The resulting siRNA oligonucleotides can be cloned as a small hairpin RNAs (shRNA) between a Plasmodium RNA Polymerase III (Pol III) promoter, which initiates synthesis at a defined distance from the promoter, and a termination sequence consisting of a string of 4-5 uridines, or other suitable constitutive promoters can be used as well. When transfected and co-expressed with a selectable marker into Plasmodium cells, siRNA expression will reduce the levels of the endogenous mRNAs corresponding toSEQ ID - Several sources are available which give detailed descriptions of the use of siRNA technology. For example, WO0044895 (Kreutzer and Limmer) specifically covers the use of small dsRNAs as therapeutics, and specifically to methods and medicaments involving the use of small dsRNAs formed from two separate strands and having a region complementary to the target gene.
- US2005026278 (Tuischl et al.) describes a key structural feature of siRNAs, namely the presence of overhangs at the 3′-end of each of the two strands and includes data on mammalian cell gene silencing. U.S. Pat. Nos. 5,898,031 and 6,107,094 (the entire contents of which are hereby incorporated by reference) describe degradation of target mRNA mediated by chemically modified RNAi-like oligonucleotides.
- We have successfully demonstrated that FRAP performs the critical neutralization of toxic heme into non-toxic hemozoin. We have also identified amino acids in FRAP, whose conversion result in protein variants in which the heme polymerase activity has been totally lost or has been compromised (Table 7). Developing a parasite which has been genetically modified in such a way, where the FRAP gene is present in the genome, but it has been modified by a genetic modification to a variant copy of the protein, which encodes a protein that is not fully functional, will give rise to attenuated parasites. Such a process has been previously demonstrated in other systems where CSP, a gene encoding a parasite protein involved in pathogenesis was swapped by genetic manipulation resulting in attenuated parasites (Tewari et al., 2005). Attenuated parasites may also be produced using siRNA vectors as described in the section above.
- As described in Example 1, expression of DNA encoding FRAP in E. Coli leads to very high expression and up to 40 mg of purified protein can be purified from a one liter shaker flask culture. Obtaining high yields for a recombinant protein and development of optimal purification strategies has long been recognized as a major bottleneck for developing therapeutics. In the field of recombinant protein expression and purification, these issues have been tackled by expressing a gene of interest fused with a second gene (commonly called as a tag), which has distinct binding properties and a high level of expression. The two most commonly utilized tags for such purposes are DNA encoding for maltose-binding protein and glutathione S transferase. These tags not only facilitate purification of protein by exploiting the distinct binding properties of the tags but also help by enhancing the expression of the gene of interest.
- The high level of expression of FRAP in its recombinant expression and its unique capabilities of interaction with heme makes this protein uniquely fitted to serve as a tag in recombinant expression vectors. FRAP-based fusions proteins are purified by affinity chromatography by exploiting its heme-binding properties in a column chromatography system, where the fusion protein binds to the column through available heme moiety and is cluted by excess of free heme. Various fusion proteins of FRAP having epitopes of CSP and TRAP may be produced by this method for use, e.g. in a vaccine.
-
- Best, A., Handoko, L., Schluter, E. and Goringer, H. U. (2005) J Biol Chem, 280, 20573-20579.
- Tewari, R., Rathore, D. and Crisanti, A. (2005) Cell Microbiol, 7, 699-707.
- Tripathi, A. K., Khan, S. I., Walker, L. A. and Tekwani, B. L. (2004) Anal Biochem, 325, 85-91.
- Ullu, E., Djikeng, A., Shi, H. and Tschudi, C. (2002) RNA interference: advances and questions. Philos Trans R Soc Lond B Biol Sci, 357, 65-70.
- Fully human monoclonal antibodies against Plasmodium or Theileria antigens are made in mice directly, when these mice are engineered to produce only human antibody chains. For example the technology practiced by companies such as Abgenix Inc. [XenoMouse technology, U.S. Pat. No. 6,657,103], Medarex Inc. and GenMab A/S [HuMab Mouse or UltiMAB technology; WO2005023177] can be used. Purified proteins as described above are used to immunize such engineered mice. Monoclonals produced in this manner are produced, screened and characterized in the standard manner. Fully human antibodies are produced using phage display methods by screening against human antibody phage display libraries. For example technologies practiced by companies such as Cambridge Antibody Technology [U.S. Pat. No. 5,969,108 and U.S. Pat. No. 6,172,197] and others, can be used to identify fully human antibodies in this manner. Phage display screening has as an added advantage that the process does not rely on animal immunization. The genes for fully human antibodies produced using engineered mice, or identified through phage display, are isolated, sequenced and cloned for expression in mammalian cell lines for high level expression using standard methods.
- Development of new drugs is urgently needed to replace major antimalarials that have become ineffective due to increasing drug resistance. During the intra-erythrocytic stage, malaria parasites proteolyse globin chains of host hemoglobin1, releasing prosthetic group heme, which is toxic to the parasite. Heme is immediately detoxified, primarily by its conversion into a metabolically inert crystalline material called hemozoin (Hz)2.3, a step essential for parasite survival and targeted by some of the most effective antimalarial drugs ever discovered, including chloroquine. These drugs exert their anti-parasite activity by binding to free heme4.5, which prevent its detoxification into Hz. Parasite factors responsible for heme detoxification are poorly identified and remain controversial6.9. In this example, the identification, genetic characterization and functional activity of a novel Plasmodium falciparum protein that efficiently converts free heme into Hz is described. The protein readily converts up to 50% of free heme into Hz, at a rate that is at least an order of magnitude higher than any of the known parasite factors6.9 capable of Hz synthesis. Therefore, the polypeptide has been designated heme detoxification protein or HDP. (Alternatively, the protein may also be designated “Fasciclin Related Adhesive Protein” or “FRAP”, as is the case in the previous examples. HDP orthologs have also been identified in rodent, simian and avian Plasmodium species. HDP is highly conserved within the Plasmodium genus and appears to be essential as it's gene disruption could not be achieved in P. falciparum parasites. By immunoelectron microscopy studies, it has ben demonstrated that after merozoite invasion, ring form parasites express and secrete this protein into the erythrocyte cytosol before any detectable amount of Hz is visible inside the parasite. Subsequently, HDP, accompanied by host hemoglobin, is delivered to the parasite food vacuole, the site of Hz formation. Together, these results establish HDP as a key parasite protein responsible for heme detoxification and therefore, its targeting could lead to the discovery of novel antimalarial drugs.
- Major clinical manifestations of malaria are associated with the development of Plasmodium parasites inside host erythrocytes. During this stage, heme is detoxified and predominantly sequestered inside the parasite's food vacuole as Hz, which is chemically and structurally identical to β-hematin2.3. The underlying mechanism, though poorly understood, is believed to be highly conserved as Hz formation occurs in all the species of Plasmodium during their intraerythrocytic development, irrespective of the host species they infect.
- HDP, a single copy, three-exon encoded10, 205 amino acid long P. falciparum polypeptide (GenBank Acc#NP—702335;
FIG. 3 ) that potently detoxifies heme into Hz (FIG. 4 c and 4 d) was identified. The HDP gene was found to be actively transcribed and expressed during the intraerythrocytic stages, a phase of the lifecycle where Hz is produced by the parasite (FIG. 4 b). The coding sequence of HDP corresponding to amino acid 1-205 (SEQ ID NO: 1) was cloned in a T7 promoter-based E. coli expression plasmid and recombinant HDP was produced and purified to homogeneity (FIG. 4 a). - In a Hz formation assay6, where heme was present in several hundred fold molar excess with respect to HDP, it was found that the protein actively converted heme into Hz, in a dose dependent manner (
FIG. 16 a-b). Hz production increased with an increase in the concentration of either free heme (FIG. 16 a) or HDP (FIG. 16 b), converting up to 50% of free heme into Hz, until the reaction reached equilibrium (FIG. 16 a). At the highest heme concentration tested, HDP produced Hz at a rate of 21 nmol/hr, which was at least 20 fold higher than that of Histidine Rich Protein II (HRP II) and unsaturated (oleic acid and mono-oleoyl glycerol) lipids (FIG. 16 a), the only known parasite components capable of Hz synthesis. This process was HDP-dependent, as in its absence, Hz production occurred at baseline (0.1-0.2 nmol/hr) levels. Fourier transform infrared spectroscopy confirmed the sequestered product as Hz, as it showed characteristic absorption peaks at 1660 and 1210 cm−1, a spectroscopic signature2 of carboxylate side group coordinated to the iron center of ferriprotoporphyrin IX (FIG. 16 c). In vivo, Hz formation occurs in an acidic (pH 4.5-5.2) milieu11.12 of the food vacuole and it was found that HDP had optimal activity in a similar environment (FIG. 16 d), that was indicative of its potential to function in the food vacuole. It is noteworthy that HRP II (and HRP III), the only known parasite proteins capable of Hz synthesis6, are only found in P. falciparum parasites, where most of the protein produced is secreted by the parasite13.14 and Hz production is unaffected in parasite clones lacking the two proteins15. This led to a suggestion that unsaturated membrane lipids could be producing Hz in the parasite7.9. However, these results clearly show that HDP is the most potent parasite factor and could be the major producer of Hz inside the parasite. - To investigate whether the heme detoxification activity demonstrated by recombinant HDP is the true representation of its role in the parasite, native HDP from erythrocytic stage P. falciparum parasites was purified. On a SDS-PAGE gel, native HDP showed an approximate molecular weight of ˜60 KDa, possibly due to dimerization, and was recognized by anti-HDP antibodies on a western blot (
FIG. 16 e). Furthermore, it was found that native HDP was able to produce Hz at levels comparable to the recombinant protein (FIG. 16 f), which indicated that in vivo, HDP could indeed be involved in Hz formation. - Hz formation is an indispensable step in parasite's lifecycle. As results from our in vitro studies inferred towards a major role for HDP in this process, its involvement was investigated in vivo by a genetic knockout experiment in erythrocytic stage P. falciparum parasites. Disruption of the HDP locus was attempted by a plasmid-based single cross over recombination (
FIG. 17 a). To promote plasmid integration at the targeted locus, transfected parasites were subjected to three drug selection cycles over a 12 week period. In two independent experiments, parasites with a disrupted HDP locus could not be obtained and the resulting transfectants episomally carried the pHDPKO plasmid (FIG. 17 b) and expressed HDP at levels comparable to the wild type parasites (not shown), Therefore, it is highly likely that HDP plays a critical role in Hz formation and its inactivation may not be possible. - Inside an infected erythrocyte, up to 75% of the total hemoglobin is degraded16 giving rise to large quantities of free heme, most of which is converted into Hz7. Having established the role of HDP in this process, its affinity for heme was investigated by isothermal titration calorimetry
FIG. 18 a). This interaction was studied by measuring the heat change associated with the binding of heme to HDP, at pH 5.6 where protein bound heme but did not make any Hz. The interaction revealed a H of −5.03 kcal/mol, a Kd of 80 nM, and a stoichiometry (n) of 2.7 heme molecules per HDP polypeptide. This affinity is at least 4 times higher than HRP II, whose affinity for heme is in 340-940 nM range18.19. - Subsequently HDP sequence were analysed for the presence of any known heme binding motif using SMART20, a domain identification tool. While HDP has no homology to any of the known heme-binding proteins, the analysis revealed that the carboxyl terminus region (amino acids 88-205) of the protein has homology (e value 3e-10) to fasciclin-l, an ancient adhesive and highly diverse domain, present in proteins of prokaryotic21 and eukaryotic22 origin (
FIG. 3 ). To investigate if this domain alone is responsible for Hz formation, two truncated variants of HDP were recombinantly produced, one encoding only the fasciclin-1 domain (residues 88-205 of SEQ ID NO: 1; protein HDP3) and the other encoding residues 1-87 of the full length protein (i.e. of SEQ ID NO: 1, protein HDP2) (FIG. 19 a-d). It was found that neither fasciclin-1 domain (HDP3) nor the amino terminus region (HDP2) alone were capable of Hz production (FIG. 18 b). Hence, a full length HDP is required for Hz production. - As stated earlier, HRP II and HRP III are only found in P. falciparum parasites but Hz formation occurs in all known species of Plasmodium. To investigate if HDP is present in all the parasite species, the genomes of seven other species of Plasmodium 23.24 were examined in silico (
FIG. 3 ). HDP orthologs were found in all the species with protein showing 60% sequence identity. Evidently, the protein is functionally conserved as a recombinantly produced P. yoelii HDP generated Hz at levels indistinguishable from its P. falciparum ortholog (FIG. 18 c). HDP seems to have an ancient lineage as its homolog was found in Theileria 25 genome (FIG. 3 ), a hemoprotozoan that sequesters heme into non-toxic aggregates during the intraerythrocytic stages of its lifecycle. - As Hz formation occurs inside the food vacuole, to be functionally relevant, one would anticipate HDP to be present inside this organelle. Though the protein lacks a classical N-terminal signal sequence or any known translocation signal that could predict its possible sorting and transport to its destined site, the presence of HDP was detected inside the food vacuole (
FIG. 20 a-d). Therefore, to comprehend its intracellular trafficking, intraerythrocytic parasites were analyzed at different stages of development, for HDP expression. It was discovered that from the early (ring) stages of infection, HDP is secreted to the host cell cytosol, before any detectable amount of Hz was visible inside the parasite (FIG. 20 a). The protein accumulated inside the cytosol of the host cell (FIG. 20 b;FIG. 21 a-c) and was not exported out of the infected RBC as it could not be detected in the concentrated culture supernatant by immunoblot (data not shown). Subsequently, as parasite development progressed, it was found that HDP, along with host hemoglobin, is trafficked to the food vacuole, through the cytostome-mediated pathway (FIG. 20 b-d;FIG. 21 a-c). By immunoelectron microscopy, we detected the uptake of HDP through the cytostome (FIG. 20 b,FIG. 21 b), its presence in the transport vesicles (FIG. 20 c) and delivery to the food vacuole (FIG. 20 d;FIG. 21 c). This novel and circuitous trafficking of HDP is indicative of a functional convergence in the parasite where host hemoglobin, HDP and parasite protease26 involved in hemoglobin proteolysis (and located in the vesicular membrane), are transported together to the food vacliole. - This is the first report of a pan-Plasmodium heme detoxifying protein that is highly efficient in catalyzing the conversion of heme into Hz. Identification of HDP not only fills an important gap in our understanding of the mechanism of Hz production in malaria parasite, but the novel “Outbound-Inbound” trafficking of HDP also reveals an interesting insight into the inner workings of the parasite. Due to the rapid emergence of multi-drig resistant parasites, several major antimalarial drugs have become ineffective and combination therapy is fast becoming a mainstay for malaria control27. This discovery opens new avenues for designing novel antimalarial drugs that specifically target HDP and thereby prevent the conversion of heme into Hz.
- Hz formation assay The assay was performed as previously described6. Briefly, equimolar amounts (0.5 nmol) of HDP, HRP II or unsaturated lipids were added to freshly prepared heme solution in 500 mM sodium acetate buffer pH 5.2, followed by incubation at 37° C. for 16 hrs. The reaction was stopped by adding SDS (0.1% final conc.). Unsequestered heme was removed by repeated washing of the pellet with 2.5% SDS and 0.1 M sodium bicarbonate (pH 9.1) followed by distilled water till no soluble heme was visible in the supernatant. Hz pellet was resuspended in 0.1 N NaOH and absorbance was measured at 400 nm. A standard curve using different concentrations of β-hematin was prepared to quantitate the amount of heme incorporated into Hz. A reaction containing buffered heme alone was used as negative control. pH dependence of HDP was evaluated in 500 MM sodium acetate buffer of different pH (pH 3.2-6.0). All the Hz formation assays were performed at least three times in triplicates.
- Purification of native HDP. Anti-HDP antibodies were raised in rabbits and affinity purified using standard protocols. Trophozoite stage P. falciparum (3D7 strain) parasites were isolated from a 20 ml culture using a MACS column (Miltenyi Biotec), and resuspended in 0.2 ml of solubilization buffer (20 mM Tris-Cl pH 7.4, 0.5% NP-40, 1× Protease Inhibitor Cocktail). The suspension was subjected to a single freeze-thaw cycle and the protein extract was clarified by centrifugation at 15,000 g for 15 min at 4° C. Affinity purified anti-HDP antibodies were coupled to AminoLink® Plus Coupling Gel using the Seize® Primary Immunoprecipitation kit (Pierce Biotechnology), and utilized for immunoprecipitation of native HDP from the total protein extract, as per manufacturer's instructions. Purity of the protein was established by silver staining and the purified protein was authenticated by an ECL-based immunoblotting system (GE Health Care).
- Binding affinity. Binding affinity of HDP for heme was evaluated by Isothermal titration calorimetry where freshly prepared heme solution was incrementally added to 5 μM HDP (in 50 mM MES, pH 5.6) present inside the ITC cell. Data was collected at 30° C. at a 420 rpm stir rate using 10 μl injections of the 100 μM heme into the protein solution. The resulting measurements delta H vs. molar ratio were fit to a single binding site model using the MicroCal Origin analysis software.
- Immunoelectron microscopy. P. falciparum infected erythrocytes were fixed in 4% paraformaldehyde/0.1% glutaraldehyde in 100 nM PIPES/0.5 mM MgCl2, pH 7.2 for 1 hr at 4° C. and used for immunoelectron microscopy as described 26. Controls omitting the primary antibody were consistently negative at the concentration of gold-conjugated secondary antibodies used in these studies.
- Targeted deletion of HDP P. falciparum 3D7 parasites was cultured in human O+erythrocytes as described previously. Ring stage parasites at 10% parasitemia were transfected by electroporation with 100 μg of super coiled pHDPKO, a pHD22Y based transfection vector containing a 509 bp fragment from the 5′ end of the HDP gene (SEQ ID NO: 2) along with human DHFR selection cassette, using low voltage/high capacitance conditions 28. Transfectants were selected in the presence of 10 nM WR99210 (a gift from Jacobus Pharmaceuticals, Princeton N.J.) and subjected to three drug selection cycles, each consisting of 21 days of growth in absence of WR99210 followed by reselection of parasites in the presence of 10 nM WR99210. Genotypes were analyzed by probing blots of Eco RV-Bam HI digested total parasite DNA, with a PCR amplified 509 bp fragment of HDP that has been cloned in the transfection vector. The signal was generated with an Alk Phos direct labelling and detection kit (GE Healthcare).
- Immunofluorescence Methanol fixed smears of infected RBC at 5% parasitemia were blocked with 2.5% normal goat serum (NGS) for 30 min and incubated with rabbit anti HDP antibodies at 1:200 for 1 h. Bound antibodies were detected using fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG diluted to 1:200. Parasite nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI). Slides were mounted with the antifade reagent (Vectorshield, KPL) and images (100×magnification) were obtained using
Olympus 1×70 inverted fluorescence microscope and a Photometrix cooled charge-coupled device camera (CH350/LCCD) driven by DELTAVISION software from Applied Precision (Seattle, Wash.). - Cloning, recombinant expression and purification of HDP Coding sequence of HDP (SEQ ID NO: 2) was amplified by RT-PCR using total RNA from the P. falciparum (3D7 strain) erythrocytic stage parasites. The amplified fragment was cloned in pET101, a V5 epitope and polyhistidine-tag encoding, T7 promoter-based E. coli expression vector, giving rise to plasmid pHDP. Protein, expressed in BL21 cells, was localized in inclusion bodies, which were isolated as described previously29. Purified inclusion bodies were solubilized in 50 mM CAPS buffer (pH 11.0) containing 1.5% N-lauryl sarkosine and 0.3 M NaCl, for 30 min and the solubilized protein was separated by centrifugation (10,000 g; 30 min). Protein was purified by affinity chromatography on His-Trap, a high performance nickel affinity column (GE Health Care) using an imidazole gradient in 50 mM CAPS pH 11.0 containing 0.3% N-lauryl sarkosine and 0.3 M NaCl. Protein-containing fractions were pooled and purified to homogeneity by gel filtration chromatography on
Superdex 200 10/300 GL column (GE Health Care), equilibrated in 25 mM CAPS (pH 11.0) containing 135 mM NaCl. PyHDP (SEQ ID NO:10) was amplified by RT-PCR using total erythrocytic stage P. yoelii RNA and cloned in pET101 plasmid. Plasmids encoding protein HDP2 and HDP3 were generated by sub-cloning using pHDP as template. Their expression and purification was performed as described above. DNA encoding P. falciparum Histidine rich protein II was cloned in pET101 and its expression and purification was performed as described previously.30 -
- 1. Francis, S. E., Sullivan, D. J., Jr. & Goldberg, D. E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 51, 97-123 (1997).
- 2. Slater, A. F. et al. An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl
Acad Sci USA 88, 325-9 (1991). - 3. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D. & Madsen, S. K. The structure of malaria pigment beta-haematin. Nature 404, 307-10 (2000).
- 4. Sullivan, D. J., Jr., Gluzman, l. Y., Russell, D. G. & Goldberg, D. E. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci USA 93, 11865-70 (1996).
- 5. Kannan, R., Sahal, D. & Chauhan, V. S. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization.
Chem Biol 9, 321-32 (2002). - 6. Sullivan, D. J., Jr., Gluzman, I. Y. & Goldberg, D. E. Plasmodium hemozoin formation mediated by histidine-rich proteins. Science 271, 219-22 (1996).
- 7. Bendrat, K., Berger, B. J. & Cerami, A. Haem polymerization in malaria. Nature 378, 138-9 (1995).
- 8. Dorn, A., Stoffel, R., Matile, H., Bubendorf, A. & Ridley, R. G. Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein. Nature 10374, 269-71 (1995).
- 9. Fitch, C. D., Cai, G. Z., Chen, Y. F. & Shoemaker, J. D. Involvement of lipids in ferriprotoporphyrin IX polymerization in malaria. Biochim Biophys Acta 1454, 31-7 (1999).
- 10. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
- 11. Yayon, A., Cabantchik, Z. I. & Ginsburg, H. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine.
Embo J 3, 2695-700 (1984). - 12. Hayward, R., Saliba, K. J. & Kirk, K. The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J Cell Sci 119, 1016-25 (2006).
- 13. Akompong, T. et al. Trans expression of a Plasmodium falciparum histidine-rich protein II (HRPII) reveals sorting of soluble proteins in the periphery of the host erythrocyte and disrupts transport to the malarial food vacuole. J Biol Chem 277, 28923-33 (2002).
- 14. Howard, R. J. et al. Secretion of a malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-infected erythrocytes. J Cell Biol 103, 1269-77 (1986).
- 15. Wellems, T. E., Walker-Jonah, A. & Panton, L. J. Genetic mapping of the chloroquine-resistance locus on
Plasmodium falciparum chromosome 7. Proc NatlAcad Sci USA 88,3382-6(1991). - 16. Goldberg, D. E., Slater, A. F., Cerami, A. & Henderson, G. B. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl
Acad Sci USA 87, 2931-5 (1990). - 17. Egan, T. J. et al. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J 365, 343-7 (2002).
- 18. Schneider, E. L. & Marletta, M. A. Heme binding to the histidine-rich protein II from Plasmodium falciparum. Biochemistry 44, 979-86 (2005).
- 19. Pandey, A. V. et al. Mechanism of malarial haem detoxification inhibition by chloroquine. Biochem J 355, 333-8 (2001).
- 20. Schultz, J., Milpetz, F., Bork, P. & Ponting, C. P. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 95, 5857-64 (1998).
- 21. Ulstrup, J. C., Jeansson, S., Wiker, H. G. & Harboe, M. Relationship of secretion pattern and MPB70 homology with osteoblast-
specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun 63, 672-5 (1995). - 22. Kim, J. E. et al. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem 275, 30907-15 (2000).
- 23. Carlton, J. M. et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 419, 512-9 (2002).
- 24. http://www.sanger.ac.uk/Projects/Protozoa/.
- 25. Pain, A. et al. Genome of the host-cell transforming parasite Theileria annulata compared with T. parva. Science 309, 131-3 (2005).
- 26. Klemba, M., Beatty, W., Gluzman, I. & Goldberg, D. E. Trafficking of plasmepsin II to the food vacuole of the malaria parasite Plasmodium falciparum. J Cell Biol 164, 47-56 (2004).
- 27. Rathore, D., McCutchan, T. F., Sullivan, M. & Kumar, S. Antimalarial drugs: current status and new developments. Expert
Opin Investig Drugs 14, 871-83 (2005). - 28. Fidock, D. A. & Wellems, T. E. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 94, 10931-6 (1997).
- 29. Rathore, D. et al. Molecular mechanism of host specificity in Plasmodium falciparum infection: role of circumsporozoite protein. J Biol Chem 278, 40905-10 (2003).
- 30. Sullivan, D. J., Jr., Gluzman, I. Y. & Goldberg, D. E. Plasmodium hemozoin formation mediated by histidine-rich proteins. Science 271, 219-22 (1996).
- It has been shown that P. falciparum HDP produces hemozoin in the parasite. In this example, it is shown that the HDP ortholog from P. vivax parasites (SEQ ID NO:7) can also produce Hemozoin (
FIG. 22 ). The experiment was performed as described according to methods described above for the previous examples. P. vivax is the second most important human malaria parasite, responsible for almost 50% of the total malaria cases. Though rarely lethal, it causes severe morbidity and is a major problem in the southeastern Asia and Latin America. Therefore, with the demonstration that HDP from P. vivax (SEQ ID NO:7) also produces Hemozoin, inhibitors of HDP developed against P. falciparum parasite could also be used to prevent or treat P. vivax malaria infections. - It has been previously shown that antibodies raised against HDP can prevent invasion of hepatocytes by P. falciparum parasites, raising the possibility that HDP could be developed as a vaccine candidate. This possibility was investigated in a P. yoelii-based mouse malaria model. Both a protein and a DNA-based approach was pursued for investigating the potential of HDP in protecting the host from malaria. Due to differences in haplotype, two different species of mice were investigated.
- Materials and Methods
- Cloning of PyHDP gene from Plasmodium yoelii into a DNA vaccine plasmid, pVRJ020: RNA from Plasmodium yoelii was used for amplification of the PyHDP gene. Primers were designed to amplify a region encoding
amino acids 1 to 205 of the PyHDP gene (SEQ ID NO:9). A BamHI site [bold sequence] was incorporated into the 5′ primer (GGAATTCAGGAGCCCTTCGGATCCAAAAAAAAATTGTAT, SEQ ID NO: 40) and the 3′ primer (CTTCGAATTGAGCTCGGATCCTCAAATTATTGGCTTATCTATGAT SEQ ID NO: 41). The 3′ primer also incorporated a stop codon [underlined sequence]. The PCR fragment (618 bp) was purified using the PCR purification kit from Qiagen and digested with BamHI. The base vector pVR10201 containing a kanamycin resistance gene was also digested with BamHI for 3 hrs at 37° C. During the last 30 min ofdigestion 1 unit/μl of shrimp alkaline phosphatase was added to dephosphorylate the ends of the vector. The digested PCR product and pVR1020 were purified after electrophoresis on a 1% agarose gel. Ligation was carried out with various vector to insert ratios. The ligation was performed for 16 hrs at 14° C. Transformed E coli, DH5α, bacteria were plated on kanamycin selective media and incubated at 37° C. for 24 hrs. Colonies contain recombinant plasmids were cultured and plasmids isolated. The plasmids were sequenced to confirm the insert sequence and orientation. Plasmid clones were transfected into VM449 cells and PyHDP expression was confirmed with western blot using 1:200 dilution of anti-PyHDP antibodies raised in mice. Large scale plasmid DNA from a confirmed PyHDP expressing pVRPyHDP clone was prepared and purified using an endotoxin-free plasmid purification Giga kit (QIAGEN Inc., Valencia, Calif.). - Immunization of Mice: All animal experiments were conducted in accordance with the guidelines indicated in the National Institutes of Health Guide to Laboratory Animal Care and were approved by the Virginia Tech Animal Care and Use Committee. Six week-old female BALB/c and A/j mice were used for the immunization and challenge experiment. Three groups of eight mice each were immunized as indicated in Table 10. This immunization schedule was repeated twice at intervals of 21 days for all the groups.
Groups - Sporozoite preparation: Anopheles stephensi mosquitoes were reared in cages at 27° C. and >80% relative humidity and were fed with 10% sucrose solution every alternate day [2]. For the development of the sporozoite stage, mosquitoes starved of sucrose for 24 hrs, were allowed to blood feed on anesthetized P yoelii infected mice for 10 minutes. Samples of salivary glands and stomach were prepared beginning 10 days post feeding to monitor the development of the mosquito stages of the parasite.
- Sporozoites were isolated using the Ozaki method 3. Briefly, on the day of challenge (day 0) the mosquitoes were anesthetized with chloroform and thorax dissected in complete M199 medium. Crushed thorax was loaded on a silanized glass wool column prepared in Eppendorf tubes, and was centrifuged at 2500 rpm to collect the flow through. The pellet from 2-3 such tubes were resuspended and pooled. Sporozoites were counted using a hemocytometer and resuspended in complete M199 medium at a concentration of 100 sporozoites per 100 μl. Immunized mice were challenged with 100 sporozoites injected via the tail vein.
- Monitoring parasitemia: Parasitemia in all mice from all the groups were monitored on alternate days by conventional Giemsa staining 4 starting on
day 4 after infection. Thin blood films were prepared by tail bleeding, air dried, and methanol fixed before staining. - Parasitemia was monitored for 20 days post infection or till it reached 40-50%.
TABLE 10 A/J BALB/c Protein Plasmid Group 1 4 4 1st: Saline + CFA [Control, 2nd: Saline + IFA Protein] 3rd: Saline + IFA Group 2 4 4 3rd: Saline + IFA 1st: pVR1020 [Control, 2nd: pVR1020 Plasmid] Group 38 8 1st: PyHDP + CFA [PyHDP] 2nd: PyHDP + IFA 3rd: PyHDP + IFA Group 4 8 8 3rd: PyHDP + IFA 1st: pVRPyHDP [pVRPyHDP + 2nd: pVRPyHDP PyHDP]
Results: A/J mice immunized with DNA construct encoding PyHDP showed almost 50% reduction of parasitemia tillDay 10 post sporozoite challenge (FIG. 23 ). However, animals immunized with PyHDP protein alone showed a marginal decrease in parasitemia (30% inhibition). Nevertheless, the initial immune response to the DNA vaccine was found to be significant. Thus PyHDP is an ideal candidate for a subunit vaccine5, and in the presence of other antigens such as PFTRAP6 and PFCSP5 may generate a protective immune response. Balb/C mice immunized with protein or the DNA vaccine construct showed no protection7. and this may be attributable to strain to strain variations in the immune system -
- 1. Price, B. M. et al. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 69, 3510-5 (2001).
- 2. Porter-Kelley, J. M. et al. Plasmodium yoelii: axenic development of the parasite mosquito stages. Exp Parasitol 112, 99-108 (2006).
- 3. Ozaki, L. S., Gwadz, R. W. & Godson, G. N. Simple centrifugation method for rapid separation of sporozoites from mosquitoes.
J Parasitol 70, 831-3 (1984). - 4. Shute, P. G. & Maryon, M. An Improved Technique for Staining Malaria Parasites with Giemsa Stain. Arch Roum Pathol Exp Microbiol 22, 887-94 (1963).
- 5. Prieur, E. et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc Natl
Acad Sci USA 101, 290-5 (2004). - 6. Schneider, J. et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
Vaccine 19, 4595-602 (2001). - 7. Belmonte, M. et al. The infectivity of Plasmodium yoelii in different strains of mice. J Parasitol 89, 602-3 (2003).
- A panel of candidate compounds were tested for their ability to inhibit HDP from P. falciparum. The protein was prepared as described above. The testing was carried out as follows:
- HTS screening for identification of HDP inhibitors. HTS screening was performed at the Chemical Genomics Center of the Broad Institute of Harvard and MIT (Cambridge, Mass.). A 2× protein stock (10 μM) was prepared in 200 mM Sodium acetate buffer at pH 5.6. and 35 μl of this solution was dispensed in each well of a 384 well plate, using an automated dispenser. Through a robotized transfer mechanism involving steel pins, each of the protein-containing well (in a 384 well plate) received 300 nl of a compound. After the addition of the compound, the plate was incubated at room temperature for 60 minutes, followed by an addition of 35 μl of freshly prepared heme solution at a concentration of 20 μM. A 1:1 mix of HDP-heme gave rise to the final concentrations of 5 and 10 μM of protein and heme in the reaction, respectively. After heme addition, the plate was incubated in dark for 60 minutes followed by the measurement of absorbance at 414 nm, utilizing a Synergy plate reader integrated with a biostack. The reactions were performed in duplicates and with controls, where the interactions were measured in the absence of the protein. The readouts were stored and analyzed for the identification of potential inhibitors of the reaction.
- Data Analysis. Statistical analysis was performed utilizing a combination of parameters and compounds that showed statistically significant inhibition were selected. Briefly, the background absorbance, which can be attributed to heme and compound alone and measured for each compound utilizing the background plate, was subtracted from the test reads. Subsequently, the net absorbance was compared to controls wells, that did not receive the test compounds and the percent decrease in absorbance was measured by the following formula:
Percent inhibition=[(Absorbance in test well/Absorbance in control wells)×100]
Activity of HDP inhibitors on P. falciparum parasites. Selected compounds were screened for their potential to inhibit the growth of P. falciparum parasites in culture. Chloroquine sensitive 3D7 strain of the parasite was utilized for analysis. Briefly, growth of P. falciparum parasites (1% parasitemia, 1% hematocrit) in RPMI 1640 medium and 0.5% albumax was evaluated in the presence of different concentrations of the inhibitors and compared with the growth where parasites were incubated with medium alone. The parasites were incubated with the inhibitors for 48 hours before the addition of SYBR Green dye for measuring parasite growth. A recently published SYBR-Green I based method was utilized for this measurement [9]. As RBCs are terminally differentiated and lack a nucleus, addition of SYBR Green to the parasite culture at the end of a desired incubation time provides a direct measurement of the DNA content of the parasite. SYBR Green fluorescence was measured using a 384 well plate spectrofluorometer with an excitation and emission wavelengths set at 490 and 530 nm, respectively. - Cell-free HTS for the identification of inhibitors of HDP-Heme interaction. Using high throughput technology and the power of combinatorial chemistry, we investigated several thousand chemical compounds for their potential to inhibit the interactions between HDP and heme. The screening was facilitated by the knowledge that HDP, on its interaction with heme, binds to it with a very strong affinity and gives a Soret peak at 414 nm. This property of HDP was exploited for designing a simplified assay that could be utilized for HTS process. A total of 2 grams of HDP was recombinantly purified from 25 Liters of E. coli culture. The purified protein was subsequently utilized in the cell-free assay for the identification of potential inhibitors of HDP-heme interactions. HTS was performed in 384 well plates where in
typical reaction 5 μM HDP was allowed to interact with 10 μM heme in the absence (control) or presence of excess of a chemical compound. The concentration of the chemical compound was in 40-50 μM range. HDP-heme interaction was measured at 414 nm in the presence of the compounds and compared with control reactions that only received the carrier (DMSO). The final concentration of DMSO in the reaction was 0.4%. - A total of 110,000 drug-like, diverse heterocyclic chemical compounds were screened during this process. These compounds were obtained from several sources including established chemical vendors (Asinex, Analyticon, Biomol, Bionet, ChemDiv, Enamine, Maybridge, Spectrum, TimTec) as well as a range of diversity oriented synthesis compounds that have been generated by academic research laboratories from around the world. Screening identified several hundred (300+) compounds (Table 11) that inhibited the reaction at a statistically significant >30% levels. Successful events in this initial screen led to the consolidation of select wells from the original library stock to generate a new second generation of plate for screening the activity of these compounds on P. falciparum parasites.
- Antimalarial activity of HDP-inhibitors on P. falciparum parasites. A total of 327 inhibitors were screened for their antimalarial activity in a P. falciparum parasite-based cellular assay. Rescreening of these compounds was performed at 20-40 micromolar final concentration. Parasites were incubated with the compounds for 60 hours followed by the measurement of parasite DNA content utilizing a fluorometric assay. The results presented in Table 11 show the percent inhibition for compounds at the highest concentration tested in the cell-based antimalaria assay. At the highest concentration tested, this screen identified 73 compounds that showed statistically significant >50% inhibition of the growth of human malaria parasite in culture (Table 11).
- Those of skill in the art will recognize that, while the particular compounds in Table 11 may be utilized in the invention, versions of these compounds (i.e. derivatives or analogs thereof) may also be developed that are optimized for in vivo use, i.e. for bioactivity. Such optimization may involve, for example, modifications to increase or decrease the charge of the molecule (e.g. to increase or decrease solubility, hydrophilicity, hydrophobicity, affinity for biological membranes, etc.); to increase toxicity to the parasite; or to decrease toxicity to the individual being treated. Such modification may also involve the substitution of charged groups (e.g. carboxyl groups replaced by sulfates or vice versa); the substitution or replacement of carbon chains (e.g. increasing or decreasing the number of carbons in an aliphatic chain, introducing branched carbon chains, double bonds, triple bonds, etc. or replacing them with unbranched aliphatic chains), etc. Other modifications may include conjugation of the molecule to other entities (or to each other) to form chimeric molecules, e.g. attachment to various targeting moieties (peptides, etc.); the attachment of lipids or lipophilic moieties; conjugation to metal ions; and the like. Further, various salts of the compounds may be utilized in the invention. All such derivatives and analogs of the compounds in Table 11 are intended to be encompassed by the present invention, so long as the resulting derivative/analog has the ability to prevent or inhibit the interaction of heme with HDP as described herein. Such compounds will typically be effective in at least the micromolar concentration range, and preferably in the nanomolar concentration range when administered in vivo.
- Those of skill in the art will recognize that certain chemical modification(s) can be introduced as desired into a given compound to obtain a new derivative with modified biological properties such as: greater antimalarial potency against a particular Plasmodium sp., a broader spectrum of antimalarial activity against diverse Plasmodium sp., enhanced oral bioavailability, less toxicity in a particular host mammal, more advantageous pharmacokinetics and/or tissue distribution in a given host mammal, and the like. Therefore, the present invention additionally provides methods for obtaining such derivatives by applying one or more well-known chemical reactions to a given compound, to provide a derivative wherein one or more phenolic hydroxyl group(s) may instead be replaced by an ester, sulfonate ester, or ether group; one or more methyl ether group(s) may instead be replaced by a phenolic hydroxyl group; one or more phenolic hydroxyl group(s) may instead be replaced be an aromatic hydrogen substituent; one or more secondary amine site(s) may instead be replaced by an amide, sulfonamide, tertiary amine, or alkyl quaternary ammonium salt; one or more tertiary amine site(s) may instead by replaced by a secondary amine; and
- one or more aromatic hydrogen substituent(s) may instead be replaced by a halogen, nitro, amino, hydroxyl, thiol, or cyano substituent.
- Numerous references describe the process of chemoinformatics and laboratory-based lead-optimization of pharmaceutical compounds in general, or antimalarial compounds specifically, and selected references are incorporated herein.
- Oprea, Tudor I. (ed.), Chemoinformatics in Drug Discovery, Methods and Principles in Medicinal Chemistry (Volume 23), Edited by Mannhold, Raimund/Kubinyi, Hugo/Folkers, Gerd. Wiley-VCH, Weinheim, Germany.
- Brown, Nathan; Lewis, Richard A. Exploiting QSAR methods in lead optimization. Current Opinion in Drug Discovery & Development (2006), 9(4), 419-424.
- Rolf W. Winter, Jane X. Kelly, Martin J. Smilkstein, Rozalia Dodean, Grover C. Bagby, R. Keaney Rathbun, Joshua I. Levin, David Hinrichs and Michael K. Riscoe, Evaluation and lead optimization of anti-malarial acridones, Experimental Parasitology, Volume 114,
Issue 1, September 2006, Pages 47-56. - Aihua Xie, Prasanna Sivaprakasam and Robert J. Doerksen, 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold, Bioorganic & Medicinal Chemistry,
Volume 14,Issue 21, 1 Nov. 2006, Pages 7311-7323. -
- 1. Francis, S. E., Sullivan, D. J., Jr. & Goldberg, D. E. (1997) Hemoglobin metabolism in the malaria parasite Plasmodium falciparum, Annu Rev Microbiol. 51, 97-123.
- 2. Goldberg, D. E., Slater, A. F., Cerami, A. & Henderson, G. B. (1990) Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle, Proc Natl Acad Sci USA. 87, 2931-5.
- 3. Fitch, C. D., Chevli, R., Banyal, H. S., Phillips, G., Pfaller, M. A. & Krogstad, D. J. (1982) Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex, Antimicrob Agents Chemother. 21, 819-22.
- 4. Kikuchi, G., Yoshida, T. & Noguchi, M. (2005) Heme oxygenase and heme degradation, Biochem Biophys Res Commun. 338, 558-67.
- 5. Leed, A., DuBay, K., Ursos, L. M., Sears, D., De Dios, A. C. & Roepe, P. D. (2002) Solution structures of antimalarial drug-heme complexes, Biochemistry. 41, 10245-55.
- 6. Pandey, A. V., Bisht, H., Babbarwal, V. K., Srivastava, J., Pandey, K. C. & Chauhan, V. S. (2001) Mechanism of malarial haem detoxification inhibition by chloroquine, Biochem J. 355, 333-8.
- 7. Sullivan, D. J., Jr., Gluzman, I. Y., Russell, D. G. & Goldberg, D. E. (1996) On the molecular mechanism of chloroquine's antimalarial action, Proc Natl Acad Sci USA. 93, 11865-70.
- 8. Kannan, R., Sahal, D. & Chauhan, V. S. (2002) Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization, Chem Biol. 9, 321-32.
- 9. Bennett, T. N., Paguio, M., Gligorijevic, B., Seudieu, C., Kosar, A. D., Davidson, E. & Roepe, P. D. (2004) Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy, Antimicrob Agents Chemother. 48, 1807-10.
TABLE 11 % Inhibition HDP- Anti- Heme malarial Plate Well SMILES Identifier IUPAC Name Interaction activity 2074 F05 CN(C)c1ccc2N═c3cc(C)c(N) 42.50 100.00 cc3═Sc2c1 2075 G11 COc1ccc(cc1)c2ncccc2O 2-(4-methoxyphenyl)pyridin-3-ol 61.75 95.80 2069 J20 Cc1ccn2cc(nc2c1)c3ccc(O) 4-(7-methylimidazo[1,2-a]pyridin-2- 47.50 93.70 c(O)c3 yl)benzene-1,2-diol 2020 P06 CCN1/C(═C/c2ccc3cc(C) 2-[(Z)-(3-ethyl-6-methoxy-1,3- 58.75 93.70 ccc3[n+]2C)/Sc4cc(OC)ccc14 benzothiazol-2(3H)-ylidene)methyl]- 1,6-dimethylquinolinium 2021 B19 CC[n+]1c(/C═C/2\SC═CN2C) 1-ethyl-6-methoxy-4-methyl-2-[(Z)- 59.75 93.30 cc(C)c3cc(OC)c4ccccc4c13 (3-methyl-1,3-thiazol-2(3H)- ylidene)methyl]benzo[h]quinolinium 2046 C02 Oc1ccc(cc1)c2nc(c([nH]2) 4,4′-(4-phenyl-1H-imidazole-2,5- 44.00 92.90 c3ccc(O)cc3)c4ccccc4 diyl)diphenol 2085 H01 Oc1cccc(Nc2nc(NCC3CCCO3) 3-[(4-{[(2R)-tetrahydrofuran-2- 64.50 92.30 c4ccccc4n2)c1 ylmethyl]amino}quinazolin-2- yl)amino]phenol 2105 K04 49.00 91.20 1413 N13 Cc1noc(c1c2ccc3OCCCOc3c2) 4-[4-(3,4-dihydro-2H-1,5- 56.25 90.80 c4ccc(O)cc4O benzodioxepin-7-yl)-3- methylisoxazol-5-yl]benzene-1,3-diol 2017 B19 Clc1ccc2oc(cc(═NCc3ccco3) N-(6-chloro-2-phenyl-4H-chromen-4- 45.25 90.60 c2c1)c4ccccc4 ylidene)-1-(2-furyl)methanamine 2099 E09 Oc1ccc(cc1)c2sc3cc(O) [6-hydroxy-2-(4-hydroxyphenyl)-1- 49.75 90.10 ccc3c2C(═O)c4ccc(OCCN5CCCCC5) benzothien-3-yl][4-(2-piperidin-1- cc4 ylethoxy)phenyl]methanone 2290 H07 Oc1cc(cc(O)c1O)C(═O) 1,2,3,4,6-pentakis-O-(3,4,5- 41.50 90.10 OC[C@H]2O[C@@H](OC(═O) trihydroxybenzoyl)-beta-D- c3cc(O)c(O)c(O)c3)[C@H](OC(═O) glucopyranose c4cc(O)c(O)c(O)c4) [C@@H](OC(═O)c5cc(O)c(O) c(O)c5)[C@@H]2OC(═O) c6cc(O)c(O)c(O)c6 2296 J02 O[C@H]1[C@H]2[C@H](CC(═O) 56.25 90.00 O)C(═O)O[C@@H]3C(COC(═O) c4cc(O)c(O)c(O) c4)O[C@@H](OC(═O)c5cc(O) c(O)c(O)c5)C(OC(═O) c6cc(O)c(O)c(OC1═O)c26) [C@@H]3OC(═O)c7cc(O)c(O) c(O)c7 2078 L04 Cc1ccc2nc(cn2c1)c3ccc(O) 4-(6-methylimidazo[1,2-a]pyridin-2- 46.50 89.70 c(O)c3 yl)benzene-1,2-diol 2011 B03 CC(C)Nc1ccc(Nc2ccnc3cc4ccccc4cc23) N-benzo[g]quinolin-4-yl-N′- 59.00 89.00 cc1 isopropylbenzene-1,4-diamine 2168 C04 OCCOc1ccc(CN2CCC[C@H](C2) 2-{(3R)-1-[4-(2- 37.75 89.00 N3C(═O)c4ccccc4C3═O) hydroxyethoxy)benzyl]piperidin-3-yl}- cc1 1H-isoindole-1,3(2H)-dione 2080 F20 Clc1ccc(CCN2COc3ccc(Cl) 6-chloro-3-[2-(4-chlorophenyl)ethyl]- 57.75 88.90 cc3C2)cc1 3,4-dihydro-2H-1,3-benzoxazine 1446 P02 Cc1cc(Nc2cc(Cl)cc(Cl)c2) N4-(3,5-dichlorophenyl)-6- 48.00 88.90 nc(N)n1 methylpyrimidine-2,4-diamine 2019 C14 CCOC(═O)c1c(c2ccccc2) (ethyl 1-benzyl-4- 49.25 88.70 n(Cc3ccccc3)c4ccc(O)c(CN(C) [(dimethylamino)methyl]-5-hydroxy- C)c14 2-phenyl-1H-indole-3-carboxylate 2144 I02 48.25 88.70 2016 E14 COc1ccc(cc1)c2c/c(═NCCc3ccccc3)/ N-[(4E)-2-(4-methoxyphenyl)-6- 45.00 88.50 c4cc(C)ccc4o2 methyl-4H-chromen-4-ylidene]-2- phenylethanamine 1406 N16 Cc1nc2ccccn2c1C3(O)C(═O) (3R)-5,7-dichloro-3-hydroxy-3-(2- 65.00 88.50 Nc4c3cc(Cl)cc4Cl methylimidazo[1,2-a]pyridin-3-yl)- 1,3-dihydro-2H-indol-2-one 1399 E08 OC(Cn1c(═N)sc2ccccc12) (1S)-1-(3,4-dichlorophenyl)-2-(2- 50.50 88.30 c3ccc(Cl)c(Cl)c3 imino-1,3-benzothiazol-3(2H)- yl)ethanol 2021 D19 COc1ccc2N(C)/C(═C/c3sc4ccccc4[n+]3C)/ 2-[(E)-(6-methoxy-1-methylquinolin- 45.25 88.00 C═Cc2c1 2(1H)-ylidene)methyl]-3-methyl-1,3- benzothiazol-3-ium 1465 J19 Nc1cccc(c1)C(═C2C═CC(═N) 4,4′-methylenebis(3-hydroxy-2- 40.75 88.00 C═C2)c3cccc(N)c3.OC(═O) naphthoic acid)-3,3′-[(4- c1cc2ccccc2c(Cc3c(O) iminocyclohexa-2,5-dien-1- c(cc4ccccc34)C(═O)O)c1O ylidene)methylene]dianiline (1:1) 2292 G08 COc1cc(O) 44.00 87.90 c-2c(CCc3cc(OC)c(OC)cc32) c1 2085 L13 CC(Nc1ncnc2ccccc12) N—[(1S)-1-phenylethyl]quinazolin-4- 38.00 87.80 c3ccccc3 amine 2020 K07 Nc1oc2c(CN3CCCCCC3) 2-amino-8-(azepan-1-ylmethyl)-3- 60.75 87.60 c(O)ccc2c(═O) (1,3-benzothiazol-2-yl)-7-hydroxy- c1c4nc5ccccc5s4 4H-chromen-4-one 1405 A21 OC(═O)c1nc2cccc3cccc([nH]1) 1H-perimidine-2-carboxylic acid 54.25 87.50 c32 1422 M20 CCOc1ccc(cc1)S(═O)(═O) N-(3-chloro-4-hydroxy-1-naphthyl)-4- 57.50 86.50 Nc2cc(Cl)c(O)c3ccccc23 ethoxybenzenesulfonamide 2012 D08 OC(Cn1c2ccccc2c3ccccc13) 1-[(2S)-3-(9H-carbazol-9-yl)-2- 87.25 86.20 C[n+]4cccc5cccc(O)c45 hydroxypropyl]-8-hydroxyquinolinium 1408 C14 Cc1cc(NN)nc2ccccc12 2-hydrazino-4-methylquinoline 57.75 86.00 1471 J20 CN1CCN(CC1)c2ccc3N═C([NH2]c3c2) 4-[5-[5-(4-methylpiperazin-1-yl)-3H- 49.00 85.80 c4ccc5N═C([NH2]c5c4) benzoimidazol-2-yl]-1,3-dihydrobenzoimidazol- c6ccc(O)cc6 2-ylidene]cyclohexa-2,5-dien- 1-one 1415 J19 CCOC(═O)c1c(OCC)[nH]c2c1cc(O) ethyl 2-ethoxy-5-hydroxy-1H- 50.50 85.20 c3ccccc23 benzo[g]indole-3-carboxylate 1441 F14 Clc1ccccc1SCc2cccc(c2) 3-(3-{[(2- 41.75 85.10 C(═O)CC#N chlorophenyl)thio]methyl}phenyl)-3- oxopropanenitrile 2082 C04 Cc1ccc(O)c(CCc2ccc(O)cc2) 2-[2-(4-hydroxyphenyl)ethyl]-6- 33.50 84.80 n1 methylpyridin-3-ol 2296 C09 O[C@H]1[C@@H](O) 43.00 84.50 [C@@H](COC(═O)c2cc(O)c(O) c(O)c2)O[C@@H](Oc3ccc(C(═O) CCc4ccc(O)cc4)c(O)c3) [C@@H]1O 1417 C16 CCN1C(═O)c2cccc3c(N) 6-amino-1-ethylbenzo[cd]indol- 44.25 82.40 ccc1c23 2(1H)-one 2033 K22 CN(C)CCNC(═O)c1cc2CSc3cc(Cl) 7-chloro-N-[2-(dimethylamino)ethyl]- 40.75 81.70 ccc3-c2s1 4H-thieno[3,2-c]thiochromene-2- carboxamide 599 O10 O═C1/C(═C\Nc2cccnc2)/ (2E)-2-[(pyridin-3- −123.00 80.30 Sc3ccccc13 ylamino)methylene]-1- benzothiophen-3(2H)-one 2041 M08 FC(F)(F)c1cccc(NC(═O) 3-[4-(9H-fluoren-9-yl)piperazin-1-yl]- 48.75 79.60 CCN2CCN(CC2)C3c4ccccc4-c5ccccc35) N-[3- c1 (trifluoromethyl)phenyl]propanamide 1464 H07 Oc1ccc(cc1n2c(═O)[nH]c3cc(ccc23) 1-[2-hydroxy-5- 55.50 79.40 C(F)(F)F)C(F)(F)F (trifluoromethyl)phenyl]-5- (trifluoromethyl)-1,3-dihydro-2H- benzimidazol-2-one 1439 119 Oc1ccccc1C(═O)NC(═O) N-(3-furylcarbonyl)-2- 51.00 77.60 c2ccoc2 hydroxybenzamide 2073 I04 Nc1cc(c2ccccc2)c3ccccc3n1 4-phenylquinolin-2-amine 38.25 77.40 2105 E08 41.75 75.80 1438 F17 Oc1ccccc1C(═O)NC(═O) N-(2-hydroxybenzoyl)-2- 60.75 75.40 c2cccs2 thiophenecarboxamide 1442 N18 Clc1ccc2c(Nc3ccccc3) 7-chloro-N-phenylquinolin-4-amine 53.25 74.30 ccnc2c1 2160 E04 Oc1cc(O)c2c(═O)cc(oc2c1) 5,7-dihydroxy-2-(3,4,5- 69.20 74.00 c3cc(O)c(O)c(O)c3 trihydroxyphenyl)-4H-chromen-4- one 1447 D13 COc1ccc(O)c(c1)C(═O) 3-(2-hydroxy-5-methoxybenzoyl)-2- 81.00 73.60 C2N(C(═O)c3ccccc23)c4ccc(C) (4-methylphenyl)isoindolin-1-one cc4 1439 G09 CCCc1ccc(cc1)C(═O)NC(═O) 2-hydroxy-N-(4- 43.25 69.80 c2ccccc2O propylbenzoyl)benzamide 1464 J17 OC(COc1cccc2[nH]c(C#N) 4-({(2S)-3-[4- 61.50 68.70 cc12)CN3CCN(CC3)C(c4ccccc4) (diphenylmethyl)piperazin-1-yl]-2- c5ccccc5 hydroxypropyl}oxy)-1H-indole-2- carbonitrile 1469 D18 Oc1ccc2c(═O)c(O)c(oc2c1) 2-(3,4-dihydroxyphenyl)-3,7- 46.75 68.50 c3ccc(O)c(O)c3 dihydroxy-4H-chromen-4-one 2144 K02 44.50 68.30 596 G10 Oc1cc(Cl)c([N+](═O)[O—]) (3aR,4R,9bR)-8-chloro-4-(4- 43.48 67.40 c2C3C═CCC3C(Nc12) chlorophenyl)-9-nitro-3a,4,5,9b- c4ccc(Cl)cc4 tetrahydro-3H-cyclopenta[c]quinolin- 6-ol 1409 B15 Oc1ccc(Cl)cc1C(═O)c2cc(C(═O) 5-(5-chloro-2-hydroxybenzoyl)-2- 42.00 66.50 Nc3ccccc3)c(═O)n(c2) oxo-N,1-diphenyl-1,2- c4ccccc4 dihydropyridine-3-carboxamide 599 O09 Oc1c(Cl)cc(Br) (2E,5E)-5-(5-bromo-3-chloro-2- 43.18 66.30 cc1/C═C\2/S/C(═N/c3ccccc3)/NC2═O hydroxybenzylidene)-2- (phenylimino)-1,3-thiazolidin-4-one 2131 A18 Oc1ccccc1NC(═O)CCCCCCC(═O) 8-[(2E)-2-(2- 42.00 66.10 N/N═C/c2ccccc2Br bromobenzylidene)hydrazino]-N-(2- hydroxyphenyl)-8-oxooctanamide 1410 N17 CC(C)(c1ccc(O)c(Cl)c1) 4,4′-propane-2,2-diylbis(2- 46.00 65.30 c2ccc(O)c(Cl)c2 chlorophenol) 1438 J17 COc1cccc(c1)C(═O)NC(═O) N-(2-hydroxybenzoyl)-3- 74.75 64.60 c2ccccc2O methoxybenzamide 587 L11 Oc1ccc(cc1)C2═NN(C(C2) 4-[(5S)-5-(4-fluorophenyl)-1-(4- −136.50 64.50 c3ccc(F)cc3)c4ccc(cc4)[N+](═O) nitrophenyl)-4,5-dihydro-1H-pyrazol- [O—] 3-yl]phenol 1409 J07 Cc1ccc(cc1)n2cc(cc(C#N) 5-(2-hydroxy-5-methylbenzoyl)-1-(4- 72.75 63.80 c2═O)C(═O)c3cc(C)ccc3O methylphenyl)-2-oxo-1,2- dihydropyridine-3-carbonitrile 2086 H09 Oc1c(CN2CCOCC2) 2-(morpholin-4-ylmethyl)-1-naphthol 80.00 62.90 ccc3ccccc13 1424 H16 CN(C)c1ccc(cc1) 4-(1H-benzimidazol-2-yl)-N,N- 43.75 62.10 c2nc3ccccc3[nH]2 dimethylaniline 1439 I09 CCc1ccc(cc1)C(═O)NC(═O) N-(4-ethylbenzoyl)-2- 51.25 60.10 c2ccccc2O hydroxybenzamide 2004 D17 COc1ccc(cc1)c2nc(═O) 2-(4-methoxyphenyl)-4H-1,3- 51.25 59.50 c3ccccc3o2 benzoxazin-4-one 1413 P10 CCCc1cc2c(═O)c(c(C)oc2cc1O) 7-hydroxy-2-methyl-6-propyl-3- 37.75 54.70 c3ccccn3 pyridin-2-yl-4H-chromen-4-one 2133 A16 Oc1ccccc1NC(═O)CCCCCC(═O) 7-[(2E)-2-(biphenyl-4- 49.50 54.30 N/N═C/c2ccc(cc2) ylmethylene)hydrazino]-N-(2- c3ccccc3 hydroxyphenyl)-7-oxoheptanamide 2144 E02 44.25 54.20 2047 H22 CCc1ccccc1NCc2c(O)c(C) 4-{[(2-ethylphenyl)amino]methyl}-5- 44.00 53.00 ncc2CO (hydroxymethyl)-2-methylpyridin-3-ol 1408 D13 CCOc1ccccc1NC(═O) N-(2-ethoxyphenyl)-2- 75.50 52.80 c2ccccc2O hydroxybenzamide 1463 A19 Oc1ccccc1C#CC#Cc2ccccc2O 2,2′-buta-1,3-diyne-1,4-diyldiphenol −82.25 51.90 2035 C06 CC1CN(C(═O)Nc2ccc(Cl) (2S)-N-(4-chlorophenyl)-2-methyl- 37.00 51.20 cc2)c3ccccc3O1 2,3-dihydro-4H-1,4-benzoxazine-4- carboxamide 1397 L19 COc1ccc(c2[nH]nc(c2c3cc4ccccc4o3) 2-[4-(1-benzofuran-2-yl)-3- 53.75 50.70 C(F)(F)F)c(O)c1 (trifluoromethyl)-1H-pyrazol-5-yl]-5- methoxyphenol 2131 D05 Oc1ccccc1NC(═O)CCCCCCC(═O) N-(2-hydroxyphenyl)-8-[(2E)-2-(1- 51.25 49.80 N/N═C/c2cccc3ccccc23 naphthylmethylene)hydrazino]-8- oxooctanamide 1442 J20 Clc1ccc2c(Nc3ccc4OCOc4c3) N-(1,3-benzodioxol-5-yl)-7- 59.00 49.50 ccnc2c1 chloroquinolin-4-amine 2015 G08 COc1ccc(/N═c/2cc(oc3ccc(O) (4E)-2-(4-methoxyphenyl)-4-[(4- 55.25 49.30 cc23)c4ccc(OC)cc4)cc1 methoxyphenyl)imino]-4H-chromen- 6-ol 2131 C18 Oc1ccccc1NC(═O)CCCCCCC(═O) 8-{(2E)-2-[(6-bromo-1,3- 66.25 49.20 N/N═C/c2cc3OCOc3cc2Br benzodioxol-5- yl)methylene]hydrazino}-N-(2- hydroxyphenyl)-8-oxooctanamide 2131 C14 COc1ccc(Br)cc1/C═N/NC(═O) 8-[(2E)-2-(5-bromo-2- 77.25 48.30 CCCCCCC(═O) methoxybenzylidene)hydrazino]-N- Nc2ccccc2O (2-hydroxyphenyl)-8-oxooctanamide 591 D04 Oc1ccc(/C═C/2\S\C(═N\c3ccccc3Cl)\ (2E,5Z)-2-[(2-chlorophenyl)imino]-5- 42.88 48.20 NC2═O)cc1[N+](═O) (4-hydroxy-3-nitrobenzylidene)-1,3- [O—] thiazolidin-4-one 2008 J17 CCN(CC)c1ncnc2c3cc(C) N,N-diethyl-8-methyl-5H- 37.25 47.20 ccc3[nH]c12 pyrimido[5,4-b]indol-4-amine 2086 M07 OC(═O)CC1Nc2ccccc2NC1═O [(2R)-3-oxo-1,2,3,4- 73.00 47.10 tetrahydroquinoxalin-2-yl]acetic acid 1453 B20 46.50 46.20 2133 N23 Oc1ccccc1NC(═O)CCCCCC(═O) 7-{(2E)-2-[(2-fluorobiphenyl-4- 74.00 45.80 N/N═C/c2ccc(c(F)c2) yl)methylene]hydrazino}-N-(2- c3ccccc3 hydroxyphenyl)-7-oxoheptanamide 2027 M05 CCC(C)NC(═O)c1cc2cc3cc(OC) 6-methoxy-N-[(1S)-1- 42.75 44.90 ccc3nc2o1 methylpropyl]furo[2,3-b]quinoline-2- carboxamide 2003 B09 OC(CNCc1ccccc1)Cn2c3ccc(Cl) (2R)-1-(benzylamino)-3-(3,6- 60.25 44.60 cc3c4cc(Cl)ccc24 dichloro-9H-carbazol-9-yl)propan-2- ol 1439 G19 Cc1nc(sc1C(═O)NC(═O)c2ccccc2O) 2-hydroxy-N-[(4-methyl-2-phenyl- 71.25 44.20 c3ccccc3 1,3-thiazol-5-yl)carbonyl]benzamide 1453 F18 46.25 43.30 588 K12 OC(═O)CN1C(═O)/C(═C\c2cc(Br) [(5E)-5-(5-bromo-3-chloro-2- 49.39 43.10 cc(Cl)c2O)/SC1═S hydroxybenzylidene)-4-oxo-2-thioxo- 1,3-thiazolidin-3-yl]acetic acid 2009 A02 Fc1cccc(c1)N2C(═O)NC(═O)/ (3-{(E)-[1-(3-fluorophenyl)-2,4,6- −130.50 42.90 C(═C\c3cn(CC#N)c4ccccc34)/ trioxotetrahydropyrimidin-5(2H)- C2═O ylidene]methyl}-1H-indol-1- yl)acetonitrile 1364 C17 Oc1cc(O)c2C(CC(═O)Oc2c1) (4S)-5,7-dihydroxy-4- 41.00 42.80 c3ccccc3 phenylchroman-2-one 1408 P11 Cc1ccc(C)c(NC(═O)c2ccccc2) N-(2,5-dimethylphenyl)benzamide 55.00 41.80 c1 1394 O14 NNc1nc(cc(n1)c2ccccc2) 2-hydrazino-4,6-diphenylpyrimidine 59.25 41.30 c3ccccc3 2100 K09 CN(C)CCCC[C@@H]1NC(═O) allyl (3R,3′R,4′S,6′R,8′S,8a′S)-6′-{4- 44.00 40.90 [C@@H]2C[C@@H]([C@@H](N2C1═O) [2-({[(3S,6R,7S,8aS)-3-[4- c3ccc(O) (dimethylamino)butyl]-6-(4- cc3)C(═O)OCCOc4ccc(cc4) hydroxyphenyl)-1,4- [C@H]5N6[C@@H]([C@@H](C(═O) dioxooctahydropyrrolo[1,2-a]pyrazin- OCC═C)[C@]57C(═O) 7-yl]carbonyl}oxy)ethoxy]phenyl}-5- Nc8ccc(I)cc87)C(═O) iodo-1′,2-dioxo-3′,4′-diphenyl- O[C@@H]([C@@H]6c9ccccc9) 1,2,3′,4′,8′,8a′-hexahydro-1′H- c % 10ccccc % 10 spiro[indole-3,7′-pyrrolo[2,1- c][1,4]oxazine]-8′-carboxylate 2069 N09 Oc1ccccc1NC(═O)c2cc(NC(═O) 5-(benzoylamino)-N,N′-bis(2- 51.25 40.60 c3ccccc3)cc(c2)C(═O) hydroxyphenyl)isophthalamide Nc4ccccc4O 2144 G02 52.00 40.50 1412 N21 Oc1ccccc1/C═C\2/SC(═S) (5E)-3-allyl-5-(2- 60.25 40.30 N(CC═C)C2═O hydroxybenzylidene)-2-thioxo-1,3- thiazolidin-4-one 2057 C10 CC1(C)c2cc(Cl) 2-chloro-8-hydroxy-10,10-dimethyl- 40.25 38.40 ccc2-n3c1cc(O)c(c4ccccc4)c3═O 7-phenylpyrido[1,2-a]indol-6(10H)- one 1402 H20 CCc1cc2c(═O)c(cOc2cc1O) 3-(1H-benzimidazol-1-yl)-6-ethyl-7- 52.00 37.40 n3cnc4ccccc34 hydroxy-4H-chromen-4-one 2001 D13 Cc1ccccc1NC(═O) 3-hydroxy-N-(2-methylphenyl)-2- 51.25 37.20 c2cc3ccccc3cc2O naphthamide 1364 N13 Clc1ccc(cc1)C(C#N)C(═O) (2S)-2-(4-chlorophenyl)-3-oxo-4- 59.25 36.90 Cc2ccccc2 phenylbutanenitrile 1366 O19 Cc1ccc(SCC(═O)c2cc(C)c(O) 1-(4-hydroxy-3,5-dimethylphenyl)-2- 47.00 35.70 c(C)c2)cc1 [(4-methylphenyl)thio]ethanone 2133 M04 Oc1ccccc1NC(═O)CCCCCC(═O) 7-[(2E)-2-(4-fluoro-3- 51.75 35.60 N/N═C/c2ccc(F)c(Oc3ccccc3) phenoxybenzylidene)hydrazino]-N- c2 (2-hydroxyphenyl)-7- oxoheptanamide 2010 M10 Oc1ccc(/C═C/2\SC(═S) (5Z)-5-(4-hydroxybenzylidene)-3- −159.50 34.40 N(CC3CCCO3)C2═O)cc1 [(2R)-tetrahydrofuran-2-ylmethyl]-2- thioxo-1,3-thiazolidin-4-one 2034 O10 Oc1ccccc1c2n[nH]c3C(═O) (4R)-5-(2-furylmethyl)-3-(2- 50.50 34.40 N(Cc4ccco4)C(c23)c5ccccc5 hydroxyphenyl)-4-phenyl-4,5- dihydropyrrolo[3,4-c]pyrazol-6(1H)- one 1409 J15 Oc1ccc(Br)cc1C(═O)c2cc(C#N) 5-(5-bromo-2-hydroxybenzoyl)-1-(2- 74.00 33.60 c(═O)n(c2)c3ccccc3F fluorophenyl)-2-oxo-1,2- dihydropyridine-3-carbonitrile 2021 D20 CCOC(═O)c1cnc2ccc(OCC) ethyl 6-ethoxy-4-{[(1R)-1- 50.25 32.70 cc2c1NC(C)CC methylpropyl]amino}quinoline-3- carboxylate 1393 M01 Cc1ccc(NC(═O)Cc2c(O) 2-(4-hydroxy-2-oxo-1,2- 36.25 32.60 c3ccccc3[nH]c2═O)cc1 dihydroquinolin-3-yl)-N-(4- methylphenyl)acetamide 1395 I06 Clc1ccc(cc1)c2nc(═O) 2-(4-chlorophenyl)-4H-1,3- 46.25 32.50 c3ccccc3o2 benzoxazin-4-one 1414 J16 Cc1[nH]nc(c1c2nc3ccccc3s2) 4-[4-(1,3-benzothiazol-2-yl)-5- 33.25 32.50 c4ccc(O)cc4O methyl-1H-pyrazol-3-yl]benzene-1,3- diol 1398 P07 CC(C)c1ccc(OCC(═O)c2ccc(O) 1-(2,4-dihydroxyphenyl)-2-(4- 37.00 32.40 cc2O)cc1 isopropylphenoxy)ethanone 1407 N22 OCc1ccc(Br)cc1c2cc([nH]n2) 4-bromo-2-[5-(2-furyl)-1H-pyrazol-3- 55.50 32.00 c3ccco3 yl]phenol 2100 F16 C[N+](C)(C)CCCC[C@@H]1NC(═O) 4-[(3S,6S,7R,8aR)-7-{[2-(4- 45.25 31.70 [C@H]2C[C@H]([C@H](N2C1═O) {(3S,3′S,4′R,6′R,8′R,8a′R)-8′- c3ccc(O)cc3) [(allyloxy)carbonyl]-5-iodo-1′,2-dioxo- C(═O)OCCOc4ccc(cc4) 3′,4′-diphenyl-1,2,3′,4′,8′,8a′- [C@@H]5N6[C@H]([C@H](C(═O) hexahydro-1′H-spiro[indole-3,7′- OCC═C)[C@@]57C(═O) pyrrolo[2,1-c][1,4]oxazin]-6′- Nc8ccc(I)cc87)C(═O) yl}phenoxy)ethoxy]carbonyl}-6-(4- O[C@H]([C@H]6c9ccccc9) hydroxyphenyl)-1,4- c % 10cccc % 10 dioxooctahydropyrrolo[1,2-a]pyrazin- 3-yl]-N,N,N-trimethylbutan-1- aminium 1397 C21 COc1ccc2[nH]c3c(ncnc3c2c1) 8-methoxy-N,N-dimethyl-5H- 43.75 31.60 N(C)C pyrimido[5,4-b]indol-4-amine 2078 N15 OC(═O)CN1C(═O)/C(═C\c2ccsc2)/ [(5E)-4-oxo-5-(3-thienylmethylene)- 42.25 31.60 SC1═S 2-thioxo-1,3-thiazolidin-3-yl]acetic acid 1445 F04 Clc1ccc2c(ccnc2c1) 7-chloro-4-piperidinoquinoline 45.50 31.40 N3CCCCC3 2015 A14 COc1cc(/C═C/C(═O)\C═C\c2ccc(cc2) (1E,4E)-1-[4- −91.00 31.20 N(C)C)cc(OC) (dimethylamino)phenyl]-5-(3,4,5- c1OC trimethoxyphenyl)penta-1,4-dien-3- one 2083 D04 CCCCc1c(nc(N)c(C#N) 2-amino-5-butyl-4-(4-hydroxy-3- 40.25 31.20 c1c2ccc(O)c(OC)c2)c3ccccc3 methoxyphenyl)-6- phenylnicotinonitrile 2015 P11 OC(═O)c1cccc(c1) 3-{2-[(1,3-dioxo-1,3-dihydro-2H- −100.00 31.20 n2cccc2C═C3C(═O)c4ccccc4C3═O inden-2-ylidene)methyl]-1H-pyrrol-1- yl}benzoic acid 1398 E06 CCOC(═O)c1ccc(NC(═O)/ ethyl 4-{[(2E)-3-(2-thienyl)prop-2- 42.75 31.10 C═C/c2cccs2)cc1 enoyl]amino}benzoate 1411 A03 Oc1c(Br)cc(NS(═O)(═O) N-(3-bromo-4-hydroxy-1-naphthyl)- 38.00 30.90 c2ccc(Cl)cc2)c3ccccc13 4-chlorobenzenesulfonamide 2290 A23 COc1cc(/C═C/2\Oc3cc(O) 74.50 30.90 ccc3C2═O)ccc1O 2031 K15 COC(═O)c1ccc2O/C(═C\c3ccc(O) methyl (2Z)-2-(4- −91.00 30.90 cc3)/C(═O)c2c1 hydroxybenzylidene)-3-oxo-2,3- dihydro-1-benzofuran-5-carboxylate 2009 C17 COc1ccccc1NC(═O)CC(c2ccccc2) (3R)-3-(2-hydroxy-4-methylphenyl)- 50.75 30.70 c3ccc(C)cc3O N-(2-methoxyphenyl)-3- phenylpropanamide 2069 O12 CCOC(═O)c1cnc2ccc(OCC) ethyl 4-(benzylamino)-6- 75.50 30.60 cc2c1NCc3ccccc3 ethoxyquinoline-3-carboxylate 1412 F08 ClC1═C(NC(═CS1)c2ccccc2) 2-chloro-5-phenyl-3-pyridin-4-yl-4H- 39.75 30.50 c3ccncc3 1,4-thiazine 2003 M11 CCS(═O)(═O)c1ccc(O)c(NC(═O) N-[5-(ethylsulfonyl)-2- 49.50 30.50 COc2ccc(OC)cc2)c1 hydroxyphenyl]-2-(4- methoxyphenoxy)acetamide 2297 E24 OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O) 52.25 30.30 cc(O)c4c3═O)c5ccc(O) cc5)[C@H](O)[C@@H](O) [C@@H]2O)[C@H](O)[C@@H](O) [C@@H]1O 1463 I17 C#Cc1ccccc1Oc2ccccc2 1-ethynyl-2-phenoxybenzene −123.75 29.80 2099 B17 CC(═CCC/C(═C/CC/C(═C/Cc1c(O) 4-hydroxy-3-[(2E,6E)-3,7,11- 60.00 29.70 c2ccccc2oc1═O)/C)/ trimethyldodeca-2,6,10-trien-1-yl]- C)C 2H-chromen-2-one 1410 C01 Cc1ccc(cc1)S(═O)(═O) {4-[(4- 70.50 29.70 c2ccc(NN)cc2 methylphenyl)sulfonyl]phenyl}hydrazine 2007 C13 CCOC(═O) ethyl 4-[(2- 73.25 29.60 c1cnc2ccccc2c1NCCc3ccccc3 phenylethyl)amino]quinoline-3- carboxylate 2100 E19 CC(═O)NCCCC[C@@H]1NC(═O) (3S,6S,7R,8aR)-3-(4- 42.25 29.60 [C@H]2C[C@H]([C@H](N2C1═O) acetamidobutyl)-6-(4- c3ccc(O)cc3) hydroxyphenyl)-1,4- C(═O)O dioxooctahydropyrrolo[1,2- a]pyrazine-7-carboxylic acid 2057 E17 Oc1c(Cc2ccccc2)c(═O) 5-benzyl-4-hydroxy-6H-pyrido[3,2,1- 52.75 29.50 n3c4ccccc4c5cccc1c53 k]carbazol-6-one 2006 P15 Oc1ccc(NS(═O)(═O)c2ccccc2) N-[3-(1,3-benzothiazol-2-ylthio)-4- 54.75 29.40 cc1Sc3nc4ccccc4s3 hydroxyphenyl]benzenesulfonamide 2037 G08 COc1cc(Nc2nc(SCC(═O) 1-(3,4-dihydroxyphenyl)-2-({4-[(3,5- 44.25 29.20 c3ccc(O)c(O)c3)nc4ccccc24) dimethoxyphenyl)amino]quinazolin- cc(OC)c1 2-yl}thio)ethanone 1439 M07 Oc1ccccc1C(═O)NC(═O) N-(cyclohexylcarbonyl)-2- 39.75 28.90 C2CCCCC2 hydroxybenzamide 1364 O16 On1c(nc2ccc(Cl)cc12)c3ccc(Cl) 6-chloro-2-(4-chlorophenyl)-1H- 57.50 28.90 cc3 benzimidazol-1-ol 2008 G14 COc1ccc(cc1)c2oc3ncn(Cc4ccccc4) 3-benzyl-5,6-bis(4- 43.50 28.80 c(═N)c3c2c5ccc(OC) methoxyphenyl)furo[2,3-d]pyrimidin- cc5 4(3H)-imine 2008 H17 CN(C)c1ncnc2c3cc(C) N,N,8-trimethyl-5H-pyrimido[5,4- 61.25 28.50 ccc3[nH]c12 b]indol-4-amine 2016 I20 COc1ccc(CN(C(═O)CCN2C(═O) 3-(1,1-dioxido-3-oxo-1,2- 44.50 28.20 c3ccccc3S2(═O)═O) benzisothiazol-2(3H)-yl)-N-(2- c4ccccc4O)cc1 hydroxyphenyl)-N-(4- methoxybenzyl)propanamide 2049 N08 FC(F)(F)c1ccc(nc1)S(═O)(═O) 2-phenyl-5-({[5- 42.50 28.00 CC2═NN(C(═O)C2) (trifluoromethyl)pyridin-2- c3ccccc3 yl]sulfonyl}methyl)-2,4-dihydro-3H- pyrazol-3-one 2043 L02 Clc1ccc(SCc2cc(═O)c3c(═O) 6-{[(4-chlorophenyl)thio]methyl}-2- 45.00 27.80 n([nH]c3[nH]2)c4ccccc4) phenyl-1H-pyrazolo[3,4-b]pyridine- cc1 3,4(2H,7H)-dione 2071 D09 Oc1ccc(Br)cc1/C═N/n2cnnc2 4-bromo-2-[(E)-(4H-1,2,4-triazol-4- 39.75 27.60 ylimino)methyl]phenol 1463 P01 CC1(C)OCC2═C(CC(CCc3ccccc3) (5S,7R)-2,2-dimethyl-5,7-bis(2- −85.25 27.40 OC2CCc4ccccc4)O1 phenylethyl)-7,8-dihydro-4H,5H- pyrano[4,3-d][1,3]dioxine 1397 C13 Cc1cc(O)n(n1)c2cccc(c2)C(F) 3-methyl-1-[3- 54.75 27.00 (F)F (trifluoromethyl)phenyl]-1H-pyrazol- 5-ol 2027 M11 N═C/1N2N═CSC2═NC(═O)\ (6E)-5-imino-6-{[1-(2-naphthyl)-1H- −109.50 26.90 C1═C\c3cccn3c4ccc5ccccc5c4 pyrrol-2-yl]methylene}-5,6-dihydro- 7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin- 7-one 2294 A05 OC1[C@H](OC(═O)c2cc(O) 50.75 26.70 c(O)c(O)c2)OC3COC(═O) c4cc(O)c(O)c(O) c4-c5c(O)c(O)c(O)cc5C(═O) O[@@H]1[C@@H]3OC(═O) c6cc(O)c(O)c(O)c6c7c(O) c(O)c(O)cc7C(═O)O 1465 K07 CCC(C)[C@@H](CO[C@@H](Cc1ccccc1) isopropyl (2S)-2-{[(2S)-2-{[(2S,3R)- 37.00 26.70 C(═O) 2-{[(2S)-2-amino-3- N[C@@H](CCS(═O)(═O)C)C(═O) mercaptopropyl]amino}-3- OC(C)C)NC[C@@H](N)CS methylpentyl]oxy}-3- phenylpropanoyl]amino}-4- (methylsulfonyl)butanoate 1410 K11 COc1ccc(/C═C/2\C(═O)N(C) (3Z)-3-(3-hydroxy-4- 52.75 26.70 c3ccccc23)cc1O methoxybenzylidene)-1-methyl-1,3- dihydro-2H-indol-2-one 2004 P09 CCOC(═O)c1c(oc2ccc(O) ethyl 4-{[(2-anilino-2- 49.75 26.60 c(CSCC(═O)Nc3ccccc3)c12) oxoethyl)thio]methyl}-5-hydroxy-2- c4ccccc4 phenyl-1-benzofuran-3-carboxylate 2296 G07 O[C@H]1[C@@H](O) 45.75 25.90 [C@@H](COC(═O)c2cc(O)c(O) c(O)c2)O[C@@H](Oc3ccc(C(═O)/ C═C/c4ccccc4)c(O)c3) [C@@H]1O 2084 H14 CCOc1ccc2[nH]c(═O) 3-benzyl-6-ethoxy-4- 71.00 25.90 c(Cc3ccccc3)c(O)c2c1 hydroxyquinolin-2(1H)-one 1442 L20 Cc1ccc(Nc2ccnc3cc(Cl)ccc23) 7-chloro-N-(3-fluoro-4- 70.25 25.90 cc1F methylphenyl)quinolin-4-amine 1465 N16 NS(═O)(═O)c1cc2c(N═CNS2(═O) 6-chloro-2H-1,2,4-benzothiadiazine- 38.50 25.80 ═O)cc1Cl 7-sulfonamide 1,1-dioxide 2075 O10 CN(C)c1ccc(cc1)C(═NO) bis[4- −119.75 25.70 c2ccc(cc2)N(C)C (dimethylamino)phenyl]methanone oxime 2037 B18 CCC(Cc1ccccc1)NC(═O) N-[(1S)-1-benzylpropyl]-6-[(4- 38.25 25.50 c2c[nH]c3ccc(cc3c2═O)S(═O) methylpiperidin-1-yl)sulfonyl]-4-oxo- (═O)N4CCC(C)CC4 1,4-dihydroquinoline-3-carboxamide 2042 N03 COc1ccc(CCN2COc3c(C) 3-[2-(4-methoxyphenyl)ethyl]-10- 41.50 25.50 c4oc(═O)cc(c5ccccc5)c4cc3C2) methyl-6-phenyl-3,4-dihydro-2H,8H- cc1 chromeno[6,7-e][1,3]oxazin-8-one 597 H21 Oc1ccccc1C2CC(═NN2c3ccc(cc3) 2-[(5S)-1-(4-nitrophenyl)-3-phenyl- −158.75 25.30 [N+](═O)[O—]) 4,5-dihydro-1H-pyrazol-5-yl]phenol c4ccccc4 2015 P13 Cc1cc(l)ccc1n2nc(cc2O)C(F) 1-(4-iodo-2-methylphenyl)-3- 41.00 25.30 (F)F (trifluoromethyl)-1H-pyrazol-5-ol 1398 K17 COC(═O)c1c(C)cc(O) methyl 1-hydroxy-3- 41.25 25.20 n2c3ccccc3nc12 methylpyrido[1,2-a]benzimidazole-4- carboxylate 2098 D22 OCCOc1ccc(cc1) (3R,3′R,4′S,6′R,8′S,8a′S)-5-(4- −84.25 25.10 [C@H]2N3[C@@H]([C@@H](C(═O) hydroxybut-1-yn-1-yl)-6′-[4-(2- O)[C@]24C(═O)Nc5ccc(C#CCCO) hydroxyethoxy)phenyl]-1′,2-dioxo- cc54)C(═O) 3′,4′-diphenyl-1,2,3′,4′,8′,8a′- O[C@@H]([C@@H]3c6ccccc6) hexahydro-1′H-spiro[indole-3,7′- c7ccccc7 pyrrolo[2,1-c][1,4]oxazine]-8′- carboxylic acid 2290 N23 COc1cc(ccc1O)c2oc3cc(O) 42.50 25.10 cc(O)c3c(═O)c2O 2094 L02 CCc1cccc(NC(═O) methyl 2,3-bis-O-(biphenyl-2- −133.75 24.90 O[C@@H]2[C@@H](CO)O[C@H](OC) ylcarbamoyl)-4-O-[(3- [C@@H](OC(═O) ethylphenyl)carbamoyl]-alpha-L- Nc3ccccc3c4ccccc4)[C@H]2OC(═O) idopyranoside Nc5ccccc5c6ccccc6)c1 2079 D18 COc1ccccc1c2nnc(o2) 2-[5-(2-methoxyphenyl)-1,3,4- 50.25 24.20 c3ccccc3O oxadiazol-2-yl]phenol 2043 M16 CC(Nc1nc2ccccc2n1CC═C) 2-{(1R)-1-[(1-allyl-1H-benzimidazol- 37.50 24.10 c3cc(Cl)ccc3O 2-yl)amino]ethyl}-4-chlorophenol 2086 O22 CC(C)C1NC(Cc2c1[nH]c3ccccc23) (1R,3R)-1-isopropyl-2,3,4,9- 71.00 23.90 C(═O)O tetrahydro-1H-beta-carboline-3- carboxylic acid 1434 C13 Cn1ncc(c1N)c2nc(cs2) 4-[4-(4-chlorophenyl)-1,3-thiazol-2- 44.50 23.70 c3ccc(Cl)cc3 yl]-1-methyl-1H-pyrazol-5-amine 2018 A06 OC(═O)c1ccc(N/C═C/C(═O) 4-{[(1E)-3-(2-furyl)-3-oxoprop-1-en- 63.50 23.20 c2ccco2)cc1 1-yl]amino}benzoic acid 2040 N04 Oc1c(CC(═O)NCc2ccccc2Cl) N-(2-chlorobenzyl)-2-(4-hydroxy-2- 39.50 23.10 c(═O)[nH]c3ccccc13 oxo-1,2-dihydroquinolin-3- yl)acetamide 1441 N12 FC(F)(F)c1cccc(SCc2cccc(c2) 3-oxo-3-[3-({[3- 48.00 23.00 C(═O)CC#N)c1 (trifluoromethyl)phenyl]thio}methyl)phenyl] propanenitrile 2057 E08 CCc1c(O)c(Cc2ccccc2)c(═O) 3-benzyl-5-ethyl-4-hydroxy-6-phenyl- 46.50 22.80 n(c3nccs3)c1c4ccccc4 1-(1,3-thiazol-2-yl)pyridin-2(1H)-one 2290 K17 Oc1ccc2C(═O)/C(═C/c3ccc(O) 49.00 22.80 c(O)c3)/Oc2c1 2026 E05 OC1C(NN═C1c2ccccc2) (4S,5S)-3,5-diphenyl-4,5-dihydro- 49.25 22.70 c3ccccc3 1H-pyrazol-4-ol 1407 H22 Cc1ccc(c2cc([nH]n2)c3cccs3) 5-methyl-2-[5-(2-thienyl)-1H-pyrazol- 47.25 22.70 c(O)c1 3-yl]phenol 2079 J15 Sc1nc(SCCOc2ccccc2) 2-[(2-phenoxyethyl)thio]quinazoline- 60.50 22.70 nc3ccccc13 4-thiol 1409 C22 Cc1ccc2[nH]c(═NC(═O) N-(6-methyl-1,3-benzothiazol-2(3H)- 40.00 22.60 c3cccs3)sc2c1 ylidene)thiophene-2-carboxamide 588 K09 Oc1c(/C═C/2\S\C(═N/c3ccccc3Cl)\ (2Z,5Z)-2-[(2-chlorophenyl)imino]-5- 45.30 22.60 NC2═O)cccc1[N+](═O) (2-hydroxy-3-nitrobenzylidene)-1,3- [O—] thiazolidin-4-one 2005 F12 COc1cc(/C═C/2\SC(═S) (2R)-2-[(5Z)-5-(4-hydroxy-3,5- 52.00 22.20 N(C(C(C)C)C(═O)O)C2═O)cc(OC) dimethoxybenzylidene)-4-oxo-2- c1O thioxo-1,3-thiazolidin-3-yl]-3- methylbutanoic acid 2027 G14 Oc1cc(nn1c2ccccc2) N-(3-chlorophenyl)-4-(5-hydroxy-1- 49.00 22.00 C3CCN(CC3)C(═S)Nc4ccccc(Cl)c4 phenyl-1H-pyrazol-3-yl)piperidine-1- carbothioamide 1396 O08 CCc1cc(C(═O)Cc2nc3ccccc3n2C) 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(1- 46.50 22.00 c(O)cc1O methyl-1H-benzimidazol-2- yl)ethanone 1405 B15 CN(C)S(═O)(═O)c1ccc(cc1) N,N-dimethyl-4-(6- 40.50 21.60 c2cn3cc(C)ccc3n2 methylimidazol[1,2-a]pyridin-2- yl)benzenesulfonamide 2049 D18 CN(C)/C═C/1\N═C(OC1═O) (4Z)-2-[2-(4-chlorophenoxy)pyridin- 66.75 21.50 c2cccnc2Oc3ccc(Cl)cc3 3-yl]-4-[(dimethylamino)methylene]- 1,3-oxazol-5(4H)-one 1442 I17 Oc1cc(nc2ccc(Br)cc12)C(F) 6-bromo-2-(trifluoromethyl)quinolin- 43.00 21.40 (F)F 4-ol 1409 L21 CC1SC(═S)NN1c2ccccc2 (5R)-5-methyl-4-phenyl-1,3,4- 114.25 21.30 thiadiazolidine-2-thione 1404 P06 Oc1cccnc1NC(═O) N-(3-hydroxypyridin-2-yl)-4- 70.00 21.30 c2ccc(Oc3ccccc3)cc2 phenoxybenzamide 2072 D14 Cc1ccc(CCSc2ccc(Cl)c(Cl) 5-{2-[(3,4-dichlorophenyl)thio]ethyl}- 69.75 21.20 c2)cn1 2-methylpyridine 1449 E20 COC(═O)c1cc(O)n(n1) methyl 5-hydroxy-1-[4- 44.50 21.20 c2ccc(cc2)C(F)(F)F (trifluoromethyl)phenyl]-1H-pyrazole- 3-carboxylate 2060 M02 CC/1Sc2ccc(Cl)cc2C(═O)\ (2R,3Z)-6-chloro-3- 43.00 21.20 C1═C\N(C)C [(dimethylamino)methylene]-2- methyl-2,3-dihydro-4H-thiochromen- 4-one 1442 N22 CCC(═O)N1CCN(CC1) 1-[4-(7-chloroquinolin-4- 41.75 21.20 c2cccnc3cc(Cl)ccc23 yl)piperazino]propan-1-one 1410 G09 CC1(C)CC(═O)C(CC(═O) N-[2-chloro-5- 43.25 20.90 Nc2cc(ccc2Cl)C(F)(F)F)C(═O) (trifluoromethyl)phenyl]-2-(4,4- C1 dimethyl-2,6- dioxocyclohexyl)acetamide 2058 D04 Oc1c(c2ccccc2)c(═O)[nH]c3ccc(F) 6-fluoro-4-hydroy-3-phenylquinolin- 43.75 20.60 cc13 2(1H)-one 2074 H22 Cc1cc(═O)[nH]c(SCC(═O) N-(4-bromophenyl)-2-[(3-cyano-4- 59.00 20.40 Nc2ccc(Br)cc2)c1C#N methyl-6-oxo-1,6-dihydropyridin-2- yl)thio]aectamide 2027 G19 CCc1ccccc1NS(═O)(═O) 6-{[(2-ethylphenyl)amino]sulfonyl}-4- 44.50 20.00 c2ccc3[nH]cc(C(═O)NCC4CCCO4) oxo-N-[(2S)-tetrahydrofuran-2- c(50 O)c3c2 ylmethyl]-1,4-dihydroquinoline-3- carboxamide 2022 D10 CC(C)NC(═O)C1(O)N(C(═O) (4R)-3-(3,4-dichlorophenyl)-4- 49.00 19.80 Nc2ccccc21)c3ccc(Cl)c(Cl) hydroxy-N-isopropyl-2-oxo-1,2,3,4- c3 tetrahydroquinazoline-4- carboxamide 2049 J02 FC(F)(F)C1═NN(C(═O)C1) 2-phenyl-5-(trifluoromethyl)-2,4- 41.75 19.30 c2ccccc2 dihydro-3H-pyrazol-3-one 1440 M20 CCCCc1c(C)[nH]c2cc(nn2c1═O) 6-butyl-2-(2-furyl)-5-methyl-4,7- 44.00 19.20 c3ccco3 dihydropyrazolo[1,5-a]pyrimidin-7- one 1394 F14 CCn1c2ccccc2c3cc(/C═N/n4cnnc4) N-[(1E)-(9-ethyl-9H-carbazol-3- 46.25 19.00 ccc13 yl)methylene]-4H-1,2,4-triazol-4- amine 1416 K22 Oc1ccc2c(cc(═O)oc2c1O) 7,8-dihydroxy-4-phenyl-2H- 51.75 19.00 c3ccccc3 chromen-2-one 1413 F17 COc1ccc(c2onc(C)c2c3cscn3) 5-methoxy-2-[3-methyl-4-(1,3- 39.00 18.90 c(O)c1 thiazol-4-yl)isoxazol-5-yl]phenol 2104 I18 73.75 18.40 2006 I09 CCN(CC)c1ccc(/C═N/CCc2ccccc2) 5-(diethylamino)-2-{(E)-[(2- 65.75 18.00 c(O)c1 phenylethyl)imino]methyl}phenol 2016 H03 ON(C(═O)Nc1ccccc1)c2ccc(Cl) 1-(4-chlorophenyl)-1-hydroxy-3- 67.50 17.90 cc2 phenylurea 2013 K04 Cc1nn(c(O)c1Sc2ccc(Cl)cc2) 4-[(4-chlorophenyl)thio]-3-methyl-1- 53.00 17.80 c3ccccc3 phenyl-1H-pyrazol-5-ol 2290 N04 Oc1ccc(c(O)c1)c2oc3cc(O) 2-(2,4-dihydroxyphenyl)-3,5,7- 65.00 17.80 cc(O)c3c(═O)c2O trihydroxy-4H-chromen-4-one 2058 E18 O═C1/C(═C\c2c[nH]c3ccccc23)/ (2S,3Z)-3-(1H-indol-3-ylmethylene)- −109.50 17.50 C(Oc4ccccc14)c5ccccc5 2-phenyl-2,3-dihydro-4H-chromen-4- one 2041 A04 CCOc1ccc(cc1)N(C)S(═O) 6-{[(4- 40.75 17.30 (═O)c2ccc3[nH]cc(C(═O) ethoxyphenyl)(methyl)amino]sulfonyl}- NCC4CCCO4)c(═O)c3c2 4-oxo-N-[(2S)-tetrahydrofuran-2- ylmethyl]-1,4-dihydroquinoline-3- carboxamide 2010 I17 CN(C)C1OC2═C(C═C1C)C(═O) (10S)-10-(dimethylamino)-9-methyl- 48.00 17.30 c3cccc4cccc2c34 7H,10H-naphtho[1,8-gh]chromen-7- one 2056 P12 Clc1ccc(cc1)N2N═C(CSc3nccc(n3) 2-(4-chlorophenyl)-5-{[(4-pyridin-3- 61.25 17.20 c4cccnc4)CC2═O ylpyrimidin-2-yl)thio]methyl}-2,4- dihydro-3H-pyrazol-3-one 1443 J06 Oc1c(Cc2ccccc2)c(═O) 3-benzyl-4-hydroxy-1,2- 63.50 16.80 [nH]c3ccccc13 dihydroquinolin-2-one 2084 K01 CC1(C)CC(═O)C2═C(C1) (4S)-4-(2-furyl)-3-hydroxy-7,7- 45.00 16.60 Nc3nn(c(O)c3C2c4ccco4) dimethyl-2-phenyl-2,4,6,7,8,9- c5ccccc5 hexahydro-5H-pyrazolo[3,4- b]quinolin-5-one 1364 E16 On1c(nc2ncccc12)c3ccc(Cl) 2-(2,4-dichlorophenyl)-1H- 61.75 16.50 cc3Cl imidazo[4,5-b]pyridin-1-ol 2030 M08 O═C(Nc1cccc(c1)c2cn3cccnc3n2) N-(3-imidazo[1,2-a]pyrimidin-2- 45.00 16.40 C4CCCC4 ylphenyl)cyclopentanecarboxamide 2078 J10 Cc1cc(═O)oc2c(C)c(O)c(CC═C) 6-allyl-7-hydroxy-4,8-dimethyl-2H- 42.25 16.20 cc12 chromen-2-one 2011 L02 CCOC(═O)c1cnc2ccc(C) ethyl 6-methyl-4-[(4-morpholin-4- 44.00 16.00 cc2c1Nc3ccc(cc3)N4CCOCC4 ylphenyl)amino]quinoline-3- carboxylate 2072 J04 Oc1c(oc2ccccc2c1═O)c3ccc(F) 2-(4-fluoro-3-phenoxyphenyl)-3- 58.50 15.90 c(Oc4ccccc4)c3 hydroxy-4H-chromen-4-one 2014 O13 CCOC(═O)c1ccc(NC(═O) ethyl 4-[({[(5R)-5-ethyl-4,6-dioxo- 49.50 15.90 CSC2═NC(═O)C(CC)C(═O) 1,4,5,6-tetrahydropyrimidin-2- N2)cc1 yl]thio}acetyl)amino]benzoate 2069 G20 CCS(═O)(═O)c1ccc(NC(═O) N-[4-(ethylsulfonyl)-2- 43.25 15.70 c2ccccc2)c(O)c1 hydroxyphenyl]benzamide 2027 E19 COc1cccc(NS(═O)(═O) N-benzyl-6-{[(3- 33.75 15.50 c2ccc3[nH]cc(C(═O)N(C)Cc4ccccc4) methoxyphenyl)amino]sulfonyl}-N- c(═O)c3c2)c1 methyl-4-oxo-1,4-dihydroquinoline- 3-carboxamide 2011 A15 O═C(Oc1cccc(Nc2ncnc3ccccc23) 3-(quinazolin-4-ylamino)phenyl 48.75 15.40 c1)c4cccs4 thiophene-2-carboxylate 2088 A12 CCOC(═O)/C═C/c1cc(ccc1O) ethyl (2E)-3-(2-hydroxy-5- 45.50 15.20 [N+](═O)[O—] nitrophenyl)acrylate 1431 J17 CSCc1ccc(cc1)C(═O)Nc2ccc(C) N-(2-hydroxy-4-methylphenyl)-4- 50.50 15.10 cc2O [(methylthio)methyl]benzamide 1415 K11 CCc1cc(c2n[nH]cc2c3nc4ccccc4n3C) 4-ethyl-6-[4-(1-methyl-1H- 46.75 14.90 c(O)cc1O benzimidazol-2-yl)-1H-pyrazol-3- yl]benzene-1,3-diol 1416 N11 CCCc1cc(═O)oc2cc(O)cc(O) 5,7-dihydroxy-4-propyl-2H-chromen- 62.50 14.90 c12 2-one 2017 K21 CC1═NN(C(═O)C1C(═O) (4S)-4-(2-bromobenzoyl)-5-methyl- 43.25 14.60 c2ccccc2Br)c3ccccc3 2-phenyl-2,4-dihydro-3H-pyrazol-3- one 1439 C09 Oc1ccccc1C(═O)NC(═O) N-[(3-chloro-1-benzothiophen-2- 73.50 14.50 c2sc3ccccc3c2Cl yl)carbonyl]-2-hydroxybenzamide 1410 H21 Oc1ccc(Oc2c(F)c(F)c(Oc3ccc(O) 4,4′-[(2,3,5,6-tetrafluoro-1,4- 37.50 14.40 cc3)c(F)c2F)cc1 phenylene)bis(oxy)]diphenol 2012 D07 COc1ccccc1CC(═O)Nc2ccc(cc2) N-[4-(1H-benzimidazol-2-yl)phenyl]- 74.00 14.20 c3nc4ccccc4[nH]3 2-(2-methoxyphenyl)acetamide 2068 J16 CC(C)CCCN1C(═O)NC(═O)/ (5E)-1-(4-methylpentyl)-5-(1H-pyrrol- −112.25 14.00 C(═C\c2ccc[nH]2)/C1═O 2-ylmethylene)pyrimidine- 2,4,6(1H,3H,5H)-trione 2293 F13 Oc1ccc(cc1)[C@H]2CC(═O) 53.25 13.90 c3c(O)cc(O)c([C@H]4[C@@H](Oc5cc(O) cc(O)c5C4═O) c6ccc(O)cc6)c3O2 1393 A03 Oc1c(CC(═O)Nc2ccc(F)cc2) N-(4-fluorophenyl)-2-(4-hydroxy-2- 37.75 13.80 c(═O)[nH]c3ccccc13 oxo-1,2-dihydroquinolin-3- yl)acetamide 1439 E21 Cc1ccc(cc1)c2nc(═O) 2-(4-methylphenyl)-4H-1,3- 52.75 13.70 c3ccccc3o2 benzoxazin-4-one 1439 A09 COc1ccccc1CC(═O)NC(═O) 2-hydroxy-N-[2-(2- 37.50 13.60 c2ccccc2O methoxyphenyl)acetyl]benzamide 2057 M10 Oc1c(Cc2ccccc2)c(═O) 3-benzyl-4-hydroxy-1- 69.25 13.60 n(c3ccccc3)c4ccccc14 phenylquinolin-2(1H)-one 2016 O15 Oc1cc(c2cc(ccc2Cl)C(F)(F) 7-[2-chloro-5- 41.00 13.60 F)c3oc(═O)sc3c1 (trifluoromethyl)phenyl]-5-hydroxy- 1,3-benzoxathiol-2-one 1415 K09 CCc1cc2c(═O)c(c3nc4ccccc4n3C) 6-ethyl-7-hydroxy-3-(1-methyl-1H- 41.75 13.50 c(oc2cc1O)C(F)(F)F benzimidazol-2-yl)-2- (trifluoromethyl)-4H-chromen-4-one 2059 D01 Cc1ccc(cc1)N2C(C(═O) (3S)-3-(2-hydroxy-4-methylbenzoyl)- 51.75 13.40 c3ccc(C)cc3O)c4ccccc4C2═O 2-(4-methylphenyl)isoindolin-1-one 1439 E09 Cc1ccc(Oc2ncccc2C(═O) 2-hydroxy-N-{[2-(4-methylphenoxy)- 81.00 13.20 NC(═O)c3ccccc3O)cc1 3-pyridinyl]carbonyl}benzamide 1413 N19 Cc1csc(n1)c2c(oc3cc(O)c(C) 7-hydroxy-6-methyl-3-(4-methyl-1,3- 44.00 13.00 cc3c2═O)C(F)(F)F thiazol-2-yl)-2-(trifluoromethyl)-4H- chromen-4-one 2091 D09 −79.00 12.70 1465 D10 CCN(CCCc1ccccc1) N-ethyl-3-phenyl-N-(3- 43.25 12.60 CCCc2ccccc2 phenylpropyl)propan-1-amine 2073 I20 CC(═O)Nc1cccc(c1O)c2cc(═O) N-[2-hydroxy-3-(4-oxo-4H-chromen- 40.50 12.60 c3ccccc3o2 2-yl)phenyl]acetamide 1413 L10 CCCc1cc(C(═O)Cc2ccc3OCOc3c2) 2-(1,3-benzodioxol-5-yl)-1-(2,4- 55.50 12.50 c(O)cc1O dihydroxy-5-propylphenyl)ethanone 2067 O04 Cc1sc2NC(NC(═O)c2c1C)/ (2R)-2-[(E)-2-(1,3-benzodioxol-5- −96.25 12.20 C═C/c3ccc4OCOc4c3 yl)vinyl]-5,6-dimethyl-2,3- dihydrothieno[2,3-d]pyrimidin-4(1H)- one 2081 H11 CCCc1cc(O)c2c(C)cc(═O) 5-hydroxy-4-methyl-7-propyl-2H- 63.25 11.80 oc2c1 chromen-2-one 1406 M17 Oc1cc(c2ccc(Br)cc2)c3oc(═O) 7-(4-bromophenyl)-5-hydroxy-1,3- 43.50 11.80 sc3c1 benzoxathiol-2-one 1413 D15 Cc1cc(O)cc2oc(c(c3cnn(c3) 7-hydroxy-5-methyl-3-(1-phenyl-1H- 43.00 11.70 c4ccccc4)c(═O)c12)C(F)(F)F pyrazol-4-yl)-2-(trifluoromethyl)-4H- chromen-4-one 2014 G14 CC(C)n1nc(O)c2C(SCC(═O) (4R)-4-(4-bromophenyl)-3-hydroxy- 42.25 11.70 Nc21)c3ccc(Br)cc3 1-isopropyl-4,8-dihydro-1H- pyrazolo[3,4-e][1,4]thiazepin-7(6H)- one 1425 M21 CCNC(═O)CC1Nc2cc(C)c(C) 2-[(2R)-6,7-dimethyl-3-oxo-1,2,3,4- 48.50 11.50 cc2NC1═O tetrahydroquinoxalin-2-yl]-N- ethylacetamide 2297 M15 COC(═O)[C@]1(Cc2ccc(O) 49.00 11.20 c(CC═C(C)C)c2)OC(═O) C(═C1c3ccc(O)cc3)O 1412 M06 CC(C)C(═O) N-[2-(1H-benzimidazol-2-yl)phenyl]- 43.00 11.10 Nc1ccccc1c2nc3ccccc3[nH]2 2-methylpropanamide 1446 D05 CC1(C)c2ccccc2-n3c1cc(O) 7-benzyl-8-hydroxy-10,10-dimethyl- 53.50 11.00 c(Cc4ccccc4)c3═O 6,10-dihydropyrido[1,2-a]indol-6-one 2081 P14 CCCc1c(O)c2ccccc2[nH]c1═O 4-hydroxy-3-propylquinolin-2(1H)- 39.00 10.60 one 1425 O02 Oc1ccc(c2n[nH]c(c2c3cnn(c3) 4-[1′-phenyl-5-(trifluoromethyl)- 40.25 10.10 c4ccccc4)C(F)(F)F)c(O)c1 1H,1′H-4,4′-bipyrazol-3-yl]benzene- 1,3-diol 2064 B02 O═C(C1═NN(C2C1C(═O) (3aS,6aS)-3-benzoyl-1,5-diphenyl- −102.50 9.80 N(C2═O)c3ccccc3)c4ccccc4) 3a,6a-dihydropyrrolo[3,4-c]pyrazole- c5ccccc5 4,6(1H,5H)-dione 1412 J10 CSc1nc2ccc(NC(═O)c3cccc(Cl) 3-chloro-N-[2-(methylthio)-1,3- 45.25 9.80 c3)cc2s1 benzothiazol-6-yl]benzamide 1395 D05 CCCn1c(nc2ccccc12)c3ccc(N) 4-(1-propyl-1H-benzimidazol-2- 39.25 9.60 cc3 yl)aniline 2077 D11 CN(C)c1ccc(cc1)C(N2CCCCC2) 6-[(S)-[4- 46.00 9.20 c3cc4OCOc4cc3O (dimethylamino)phenyl](piperidin-1- yl)methyl]-1,3-benzodioxol-5-ol 1405 H15 Cc1oc2cc(O)ccc2c(═O) 3-(4-bromophenyl)-7-hydroxy-2- 51.25 9.20 c1c3ccc(Br)cc3 methyl-4H-chromen-4-one 2073 K12 CC(NC(═O)Oc1c(Cl)cc(Cl) 2,4-dichloro-1-naphthyl [2,2,2- 53.00 9.20 c2ccccc12)(C(F)(F)F)C(F)(F)F trifluoro-1-methyl-1- (trifluoromethyl)ethyl]carbamate 2018 O08 Cc1ccc(cc1)C2═C/C(═C/c3ccc(o3) 3-(5-{(Z)-[5-(4-methylphenyl)-2- 62.75 8.60 c4cccc(c4)C(═O)O)/ oxofuran-3(2H)-ylidene]methyl}-2- C(═O)O2 furyl)benzoic acid 2010 P21 CCOC(═O)c1c(CSc2ccc(C) ethyl 6-bromo-4- 51.00 8.60 cc2)n(C)c3cc(Br)c(O)c(CN(C) [(dimethylamino)methyl]-5-hydroxy- C)c13 1-methyl-2-{[(4- methylphenyl)thio]methyl}-1H-indole- 3-carboxylate 1408 L07 Oc1ccccc1C(═O)Nc2cccnc2 2-hydroxy-N-pyridin-3-ylbenzamide 56.00 8.40 1469 I17 Oc1ccc(CCC(═O)c2c(O)cc(O) 3-(4-hydroxyphenyl)-1-(2,4,6- 45.50 7.90 cc2O)cc1 trihydroxyphenyl)propan-1-one 1414 B12 CCS(═O)(═O)c1ccc(O)c(c1) 2-[5-(ethylsulfonyl)-2- 37.00 7.80 N2C(═O)c3cccc4cccc(C2═O) hydroxyphenyl]-1H- c34 benzo[de]isoquinoline-1,3(2H)-dione 1406 I10 Cc1ccc(c(C)c1)n2c(N)c(C#N) 2-amino-1-(2,4-dimethylphenyl)-1H- 46.75 7.50 c3nc4ccccc4nc23 pyrrolo[2,3-b]quinoxaline-3- carbonitrile 1425 A04 COc1ccc(c2n[nH]c(c2c3cnn(c3) 3-methoxy-2-methyl-6-[1′-phenyl-5- 32.75 7.30 c4ccccc4)C(F)(F)F)c(O) (trifluoromethyl)-1H,1′H-4,4′- c1C bipyrazol-3-yl]phenol 2018 C20 OC(═O)CC(N1C(═O)/ (2S)-2-[(5E)-5-(1H-indol-3- 44.50 7.30 C(═C\c2c[nH]c3ccccc23)/SC1═S) ylmethylene)-4-oxo-2-thioxo-1,3- C(═O)O thiazolidin-3-yl]succinic acid 1409 P14 Oc1ccccc1C(═O) N-benzyl-2-hydroxybenzamide 43.00 7.10 NCc2ccccc2 2058 B10 Cc1nn(c(O)c1Cc2c(Cl) 4-(2,6-dichlorobenzyl)-3-methyl-1- 45.50 6.90 cccc2Cl)c3ccccc3 phenyl-1H-pyrazol-5-ol 2025 O12 Clc1ccccc1CNS(═O)(═O) N-(2-chlorobenzyl)-2-phenyl-1H- 45.50 6.80 c2ccc3[nH]c(nc3c2)c4ccccc4 benzimidazole-5-sulfonamide 2072 F12 CCOC(═O)Oc1c(Cl)cc2oc(═O) 4-bromo-6-chloro-2-oxo-1,3- 50.00 6.40 sc2c1Br benzoxathiol-5-yl ethyl carbonate 2069 I05 Cc1cccc2c(O)c(/C═C/3\C(NN(C3═O) 4-hydroxy-8-methyl-3-{(E)-[(3R)-5- 47.25 6.20 c4ccccc4)c5ccccc5) oxo-1,3-diphenylpyrazolidin-4- c(═O)[nH]c12 ylidene]methyl}quinolin-2(1H)-one 1441 L02 Clc1ccc(SCc2cccc(c2)C(═O) 3-(3-{[(4- 42.50 6.00 CC#N)cc1 chlorophenyl)thio]methyl}phenyl)-3- oxopropanenitrile 2049 B03 CN(/N═C/c1cc(Cl)cc(Cl)c1O) 3,5-dichloro-2-hydroxybenzaldehyde 56.00 5.90 C(═S)NC(C)(C)C N-tert-butyl-N′- methylthiosemicarbazone 2069 I04 Oc1ccc(Cl)cc1Sc2cc(Cl) 2,2′-thiobis(4-chlorophenol) 41.25 5.80 ccc2O 1414 B15 CC(C)CC1C(═C(N)OC2═C1C(═O) (4S,7R)-2-amino-4-isobutyl-5-oxo-7- 62.25 5.40 CC(C2)c3ccccc3)C#N phenyl-5,6,7,8-tetrahydro-4H- chromene-3-carbonitrile 1409 M11 Oc1c(Cl)cc(Cl)cc1C(═O) (3,5-dichloro-2- 67.50 5.40 c2cnoc2 hydroxyphenyl)(isoxazol-4- yl)methanone 1414 J04 CC(C)(C)C(═O)Nc1ccc(O)c(c1) N-[3-(1,3-benzothiazol-2-yl)-4- 46.75 5.30 c2nc3ccccc3s2 hydroxyphenyl]-2,2- dimethylpropanamide 1416 D17 c1cnc2ccc(cc2c1) 3,6′-biquinoline 38.00 4.70 c3ccc4ncccc4c3 2011 E12 CC(Oc1ccc(Cl)cc1Cl)C(═O) (2R)-2-(2,4-dichlorophenoxy)-N-(5- 62.25 4.70 NC2═NN(C(═O)C2)c3ccccc3 oxo-1-phenyl-4,5-dihydro-1H- pyrazol-3-yl)propanamide 2144 J08 45.50 3.90 1426 J16 Oc1ccc(NS(═O)(═O)c2cccs2) N-[3-(1,3-benzothiazol-2-ylthio)-4- 55.75 3.90 cc1Sc3nc4ccccc4s3 hydroxyphenyl]thiophene-2- sulfonamide 588 M05 CCN(CC)c1ccc(/C═C\2/SC(═O) (5E)-5-[4- −138.00 3.50 N(CNc3ccccc3OC)C2═O) (diethylamino)benzylidene]-3-{[(2- cc1 methoxyphenyl)amino]methyl}-1,3- thiazolidine-2,4-dione 2058 E04 Oc1c(c2ccccc2)c(═O) 4-hydroxy-5-phenyl-6H-pyrido[3,2,1- 43.75 3.10 n3c4ccccc4c5cccc1c53 jk]carbazol-6-one 1443 G08 Cc1ccc(Sc2cccc3nc(N)nc(N) 5-[(4-methylphenyl)thio]quinazoline- 37.50 2.50 c23)cc1 2,4-diamine 2020 K14 CCc1ccc(cc1)C2C3═C(CCCC3═O) (4R)-4-(4-ethylphenyl)-3-hydroxy-2- 61.00 2.30 Nc4nn(c(O)c24) phenyl-2,4,6,7,8,9-hexahydro-5H- c5ccccc5 pyrazolo[3,4-b]quinolin-5-one 1424 I20 CC(═O)n1cc(c2c(O) 3-(1-acetyl-1H-indol-3-yl)-4-hydroxy- 51.50 2.00 c3ccccc3oc2═O)c4ccccc14 2H-chromen-2-one 2081 D13 N(c1ccccc1)c2nc(nc3ccccc23) N,2-diphenylquinazolin-4-amine 50.00 1.30 c4ccccc4 1398 D22 ClC1ccc(cc1)C(═O) 2-anilino-2-oxoethyl 2-(4- 58.00 0.80 c2ccccc2C(═O)OCC(═O)Nc3ccccc3 chlorobenzoyl)benzoate 1394 A01 Fc1ccc(cc1)C(═O)Nc2cccc(c2) 4-fluoro-N-[3- 28.00 0.00 C(F)(F)F (trifluoromethyl)phenyl]benzamide 1417 A07 *c1ccccc1C2C(═O)N(C) 34.75 0.00 c3ccccc3C2═O 2030 A14 C(c1ccccc1)n2cc3c(nnc3c4ccccc24) 5-benzyl-3-phenyl-5H-pyrazolo[4,3- 51.00 0.00 c5ccccc5 c]quinoline 1413 B06 CCCCc1cc(C(═O)Cc2ccccn2) 1-(5-butyl-2,4-dihydroxyphenyl)-2- 48.75 0.00 c(O)cc1O pyridin-2-ylethanone 1416 C02 CCOc1ccc2C(═O)/C(═C\c3ccccc3O)/ (2E)-6-ethoxy-2-(2- 36.25 0.00 Sc2c1 hydroxybenzylidene)-1- benzothiophen-3(2H)-one 1397 C08 COc1ccc(/C═C/C(═O)Nc2ccc(C) (2E)-3-(3,4-dimethoxyphenyl)-N- 50.50 0.00 c(C)c2)cc1OC (3,4-dimethylphenyl)acrylamide 1415 C11 CCc1cc(C(═O)Cn2cnc3ccccc23) 2-(1H-benzimidazol-1-yl)-1-(5-ethyl- 42.00 0.00 c(O)cc1O 2,4-dihydroxyphenyl)ethanone 1422 C11 COc1cc(Cn2c(nc3ccccc23) 4-[1-(4-hydroxy-3-methoxybenzyl)- 41.75 0.00 c4ccc(O)c(OC)c4)ccc1O 1H-benzimidazol-2-yl]-2- methoxyphenol 1417 C14 CCC(C)Sc1nnc(NC(═O) N-(5-{[(1S)-1-methylpropyl]thio}- 42.00 0.00 c2ccccc2C(F)(F)F)s1 1,3,4-thiadiazol-2-yl)-2- (trifluoromethyl)benzamide 1418 D05 COCC(═O)Oc1c(Sc2ccc(C) 3-methyl-4-[(4-methylphenyl)thio]-1- 40.75 0.00 cc2)c(C)nn1c3ccccc3 phenyl-1H-pyrazol-5-yl methoxyacetate 1469 D07 COc1cc(O)c2c(═O)c(O)c(oc2c1) 2-(3,4-dihydroxyphenyl)-3,5- 48.50 0.00 c3ccc(O)c(O)c3 dihydroxy-7-methoxy-4H-chromen- 4-one 1446 D07 Oc1cc2nnnn2nc1c3ccccc3 6-phenyl[1,2,3,4]tetraazolo[1,5- 43.50 0.00 b]pyridazin-7-ol 1412 D10 COc1ccc(cc1OC)C(═O) 3,4-dimethoxy-N-(4-methyl-1,3- 53.25 0.00 Nc2nc3c(C)cccc3s2 benzothiazol-2-yl)benzamide 1432 D13 Oc1c(Cc2ccccc2)c(═O) 6-benzyl-7-hydroxy-2,3-dihydro- 68.75 0.00 n3CCCc4cccc1c43 1H,5H-pyrido[3,2,1-ij]quinolin-5-one 1408 D15 Cc1ccc(NC(═O)c2ccccc2O) 2-hydroxy-N-(4- 62.25 0.00 cc1 methylphenyl)benzamide 2080 E05 Cc1ccc(cc1)N2COc3ccc(Cl) 6-chloro-3-(4-methylphenyl)-3,4- 41.50 0.00 cc3C2 dihydro-2H-1,3-benzoxazine 1426 F20 CCCCN1C(═O)C2ON(C(C2C1═O) (3S,3aR,6aR)-3-(5-bromo-2- 43.00 0.00 c3cc(Br)ccc3O) hydroxyphenyl)-5-butyl-2- c4ccccc4 phenyldihydro-2H-pyrrolo[3,4- d]isoxazole-4,6(3H,5H)-dione 1442 G19 Oc1cc(nc2c(OC(F)(F)F) 8-(trifluoromethoxy)-2- 52.75 0.00 cccc12)C(F)(F)F (trifluoromethyl)quinolin-4-ol 1410 H10 Cc1nn(c2ccccc2)c3[nH]c(═O) 3-methyl-1-phenyl-4- 40.50 0.00 cc(c13)C(F)(F)F (trifluoromethyl)-1,7-dihydro-6H- pyrazolo[3,4-b]pyridin-6-one 1438 H17 Oc1ccccc1C(═O)NC(═O) N-(2-hydroxybenzoyl)-4- 58.00 0.00 c2ccc(cc2)C(F)(F)F (trifluoromethyl)benzamide 1412 I04 Cc1nc2ccc(NC(═O)/C═C/c3ccccc3) (2E)-N-(2-methyl-1,3-benzothiazol- 62.50 0.00 cc2s1 6-yl)-3-phenylacrylamide 1399 I05 NC(═O)c1ccc(NC(═O) N-(4-carbamoylphenyl)-1-phenyl-3- 39.50 0.00 c2cn(nc2c3cccs3)c4ccccc4)cc1 (2-thienyl)-1H-pyrazole-4- carboxamide 1436 I16 Cc1nc(nc(SCC(═O)c2ccccc2) 2-{[5-chloro-6-methyl-2-(2-pyridinyl)- 45.75 0.00 c1Cl)c3ccccn3 4-pyrimidinyl]sulfanyl}-1-phenyl-1- ethanone 1409 I20 Cc1ccc(cc1)S(═O)(═O) N-(5-hydroxy-1-naphthyl)-4- 44.25 0.00 Nc2cccc3c(O)cccc23 methylbenzenesulfonamide 1394 I20 N/1/C(═N\c2ccccc2)/ N,N′-1H-isoindole-1,3(2H)- 46.25 0.00 c3ccccc3\C1═N\c4ccccc4 diylidenedianiline 1410 J05 S═c1cc(sc2ccccc12) 2-phenyl-4H-thiochromene-4-thione 45.50 0.00 c3ccccc3 1416 J09 CCC1CCCCN1Cc2c(O)cc(C) 4-{[(2S)-2-ethylpiperidin-1-yl]methyl}- 39.00 0.00 c3c4ccccc4c(═O)oc23 3-hydroxy-1-methyl-6H- benzo[c]chromen-6-one 1396 J14 CCCn1c(/N═C/c2c[nH]c3ccccc23) N-[(1E)-1H-indol-3-ylmethylene]-1- 66.00 0.00 nc4ccccc14 propyl-1H-benzimidazol-2-amine 1439 K19 Oc1ccccc1C(═O)NC(═O) N-(2,3-dihydro-1-benzofuran-5- 80.00 0.00 c2ccc3OCCc3c2 ylcarbonyl)-2-hydroxybenzamide 1408 L13 Oc1ccc(Cl)cc1C(═O) 5-chloro-2-hydroxy-N- 42.25 0.00 Nc2ccccc2 phenylbenzamide 1415 L17 COc1cccc(c1)C(═O) 3-methoxy-N-(3-[1,3]oxazolo[4,5- 36.00 0.00 Nc2cccc(c2)c3nc4ncccc4o3 b]pyridin-2-ylphenyl)benzamide 2293 L18 O[C@H]1[C@@H](Oc2c([C@H]3[C@@H](Oc4cc(O) 47.25 0.00 cc(O) c4C3═O)c5ccc(O)cc5) c(O)cc(O)c2C1═O)c6ccc(O) cc6 1415 L21 CC(═O)N/C(═C\c1ccccc1)/ (2Z)-2-acetamido-N-(3,5- 48.00 0.00 C(═O)Nc2cc(C)cc(C)c2 dimethylphenyl)-3-phenylacrylamide 1404 M10 Cc1cc(═O)[nH]c(SCC(═O) 2-[(3-cyano-4-methyl-6-oxo-1,6- 60.25 0.00 Nc2cccc3ccccc23)c1C#N dihydropyridin-2-yl)thio]-N-1- naphthylacetamide 593 O09 COc1cccc(/C═C\2/S/C(═N\c3cc(C) (2Z,5E)-2-[(3,5- −1.00 0.00 cc(C)c3)/NC2═O)c1O dimethylphenyl)imino]-5-(2-hydroxy- 3-methoxybenzylidene)-1,3- thiazolidin-4-one 2073 O11 Cn1c(═O)n(C)c2c(O)c([nH]c2c1═O) 6-(4-chlorophenyl)-7-hydroxy-1,3- 42.50 0.00 c3ccc(Cl)cc3 dimethyl-1H-pyrrolo[3,2- d]pyrimidine-2,4(3H,5H)-dione 2160 P06 Oc1ccc2c(═O)cc(oc2c1O) 7,8-dihydroxy-2-phenyl-4H- 54.25 0.00 c3ccccc3 chromen-4-one 1398 P09 Cc1cc(O)cc(O)c1C(═O) 1-(2,4-dihydroxy-6-methylphenyl)-2- 54.25 0.00 COc2ccccc2 phenoxyethanone -
Claims (42)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/549,482 US20070148185A1 (en) | 2005-10-14 | 2006-10-13 | Novel therapeutic target for protozoal diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/249,355 US7438916B2 (en) | 2005-10-14 | 2005-10-14 | Therapeutic target for protozoal diseases |
US11/549,482 US20070148185A1 (en) | 2005-10-14 | 2006-10-13 | Novel therapeutic target for protozoal diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/249,355 Continuation-In-Part US7438916B2 (en) | 2005-10-14 | 2005-10-14 | Therapeutic target for protozoal diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070148185A1 true US20070148185A1 (en) | 2007-06-28 |
Family
ID=37948378
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/249,355 Active 2026-04-17 US7438916B2 (en) | 2005-10-14 | 2005-10-14 | Therapeutic target for protozoal diseases |
US11/549,482 Abandoned US20070148185A1 (en) | 2005-10-14 | 2006-10-13 | Novel therapeutic target for protozoal diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/249,355 Active 2026-04-17 US7438916B2 (en) | 2005-10-14 | 2005-10-14 | Therapeutic target for protozoal diseases |
Country Status (2)
Country | Link |
---|---|
US (2) | US7438916B2 (en) |
WO (1) | WO2007047579A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060239909A1 (en) * | 2005-03-22 | 2006-10-26 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
WO2009097695A1 (en) * | 2008-02-08 | 2009-08-13 | Chlorion Pharma, Inc. | Arylmethylidene heterocycles as novel analgesics |
WO2010035727A1 (en) * | 2008-09-25 | 2010-04-01 | 塩野義製薬株式会社 | Novel pyrrolinone derivative and medicinal composition containing same |
WO2007047579A3 (en) * | 2005-10-14 | 2011-05-26 | Virginia Tech Intellectual Properties, Inc. | A novel therapeutic target for protozoal diseases |
WO2012026491A1 (en) * | 2010-08-26 | 2012-03-01 | 国立大学法人京都大学 | Pluripotent stem cell cardiomyocyte differentiation-promoting agent |
WO2012066330A1 (en) * | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
DE102011000207A1 (en) * | 2011-01-18 | 2012-07-19 | Forschungsverbund Berlin E.V. | N-Arylaminomethylenbenzothiophenone as a drug |
WO2013093320A1 (en) * | 2011-12-22 | 2013-06-27 | Diverchim | Novel anti-aging and depigmenting cosmetic compositions |
US20140088082A1 (en) * | 2008-07-23 | 2014-03-27 | The U.S.A., as represented by the Secretary, Department of Health and Human Services. | Inhibitors of the plasmodial surface anion channel as antimalarials |
CN103819476A (en) * | 2013-03-05 | 2014-05-28 | 中国人民解放军第二军医大学 | Pyrrolidone pyrazole compound and purposes thereof as drugs |
US20140275119A1 (en) * | 2013-03-15 | 2014-09-18 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US8895284B2 (en) | 2000-03-03 | 2014-11-25 | President And Fellows Of Harvard College | Class II human histone deacetylases, and uses related thereto |
CN104876936A (en) * | 2015-05-25 | 2015-09-02 | 中国人民解放军第二军医大学 | Preparation of 2-hydroxy-1, 2-di-2-pyridylethanone and pyrazole class compound and application as medicine |
US20150265550A1 (en) * | 2012-10-12 | 2015-09-24 | Case Western Reserve University | Anti-virulance compositions and methods |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9303034B2 (en) | 2013-12-19 | 2016-04-05 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
US9434686B2 (en) | 2008-07-23 | 2016-09-06 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9540317B2 (en) | 2009-08-11 | 2017-01-10 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
CN106518750A (en) * | 2015-09-15 | 2017-03-22 | 中国疾病预防控制中心寄生虫病预防控制所 | Carbazole alkamine compound and preparation method thereof and application for parasitic disease resistance |
US9969679B2 (en) | 2012-07-10 | 2018-05-15 | Dana-Farber Cancer Institute, Inc. | Anti-proliferative compounds and uses thereof |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
US10227282B2 (en) * | 2010-03-08 | 2019-03-12 | Case Western Reserve University | Anti-virulence compositions and methods |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
CN109608415A (en) * | 2019-01-21 | 2019-04-12 | 暨南大学 | Thiazole carboxamides class compound and its synthesis and application |
US10350217B2 (en) * | 2012-09-04 | 2019-07-16 | University Of Massachusetts | Antifungal agents and uses thereof |
CN111406752A (en) * | 2020-04-23 | 2020-07-14 | 中国农业科学院植物保护研究所 | Application of dihydropyrrolopyrazolone derivative as chitinase inhibitor or nematicide |
US11382882B2 (en) | 2010-03-08 | 2022-07-12 | Case Western Reserve University | Anti-virulence compositions and methods |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8641746B2 (en) | 2005-05-31 | 2014-02-04 | J.W. Medical Systems Ltd. | In situ stent formation |
WO2008144507A2 (en) * | 2007-05-16 | 2008-11-27 | President And Fellows Of Harvard College | Spirooxindole inhibitors of aurora kinase |
WO2009049421A1 (en) * | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
KR100900837B1 (en) | 2007-12-07 | 2009-06-04 | (주)두비엘 | A powerful vaccine composition comprising lipopeptide and poly(i:c) as an adjuvant |
US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
CN107595841A (en) | 2009-01-09 | 2018-01-19 | 得克萨斯州大学系统董事会 | Preceding neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
CA2804161A1 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9115205B2 (en) | 2010-10-18 | 2015-08-25 | The United States Of America, As Represented By The Secretary Of The Army | Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression |
CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
US11267807B2 (en) * | 2015-10-28 | 2022-03-08 | The Brigham And Women's Hospital, Inc. | Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3636208A (en) * | 1969-10-28 | 1972-01-18 | Daiichi Seiyaku Co | Method for treating malaria |
US20060035926A1 (en) * | 2004-08-13 | 2006-02-16 | Shiow-Ju Lee | Benzothiazolium compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002077195A2 (en) | 2001-03-26 | 2002-10-03 | Walter Reed Army Institute Of Research | Plasmodium falciparum ama-1 protein and uses thereof |
US7438916B2 (en) * | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
-
2005
- 2005-10-14 US US11/249,355 patent/US7438916B2/en active Active
-
2006
- 2006-10-13 US US11/549,482 patent/US20070148185A1/en not_active Abandoned
- 2006-10-13 WO PCT/US2006/040367 patent/WO2007047579A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3636208A (en) * | 1969-10-28 | 1972-01-18 | Daiichi Seiyaku Co | Method for treating malaria |
US20060035926A1 (en) * | 2004-08-13 | 2006-02-16 | Shiow-Ju Lee | Benzothiazolium compounds |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895284B2 (en) | 2000-03-03 | 2014-11-25 | President And Fellows Of Harvard College | Class II human histone deacetylases, and uses related thereto |
US9572854B2 (en) | 2005-03-22 | 2017-02-21 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
US20060239909A1 (en) * | 2005-03-22 | 2006-10-26 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
US10172905B1 (en) | 2005-03-22 | 2019-01-08 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
WO2007047579A3 (en) * | 2005-10-14 | 2011-05-26 | Virginia Tech Intellectual Properties, Inc. | A novel therapeutic target for protozoal diseases |
WO2009097695A1 (en) * | 2008-02-08 | 2009-08-13 | Chlorion Pharma, Inc. | Arylmethylidene heterocycles as novel analgesics |
US20140088082A1 (en) * | 2008-07-23 | 2014-03-27 | The U.S.A., as represented by the Secretary, Department of Health and Human Services. | Inhibitors of the plasmodial surface anion channel as antimalarials |
US9394316B2 (en) * | 2008-07-23 | 2016-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
US9974796B2 (en) | 2008-07-23 | 2018-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
US9434686B2 (en) | 2008-07-23 | 2016-09-06 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
US10881669B2 (en) | 2008-07-23 | 2021-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the plasmodial surface anion channel as antimalarials |
JP5637562B2 (en) * | 2008-09-25 | 2014-12-10 | 塩野義製薬株式会社 | Novel pyrrolinone derivative and pharmaceutical composition containing the same |
US8575197B2 (en) | 2008-09-25 | 2013-11-05 | Shionogi & Co., Ltd. | Pyrolinone derivative and pharmaceutical composition comprising the same |
WO2010035727A1 (en) * | 2008-09-25 | 2010-04-01 | 塩野義製薬株式会社 | Novel pyrrolinone derivative and medicinal composition containing same |
US20110183939A1 (en) * | 2008-09-25 | 2011-07-28 | Shionogi & Co., Ltd. | Novel pyrolinone derivative and pharmaceutical composition comprising the same |
US9540317B2 (en) | 2009-08-11 | 2017-01-10 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
US10059657B2 (en) | 2009-08-11 | 2018-08-28 | President And Fellows Of Harvard College | Class-and isoform-specific HDAC inhibitors and uses thereof |
US10227282B2 (en) * | 2010-03-08 | 2019-03-12 | Case Western Reserve University | Anti-virulence compositions and methods |
US11382882B2 (en) | 2010-03-08 | 2022-07-12 | Case Western Reserve University | Anti-virulence compositions and methods |
WO2012026491A1 (en) * | 2010-08-26 | 2012-03-01 | 国立大学法人京都大学 | Pluripotent stem cell cardiomyocyte differentiation-promoting agent |
CN103209968B (en) * | 2010-08-26 | 2015-08-05 | 国立大学法人京都大学 | Pluripotent stem cell cardiomyocyte differentiation-promagent agent |
JP5930205B2 (en) * | 2010-08-26 | 2016-06-08 | 国立大学法人京都大学 | Promoting myocardial differentiation of pluripotent stem cells |
CN103209968A (en) * | 2010-08-26 | 2013-07-17 | 国立大学法人京都大学 | Pluripotent stem cell cardiomyocyte differentiation-promoting agent |
US8658425B2 (en) | 2010-08-26 | 2014-02-25 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
WO2012066330A1 (en) * | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
DE102011000207A1 (en) * | 2011-01-18 | 2012-07-19 | Forschungsverbund Berlin E.V. | N-Arylaminomethylenbenzothiophenone as a drug |
WO2013093320A1 (en) * | 2011-12-22 | 2013-06-27 | Diverchim | Novel anti-aging and depigmenting cosmetic compositions |
JP2015502391A (en) * | 2011-12-22 | 2015-01-22 | ダイバーキンDiverchim | Novel anti-aging and depigmenting cosmetic composition |
CN104203927A (en) * | 2011-12-22 | 2014-12-10 | 迪弗奇姆公司 | Novel anti-aging and depigmenting cosmetic compositions |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
US9969679B2 (en) | 2012-07-10 | 2018-05-15 | Dana-Farber Cancer Institute, Inc. | Anti-proliferative compounds and uses thereof |
US10350217B2 (en) * | 2012-09-04 | 2019-07-16 | University Of Massachusetts | Antifungal agents and uses thereof |
US20150265550A1 (en) * | 2012-10-12 | 2015-09-24 | Case Western Reserve University | Anti-virulance compositions and methods |
US9782363B2 (en) * | 2012-10-12 | 2017-10-10 | Case Western Reserve University | Anti-virulance compositions and methods |
CN103819476A (en) * | 2013-03-05 | 2014-05-28 | 中国人民解放军第二军医大学 | Pyrrolidone pyrazole compound and purposes thereof as drugs |
CN103819476B (en) * | 2013-03-05 | 2016-08-17 | 中国人民解放军第二军医大学 | Pyrrolidone pyrazole compound and the purposes as medicine thereof |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US20140275119A1 (en) * | 2013-03-15 | 2014-09-18 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9296754B2 (en) * | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US10085989B2 (en) | 2013-12-19 | 2018-10-02 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US11123348B2 (en) | 2013-12-19 | 2021-09-21 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9303034B2 (en) | 2013-12-19 | 2016-04-05 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9700559B2 (en) | 2013-12-19 | 2017-07-11 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US10596175B2 (en) | 2013-12-19 | 2020-03-24 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
CN104876936A (en) * | 2015-05-25 | 2015-09-02 | 中国人民解放军第二军医大学 | Preparation of 2-hydroxy-1, 2-di-2-pyridylethanone and pyrazole class compound and application as medicine |
CN106518750A (en) * | 2015-09-15 | 2017-03-22 | 中国疾病预防控制中心寄生虫病预防控制所 | Carbazole alkamine compound and preparation method thereof and application for parasitic disease resistance |
CN106518750B (en) * | 2015-09-15 | 2021-06-01 | 中国疾病预防控制中心寄生虫病预防控制所 | Carbazole amino alcohol compound, preparation method thereof and application of carbazole amino alcohol compound in resisting parasitic diseases |
CN109608415A (en) * | 2019-01-21 | 2019-04-12 | 暨南大学 | Thiazole carboxamides class compound and its synthesis and application |
CN111406752A (en) * | 2020-04-23 | 2020-07-14 | 中国农业科学院植物保护研究所 | Application of dihydropyrrolopyrazolone derivative as chitinase inhibitor or nematicide |
Also Published As
Publication number | Publication date |
---|---|
WO2007047579A3 (en) | 2011-05-26 |
US7438916B2 (en) | 2008-10-21 |
WO2007047579A2 (en) | 2007-04-26 |
US20070087012A1 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070148185A1 (en) | Novel therapeutic target for protozoal diseases | |
van Dijk et al. | A central role for P48/45 in malaria parasite male gamete fertility | |
Takala et al. | Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’ | |
US7303751B2 (en) | Anti-plasmodium compositions and methods of use | |
US11554165B2 (en) | Vaccine for falciparum malaria | |
US10265313B2 (en) | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | |
Simwela et al. | Current status of experimental models for the study of malaria | |
Avendaño et al. | Cryptosporidium spp. CP15 and CSL protein-derived synthetic peptides’ immunogenicity and in vitro seroneutralisation capability | |
US20060222650A1 (en) | Broad spectrum pyrogenic antagonists and vaccines directed against pyrogenic exotoxins | |
KR0152245B1 (en) | Eimeria tenella vaccine | |
JP2002504302A (en) | ribG | |
US11692026B2 (en) | Antibodies to PfGARP kill Plasmodium falciparum malaria parasites and protect against infection and severe disease | |
US20050123557A1 (en) | AntiI-protozoal vaccine | |
US20220072115A1 (en) | Malaria antigens on the surface of erythrocytes and merozoites and protective antibodies | |
US20050260224A1 (en) | Vaccine based on a cellular penetration factor from an apicomplexan parasite | |
Lindt | Expression of the P-glycoprotein Homologue1 on food vacuoles isolated from Chloroquine-sensitive and resistant Plasmodium falciparum strains | |
Bucsu | Plasmodium chabaudi adami: vaccine antigens and antigenic variation | |
Weiqi | Expression and characterization of Plasmodium falciparum chloroquine resistance transporter (PfCRT) in Pichia pastoris | |
Lee | Molecular Studies on the Folate Biosynthetic Pathway of the Human Malaria Parasite Plasmodium falciparum | |
Uthaipibull | Plasmodium falciparum merozoite surface protein 1: Antigenicity, immunogenicity and structure | |
JP2017210441A (en) | Malaria vaccine | |
JP2002506624A (en) | Staphylococcus aureus SPOOJ2: polynucleotides and proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSIT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RATHORE, DHARMENDAR;JANI, DEWAL;NAGARKATTI, RANA;REEL/FRAME:019023/0292 Effective date: 20070208 Owner name: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC., VIRGI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY;REEL/FRAME:019023/0368 Effective date: 20070220 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |